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Summary of Thesis:
Ureaplasmas are some of the smallest and simplest free-living organisms known. 
Little is understood regarding the effects of the complement system upon clearance of 
these pathogens, but when the immune system fails to control Ureaplasma 
colonization disease, such as chronic lung disease of prematurity (CLD), can occur. 
Treatment of such Ureaplasma infections, especially in neonates, is limited by 
pathogen and host factors. Treatment can be further compromised by antibiotic 
resistance.
Firstly this thesis examines an in vitro system for determining the bactericidal capacity 
of a selection of human sera against four representative serovars of Ureaplasma 
parvum. Results showed that the classical activation pathway was essential for the 
killing of all U. parvum serovars, with little effect being attributed to the alternative or 
lectin pathways. Additionally serovar 3 was shown to be the most serum sensitive 
isolate.
Secondly the association between presence of Ureaplasma and 16S rRNA with 
development of CLD was examined in a prospective cohort of 192 neonates. Data 
suggested that presence of Ureaplasma as well as 16S rRNA was significantly 
associated with development of CLD as well as increased levels of inflammatory 
mediators IL-6 and IL-8.
Finally a retrospective cohort of 61 Ureaplasma isolates was examined for resistance 
to various antibiotics. High level macrolide resistance in isolate UHWO10 resulted 
from a two amino acid deletion within the L4 ribosomal protein (R66Q67). Tetracycline 
resistance in isolate HPA23 resulted from the presence of the tetM gene while a 
ciprofloxacin resistance in isolate HPA18 resulted from a D82N substitution within the 
ParC protein. No differences were found in the GyrA, GyrB or ParE proteins. 
Comparison of type II topoisomerase genes from all Ureaplasma serovars revealed 
that mutations previously associated with resistance where wrongly identified and 
were a result of species or serovar specific polymorphisms.
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Chapter 1 - Introduction
Thesis overview
In this introduction I aim to summarize the current literature regarding the 
neonatal pathogens classified within the genus Ureaplasma. I will discuss 
aspects of the organisms basic biology, its role in disease, as well as its 
susceptibility and resistance to a number of antibiotics. I will also introduce 
some of the additional key concepts which are found within in this thesis such 
as chronic lung disease of prematurity as well as an overview of the 
complement cascade and how these topics relate to Ureaplasma and 
disease.
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Chapter 1 - Introduction
1.1 Ureaplasma spp.
1.1.1 Classification of Ureaplasma spp.
Ureaplasma spp. are taxonomically placed in the phylum Firmicutes, class 
Mollicutes, order Mycoplasmatales, family Mycoplasmataceae and genus 
Ureaplasma. First isolated from men with non-gonococcal urethritis (NGU) 
(Shepard, 1954), these organisms were originally referred to as T- 
mycoplasmas due to their tiny colonies produced relative to other 
mycoplasmas, but due to their ability to utilize urea as an energy source the 
new genus of Ureaplasma was created (Robertson et al. 2002). Prior to 
2002, the human Ureaplasmas comprised of a single species, Ureaplasma 
urealyticum, which was divided into 2 biovars. Biovar 1, included serovars 1, 
3, 6 and 14, whereas biovar 2 included serovars 2, 4, 5, 7, 8, 9, 10, 11, 12 
and 13. In 2002, the biovars for U. urealyticum were officially reclassified into 
two distinct human associated species Ureaplasma parvum (previously biovar 
1) and U. urealyticum (previously biovar 2) (Robertson et al. 2002). U. 
parvum, with serovar 3 being the species prototype strain, contain the 
smallest genomes ranging from 0.75 -  0.77 Mb whereas U. urealyticum 
species, with serovar 8 being the species prototype strain, all contain larger 
genomes ranging from 0.83 -  0.94 Mb.
1.1.2 Characteristics of Ureaplasma spp.
Ureaplasma spp. are small (0.2pm) pleomorphic mucosal pathogens (Figure 
1.1) which require sterols for growth and like other members of the class 
Mollicutes, do not possess a cell wall (Robertson et al. 2002). They are 
surrounded by a triple layered membrane with an electron dense outer
3
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surface (Black et al. 1972). A property unique among Mycoplasmas is their 
ability to hydrolyse urea into ammonia. Ammonia which accumulates 
intracellularly, as a result of urea hydrolysis by the urease enzyme, creates an 
electrochemical gradient in which ATP is generated. Smith et al. showed that 
this unique property among Mollicutes was essential for 95% of energy 
production by the addition of the urease inhibitor flurofamide which reduced 
de novo ATP synthesis to 5% (Smith et al. 1993).
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A.
Figure 1.1. Micrographs of Ureaplasma spp. (A) Microcolonies of 
Ureaplasma showing urease activity (bar=100pm). (B) Transmission electron 
micrograph of Ureaplasma showing the small size of cells (bar = 0.5pm) 
(Robertson et al. 2002).
5
Chapter 1 - Introduction
1.1.3 Genome and coding capacity
In 2000, Glass et al., published the complete genome sequence of U. parvum 
serovar 3 ATCC 700790 (Glass et al. 2000). The total genome contained 
751,719 bp with a G+C content of 25.5% which is typical of Mollicutes as well 
as bacteria with reduced genome sizes. A total of 613 predicted protein- 
coding genes along with 39 genes encoding RNAs were identified, which in 
total accounted for 93% of the genome. More recently projects have been 
undertaken to sequence the remaining 13 serovars of the human associated 
Ureaplasmas which will provide insight in to the genetic diversity among 
Ureaplasma. The UGA codon in all other organisms functions as a terminal 
stop codon (opal), but in Ureaplasma and Mycoplasma encode the amino acid 
tryptophan (Blanchard, 1990). The small coding capacity of mycoplasmas is 
a result of genome reduction over time. A consequence of such genome 
reduction is the loss of non-essential genes which can be found in other 
bacteria, sometimes limiting the organism to obligate dependence upon a 
host. One illustration of the limitations of gene loss is the complete reliance of 
ureaplasmas, as well as other Mollicutes, on the thymidine kinase (TK) 
enzyme salvage pathway for de novo systhesis of DNA precursors. TK 
transfers phosphates from nucleosides, such as ATP, to the 5’ hydroxyl group 
of pyrimidine deoxyribonucleoside (Carnrot et al. 2003).
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1.1.4 Virulence factors of ureaplasmas
1.1.4.1 Urease production
As well as being essential for 95% of the energy production in Ureaplasma, 
urease has also been proposed as a significant virulence factor. The ability of 
Ureaplasma to colonize regions such as the upper urinary tract and cause 
infective kidney stones is dependent on the ability to hydrolyse urea. Ligon 
and Kenny found that when trying to raise monoclonal antibodies to viable 
Ureaplasma in mice, death was experienced only 5 minutes after inoculation 
(Ligon and Kenny, 1991). However, mice which received whole bacteria 
which were pre-treated with the potent urease inhibitor, flurofamide, were 
shown to be protected against the urease activity and did not show any sign 
of adverse symptoms. As a result of these experiments ammonia toxicity was 
determined to be the cause of death for mice injected with Ureaplasma in the 
absence of inhibitor. The authors discussed that although numbers found in a 
normal infection would not be as high as those used in the mouse model, it 
would be likely that local tissue damage would occur thus causing an 
inflammatory response.
1.1.4.2 Ureaplasma phospholipases
It is accepted that there is a significant link between intrauterine infection and 
preterm birth (Andrews et al. 2000). Phospholipase (PL) activity in bacteria 
has been suggested as a contributing factor to premature birth, by hydrolyzing 
placental membrane phospholipids, resulting in an increase in free 
arachidonic acid followed by increase in prostaglandins. The presence of PL
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A1, A2 and C activity in Ureaplasma was first noticed by De Silva and Quinn 
(De Silva and Quinn, 1986). Later work by the same group determined that 
there was great variation in activity of these enzymes between different 
serovars with PL A2 activity being 3-fold greater in serovar 8 than that of 
serovars 3 or 4. The authors suggested that this variation was a possible 
explanation for varied clinical outcomes in patients colonized with these 
organisms (De Silva and Quinn, 1991). The functional conditions at which the 
enzymes work optimally also differ between the PL: PL A1 ’s optimal range is 
between pH 8.5 -  9 whereas PL A2’s optimal range is pH 7, notably with 50- 
100 fold greater activity than that of PL A1 (DeSilva and Quinn, 1999). PL C 
on the other hand has a more acidic preference with an optimal range of pH 6. 
Although the enzymes have been studied, the published genome sequence 
data did not identify any putative orthologous sequences, possibly due to 
sequence divergence compared to other bacterial species (Glass et al.
2000). Non-ureap/asma derived PL A2 has been shown to inhibit pulmonary 
surfactant in vitro (Schrama et al. 2001) which has led to suggestions that, 
inhibition of pulmonary surfactant by Ureaplasma PL A2 might be a 
mechanism of causing lung injury (Cultrera et al. 2006).
1.1.4.3 Ureaplasma IgA protesase
IgA is the most predominant immunoglubulin in mucosal layers, the presence 
of an IgA proteases suggests an essential virulence factor. Kapatais- 
Zoumbos K et al., demonstrated that the production of IgA proteases was host 
specific with human Ureaplasma only producing proteases capable of 
degrading human IgA which was specific for lgA1 and not lgA2 (Kapatais-
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Zoumbos et al. 1985). This specificity suggests co-evolution between 
specific Ureaplasma species and their host. The specific region within the 
lgA1 which the enzyme cleaves was determined by Spooner et al., who 
deduced via N-terminal sequencing that cleavage occurs between proline and 
threonine between residues 235 and 236 (Spooner et al. 1992). The 
absence of this region in lgA2 explains the enzymes specificity. Interestingly 
as with the PL discussed earlier, no orthologues for the protease were found 
within the sequenced genome.
1.1.4.4 Haemolysins
The sequenced SV3 genome contained two hypothesized enzymatic 
haemolysins. The haemolysin transcribed from the hlyA gene is thought to be 
the predominant of the two with hlyC being an orthologue of one found in M. 
pneumoniae (Glass et al. 2000). The haemolysin encoded by hlyA maybe a 
significant virulence factor of the Ureaplasma as data from mycobacteria 
demonstrate that the gene is only present in pathogenic species of the genus 
(Wrenefa/. 1998).
1.1.4.5 The multiple banded antigen
The multiple banded antigen (MBA) of Ureaplasma has been proposed as 
being one of the predominant antigens recognized during infection (Watson et 
al. 1990). As the names suggests immunoblots of Ureaplasma probed with 
monoclonal antibodies (MAbs) produce a laddering “multiple banded” effect 
and has been proposed to function as an adhesin (Monecke et al. 2003;
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Manchee and Taylor-Robinson, 1969). Watson et al., showed using sera 
from infected patients, as well as MAbs, that the antigens contain both 
serovar specific and pan-serovar cross-reacting epitopes. The protein is 
composed of N-terminal signal peptide with a hydrophobic core and a 
lipoprotein lipid attachment site at a cysteine (Zheng et al. 1995) whereas the 
final two thirds of the C-terminal end of the protein is comprised of multiple 
repeat units. In the case of SV3, the repeats consist of the amino acids 
GKEQPA. Figure 1.2 shows a generalised structure of the MBA with the C- 
terminal repeat units for all serovars as described by Kong et al., 2000 (Kong 
etal. 2000).
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peptide
N-
Repetitive
region
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B.
Species
U.p
U.p
U.p
u.p
U.u
U.u
U.u
Serovar
SV1
SV3
SV6
SV14
SV2, 5, 8
SV10
SV4, 12, 13
C-terminal repeats
QQPGKE
QPAGKE
PGKE
QQPAGKE
TKPGSGET
TQPGSGST
TSPEKPGNGT
Figure 1.2. Structure of the multiple banded antigen of spp. (A)
The protein contains an N-terminal signal peptide (green) followed by a 
species conserved non-repetitive region (blue). Two thirds of the C-terminal 
consists of repetitive amino acid sequences (Yellow). (B) Amino acid repeats 
contain differences between serovars (Kong 2000). No repeat regions 
have been detected in SV9, 7 and 11. U.p and U.u denote and
urealyticum, respectively.
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The ability to evade a host immune response is an adaptive strategy 
employed by a number of pathogenic bacteria. Ureaplasmas have several 
proposed mechanisms to keep one step ahead of the immune system by 
varying its surface antigenicity. Phase variation was the initial mechanism of 
altering the antigenicity of MBA (Zheng et al. 1995). Zheng et al., described 
how a clinical SV3 strain isolated from lung tissue of a new born infant 
contained two major bands of 53 and 68.5 KDa via immunoblotting. This 
isolate was sub-cloned and found that clones 1 and 21 expressed the 53 KDa 
protein and a clones 16 and 19 expressed the 68.5 KDa protein. PCR 
analysis showed no difference in fragments size of the N-terminal region 
between clones, but clones 1 and 21 had smaller C-terminal PCR products 
relative to clones 16 and 19 suggesting deletion of repeat units. A second 
mechanism of variation results in an on/off switching of the MBA gene. 
Monecke et al., co-incubated Ureaplasma from both species with HeLa cells 
and/or erythrocytes and compared the immunoblot profiles of parental strains 
to non-adherent strains (Monecke et al. 2003). Unlike previously reported by 
Zheng et al., (Zheng et al. 1995) phase variation did not occur, but instead 
there was complete loss of antibody reactivity. Total removal of all repeat 
units was dismissed as the reason for this loss of reactivity due to PCR failing 
to amplify the non-repetitive region of MBA in the negative mutants. Later 
work by Zimmerman et al., (Zimmerman et al. 2009) proposed this on/off 
switching of MBA to coincide with respective off/on switching of adjacent 
Upvmp376 protein. They suggests that the non-repeat region of the MBA can 
either drive transcription of MBA, or as a result of a recombinant inversion
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event, will flip its orientation and drive transcription of the oppositely oriented 
Upvmp376 protein.
1.1.4.6 Ureaplasma pathogenicity island
Genomic analysis has revealed a hypothetical pathogenicity island (PAI) 
within the genome of U. parvum (Momynaliev et al. 2007). The 19,943bp 
region designated UU145-UU170 has a number of characteristics suggesting 
its role as a PAI which has been acquired horizontally. The researchers 
proposed this region as a PAI on the following observations: the PAI was not 
seen in all clinical isolates screened; the PAI has a conserved length; the site 
at which it is inserted into the genome is directly linked to tRNA genes, which 
have previously been hypothesized as anchorage points for horizontally 
transferred elements. The greatest supporting evidence was the presence of 
genes encoding proteins essential for horizontal transfer such as the in:ripX 
intergrase-recombinase enzyme and the phage recombinase enzyme. 
Examination of genes within the element showed adhesin homologues, which 
may be of significance to virulence. Normally PAI have a skewed G+C 
content relative to the rest of the host genome, but in this case the G+C 
contents were very similar. Further comparative genomic analysis showed 
that the tetranucleotides GCGC and CGCG were not present within the 
element, but prolific among other regions of the Ureaplasma genome.
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1.1.5 Detection, quantification and serotyping of Ureaplasma 
spp.
1.1.5.1 Culture and quantification of Ureaplasma spp.
Ureaplasmas are generally regarded as fastidious in their growth 
requirements. Ammonia production as a result of urea hydrolysis in 
Ureaplasma has provided the foundations to culture based detection 
methods. The preference of Ureaplasma of an acidic culture medium has 
also been useful for promoting Ureaplasma growth relative to other bacteria 
as well. Using a pH indicator, such as phenol red, it is possible to see a shift 
in media pH from around 6.5-6.8 to a more neutral pH. This is essential as 
Ureaplasma cultures never reach turbidity due to the toxic nature of the 
metabolites produced, as well as decreased growth with increasing the pH 
and depletion of urea, precipitating a rapid death phase. Broth cultures are 
incubated at 37 °C in atmospheric conditions with colour change in broth 
cultures taking 24 -  48 hours depending on the size of the inoculum. Agar 
plates require 5 % CO2 and can take 1 - 5  days. A microscope or hand lens 
is required to examine plates due to the tiny colonies that form. Unlike 
conventional mycoplasmas, such as M. hominis, which produce a “fried-egg” 
morphology, Ureaplasma colonies produce brownish zones as a result of 
urease activity (Figure 1.1 A). When working with liquid cultures it is 
recommended to make serial dilutions of the inoculum to around 10'7 so to 
dilute any potential inhibitors such as antibiotics, antibodies or built up 
ammonia. Serial 10-fold dilutions in a micro-titre plate are used to quantify the 
numbers of Ureaplasma in the original specimen as colour changing units
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(CCU). The CCU is determined when there is no more colour change from 
the 10-fold dilutions (usually 48 hours post-innoculation). The final well in 
which colour change occurred is regarded as 1 CCU. By working back 
through the dilution gradient it is possible to determine the number of CCU’s 
in the original culture.
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Figure 1.3. The method for determining the number of Ureaplasma 
colour changing units (CCU) in a culture. (A) A sample of unknown 
CCU is titrated 1:10 in a microtitre plate in Ureaplasma specific media. 
Cultures are then incubated at 37 °C for 48 hours until colour change 
has ceased (B). The final well which colour change occurs is regarded 
as 1 CCU. By working back through the dilution gradient it can be 
concluded that there were 106 CCU in the original culture at the time of 
inoculation.
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1.1.5.2 Molecular detection of Ureaplasma
PCR has been essential for the detection of many bacterial pathogens with 
fastidious growth requirements. A number of primers are now available which 
amplify genes including the urease genes, 16S rRNA gene, 16S-23S 
intergenic spacer region and the multiple banded antigen (MBA) gene and 
have been used to associate Ureaplasma with arthritic conditions, male and 
female genitourinary specimens, as well as neonatal respiratory specimens 
(Colaizy et al. 2003). Blanchard et al., (Blanchard et al. 1993) designed 
primers to amplify a 430 bp region of the ureA gene. These primers were 
applied to all 14 serovars and could detect to a level of 1-10 colony forming 
units (c.f.u.). These primers are selective for Ureaplasma and have been 
tested against other common neonatal pathogens to confirm a high stringency 
against false positive results.
A highly sensitive method for detecting Ureaplasma was also developed by 
Benstein et al. (Benstein et al. 2003a; Benstein et al. 2003b). The group first 
developed an in situ hybridization assay using a 100 bp biotinylated DNA 
probe specific for the urease gene of Ureaplasma (Benstein et al. 2003a). 
The probe was able to demonstrate that Ureaplasma was associated with 
lung epithelial cells from newborn mice inoculated with Ureaplasma. It was 
also possible to detect Ureaplasma inside alveolar macrophages suggesting 
the organism’s prior presence within the lower respiratory tract. This 
technique was then applied to lung autopsy tissue from fourteen patients, nine 
of which showed histology consistent with CLD at autopsy. Seven out the 
nine CLD cases were Ureaplasma culture positive (Benstein et al. 2003b).
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Interestingly, the assay detected the presence of Ureaplasma in all the CLD- 
like tissue samples, including those which were Ureaplasma culture negative. 
These data suggest that the detection rate in many studies may under­
represent the true incidence of Ureaplasma in CLD patients when using 
standard culture techniques alone as well as the clearance of bacteria via the 
immune response.
1.1.5.3 Typing of Ureaplasma isolates
Ureaplasmas were first typed using a metabolic inhibition (Ml) assay in which 
anti-sera to a range of isolates were raised in rabbits (Purcell et al. 1966). 
Ureaplasma isolates, including the strain used for immunisation, were added 
to a range of known dilutions of the anti-sera in the presence of guinea pig 
serum as a source of complement. The absence of colour change was used 
as confirmation of a positive recognition of the antiserum for that strain and 
the strength of recognition was determined by titring the effect of the specific 
antibodies. Draw backs of this methodology was that it only took into account 
classical “antibody-dependent” complement killing pathway and did not 
consider any potential effects from the lectin or alternative pathways which 
are discussed in section 1.4.3 and 1.4.4, respectively. In addition, the assay 
was run in medium containing urea, a known nucleophilic acceptor which 
would inhibit the complement activity which the assay was dependent upon.
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1.1.5.4 Pulse-field gel electrophoresis (PFGE) for typing 
Ureaplasma isolates
Current characterisation of Ureaplasma serovars is largely carried out using 
PCR based methodologies whereas Pulse-Field Gel Electophoresis (PFGE) 
had been the gold standard method for typing bacterial isolates. Moser et al. 
examined the ability of PFGE to characterize Ureaplasma into individual 
species and then into separate serovars (Moser et al. 2006). Results showed 
that using restriction enzymes which cut the Ureaplasma genome 
infrequently, such as BssHII, they were able to differentiate between U. 
parvum and U. urealyticum. To determine the method’s clinical application, 
five clinical isolates of serovar 6 were compared to that of the U. parvum SV6 
reference strain. Results showed that variation in banding patterns occurred 
between clinical isolates compared to the reference strain. Variation in results 
was also noticed in serovar 8 following serial passages. It was proposed that 
the rate of mutation within particularly variable regions led to rapid gain and 
loss of restriction sites, which caused alterations in banding patterns even 
after a couple of propagation passages of defined strains.
1.1.5.5 PCR and sequencing for typing Ureaplasma
One of the most accurate and rapid methods of determining the species of 
Ureaplasma within a clinical sample was developed by Teng et al., (Teng et 
al. 1994). Primer set UM-1 amplified the 5’ region of the MBA gene to 
exploiting the reduced coding capacity of U. parvum serovars relative to U. 
urealyticum therefore producing differential sized PCR products of 403 bp and
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448 bp, respectively. By direct sequencing the UM-1 PCR product it is further 
possible to determine the SV of U. parvum isolates by comparison of -54 to - 
56 regions and the -82 to -84 regions, unfortunately due to sequence 
conservation among U. urealyticum, serovar determination in the region is not 
possible. By sequencing the whole 5’ and partial repeat region of the 3’ 
region of the MBA from all 14 serovars Kong et al., (Kong et al. 2000) 
showed that U. urealyticum could be divided into five different MBA 
genotypes. Genotype A consisted of serovars 2, 5 and 8; genotype B serovar 
10, genotype C 4, 12 and 13; genotype D serovar 9 and genotype E with 
serovars 7 and 11.
1.1.5.6 Real-time PCR detection for Ureaplasma
A highly sensitive method for detecting bacteria with fastidious growth 
requirements, such as Ureaplasma, is real-time PCR. A number of studies 
have examined the use of this technique to detect Ureaplasma in a variety of 
clinical samples. Yi et al., designed primers against the urease gene which 
allowed the simultaneous detection as well as speciation of Ureaplasma in 
two reference strains as well as confirming 42 strains which the species had 
been determined by PCR and sequencing (Yi et al. 2005). The investigators 
subsequently examined 87 clinical specimens and confirmed that the method 
was more sensitive than direct culture. A similar study published in the same 
year by Mallard et al., again used the urease gene as a target for a real-time 
probe (Mallard et al. 2005). In contrast to the study by Li et al., the probes 
were more rigorously tested against a range of sixteen clinically relevant 
bacteria including seven urease-producing species. Results showed that the
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probes were specific for the Ureaplasma urease as well as having a sensitivity 
of detecting five copies of the gene per reaction. As only a single copy of the 
ureB gene has been identified in the sequenced genome of SV3, this would 
correspond to five bacteria per reaction (Glass et al., 2000).
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1.1.6 Ureaplasma and disease
Ureaplasmas were first identified as a human pathogen in 1954, when it was 
isolated from the urethra of a male patient with NGU (Shepard, 1954). Since 
the initial report, Ureaplasma infection has been linked to NGU (Horner et al.
2001), infertility (Reichart et al. 2001), infectious kidney stones (Hedelin et al. 
1984), arthritis in hypogammaglobulinemic patients (Frangogiannis and Cate, 
1998; Furr et al. 1994; Taylor-Robinson et al. 1985), pelvic inflammatory 
disease (Abele-Horn et al. 1997a), meningitis in adults (Geissdorfer et al. 
2008), kidney abscess in transplant patients (Eilers et al. 2007), pericarditis 
(Tarrant et al. 2009) as well as multiple diseases in neonates (Waites et al. 
2005).
1.1.6.1 Ureaplasma and disease in adults
After the first link between Ureaplasma and NGU in the 1950’s, studies have 
continued to examine this association. One study providing evidence for the 
role of Ureaplasma to induce NGU was carried out by D. Taylor-Robinson and
G. W. Csonka who self-inoculated themselves with two clinically isolated SV5 
strains (Taylor-Robinson et al. 1977). The first volunteer showed signs of 
dysuria following inoculation, but following treatment with tetracycline cleared 
the infection and symptoms resolved. The second volunteer also developed 
symptoms of NGU, but additionally urinary threads were noticed in the urine. 
The volunteer responded to treatment, but threads persisted. Seminal fluid 
showed that the prostate was infected and was contributing to the urinary 
threads.
22
Chapter 1 - Introduction
Horner et al., (Horner et al. 2001) tested 114 patients with acute NGU for 
Chlamydia trachomatis, Mycoplasma genitalium and Ureaplasma spp and 
compared these with 64 NGU negative controls. They found that after 
multivariate analysis controlling for C. trachomatis, M. genitalium, and sexual 
lifestyle Ureaplasma were not associated with acute NGU, whereas on 
univarite analysis they were. The authors suggested that although in their 
study Ureaplasma was not associated with acute NGU, possibly due to the 
high carriage rate in the sexually active control group, it does cause disease 
in a subset of patients. They proposed that infection with symptoms is caused 
on initial exposure, but patients develop tolerance over time which then 
results in the high carriage rate. An additional interesting finding was that 
detection of Ureaplasma in the control group was associated with a recent 
change in sexual partner. Of the 114 acute NGU patients, 86 men re­
attended the clinic within 10 to 92 days post treatment with either doxycycline 
or erythromycin, in which Ureaplasma detection was then significantly 
associated with chronic NGU in patients which were symptomatic. This may 
additionally suggest a high rate of antibiotic resistance within this population.
Brown et al., (Brown et al. 1983) showed a differential serological response 
between Ureaplasma positive NGU patients and Ureaplasma positive healthy 
controls by developing an enzyme linked immunosorbant assay (ELISA) for 
the detection of IgG, IgM and IgA in acute and convalescent phase sera. 
Antibody titres were significantly higher in culture positive NGU patients 
relative to that of culture positive healthy controls. A further interesting result 
was the degree of change in each antibody titre. Ureaplasma positive control
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patients had a significantly lower change in antibody titre over a four to six 
week time period relative to Ureaplasma positive NGU patients. The authors 
suggested that the presence of antibody alone was not useful in determining a 
relationship between infection and disease, but perhaps the degree of change 
in titre would be a more valid measure to correlate disease with infection. 
One draw back of the assay was the inability to differentiate between which 
serovars the antibody response was raised to, which is most likely a result of 
the cross reactive epitopes in the MBA which were described earlier.
1.1.6.2 Ureaplasma and its role in chorioamnionitis and preterm 
birth
The amniotic sac which surrounds the developing fetus consists of an outer 
and inner membrane known as the chorion and amnion, respectively. 
Inflammation of this region, chorioamnionitis, has been linked to spontaneous 
abortion, preterm birth as well as development of chronic lung disease (CLD) 
which will be discussed further in section 1.2.4. Ureaplasma are believed to 
be one of the leading causes of such inflammation due to being the most 
commonly isolated organism from mothers with the condition (Cassell et al. 
1986; Yoon et al. 1998). Amniocentesis samples have shown that 
colonisation of the chorioaminon by Ureaplasma can occur in the presence of 
intact membranes as early as the second trimester at weeks 15-20 (Cassell et 
al. 1983; Gerber et al. 2003; Perni et al. 2004). Abele-Horn et al. showed 
that from 170 mothers positive for Ureaplasma colonisation 10% experienced 
chorioamnionitis compared to none in the Ureaplasma negative group. 
Additionally 35% of the Ureaplasma positive group had premature rupture of
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membranes compared to 12% in the control group and 41% delivered 
prematurely compared to only 10% (Abele-Horn et al. 1997b). Intrauterine 
infections are a significant risk factor in preterm delivery. The presence of 
bacteria induces an inflammatory response resulting in the production of 
prostaglandins giving uterine contractions, cervical dilations and membrane 
rupture (Waites et al. 2009). Due to the strong evidence associating 
Ureaplasma with chorioamnionitis, it is not unreasonable to implicate 
Ureaplasma in the role of preterm birth.
1.1.6.3 Ureaplasma and disease states of neonates
Ureaplasmas can be transmitted vertically from mother to child via a number 
of routes including ascending the genital tract, haematogenously, and 
contraction from the birth canal during birth. Rates of maternal transmission 
of Ureaplasma are strongly inversely correlated with birth weight and 
prematurity with infants born during the second trimester weighing less than 
1,500 g having the highest rate (Chua et al. 1998; Izraeli et al. 1991). Chua 
et al. (Chua et al. 1998) determined the rate of transmission from mothers 
with cervical colonisation of Ureaplasma to their child was 88.2%. This data 
confirms that of earlier studies by Izraeli et al. who had found rates of 
transmission to be 80% (Izraeli et al. 1991). A number of conditions in 
neonates have been associated with Ureaplasma infection following 
transmission from the mother which include meningitis, systemic infection, 
pneumonia and CLD .
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1.1.6.4 Central nervous system and systemic Ureaplasma 
infections in neonates
Rates of systemic bacterial infection has been predicted to be 4-fold higher in 
neonates less then 2.5 Kg relative to those of a greater birth weight. Group B 
Streptococci and Escherichia coli are known as leading infectious agents of 
the central nervous system (CNS) in this patient group, but since the mid- 
1980s a body of evidence has been growing to support the idea of 
mycoplasmas as a causes of systemic (circulating) infections, as well as 
presence in the cerebrospinal fluid (CSF) coincident with meningitis and brain 
abscesses (Rao et al. 2002). Mycoplasma presence in neonatal has been 
hypothesised to originate from lung colonisation which spreads to the CSF via 
a haematogenous route. Two sets of data support this hypothesis: Firstly, a 
study of 19 infants with positive Ureaplasma endotracheal aspirates (ETA) 
were examined for systemic infection. 26% of blood cultures were positive for 
the organism, demonstrating a link between lung colonization and systemic 
infection (Cassell et al. 1988). Secondly, a study by Waites et al. showed 
Ureaplasma was isolated from the lower respiratory tract of half of patients 
with a positive CSF culture and the authors proposed that the lungs were the 
original source of the infection (Waites et al. 1988).
In 1988, Waites et al. studied CSF from 100 predominately preterm neonates, 
8% were positive for Ureaplasma and 5% were positive for Mycoplasma 
hominis with suggesting that Mollicutes were most common organisms 
isolated from the CSF of very low birth weight preterm infants (VLBW) infants 
(Waites et al. 1988). A second study by Waites et al. in 1990 again looked
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for Ureaplasma and M. hominis in 318 infants born near to or at term (Waites 
et al. 1990). M. hominis was found in 9 patients where as Ureaplasma was 
found in 5. From the total of 14 patients with positive cultures, 5 cleared 
spontaneously without treatment and one infected infant died with evidence of 
meningitis. Spontaneous clearance of Ureaplasma has also been 
documented in other studies (Neal et al. 1994). A case report describes the 
clearance Ureaplasma from the CSF of on 28 week neonate using 
chloramphenicol following the isolation of an erythromycin-resistant strain 
(Hentschel et al. 1993).
The true rate at which Ureaplasma and other mycoplasmas are isolated from 
neonatal CSF may be under-reported as a result of not being detected by 
Gram stains, as well as not being detected by routine bacterial culture. For 
this reason, it has been recommended that examination for mycoplasmas in 
the CSF should be carried out in all neonatal samples which are negative 
upon Gram stain examination and/or culture with pleocytosis, hydrocephalus 
or radiographic signs of CNS infection (Waites et al. 1993).
1.1.6.5 Ureaplasma as a causative agent of neonatal pneumonia
One of the earliest bodies of evidence for the causative role of Ureaplasma in 
neonatal pneumonia came from a study of 290 neonatal deaths occurring 
from congenital pneumonia. Ureaplasma was found in 23 of the 290 samples 
examined, with all but two from still born births. The authors suggested that 
an infection in utero resulting from transition of the bacteria through intact 
foetal membranes (Tafari et al. 1976). A case report commented on the
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isolation of Ureaplasma from a neonate who died from pneumonia shortly 
after birth. A significant amount of lung inflammation and hyaline membrane 
disease (and early pseudonym for respiratory distress syndrome) was 
documented in post-mortem samples giving further evidence for the role of 
Ureaplasma in the onset of pneumonia (Brus et al. 1991). Pacifico et al., 
examined 94 infants and 53% of Ureaplasma-positive infants showed 
radiographic signs of pneumonia relative to 21% of those with a Ureaplasma 
negative culture. The study concluded that VLBW infants colonised with 
Ureaplasma were twice as likely to develop pneumonia than non-colonised 
infants (Pacifico et al. 1997). Rudd and colleagues found that two separate 
strains of Ureaplasma isolated from infants with pneumonia were able to 
cause pneumonia in newborn mice, but those who were 2 weeks old were 
less susceptible, suggesting an age-dependent risk factor (Rudd etal. 1989).
Several investigators have suggested a link between congenital pneumonia 
resulting from Ureaplasma and the onset of chronic lung disease of 
prematurity (CLD). Cassell et al. suggested that Ureaplasma may lead to 
CLD by initially causing neonatal pneumonia. If the pneumonia goes 
undetected, then oxygen requirement will likely increase thus setting up 
further conditions which will increase the risk of developing CLD (Cassell et al. 
1993).
1.1.6.6 Differential pathogenicity of Ureaplasma
Onset of infectious disease may not only be dependent upon the genus or 
species of the organism present, but in some cases the serotype, as with
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Haemophilus influenzae serotype B can which can account for around 95% of
H. influenzae invasive disease in children (van Alphen and Bijlmer, 1990). It 
has been proposed that this species or serovar association with disease 
occurs in Ureaplasma accounting for why some neonates develop disease, 
but results are far from conclusive. An argument for species specific 
pathogenicity was offered by Deguchi et al. who compared the incidence of 
each species between 572 male patients with NGU and a control group of 141 
men with no signs of urethritis. Results showed that numbers of patients with 
U. urealyticum were significantly higher in patients with NGU (15.8%) than 
those of the control group (7.8%), whereas there was no significant difference 
between NGU patients and the control group with U. parvum. The authors 
concluded that the low levels of U. parvum may reflect colonization rather 
than infection (Deguchi et al. 2004). Katz et al. examined whether there was 
a link between colonization with U. parvum or U. urealyticum and clinical 
outcome in a neonatal population (Katz et al. 2005). Results showed that U. 
parvum was the most commonly isolated from ETA from neonates, but no link 
was seen between the isolation of a single species and adverse clinical 
outcome. A significant number of infants colonized with both species 
developed CLD relative to those who did not develop the condition. 
Alternatively, Cultrera et al. found that from a study of 50 infants, 24 with and 
26 without respiratory distress syndrome (RDS), only infants colonized with U. 
parvum developed RDS whereas a number without RDS had U. urealyticum 
(Cultrera et al. 2006). The significance of both these studies is questionable 
due to the low numbers of individuals therefore a larger study size is needed 
to determine a true role. A study of invasive isolates was carried out by
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Zheng et al., (Zheng et al. 1992) who used MAbs to look at serovar 
differences in invasive disease from ten CSF and three blood isolates from 
varying neonates. They found that of the CSF isolates, 1 isolate was an SV1, 
2 were SV3, 1 was SV6, 1 was SV 8 and 2 were SV10 and 3 unknown. For 
the Ureaplasma isolated from blood, 2 out of the 3 were unknown, while the 
remaining isolate was found to be SV3. This suggests that there was no 
difference between serovars, but virulence may lie in the ability of the 
organism to vary its surface antigens. As mentioned earlier, this study by 
Zheng et al. demonstrated that Ureaplasma have the ability to vary their 
antigen expression and this could ultimately be more significant in disease 
progression rather than serovar (Zheng et al. 1992).
From these results no conclusive agreement has been reached. Results have 
varied between studies, cross reactivity of antibodies remains poorly defined 
and studies are always underpowered due to small study group sizes. To 
ascertain a potential role of either a specific species or serovar in 
pathogenicity, more serovar specific reagents and larger well controlled 
studies are required.
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1.2 Chronic lung disease of prematurity
1.2.1 Chronic lung disease of premetuirty; an overview
CLD, also known as bronchopulmonary dysplasia (BPD), is a disease 
primarily seen in preterm neonates resulting from a number of aetiologies. It 
was first defined in 1967 by Northway et al., who noted that preterm infants 
who had received mechanical ventilation and oxygen therapy had significant 
lung injury (Northway et al. 1967). Northway originally defined the disease as 
a chronic lung disease that affected preterm infants with respiratory distress 
syndrome (RDS). Since the initial definition, a number of modifications have 
been made to better describe the disease, such as the need for continued 
oxygen dependence over 28 days. Additional modifications included 
correction for gestational age after 36 weeks, or 28 days of ventilation along 
with characteristic chest x-rays. A study examining infants born extremely 
prematurely (before 26 weeks gestational age) found that at six years of age 
13 % had developed cerebral palsy and 13 % had severe sensory impairment 
(Costeloe, 2006), suggesting up to a quarter of this group will have life long 
sequelae.
1.2.2 The changing aetiology and clinical presentation of CLD
The epidemiology of the disease has also evolved since Northway’s first 
observations. Initially CLD was common in neonates who were born at 30-32 
weeks gestation, which was the limit of survival at that time. As surfactant 
therapy, better ventilation techniques and increasing palliative care methods 
have evolved over the last 20 years, the trend has now been skewed towards 
CLD being primarily a disease of VLBW. Sixty-seven percent of neonates
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with birth weights between 500 to 750 g develop CLD, compared to only 1% 
of those weighing 1,250 to 2,500 g (Bancalari et al. 2003). A variation in the 
presentation of CLD between the late 1960s and that of today has resulted in 
the idea of “old” and “new” CLD especially after the introduction of antenatal 
steroids and postnatal surfactant treatment. New CLD differs from old in 
causation as well as resulting lung pathology. Old CLD was characterized by 
smooth muscle hyperplasia, extensive fibrosis and inflammation within the 
lung, all of which were related to harsh ventilation strategies including 
barotrauma, volutrauma and oxygen toxicity. As therapeutic strategies for 
preterm infants changed, such as administration of surfactants (so to reduce 
surface tension and allowing inflation of surfactant deprived lungs), 
administration of antenatal glucocortoicoids and better, less harsh ventilation 
techniques were used the numbers of larger birth weight preterms with CLD 
began to decrease. As a result of the improved therapeutic strategies, 
survival rates for more premature infants also increased, which subsequently 
altered the pathological hallmarks and underlying mechanisms of CLD (“new 
CLD”). The new form is primarily seen in extremely preterm infants, born at 
24-26 weeks, and infrequently in the larger preterms, in which CLD had been 
previously present (Coalson, 2006). Histological data from autopsied lung 
tissue of extreme preterm infants with CLD noted a shift in the histology 
towards large and simplified alveoli which were decreased in number, had 
variable interstitial fibroproliferation and variable smooth muscle hyperplasia 
(Figure 1.3) (Coalson, 2003). New CLD is due to the highly immature status 
of the neonatal lung as infants were born during the late canlicular and early 
saccular stage of lung development. At this early stage of development,
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alveolarisation (the formation of terminal saccules and production of 
surfactant) has yet to begin, compared with those born at a later gestational 
age. A lack of alveolarisation, which begins at 32 weeks, means that the lung 
is not prepared for gaseous exchange (Coalson, 2003). Unlike old CLD, a 
number of infants that develop the new form do not present with initial 
respiratory complications, such as RDS. It has been hypothesized that an in 
utero infection, such as chorioamnionitits, may promote lung maturation 
through induction of natural corticosteroids, but limit the lung for future full 
development (Watterberg et al. 1996).
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Figure 1.4. Comparison of lung biopsy between neonatal lungs with old (A) 
and new (B) CLD. (A) Lung biopsy from a 26 week old neonate who did not 
receive antenatal surfactant. The (*) denotes an area of dilated alveoli. (B) 
Lung biopsy from a 28 week gestation infant who received prenatal steroids 
and postnatal steroids. AD denotes alveolar ducts with alveolar structure 
(arrow). (Coalson, 2003).
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1.2.3 Animal models of CLD
Animal models have significantly aided understanding the pathogenesis of 
CLD. Although not a direct representation of lung development and injury as 
seen in humans, models have allowed a mechanistic approach to elucidating 
contributing factors to the disease. To date there is no single animal model 
which mimics all risk factors contributing to CLD, but the ability to induce lung 
inflammation in offspring following experimental preterm birth, even through 
induced chorioamionitis, have been created (Coalson, 2006). Baboon models 
have been developed to represent the old CLD model by delivering young 
baboons at 140 days gestation (76% of normal gestation) representing 
samples from the saccular to alveolar stages of development. Further 
similarities to old style CLD were made by administration hyperoxic conditions 
via 100% oxygen while not administering antenatal surfactant (Coalson, 
2006). The results from these studies demonstrated, as in the human form of 
CLD, levels of inflammatory cytokines were up-regulated in result of hyperoxic 
conditions. A lamb model developed by Bland and colleagues used lambs 
delivered at 124 + 3 days to represent extremely premature human infants at 
24 to 26 weeks who were in the saccular stage of development (Bland et al. 
2000). Lambs were intubated for 3 to 4 weeks with results which combined 
pathology of both old and new CLD with muscle hyperplasia and large- 
simplified alveoli, respectively.
1.2.4 Association between Ureaplasma and CLD
During the late 1980s a number of independent studies found a significant link 
between neonates colonized with the Ureaplasma and the development of
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CLD (Cassell et al. 1988; Sanchez and Regan 1988; Wang et al. 1988). The 
studies by Sanchez and Regan as well as Wang et al., concluded that oxygen 
toxicity and other ventilation related traumas alone could not account for CLD, 
thus Ureaplasma had a definite role in CLD development. An additional 
finding by Cassell et al. showed infants weighing <1,000 g had a two-fold 
increase of mortality, when colonisation of Ureaplasma was identified. The 
results from these studies provided crucial information that VLBW infants 
were a high risk group for colonization by Ureaplasma and developing CLD. 
Additional supporting information came from Payne and colleagues in 1993 
who examined nasopharyngeal aspirates (NPA) from infants born <1,251 g 
(Payne et al. 1993). Results showed that neonates with evidence of 
Ureaplasma colonisation had an increased (1.66-fold) relative risk for 
developing CLD compared to non-colonised neonates. This study provided 
useful information regarding the mode of vertical transmission of Ureaplasma 
from the mother to child. Infants born vaginally had a 4.5-fold increased 
chance of colonization relative to those born by caesarean section. This was 
likely due to contraction of bacteria during passage of the neonate through the 
birth canal. Payne et al. also commented on the sensitivity of sample type for 
detection of Ureaplasma. Positive samples from NPA correlated poorly with 
ETA and that site of specimen effected rates of colonization. They 
determined that ET samples were the best for examining colonization of lower 
respiratory tract.
Abele-Horn et al. in 1997 found in a study of 253 pregnant women (170 
Ureaplasma-positive, 83 Ureaplasma negative) that the risk of developing
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CLD was 17% vs. 4% in infants <1,500 g, respectively (Abele-Horn et al. 
1997b). The study also showed that there was a significant relationship 
between Ureaplasma colonization and premature rupture of membrane (12% 
vs. 35%; p < 0.001), preterm birth (10% vs. 41%; p < 0.001) as well as 
chorioamnionitis (0% vs. 10%; p < 0.05).
It has been argued that determining the role of Ureaplasma in development of 
CLD has been hampered by studies containing low numbers of neonates. For 
this reason a number of meta-analyses have been performed to collate the 
data from the numerous studies and examine the association of Ureaplasma 
and CLD. In 1995, Wang demonstrated an overall relative risk of 1.72 for 
collective investigations for likelihood of colonized patients developing CLD 
(Wang et al. 1995). A second meta-analysis examined the data from 23 
studies consisting of 2216 infants defined as having CLD at 28 post natal 
days and 751 infants defined as having CLD at 36 weeks post-menstrual age. 
There was a significant association between Ureaplasma and CLD in both 
defining criteria (Schelonka et al. 2005).
1.2.5 Inflammatory potential of Ureaplasma and relationship to 
cytokines and CLD
The link between inflammatory markers and development of CLD was 
demonstrated by Yoon et al. who examined the correlation between CLD and 
amniotic cytokine levels in a study of 69 neonates (Yoon et al. 1997). Those 
who were born from mothers with high median amniotic fluid levels of IL-6, 
TNF-a, IL-1 p and IL-8 were significantly more likely to develop CLD than
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those who did not. With evidence such as this, researchers have looked at 
the inflammatory potential of Ureaplasma. The ability of Ureaplasma to 
induce an inflammatory response has been proven through a number of 
clinical, cell line and animal model studies which have been related back to 
development of CLD. Baier et al. found that Ureaplasma could stimulate 
other inflammatory mediators such as MCP-1 and IL-8 which were 
significantly elevated in CLD patients, and the levels of these cytokines were 
significantly increased in ETA were from Ureaplasma positive patients, 
relative to those who were negative (Baier et al. 2001). A further study by 
Kotecha et al., examined a greater range of inflammatory markers, as well as 
levels of pulmonary neutrophils and alveolar macrophages. Levels of IL- 
1beta, IL-6, IL-8, soluble intercellular adhesion molecule-1 (ICAM), pulmonary 
neutrophils and alveolar macrophages were all significantly increased in 
Ureaplasma positive patients (Kotecha et al. 2004). These results of 
increased leukocyte counts were similar to those found by Viscardi et al., who 
looked at autopsy sections from infants who had died resulting from both 
Ureaplasma induced and non-l/reap/asma induced pneumonia. Absolute 
neutrophil counts were 3-fold higher in Ureaplasma induced pneumonia than 
in pneumonia caused by other pathogens, but there was also a predominance 
of alveolar macrophages relative to neutrophils in i/reap/asma-infected 
patients (Viscardi et al. 2002). This predominance of macrophages may be 
partially due to the ability of Ureaplasma to stimulate MCP-1 release.
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1.2.6 Inflammatory response to Ureaplasma in cell line studies
In vitro analysis of relevant cell lines under defined conditions mimicking 
Ureaplasma colonisation have also provided useful information. Although not 
a full biological system, these systems have been successfully used to 
examine inflammatory regulators in response to Ureaplasma infection, 
dissecting the potential contribution of each to in vivo development of CLD in 
the presence of Ureaplasma. Stancombe et al. showed that Ureaplasma can 
cause significant production of IL-6 and IL-8 from pulmonary fibroblast in vitro, 
which supports the findings of previous clinical studies (Stancombe et al. 
1993). As well as fibroblasts, in vitro culture data has shown that macrophage 
cell lines, rat alveolar macrophage and macrophage from ETA all respond in 
similar ways to Ureaplasma. Levels of TNF-alpha and IL-6 have been 
reported to increase from 14 to 84% and 46 to 268%, respectively, as a result 
of Ureaplasma antigen (Li et al. 2000).
1.2.7 Animal models of Ureaplasma infection and CLD
A range of animal models for Ureaplasma infection have been developed in 
varying host species under differing experimental disease states. Early work 
by Furr and Taylor-Robinson found it was only possible to establish 
experimental vaginal Ureaplasma colonisation in mice with human isolates 
when mice had been pre-treated with oestradiol (Furr and Taylor-Robinson, 
1989). This work was later expanded to examine variation in colonisation 
between Ureaplasma serovars 5, 8 and 10 (Taylor-Robinson and Furr, 2002). 
Data showed that BALB/c mice again had to be treated with oestradiol for 
initial colonization to occur with any of these serovars. Serovar 8 yielded the
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highest rate of colonization (100% colonization) and longest period of 
colonization at 84 days, with 6 mice (60%) still colonized at 158 days. Two 
out of the 10 mice experienced spread from the vagina to the right ovary in 
one case and the liver and kidney in another. Colonisation was less 
persistent in strains 5 and 10, with 4/10 and 7/10 mice colonised, respectively.
Mouse models of pneumonia have also been developed to understand the 
role of host response to Ureaplasma, as well as providing supporting 
evidence for the organism’s role in development of lung disease. Viscardi et 
al., described three distinct stages of Ureaplasma infection in the lung, firstly 
acute inflammation in days 1-2, followed by resolution of acute inflammation 
at days 3-7 and finally chronic lung inflammation and lung injury in days 14-28 
(Viscardi et al. 2002). A major histopathological finding was the loss of 
ciliated respiratory epithelium. It was hypothesized that the loss of cilia was a 
result of Ureaplasma adhesion followed by release of toxic compounds from 
the organism such as ammonia, hydrogen peroxide or hemolysins which may 
result in predisposition to secondary bacterial infections. An earlier study 
looked at the effects of both Ureaplasma pneumonia in newborn mice and the 
effects of hyperoxia: 80% oxygen was applied to new born mice which had 
been inoculated with serovar 10. Results suggested that high levels of 
oxygen resulted in persistence of Ureaplasma, as well as increasing the 
inflammatory response (Crouse et al. 1990).
A series of baboon models of Ureaplasma infection have also been 
developed. In 1993, Walsh et al. (Walsh et al. 1993) described a primate
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model of Ureaplasma infection in premature infants. Three premature 
baboons delivered at 138-141 days (term 180), which represent human 
characteristics of delivery at 30-32 weeks, were exposed to Ureaplasma and 
maintained at 100% oxygen throughout the study. Two of the infected 
animals developed pathological findings of acute bronchitis which was absent 
in animals of the control group. A second baboon model of Ureaplasma 
infection examined the effects of Ureaplasma upon lung pathology following 
intra-uterine infection. Infant baboons in the exposed group showed 
persistent levels of IL-6 and IL-8 in ETA samples and reduced lung function 
relative to controls (Yoder et al. 2003). A more recent baboon model of 
Ureaplasma lung infection proved that infection resulted in increased IL-1- 
beta, extensive fibrosis and higher concentrations of TGFbetal (Viscardi etal. 
2006).
1.2.8. Infection and development of CLD
Although Ureaplasma have been the primary organism associated with the 
development of CLD some investigators have looked at the role of other 
bacterial species. Lahra et al., examined a cohort of nearly 800 preterm 
infants over a twelve year period and found that neonatal sepsis was strongly 
associated with CLD (Lahra et al. 2009). Miralles et al., utilized molecular 
methods for identifying the presence of bacteria using PCR primers specific 
for the highly conserved region of the bacterial 16S rRNA gene. By 
examining extracted DNA from BAL samples from 41 preterm infants, they to 
demonstrated a link between infection and CLD (Miralles et al. 2005).
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1.3 The complement system
1.3.1 Function of the complement system
The complement system is a major first line defence against invading 
pathogens. Composed of more than 30 soluble and surface associated 
proteins, the complement system additionally functions to clear apoptotic cells 
as well as bridging the gap between the innate and adaptive immune systems 
(Walport, 2001). Three pathways exist to activate the complement cascade in 
response to differing initiators, but converge at the hydolysis of central C3 
component by their respective pathway C3 convertases. From the central C3 
conversion, all pathways elicit killing of pathogens either through the formation 
of the terminal membrane attack complex (MAC), resulting in cell lysis, or 
through phagocytosis of complement opsonised cells. These pathways are 
represented in Figure 1.5.
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Figure 1.5. An overview of the three activation pathways of the complement 
system. The complement system can be activated by three independent 
activation pathways. The classical pathway is activated by an 
antigen/antibody complex; the lectin pathways is activated by pattern 
recognition molecules such as mannose binding lectin, binding to pathogen 
specific carbohydrates; the alternative pathway is activated by the 
spontaneous hydrolysis of C3. All pathways converge at the conversion of C3 
in to C3a and C3b. The cascade continues in the final formation of the 
membrane attack complex leading to cell lysis. The complement systems is 
tightly regulated by a number of regulators (blue lettering)
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1.3.2 The classical pathway
The first pathway to be discovered was the classical complement pathway 
(CP). It was found to be a heat-labile component of serum which acted to 
“complement” the antibody killing of bacteria. Initiation of the pathway begins 
when the primary component of the pathway, C1q, and its additional bound 
tetramer of two C1r and two C1s molecules, bind to cell associated IgG or 
IgM. This binding causes the auto-activation of C1r which in turn activates the 
serine protease C1s causing cleavage of C4 into the fragments C4b, which 
covalently binds to the activator cell, and C4a which is released where it 
exhibits pro-inflammatory effects. C2 binds to the cell bound C4b, which also 
becomes cleaved by C1s to produce the split products C2a and C2b. C2b is 
released, whereas C2a remains bound to C4b complex to form (C2aC4b) the 
C3 convertase of the classical pathway. C4b has no enzymatic role in the C3 
convertase but acts as an anchor for C2b where the enzymatic activity lies.
1.3.3 The lectin pathway
The lectin pathway (LP) is the most recently discovered of the complement 
pathways and varies when compared to the CP by being independent of 
antibody binding (Turner, 2003). Activation results from pattern recognition 
molecules (PRM) such as mannose binding lectin (MBL) or ficolins binding to 
pathogen-associated molecular patterns (PAMP) found only on "foreign” cells. 
These include simple and complex carbohydrates with 3- and 4-OH groups 
across the equatorial plane of the sugar (Weis et al. 1992). Like the C1q,r,s 
complex, MBL exists in complex with serine proteases known as MBL-
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associated serine proteases (MASP) MASP-1, MASP-2, MASP-3 and Map19. 
Structurally and functionally similar to C1r and C1s, MASP-2 acts like C1r in 
that it auto-activates upon MBL binding to a surface, but functions like C1s in 
that it cleaves C4 and C2 into their respective split products. MASP-1 does 
not activate C4, but direct cleavage of C3 has been suggested (Matsushita 
and Fujita, 1995).
1.3.4 The alternative pathway
The alternative pathway, unlike the CP and LP, is activated by spontaneous 
hydrolysis of C3 and subsequent deposition of cleaved C3 to cells. An 
additional difference is the nomenclature used with components of the AP 
commonly referred to as factors. Deposited C3b is bound by factor B, a 
homologue protein to C2, which is then cleaved by factor D to give C3bBb or 
the alternative pathway C3 convertase. This complex is stabilised by 
properdin (also known as factor P). The absence of polyanionic structures, 
such as sialic acid, on microbial cells results in a failure to recruit the powerful 
complement regulator factor H and the C3 convertase amplifies unregulated 
resulting in substantial deposition of C3b and membrane attack complex 
formation. Failure to recruit complement regulators is one of the important 
mechanisms for innate immune discrimination between self and foreign 
invading microbes.
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1.3.5 Terminal complement pathway and formation of the 
membrane attack complex (MAC)
Cleaved C3 then binds to either C3b or C4b of the AP or CP/LP C3 
convertases, respectively, acting as a receptor of for C5 in the newly formed 
C5 convertase complex (i.e. C3bBb3b or C4b2a3b), that activates C5 through 
cleavage to C5a and C5b. This is the first step of the terminal lytic pathway 
and the last point of which cleavage is required for complement component 
recruitment. The end result being the formation of the membrane attack 
complex (MAC) which constitutes the lytic component of the complement 
pathway. Non covalent sequential addition of C6, C7, C8 molecules to the 
C5b molecule, results in increasing hydrophobicity of the complex, driving it 
further into the activating membrane, then up to 12 C9 molecules generate a 
amphipathic pore that disrupts the osmotic balance. There is some 
suggestion that C5b678 is sufficiently “leaky” to cause lysis in sufficient 
numbers.
1.3.6 Regulators of complement activation (RCA)
Due to the potential destructive capabilities of the complement system 
measures are needed to prevent damage upon host cells. Regulators of 
complement activation (RCA) are a series of either bound or circulating 
proteins which keep the complement system in order at numerous check 
points of the cascade and aid in differentiating self from non-self cells. Using 
factor H (fH) as an example of an RCA, it functions by regulating the AP in 
two ways. Firstly it acts as a cofactor for factor I cleavage of C3b to produce 
inactive iC3b, disabling the ability to form a functional C3 convertase.
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Secondly it accelerates the dissociation of Bb from C3b limiting the amount of 
further C3b produced. Auto-immune diseases such as atypical haemolytic 
uremic syndrome (aHUS) result from genetic abnormalities in genes encoding 
these regulators, such as fH, leading to reduced or failed regulation of 
complement activation at the filtering surface of the kidneys (Atkinson and 
Goodship, 2007).
1.3.7 The complement system of neonates
As newborn infants do not have previous exposure to immunogens and their 
adaptive immune system is sluggish and under-developed, their innate 
immunity plays a large role in the defence against infection. The complement 
system in neonates is also immature relative to adults; therefore, may 
predispose to infection (with increasing immaturity and infection predisposition 
being inversely proportional to gestational age). Drossou et al., 1995 looked 
at levels of opsonins IgG, IgG subclasses, IgM, C3 and C4 in neonates of 
three groups of neonates 26-30 weeks, 31-37 weeks and 37-39 weeks 
(Drossou et al. 1995). They found that the levels of opsonin were dependent 
on the infants postnatal age as well as gestational age. The levels of 
opsonins were half to two thirds that of healthy adults, but levels reached that 
of adults by third or sixth month of life.
Studies examining amounts of C2 and C4 in preterm infants found levels of 
62-85% and 42-73% of adult values (Sonntag et al. 1998; Miyano et al. 
1996; Drew and Arroyave, 1980; Wolach et al. 1994), but with levels 
increasing to the adult range by 1-6 months of age. Factor B and properdin of
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the AP are also reduced in neonates at 27-64% and 13-72%, respectively 
(Wolach et al. 1997; Drew and Arroyave, 1980). It is only C7 of the terminal 
pathway which does not seem to be dramatically deficient in either term or 
preterm infants with ranges between 95 -  120% and 73 -  75% (Wolach et al. 
1997; Johnson et al. 1983). It seems that although levels of complement 
components are deficient there is no effect upon the ability on activation. 
Hogasen et al. demonstrated that in preterm infants who were born from 
mothers with PPROM activation products C3bBbP and SC5b-9 were 1.5 and 
2 times greater than that of healthy term infants (Hogasen et al. 2000).
As there is no gestational age effect of upon complement activation, 
appropriate levels of free and bound complement regulators are crucial. 
Consistent ranges of C4-binding protein (C4BP) have been found in term 
neonates at 18-28% (Malm et al. 1988; Sthoeger et al. 1989) whereas 
ranges from 61-75% of factor H have been found in term infants (Davis et al. 
1979; Johnson et al. 1983). These reduced levels of regulators in the 
presence of unaffected activation can potentially give rise to damage to self.
1.3.8 Complement and its role in Ureapiasma infection
A limited body of literature is available on the role of complement in the 
clearance of Ureapiasma infections. As discussed in section 1.1.4.5, an 
antibody response is raised in patients infected with Ureapiasma suggesting a 
role in clearance of infection (Brown et al. 1983). A single study by Benstein 
et al., examined the ability of MBL to bind the surface of Ureapiasma 
(Benstein et al. 2004). They demonstrated binding of human MBL to
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Ureapiasma, but did not provide any data regarding a functional role. To 
date, no report has commented on the role of the alternative pathway in 
clearance of Ureapiasma. A single report suggested the ability of C1q to bind 
directly to Ureapiasma as evidenced by the increased rate of C1r and C1s 
activation relative to spontaneous cleavage in the absence of Ureapiasma. 
Additional findings from this study suggested an inability of complement alone 
to result in killing, but these results utilised non-standardised methods and the 
methodology and results were not as conclusive as the conclusions that were 
drawn.
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1.4 Antimicrobial therapy against Ureapiasma
1.4.1. Intrinsic antibiotic resistance in Ureapiasma and 
therapeutic considerations
A number of physiological factors of Ureapiasma provide intrinsic resistance 
to a number of clinically available antibiotics, which include cell wall inhibitors 
such as the (3-lactams and glycopeptides due to the lack of a cell wall, RNA 
polymerase targeting rifampins due to mutation in the beta-subunit of RNA 
polymerase (Gaurivaud et al. 1996), folic acid synthesizing sulphonamides 
and trimethoprim, as well as a the protein synthesis inhibiting lincosamides 
(Waites et al. 2005). Aminoglycoside antibiotics, which are routinely used to 
treat Gram-negative sepsis in neonates, have unreliable activity against 
Ureapiasma. Cassell et al., commented on the ability to isolate Ureapiasma 
from CSF, blood culture and LRT in neonates following greater than three 
days of treatment with gentamicin (Cassell et al. 1993). A further protein 
synthesis targeting antibiotic, like the aminoglycosides, is chloramphenicol. 
Chloramphenicol generally has good activity against Ureapiasma as seen in a 
number of clinical case-studies (Geissdorfer et al. 2008; Hentschel et al. 
1993) as well as in vitro data on susceptibility test (Matlow et al. 1998; Waites 
1992), but the drug is not routinely used in treatment and is reserved for 
cases of antibiotic resistant strains. For these reasons stated above therapy 
is restricted to a small number of agents including the tetracyclines, 
macrolides and fluoroquinolones. Further complications for therapy arise in 
neonates who are colonized with Ureapiasma. Tetracycline use in neonates 
is restricted due to effects of bone toxicity and deposition within calcifying 
tissue, but has been reported in a limited number of CSF infections (Rao et al.
50
Chapter 1 - Introduction
2002; Waites et al. 1993). As quinolone usage in neonates is additionally 
restricted due to effects of cartilage development, the macrolides are the 
preferred drug of choice
1.4.2. The macrolides
1.4.2.1 Macrolide structure and mode of action
The macrolide family of antibiotics are of great clinical significance in many 
patients groups, including paediatrics, but their use is becoming compromised 
due to increasing numbers of antibiotic resistant organisms (Jacobs and 
Johnson, 2003). Erythromycin, the first clinically available macrolide, as well 
as clariythromycin are composed of a 14 membered lactone rings where as 
the newer azithromycin is composed of a 15 membered ring (Figure 1.6). In 
addition to being antibacterial, they also exhibit anti-inflammatory properties 
which have been utlized in managing conditions such as cystic fibrosis and 
asthma, which could be potentially used in the management of CLD (Jaffe 
and Bush, 2001).
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Figure 1.6. Structures of the macrolide antibiotics used in the study. A 
Erythromycin, B Clarithromycin, C Azithromycin.
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Macrolides inhibit protein synthesis by binding within the exit tunnel of the 50s 
ribosomal subunit, therefore preventing elongation of the peptide chain 
(Vester and Douthwaite, 2001). Macrolide binding to the ribosome has been 
mapped to the 50s ribosomal subunit, but more specifically to the 23S 
ribosomal RNA (rRNA). Binding results primarily from hydrogen bonds 
forming between the C5 sugars of the drug and the specific nucleotides 
A2058 and A2059 within domain V of the peptidyl loop.
1.4.2.2 Mechanism of macrolide resistance in Ureapiasma spp.
Macrolide resistance can result from either target site modification, which can 
be mutational or post-transcriptional or by active efflux. A trend is clear 
between the number of ribosomal operons within the bacterial genome and 
methods by which bacteria exhibit macrolide resistance (Vester and 
Douthwaite, 2001). Bacteria with 1 to 3 ribosomal operons such as the 
Mycoplasma pneumoniae, Helicobacter pylori and Propionibacterium acnes 
confer resistance via mutations within domain V of their 23S rRNA (Figure 
1.7), whereas bacteria with 4 to 9 operons such as Neisseria gonorrhoeae 
and Clostridium perfringens mediate resistance via methylation and/or efflux 
pumps (Table 1.1).
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Figure 1.7. An indication of the predominant nucleotide at which mutations can 
give rise to macrolide resistance. Mutations in domain V of the pepdityl-transferase 
loop of the 23S rRNA can give macrolide resistance with mutation at position 2058 
yielding high levels of resistance. Image adapted from Pereyre et al. (Pereyre et 
al. 2006).
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Organism Mechanism No. of rRNA operons
Mycoplasma pneumoniae 23S RNA mutation 1
Mycobacterium avium 23S RNA mutation 1
Mycobacterium intracellulare 23S RNA mutation 1
Helicobacter pylori 23S RNA mutation 2
Treponema pallidum 23S RNA mutation 2
Propionibacterium acnes 23S RNA mutation 3
Streptococcus pneumoniae 23S RNA mutation 4
Neisseria gonorrhoeae Methylation & efflux 4
Staphylococcus aureus Methylation 6
Clostridium perfringens Methylation 9
Table 1.1. Macrolide resistance mechanisms found in pathogens and their 
respective numbers of rRNA operons. Adapted from Vester and Douthwaite 
paper (Vester and Douthwaite, 2001).
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Additional mutations in the apparatus of the ribosome, such as ribosomal 
proteins L4 and L22, have been linked to reduced susceptibility to macrolides. 
It is believed that mutations within these proteins can alter protein-RNA 
interactions thus giving resistance (Gregory and Dahlberg, 1999).
The first mechanistic description of macrolide resistance in Ureapiasma was 
presented by Palu et al. (Palu et al. 1989). Investigators described that a 
highly resistant strain also had a dramatically reduced ribosomal binding of 
radiolabelled erythromycin. With this evidence, as well as the association 
between rRNA operons and methods of resistance, the most likely 
mechanism would be via selection of point mutations in the 23S rRNA. A 
series of macrolide resistant U. parvum strains were produced in vitro by 
serial passage of a sensitive Ureapiasma strain in increasing sub-inhibitory 
concentrations of antibiotic. Resistance to various macrolides resulted from 
point mutation of A2058 with or without mutation of additional adjacent bases, 
occasionally combined with additional mutations within the ribosomal 
accessory proteins L4 and L22 (Pereyre et al. 2007). Prior to the work 
presented in this thesis, the mechanism of macrolide resistance had yet to be 
demonstrated in any clinical isolate.
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Data from the genome of U. parvum serovar 3 has shown two multi-drug and 
toxin extrusion (MATE) exporters as well as an array of ATP-binding cassette 
(ABC) transporters (Glass et al. 2000). Inhibition of an ABC transporter in 
Mycoplasma hominis can increase intracellular erythromycin concentrations 
greater than two-fold, although the organism is intrinsically resistant due to 
established mutations within its 23S rRNA (Pereyre et al. 2002). The efflux 
systems encoded within the genome of Ureapiasma may also play a role in 
any erythromycin resistant strains.
1.4.3. The tetracyclines
1.4.3.1 Tetracycline structure and mode of action
The tetracylines are a second family of antibiotics which function to inhibit 
bacterial protein synthesis (Figure 1.8). Many of the tetracyclines in clinical 
use today, such as doxycycline, are synthetic derivatives of chlorotetracycline 
which was originally isolated in 1948 from Streptomyces aureofaciens. They 
act bacteriostatically by binding to the 30S ribosomal subunit and prevent the 
attachment of charged tRNAs to the A site. They have a broad spectrum of 
activity against most Gram-positive and Gram-negative bacteria and due to 
their ability to enter eukaryotic cells, tetracyclines are active against 
intracellular pathogens such as Chlamydia trachomatis and Rickettsia 
rickettsii.
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Figure 1.8. Chemical structures of (A) tetracycline and (B) doxycycline.
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1.4.3.2 Mechanisms of tetracycline resistance in Ureapiasma spp.
One means by which bacteria mediate tetracycline resistance is due to the 
acquisition of a tetracycline resistance gene such as tetM or tetO, which have 
been found in both Gram-positive and Gram-negative bacteria, or tetA -  te tf 
which are confined to Gram-negative (Blanchard et al. 1992). Tetracycline 
resistance in Ureapiasma was first documented in 1974 by Ford and Smith 
from a patient with NGU (Ford and Smith, 1974). In 1986, Roberts and Kenny 
determined that resistance to tetracycline was mediated via the presence of 
tetM gene (Roberts and Kenny, 1986a). To date, only tetM has been isolated 
from Ureapiasma spp. and has been shown to be present upon the Tn 1545- 
like transposon (de Barbeyrac et al. 1996). It has been hypothesized that 
transposition of the tetM gene from a Streptococci to Ureapiasma may have 
been the original source of the tetracycline resistance determinant (Roberts 
and Kenny, 1986a).
An early report suggested that tetracycline resistance was present in 10% of 
Ureapiasma isolates from men with NGU (Evans and Taylor-Robinson, 1978) 
which was later confirmed in 1986 when 10% resistance was again found in 
Ureapiasma isolated between 1973 and 1983 (Taylor-Robinson and Furr, 
1986). Interestingly, it was noted that 39% of the tetracycline resistant strains 
also showed resistance to erythromycin, whereas only 9% of the tetracycline 
sensitive strains were erythromycin resistant. Roberts and Kenny determined 
that the incidence of tetracycline resistance was 20% in 63 isolates, all of 
which contained the tetM gene (Roberts and Kenny, 1986b).
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1.4.4. The fluoroquinolones
1.4.4.1 Fluoroquinolone structure and mode of action
The quinolones are a family of bacteriocidal antibiotics which disrupt DNA 
replication by binding to enzyme-DNA complexes during replication leading to 
the death of the cell. The quinolones have under gone numerous structural 
re-engineering to both broaden their spectrum of activity and increase their 
potency against resistant isolates. The basic structure of all quinolones is 
orientated around the 4-quinolone centre with modifications leading to the 
recognised classification into four groups (Figure 1.9). The first group 
consisted predominantly of nalidixic acid which had a limited antimicrobial 
activity against Gram-negative organisms such as E. coli. The addition of 
fluorine at C-6 greatly expanded the spectrum of activity to include P. 
aeruginosa giving the first of the fluoroquinolones, ciprofloxacin. Levofloxacin 
is another example of a second (and sometimes argued third) generation 
fluoroquinolone. This drug has an extended spectrum of activity against 
Gram-positives with excellent activity against Ureapiasma both in vitro 
(Bebear et al. 2000; Waites et al. 2003) as well as in vivo (Eilers et al. 2007) 
with only a limit number of resistant strains identified (Duffy et al. 2006). 
Further modifications to the structural core lead to the generation of groups 3 
and 4 which had greater Gram-positive properties as well as some anaerobic 
activity. Moxifloxacin is an example of a group 4 fluoroquinolone in which 
chemical modification, the addition of a methoxy moiety at C-8, has been 
used to overcome cross-resistance.
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Figure 1.9. Chemical structure of a group 1 quinolone, naladixic acid (A), and 
a group 2 ciprofloxacin (B). The addition of fluorine at C-6 as seen in 
ciprofloxacin greatly enhanced the drugs spectrum of activity and improved its 
pharamacokinetic properties by increasing the half life of nalidixic acid from 
around 1.5 hours to 3-4 hours in ciprofloxacin.
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Quinolones act by binding to the type II topoisomerase enzymes of bacteria, 
namely DNA gyrase and topoisomerase IV. DNA gyrase is composed of four 
structural subunits; two encoded by the gyrA gene and two from the gyrB 
gene. Topoisomerase IV is structurally homologues to DNA gyrase with two 
subunits encoded by the parC gene and two from the parE gene, respectively. 
It is hypothesised that the negatively charged DNA binds to the enzymes 
along a positively charged stretch within the alpha helix near the tyrosine 
active site involved in DNA cleavage. Although the enzymes are structurally 
similar they have marginal differences in activity. DNA gyrase predominantly 
functions to introduce positive supercoils in DNA ahead of the progressing 
replication fork, whereas topoisomerase IV’s primary role is to de-catenate the 
two circular daughter chromosomes following replication. Additional 
differences are preferential sites of action: the gyrase proteins for Gram- 
negative bacteria and the topoisomerase IV proteins for Gram-positive 
bacteria (Blanche et al. 1996). This data is supported by quinolone resistant 
mutants as Gram-negative resistant mutants generally contain mutations 
within the gyrA or gyrB genes, whereas resistant Gram-positive organisms 
contain mutations within the parC or parE genes (Gellert et al. 1977; Fournier 
and Hooper, 1998).
1.4.4.2 Mechanisms of fluoroquinolone resistance in Ureapiasma 
spp.
Prior to this thesis, a total of 32 clinical isolates of fluoroquinolone-resistant 
Ureapiasma had been described from five individual reports. Substitutions of 
Ser83Leu in the ParC protein, or a triple substitution of Asp112Glu in GyrA
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protein along with Ala125Thr and Ala136Thr in ParC protein, all within the 
quinolone resistance determining regions (QRDRs), being most commonly 
noted (Bebear et al. 2000; Bebear et al. 2003; Geissdorfer et al. 2008; Xie 
and Zhang, 2006; Zhang et al. 2002).
1.4.5 Sensitivity testing of Ureapiasma
The inability of the Ureaplasmas to grow as a lawn upon solid media prevents 
the use of conventional disk diffusion techniques by which antibiotic 
impregnated disks are placed upon confluent lawn and zones of inhibition are 
recorded. Although Ureapiasma do not grow to a visible turbidity in liquid 
culture, the use of a pH indicator within culture media, gives a visible and 
qualitative result of Ureapiasma growth (Purcell et al, 1966). This property 
has been adapted for use in the microbroth dilution technique whereby 
organisms are grown in a series of broth cultures which contain doubling 
dilutions of antibiotics in the range of around 64 pg/ml through to 0.025 pg/ml.
In 1993 Kenny and Cartwright demonstrated three variables which 
significantly alter the MIC of erythromycin result of a single Ureapiasma 
isolate (Kenny and Cartwright, 1993). The most dramatic variable was pH. It 
is common knowledge that pH of test media can dramatically affect the 
efficacy of erythromycin, which is not limited to studies on Ureapiasma. The 
MIC for ATCC 29213 S. aureus was 64-fold different between culture at pH 6 
and 7.4 (Waites et al. 1992). Kenny and Cartwright described that MICs 
were 4- to 16-fold higher at the more acidic pH of 6 than at a neutral 7 with
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MICs of 8 pg/ml when the media was pH 6 dropping to as low as 0.25pg/ml at 
pH 7.
When using the microbroth technique for sensitivity testing of other 
organisms, the McFarland standards have been used as an approximate 
reference for number of bacteria in an inoculum, which are based on 
densitometric measurement of culture turbidity. As Ureapiasma do not grow 
to a visible turbidity, and the degree of colour change is not indicative of cell 
numbers, it is difficult to adjust inoculum size without prior knowledge of cell 
numbers. Kenny and Cartwright found that as the inoculum size increased so 
did the MIC. When testing serovar 8, they observed up to an 8-fold increase 
in MIC from an inoculum size of 45 CCU50 to 4500 CCU50. This result was 
likely due to overwhelming of the antibiotic by numbers of cells. A result of 
this observation, many groups set up 10-fold serial dilutions to titre the 
inoculum size and agree that the result is only valid if the input inoculums was 
between 104 to 105 CCU (Matlow et al. 1998; Waites et al. 1992).
The final parameter that was observed was incubation time. MICs increased 
4 to 16 fold from 2 to 5 days post inoculation irrespective of media pH and 
inoculum size. Recommendations that were proposed at the conclusion of 
the study were, several inoculum sizes should be used in each sensitivity test, 
the media should be of a standard pH and incubation time should be 48hrs.
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1.4.6 Antibiotic resistant Ureapiasma in neonatal samples
A limited number of reports have been made regarding the trends in 
resistance among Ureapiasma isolates from neonates, but due to the lack of a 
standardised methodology, results are difficult to compare. The methodology 
described by Waites et al. has formed the basis for many later studies (Waites 
et al. 1992). Using this methodology the in vitro activity of six antibiotics 
including erythromycin and doxycycline, were screened against 43 
Ureapiasma isolates from neonates. In vitro resistance was seen in 1 or more 
isolates to each antibiotic except erythromycin. Although resistance to 
erythromycin was not seen, a proportion of isolates were designated to have 
intermediate resistance. A small study of 10 isolates from ETA samples from 
Malaysian neonates with RDS identified one tetracycline resistant isolate, two 
ciprofloxacin resistant isolates, with all ten isolates being susceptible to 
erythromycin. As expected all isolates were resistant to lincomycin and 
sulfamethozazole-trimethoprim (Tay et al. 1997). A third study examined the 
sensitivity of twenty-one Ureapiasma isolates obtained from ETA samples 
from VLBW neonates. Isolates were screened against ciprofloxacin, 
gentamicin, chloramphenicol erythromycin, azithromycin and doxycycline. 
Although the authors did not define if isolates were sensitive or resistant, due 
to the absence of standardised breakpoints, they did show that 
chloramphenicol, doxycycline and azithromycin had the greatest activities in 
vitro (Matlow et al. 1998).
65
Chapter 1 - Introduction
1.5 General hypothesis
Ureapiasma and complement
>  Human serum will kill Ureapiasma by activation of all three complement 
activation pathways
> Serovars vary in susceptibility to complement-mediated killing
Role of infection in the development of CLD
> Neonates with presence of Ureapiasma in lung samples are more 
predisposed to developing CLD
> Neonates with presence of 16S rRNA in lung samples are more 
predisposed to developing CLD
> Ureapiasma are more prevalent with decreasing gestational age
Antibiotic resistance in Ureapiasma spp.
> Individual clinical isolates of Ureapiasma with resistance to three 
separate classes of antibiotics exist in samples taken from neonates.
> Resistance to macrolides will result from mutations in 23S rRNA
> Resistance to tetracycline will result from presence of the tetM gene
> Resistance to fluoroquinolone will result from mutations within the 
QRDRs of the type II topoisomerase proteins
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1.6 Aims
Ureapiasma and complement
❖ To develop an assay for determining the predominant complement 
activation pathway involved in killing of U. parvum
❖ Determine if any variation in susceptibility occurs between different 
serovars of U. parvum
Role of infection in the development of CLD
❖ Determine the best way to detect Ureapiasma in samples from 
neonates
❖ Address the role of Ureapiasma in the development of CLD
❖ Address the role of general bacterial infection in the development of 
CLD
Antibiotic resistance in Ureapiasma spp.
♦> To develop a method of detecting antibiotic resistance without prior 
measurement of input bacterial numbers
❖ To determine the rate of antibiotic resistance in a retrospective cohort 
of neonatal patient samples
❖ Identify the molecular mechanisms behind identified resistant 
phenotypes to macrolide, tetracycline and quinolone antibiotics
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2.1 Culturing Ureapiasma spp.
2.1.1 Ureapiasma selective culture medium and culture 
conditions
Ureapiasma selective medium (USM) was purchased from Mycoplasma 
Experience Ltd. (Surrey, UK). USM consisted of a simple broth base medium 
supplemented with yeast extract, 1 g/L urea, and 10% heat-inactivated 
porcine serum, with phenol red as the pH indicator (starting pH, 6.65) and with
2.5 pg/ml amphotericin B and 0.25 mg/ml ampicillin. Cultures were either 
performed in flat-bottom or “V”-bottomed 96-well plates, where indicated, 
covered with adhesive sealing tape (Elkay, Basingstoke) or in 7 ml bijoux 
containers (Elkay, Basingstoke) and incubated in a humidified tissue culture 
incubator set at ambient C 02 concentration at 37 °C.
2.1.2 Ureapiasma isolates
The prefix UHW represented samples obtained from the University Hospital of 
Wales whereas the prefix HPA represented those kindly donated by Dr 
Victoria Chalker from the Health Protection Agency, Colindale. Type strains 
of known serovar were also obtained from HPA, although SV1 (DKF-1) and 
SV9 (Vancouver isolate) were originally obtained from the Institute of Medical 
Microbiology, University of Aarhus, Denmark. The main strains used in this 
study are outlined in Table 2.1
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DKF-1 U.p 1
HPA11 U.p 1
HPA18 U.p 1
UHWO10 U.p 1
UHWP2 U.p 1
UHWQ3 U.p 1
HPA1 U.p 3
HPA5 U.p 3
HPA7 U.p 3
HPA14 U.p 3
HPA29 U.p 3
HPA2 U.p 6
HPA23 U.p 6
HPA10 U.p 14
HPA32 U.p 14
UHWJM U.p N.D
Vancouver U.u SV9
HP A3 U.u N.D
HPA6 U.u N.D
HPA12 U.u N.D
HPA17 U.u N.D
HPA20 U.u N.D
Table 2.1. Overview of the Ureapiasma isolates examined in this thesis. U.p 
indicates U. parvum and U.u indicates U. urealyticum. Spp. indicates the 
species of Ureapiasma and SV the serovar. Serovar of U. parvum was 
determined whereas the serovar of U. urealyticum was not. N.D = not 
determined.
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2.1.3 Culturing of Ureapiasma from clinical samples
Initially 25pl of either gastric fluid (GF), nasopharnaneal aspirate (NPA), 
endotracheal aspirate (ETA) or bronchial alveolar lavage (BAL) was added to 
2 ml of USM within a 7 ml bijoux. Cultures were incubated at 37 °C and 
checked for colour change every 24 hours for 1 week. 200 p of pure positive 
cultures were pelleted by centrifugation at 16 000 xg for 10 min followed by 
removal of all USM supernatant. Pellets were resuspended in 50 pi sterile 
water, heat lysed by incubation at 95 °C for 10 min. 1 pi, as well as 1 pi of a 
1:100 and 1:1000 dilution, were used to confirm the presence of Ureapiasma 
by PCR as described in section 2.4.3.3. Mixed cultures were prepared in the 
same way as pure Ureapiasma cultures but were resuspended in 100 pi 
sterile water. A “false-negative control” was included where samples were 
spiked with 1:1 Ureapiasma DNA to sample DNA to rule out the presence of 
PCR inhibitors.
2.1.4 Quantification
When quoting numbers of Ureapiasma the standard unit stated is colour 
changing units (CCU). To determine the number the number of CCU within a 
sample or culture a series of 1:10 dilutions are made as follows. 180 pi of 
USM was added to a single column (8 wells) of a 96 well plate. 20 pi of 
sample was inoculated into the first well to give an initial 1:10 dilution. From 
this well the process is repeated down the plate to the 7th well give a dilution 
gradient to 10‘7. The final well remained uninoculated to serve as a negative
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control, to rule out false positives. Plates were then incubated for 48 hours at 
which time colour change had ceased. The final well in which colour change 
occurred was denoted as 1 CCU. By knowing the dilution of the well giving 1 
CCU, the number of CCU in the initial sample could be calculated (Figure 
2 .1).
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Figure 2.1. Quantification of Ureaplasma. The number of colour changing 
units (CCU) is calculated by titrating out culture of unknown CCU 1:10 in a 
microtitre plate (A). Cultures are then incubated at 37 oC for 48 hours until 
colour change stops. The final well in which colour change occurs is 
designated as 1 CCU. By working back through the dilution gradient it is 
possible to determine that in the original culture there was 106 CCU.
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2.1.5 Long term storage and thawing of Ureaplasma spp. 
isolates
Ureaplasma positive cultures were sub-cultured 1:100 and 1:1000 into 2 ml 
cultures and incubated overnight. 250 pi aliquots were made into 2 ml 
cryovials (Starlab, Milton Keynes) which were then frozen directly at -80 °C. 
When frozen isolates were required, cryovials were defrosted on ice then sub­
cultured 1:10 into 180 pi USM followed by serially diluted out to 10~5 and 
incubated overnight. The next day, inoculum was prepared by diluting the 
final well which was starting to show colour change by 1:10 into USM to 
provide enough culture of a uniform number of CCU for multiple samples. If 
greater than 180 pi of O/N culture was needed, then the final two wells 
showing colour change were pooled and expanded to an appropriate final 
volume. This method provided an inoculum of about 104-105 CCU
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2.2. Complement studies
2.2.1 Preparation of human serum
Volunteer blood was collected from 9 healthy females (VxF) and 3 healthy 
males (VxM) of unknown Ureaplasma colonisation status into 20 ml glass 
universal bottles. Blood was allowed to clot at room temperature for 1 hour. 
Following incubation, the clot was dislodged from the wall of the bottle and 
incubated for an addition hour on ice to allow the clot to contract further. 
Samples were centrifuged at 1000 xg for 10 min. Supernatant (serum) was 
then dispensed into 1.5 ml tubes and centrifuged again at 16 000 xg for 1 min 
to remove uncoagulated red blood cells. 250 pi aliquots of normal human 
serum (NHS) were made into 0.6 ml tubes which were then stored at -80 °C 
until required. To obtain heat-inactivated serum (HI-NHS), aliquots were 
incubated at 56 °C for 30 min. This process inactivates C2 (required for the 
classical and lectin pathways) and factor B (required for the alternative 
pathway). 50% NHS and 50% HI-HNS were prepared by mixing 1:1 v/v with 
veronal buffered saline (Complement Fixation Buffer; Oxoid, Baisingstoke) 
unless stated otherwise.
2.2.2 Complement killing assay
Ureaplasma cultures were prepared as stated in section 2.1.5. 200 pi of 
culture was added, in duplicate, to the well of a point bottomed 96 well plate 
(Figure 2.2). Plates were sealed and centrifuged at 3600 xg for 10 min 
followed by careful aspiration of the supernatant by angling the plate towards
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the operator and drawing the liquid from the top of the conical ridge so to 
avoid disrupting the pellet. Pellets were resuspended in 200 pi 50% NHS 
diluted in VBS. A 50% serum matched heat inactivated control (50% HI-NHS) 
was run in parallel as a direct comparison for later calculation of killing. Plates 
were incubated at 37 °C for 1 hour then centrifuged as described above. 
Pellets were resuspended in 200 pi USM and transferred to a fresh 96 well flat 
bottom plate where both NHS and HI-NHS exposed Ureaplasma were titrated 
1:10 for 3 dilutions then 1:2 for 8 dilutions giving a dilution gradient to 2.56 x 
10'5. Plates were sealed and incubated for 48 hours until colour change had 
ceased. Degree of killing was determined by calculating the fold decrease in 
CCU from the HI-NHS relative to the NHS. For experiments in which the 
classical and lectin pathways were knocked-out leaving the alternative 
pathway intact, VBS was substituted with alternative pathway buffer (APB) 
(VBS supplemented with 10 mM EGTA & 10 mM Mg2+). EGTA was used in 
the alternative pathway buffer as it specifically chelates Ca2+ from serum 
which the classical pathway (CP) and lectin pathway (LP) are dependent on 
for activation. Only Mg2+ is required for the assembly of the C3bBb complex 
of the alternative pathway (AP), and alternative pathway buffer contains an 
additional 10 mM Mg2+ even though EGTA has a very low affinity for this 
cation.
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Figure 2.2. Schematic diagram of the 96-well plate set up of complement 
killing assay for four Ureaplasma isolates (A - D) under two conditions. (1) 
50% heat inactivated normal human serum (HI-NHS) and (2) 50% normal 
human serum (NHS). Following complement attack Ureaplasma were titrated 
out as set out in the plate above, initially 1:10 dilutions followed by 1:1 
dilutions, to determine the fold reduction of colour changing units between HI- 
NHS and NHS.
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2.2.3 IgG depletion of serum with protein A and protein G- 
sepharose columns
A HiTrap™ Protein A-sepharose column (GE HEALTHCARE, Slough) was 
used to deplete IgG (sub-classes 1, 2 and 4) from three volunteers with low 
killing (including two sero-negative sera) and three with high killing to the four 
representatives of the serovars. Columns were regenerated by passing 10 
volumes of VBS through at a flow rate of 1ml/min using a 10 ml syringe 
(ELKAY, Basingstoke). One ml of serum was loaded onto the column and 
pushed through with 1 ml VBS. Eluted serum was passed through a second 
time to ensure full IgG depletion and was stored at a 50 % concentration in 
VBS. Bound antibody was eluted with 200 mM glycine pH2.5. Columns were 
then stored in 20 % ethanol. For complete depletion of all IgG subclasses 
(lgG1, 2, 3 and 4) a 5ml HiTrap™ Protein G-sepharose column (GE 
HEALTHCARE, Slough) was used. IgG depletion was identical to that 
described above for the Protein A column, but with the modification of adding 
2 ml of human serum, instead of only 1ml, and only passing the contents 
through the column once (this was due to the larger column size of the Protein 
G column (5 ml) verses the Protein A (1 ml)).
2.2.4 MBL depletion and ELISA
Levels of MBL in each of the samples were assayed using the MBL Oligomer 
ELISA Kit (BIOPORTO Diagnostics, Denmark) as per manufacturer’s 
instructions. MBL was depleted from 1 ml NHS by circulating ice cold serum 
through a mannan-agarose column on ice (carried out by Dr Brad Spiller). To
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confirm successful MBL depletion, MBL levels in each serum sample were 
measured using the commercial MBL ELISA kit post-depletion. No samples 
were found to have more than 49 ng/ml MBL (which represents non-functional 
MBL as it would not bind mannan-sepharose).
2.2.5 Adapting Ureaplasma into a pig-serum free system
HPA5 (SV3) was adapted to growing in USM without 10 % pig serum, but 
supplemented with 1 % HI-NHS from either MBL depleted VxF1 or VxF9. 
Ureaplasma cultures grown in USM with pig serum were titrated out to 10'6 in 
USM supplemented with 1% HI-NHS from either MBL depleted VxF1 or VxF9 
and incubated at 37 °C for 24 hours. The final well in which colour change 
occurred was subsequently titrated out in modified USM with HI-MBL depleted 
serum. This process was repeated a total of three times to ensure that no 
residual pig MBL-decorated bacteria would be present.
2.2.6 Sodium Dodecyl Sulphate Polyacrylamide Gel 
Electrophoresis (SDS-PAGE)
5 ml Ureaplasma cultures were centrifuged at 16000 xg for 10 min and the 
resultant pellets washed three times in sterile PBS. Pellets were then 
resuspended in 25 pi PBS and 25 pi LDS buffer (Invitrogen, Paisley). 
Samples were boiled for 2 min and 7 pi sample loaded on to SDS-PAGE gel 
which was set up as follows: Gel casting apparatus was set up as directed by 
manufacturer (BIORAD, Hertfordshire, UK) and resolving gels were made up 
to using the volumes indicated in Table 2.2 and poured leaving 1 . 5 - 2  cm
79
Chapter 2 - Materials and Methods
space. 200 pi of butanol was immediately overlaid to level out the top of the 
resolving gel which was washed off with de-ionised water after the gel had 
polymerised. The stacking gel was prepared as shown in Table 2.2 and 
poured on top of the set resolving gel with the addition of a gel comb which 
was removed after the gel had polymerised. Plates containing set gels were 
set up in the running tank with the central reservoir filled with 1x running buffer 
(25 mM tris, 192 mM glycine and 0.1% SDS at pH 8.3). 11.5 pi of total ladder 
containing a mixture of 7.5 pi of SeeBlue® Plus 2 Prestained standard 
(Invitrogen, Paisley) ladder combined with 4 pi of MagicMark™ XP Western 
Protein Standard (Invitrogen, Paisley) and loaded along side samples. Gels 
were electrophoresised 150 V at approximately 120 mA for about 1 hour (until 
the dye front reached the bottom of the gel).
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Reagent 4%
40% bis/acrylamide 
37.5:1
1.012 ml
dH20 6.4 ml
Upper buffer buffer pH 6.8 2.4 ml
10% APS w/v 100 pi
TEMED 40 pi
Reagent 7.5%
40% bis/acrylamide 
37.5:1
1.93 ml
dH20 5.47 ml
Lower buffer buffer pH 8.8 2.5 ml
10% APS w/v 100 pi
TEMED 10 pi
Table 2.2. Recipes for pouring a 7.5 % resolving SDS-PAGE gel with a 4 % 
stacking gel for the resolution of proteins between 50- 120 kDa.
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2.2.7 Western blotting
Proteins were transferred from gels to 0.22 pm nitrocellulose membranes 
using BioRad Mini-Protean 3 system as indicated by manufacturer 
instructions. Transfer was carried out in a transfer tank with the transfer 
cassette, 1x transfer buffer (14.4 g/L, 3.03g Tris 20 % methanol), an ice pack 
to keep the transfer buffer cool and a magnetic stir bar to circulate buffer. 
Transfers were run at 100 V for 1 hour. Nitrocellulose membranes containing 
transferred proteins were placed within a 50 ml falcon tube (Elkay, 
Basingstoke) and blocked for 1 hour with 10 ml blocking buffer (5% w/v non­
fat milk and 2% w/v BSA) on a roller. Membranes were probed with 1:100 HI- 
NHS, diluted in blocking buffer, for 30 min followed by three washes in PBST. 
To detect bound human IgG, a goat anti-human IgG (Fc specific) peroxidise- 
conjugated secondary antibody (Sigma, UK), diluted 1:1000 in blocking buffer, 
was incubated for 30 min. Membranes were washed three times in PBST and 
subsequently in PBS before developing with Pierce® ECL Western Blotting 
Substrate (Thermo scientific, Loughborough). For blots which were IgG sero­
negative a goat anti-human IgG, A, M polyvalent peroxidise-conjugated 
antibody, diluted 1:1000 in blocking buffer, (Sigma, UK) was used.
2.2.8 Isolation of Ureaplasma lipoproteins using Triton X-114 
(TX-114)
A 5 ml overnight culture of Ureaplasma was grown as described in section 
2.1.5. The culture was centrifuged at 13, 000 xg and pellets were washed 
three times in ice cold tris buffered saline (TBE). The pellet was then
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resuspended in 200 pi ice cold TBS with 0.5 % TX-114 and vortexed several 
times, but while keeping the sample chilled. This suspension was then 
layered on top of 300 pi of frozen TBS with 6 % sucrose and 0.06 % TX-114 
and incubated in a water bath at 37 °C for 3 min in which time cloud point will 
be reached. The sample was then centrifuged at 300 xg at room temperature 
for 3 min followed by removing the upper aqueous phase. To the lipid phase 
was added 40 pi 10 % SDS and 40 pi of LDS and frozen at -20 °C until 
analysis.
2.2.9 CH50 assay
The CH50 assay was used to asses the optimal concentration of a-C1q 
globular head antibody so to identify the role of direct C1q binding on SV3. 
Two lots of 1.5 ml sheep erythrocytes were aseptically decanted into 1.5 ml 
micro-centrifuge tubes. These were centrifuged at 5000 rpm for 3 min. 
Supernatant was removed and pellets were washed in 1.5 ml PBS three 
times. 5 ml of PBS was added to two lots of universal containers, one of 
which received 25 pi of amboceptor antibody (rabbit a-sheep erythrocyte 
antibody) while the other received 200 pi of washed sheep erythrocyte pellet. 
These two solutions were pooled together giving a 2x solution of erythrocytes. 
This was incubated at 37 °C for 30 min with vortex every 10 min. Following 
sensitisation the 2% mix was centrifuged at 1000 xg for 2 min, resuspended 
with 10 ml PBS and washed in PBS twice. Two washes in VBS followed and 
the sensitised erythrocytes were diluted to 1% in VBS. The a-C1q globular 
head antibody (clone 2204) was kindly donated by Professor Moh Daha
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(Leiden University, Netherlands) and was incubated with serum samples by 
adding 7 pi and 14 pi of antibody (1 mg/ml anti-C1q, final concentrations 70 
pg/ml and 140 pg/ml, respectively) and then incubated for 30 min to compete 
out any C1q. As the antibody was obtained in a PBS buffer, an equal volume 
of PBS was additionally tested in parallel to determine the inhibition of 
classical pathway by calcium chelation mediated by the PBS carrier. Samples 
were then diluted 1:20 in VBS, in preparation for the assay. In each row of a 
flat bottom 96-well plate, 50 pi of water was added to row A. 50 pi of the 1:20 
serum was added to row B. Wells C-H received 50 pi VBS. Well C received 
an additional 100 pi of the 1:20 serum dilution. 2:3 dilutions were made down 
the plate from well C to well G where 100 pi was discarded. Well H remained 
as a serum-free VBS negative lysis control. The 2% erythrocyte solution was 
diluted 1:1 to give a working 1% solution of which 50 pi was added to every 
well. The plate was then incubated at 37 °C for 30 min, with absorbance 
readings being taken every 3 min in a plate reader at wavelength 690nm.
2.2.10 Concentration of a-C1q globular head antibody
The results from the CH50 assay showed some effect from the PBS in the 
aC1q buffer therefore to reduce the non-specific effects of PBS in the killing 
assay the stock was concentrated to 5 mg/ml as follows. 600 pi of 1 mg/ml 
stock was added to a Vivaspin centrifugal protein concentrator column 
(molecular mass cut-off 50 kDa) (Fisher, Loughborough). The column was 
spun at 5 000 rpm in a bench top centrifuge for 20 min. This was sufficient
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time for 480 pi of solution to pass through leaving 120 pi of concentrated 
antibody at 5 mg/ml.
2.2.11 Preparation of serum for C1q-blocked killing assay
100 pi of serum was incubated with 7 pi of 5 mg/ml a-C1q antibody (350 
pg/ml final concentration) for 30 min prior to the killing assay. Run conditions 
were then as described in section 2.2.2. An isotype matched control antibody 
(anti-HHV8 KCP antibody) was run along side to control for any non-specific 
differences as a result of protein concentration (Mark et al. 2007).
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2.3 Clinical samples
2.3.1 Ethics
All samples were collected after ethical approval from patients located on the 
Neonatal intensive care or high dependency units at the University Hospital of 
Wales, Cardiff, U.K. by the following; Dr Nicola Maxwell or Dr Phillip Davies 
(BAL samples), Sister Diane Nutall (GF, ET and NPA) and Sisters Jenny 
Webb or Louise Bridge (GF).
2.3.2 Gastric fluid (GF)
Infants admitted to the neonatal unit frequently have a nasogastric or 
orogastric tube inserted as part of their routine neonatal care. The tubes are 
aspirated at the time of insertion to obtain gastric fluid which is pH tested in 
order to assess the correct situation of the tube in the stomach. Aspirated 
gastric fluid was saved in an occluded syringe and refrigerated until 
appropriate, signed informed consent could be obtained from the infant’s 
parents. Gastric fluid was taken once only from infants who had a naso- or 
oro-gastric tube inserted within 2 hours of birth and who had not previously 
had a milk feed.
2.3.3 Endotracheal aspirate (ETA)
Infants requiring mechanical ventilation regularly have endotracheal suction 
performed as part of their routine care. Following signed, informed parental 
consent, endotracheal secretions were collected in a suction trap during
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routine endotracheal suctioning on a twice weekly basis until the infant was 28 
days old or until extubated, whichever occurred first. Briefly, a size 6 French 
Gauge (FG) suction catheter was introduced into the endotracheal tube and 
advanced to a predetermined length so that the tip of the catheter would 
reach but not extend beyond the tip of the endotracheal tube and a suction 
pressure of 8-12kPa was applied as the catheter was withdrawn, in order to 
obtain any secretions remaining in the catheter following the suction 
procedure, 2 ml of sterile saline was suctioned through the catheter into the 
suction trap before it was disconnected from the suction tubing. Samples were 
immediately refrigerated and then transferred to the laboratory within 12 
hours. If an infant was having bronchoalveolar lavage performed (see section
2.3.5 below), the BAL procedure replaced routine endotracheal suctioning and 
thus no ET sample was obtained at the same time.
2.3.4 Nasopharyngeal aspirate (NPA)
Non-intubated infants receiving continuous positive airway pressure (CPAP) 
and infants who had been extubated to CPAP following a period of ventilation 
intermittently require nasopharyngal suction to keep their upper airway patent 
and free of a build up of secretions. Again following signed, informed parental 
consent, the secretions obtained at such routine suctioning procedures were 
collected in a suction trap on a twice weekly basis until the infant was 28 days 
old or no longer required nasopharyngeal suction. The samples were 
refrigerated until transfer to the laboratory (always <12 h post-collection).
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2.3.5 Bronchioalveolar lavage (BAL)
BAL is a well established clinical and research technique that is safe and well 
tolerated in mechanically ventilated neonates, provides reproducible results 
and no long term adverse effects.
A large number of the infants included in this study were involved in another 
study of neonatal BAL. For the purpose of the study, BAL was performed daily 
for the first week of life and then twice weekly until the infant was 28 days old 
or until the infant was extubated, whichever occurred first. Preterm infants in 
the neonatal unit in Cardiff routinely receive exogenous surfactant therapy at 
birth and again at 12 hours of age. In order to minimise any wash out of 
surfactant, the first BAL was performed at 12 hours of age, immediately prior 
to the administration of the second surfactant dose. Timing of subsequent 
lavages was co-ordinated in order to replace the routine endotracheal suction. 
If an infant was judged too unwell by the attending clinician to tolerate a BAL, 
the procedure was withheld.
BAL was performed using the guidelines set out by the European Respiratory 
Society task force on BAL in children (de Blic 2000) and as previously 
described, Briefly, with the infant lying supine and the head turned to the left, 
a size 6FG catheter was gently introduced down the endotracheal tube until 
resistance was felt. Then 1 ml/kg of 0.9% saline (up to a maximum of 2ml) was 
instilled via the catheter. The catheter was then connected to 8-12 kPa of 
suction pressure and the lavage fluid was suctioned back and collected in a 
suction trap as the catheter was withdrawn. The ventilator was reconnected
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and the infant’s heart rate and saturations, which may have dipped during 
suction, were allowed to return to normal before the procedure was repeated 
a second time. The BAL fluid was pooled from the two lavages, placed on ice 
and immediately transported to the laboratory for analysis.
2.3.6 Measurement of /L-6 and IL-8 concentrations in BAL 
samples by ELISA
IL-6 and IL-8 ELISA’s were run by Dr Eamon McGreal and Dr Mallinath 
Chakraborty from the Department of Child Health. IL-6 in BAL samples were 
measured in 11 term, 21 RDS, 24 CLD and 7 babies who died by ELISA (IL-6 
DuoSet ELISA kit, R&D Systems, UK) according to manufacturer’s 
instructions. IL-8 was measured in all the above samples less 1 infant who 
died (OptiEIA ELISA kit, BD, UK).
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2.4 Molecular genetic methods
2.4.1 Preparation of clinical samples prior to DNA/RNA 
extraction
Samples were thawed on ice for 20 min then centrifuged at 2400 xg to collect 
the sample in the bottom of the tube. Samples were then transferred to 1.5ml 
microcentrfuge tube (Elkay, Basingstoke) and centrifuged in a bench top 
centrifuge at 16,000 xg for 10 min followed by the removal of 25pl aliquots of 
supernatant which were frozen at -20 °C for future analysis.
2.4.2 DNA/RNA extraction of GA, NPA, ET and BAL samples
DNA/RNA extractions were carried out using the commercially available 
QIAGEN® RNA/DNA Mini kit (25) (Qiagen, Crawley). 10Opil of cell pellet and 
supernatant was transferred to a 1.5ml tube. Cells were lysed with 500pl lysis 
Buffer QRL1 and vortexed for 10 seconds then passed 5 times through an 18- 
or 20- gauge needle. 500pl of Buffer QRV1 was added followed by thorough 
vortexing. Lysed samples were then centrifuged at 16,000 xg for 20 mins at 4 
°C to pellet cellular debris. Supernatant containing released nucleic acid was 
transferred to a fresh 2ml collection tube. Nucleic acids were precipitated with 
0.8 volumes (0.8 ml) of ice cold isopropanol on ice for 5 min. Samples were 
then centrifuged at 16,000 xg for 30 min at 4 °C. During this time QIAGEN- 
tips were equilibrated with 1ml of Buffer QRE. Following centrifugation 
supernatants from samples were discarded with the nucleic acid pellet 
resuspended and dissolved in 150 pi of Buffer QRL1 by heating tubes for 6
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min at 60 °C. To increase binding of RNA to the QIAGEN-tip 1.35 ml of Buffer 
QRV2 was added to the nucleic acid suspension. To prevent any non­
dissolved nucleic acid from blocking the QIAGEN-tip the sample was 
centrifuged at 5,000 xg for 5 min at 4 °C. Supernatant was added to the 
QIAGEN-tip and allowed to pass by gravity. Flow-through was collected and 
stored at room temperature for later isolation of DNA. 2 ml of Buffer QRW 
was applied to the column and allowed to pass through removing any 
contaminating proteins or polysaccharides while retaining nucleic acid 
binding. 2 ml of Buffer QRUr , which had been preheated to 45 °C, was used 
to elute off bound RNA from the column. Collected RNA was precipitated 
using 1 volume of ice-cold isopropanol and placed on ice while the DNA from 
the earlier steps was rebound to the QIAGEN-tip and washed with 3 ml of 
Buffer QC. DNA was eluted off the column with 2 ml of preheated (45 °C) 
Buffer QC. DNA was precipitated with 0.7 volumes of RT isopropanol for 10 
min. Both DNA and RNA were centrifuged at 16,000 xg for 30 min at 4 °C. 
Supernatant was carefully removed and pellets washed with 500 pi of ice-cold 
70 % ethanol, vortexed and centrifuged at 16,000 xg for 20 mins at 4 °C. This 
step was then repeated. DNA and RNA pellets were left to air dry for 10 min 
at RT by inverting tubes on paper towel. DNA and RNA were resuspended in 
100 pi and 50 pi of RNAse free water, respectively. To dissolve nucleic acids 
samples were heated to 60 °C for 3 min, vorterxed for 5 seconds and pulsed- 
down to collect the dissolved nucleic acid in the bottom of the tube. The 
heating and vortexing process was repeated twice more to ensure full 
solubilisation of nucleic acid. Both DNA and RNA were then stored at -  20 °C 
until later analysis.
91
Chapter 2 - Materials and Methods
2.4.3 Polymerase chain reaction (PCR)
All polymerase chain reactions (PCR) were carried out in 200pil PCR tubes 
(Starlab, Milton Keynes) with all batches containing a known positive control, 
specific for the PCR in question, and a negative control (sample mix without 
DNA) to rule out false negatives and false positives, respectively. Mixtures for 
PCR can be found in Table 2.3 with a full list of primers in Table 2.4 with all 
reactions following the cycling parameters, unless stated otherwise, of 
denaturation of 94 °C for 5 min, followed by 35 cycles of denaturation at 94 °C 
for 30 seconds, annealing at the temperature stated in Table 2.4 for 1 min 
followed by an extension of 72 °C for 1 min/Kb of product. A final extension of 
10 min followed and products were cooled to 4 °C until needed. All PCR 
reactions were run in QB96 Server Gradient Thermal Cyclers (Quanta, 
Surrey).
dH20 11.15 ul
5x Taq buffer 4.0 ul
MgCI2 (25 mM) 1.2 ul
dNTP (10 mM) 0.4 ul
Forward primer 1 ul (5 pmol)
Reverse primer 1 ul (5 pmol)
GoTaq 0.25 ul
DNA template 1 ul
Final volume 20 jul
Table 2.3. Reagents and volumes used for a 20 pi polymerase chain reaction 
(PCR).
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Table 2.4. Primers used in this thesis
Name________ Sequence________________________________ Tm Size__________Ref
Detection of human DNA
Human mitochondrial cytochrome oxidase (HMCO)
H6A 5’ ATGACCCACCAATCACATGCCTATCA 3’ 59 823 (Fryefa/ 2004)
H6B 5’ ACTAGTTAATTGGAAGTTAACGGTACTA 3’
Detection of bacterial DNA
16s rRNA gene
27f 5’ AGAGTTTGATC(AC)TGGCTCAG 3’
1492r 5’ TACGG(CT)TACCTTGTTACGACT T 3’
Ureaplasma spp. detection
Urease gene
U4 5’ ACGACGTCCATAAGCAACT 3’
U5 5’ CAATCTGCTCGTGAAGTATTAC 3’
See 1465 (Daviese' a/- 2009) 
methods
54 430 (Blanchard et al. 1993)
Multiple banded antigen (5’ region)
UM-1
UMS-125 5’ GTATTTGCAATCTTTATATGTTTTCG 3’
1994)
UMA226
52
5’ CAGCTGATGTAAGTGCAGCATTAAATTC 3’
Macrolide resistance primers
Domain V of the 23S rRNA -  Operon I 
MH23S-11 5’ TAACTATAACGGTCCTAAGG 3’
UP23S-OP1 5’ ACCACCATTCAATGTTTGAC 3'
403(l/.p) (Te"9 et a/ 
448(1/. t/)
56 1 339 (Pereyre et a*' 2007)
Domain V of the 23S rRNA -  Operon II 
MH23S-11 5’ TAACTATAACGGTCCTAAGG 3’
UP23S-OP2R2 5’ CGTATACTTTGCCATAGTGTTGCC 3’
56 1 427 (Pereyre 0t al- 2007)
L4
UPL4-U 5’ TCTATTGATGGTAACTTCGC 3’ 60 392 <Pereyree' a/ 2007)
UPL4-R 5’ GTTGAAGGTGTTTCTAAATCGC 3'
L22
UPL22-U 5’ TTCGCACCGTAAAGCTTCTC 3’
UPL22-R 5’ GTTCTGGATCAACGTTTTCG 3’
Tetracycline resistance primers
tetM primers for screening
TetMF 5’ TTATCAACGGTTTATCAGG 3’
TetMR 5’ CGTATATATGCAAGACG 3’
Sequencing remaining tetM gene
TetMF-78 5’ GTATACCTATGGTTATGC 3’
TetMR 5’ CGTATATATGCAAGA CG 3’
TetMF
1992)
5’ TTATCAACGGTTTATCAGG 3’ 
TetMR 2123 5’ GCATTTCGGACAATAGAGGGGG 3’
60 458 (pereyre et a/ 2007)
48 397
48
(Blanchard et al. 1992)
901
(Blanchard et al. 1992)
54 1 715 (Blanchard et al-
Ciprofloxacin resistance primers
GyrA QRDR
gyrAA 5’ TTGCTGCTTTCGAAAACGG 3’ 50 336 (Bebearefa/ 2000)
gyrA-2 5’ CTGATGGTAAAACACTTGG 3’
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Sequencing remaining gyrA gene
gyrAA 5' TTGCTGCTTTCGAAAACGG 3’
gyrA 1655R 5’ CCTTGTACACCTACACCAC 3’
gyrA 1504F 
gyrA 2743R
GyrB QRDR 
gyrB-3 
gyrB-4
5’ GGTGATGAGCGTCGTACAG 3’ 
5’ CCTGCAACTTCACCAATTG 3’
5’ CCTGGTAAATTAGCTGACTG 3’ 
5’ TTCGAATATGACTGCCATC 3’
Sequencing remaining gyrB gene
gyrB -98F 5’ GAAAATAGACGTGGTCG 3'
gyrB-4 5' TTCGAATATGACTGCCATC 3'
gyrB-3 5' CCTGGTAAATTAGCTGACTG 3’
gyrA-2 5' CTGATGGTAAAACACTTGG 3'
ParC QRDR
parC-5 5’ ACGCAATGAGTGAATTAGG 3’
parC-6 5’ CACTATCATCAAAGTTTGGAC 3’
Sequencing remaining parC gene
parC-5 5’ ACGCAATGAGTGAATTAGG 3'
par 1545R 5’ GTATCCATCACGACTTATTAC 3’
parC 1367F 5’ GCTAAAACGCTACAAGAACG 3’
pare 2553R 5’ CAACGTTGGCATAAATTGG 3’
ParE QRDR
parE-1 5’ ATGGGCGGAAAATTAACGC 3’
parE-8 5' CTTGGATGTGACTACCATCG 3’
Sequencing remaining parE gene
parE -54 5’ CAGCAACCATTTTATGCCGATCC 3’
parE-8 5' CTTGGATGTGACTACCATCG 3'
parE-1 5' ATGGGCGGAAAATTAACGC 3'
pare-6 5' CACTATCATCAAAGTTTGGAC 3’
50 1456 (Bebear etal. 2000)
50 1258 {U.p)
1270 (U.u)
55 310 (Bebear et al. 2000)
50 1668
(Bebear ef al. 2000)
50 1249(Bebear ef al. 2000)
55 309 (Bebear et al. 2000)
50 1397
50 1318 (U.p)
1324 {U.u)
55 313 (Bebear et al. 2000)
50 1576
50 1182 (Bebear et al. 2000)
Table 2.3 continued. All primers used in this thesis. * indicates primers 
designed in this study. U.p = U. parvum. U.u = U. urealyticum
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2.4.3.1 PCR for the Human mitochondrial cytochrome oxidase 
(HMCO) gene
To assess the success and integrity of DNA extractions from clinical samples 
a PCR for the HMCO gene was carried out (Table 2.4) (Fry et al. 2004). 
Presence of an 823 bp product indicated that DNA was successfully isolated 
from the sample.
2.4.3.2 PCR for detection of the bacterial 16S rRNA gene
Detection of bacterial DNA was carried out by the amplification of the bacterial 
16s rRNA gene; a highly conserved region across the bacterial kingdom 
(Lane 1991). Cycling parameters differed to those stated in section 2.4.3 as 
follows. Initial denaturation was performed at 94 °C for 10 min. This was 
followed by a touch-down protocol where samples were denatured at 94 °C 
for 1 min with annealing at 67 °C for 40 seconds and extension at 72 °C for 1 
min. This was repeated for a total of 20 cycles in which the annealing 
temperature decrease by 1 °C per cycle. An immediate second round of 
cycling consisted of denaturation at 94 °C for 1 min followed by 47 °C for 1 
min and extension at 72 °C for 1.5 min. This was repeated for a total of 20 
cycles in which the extension time increase by 1 second per cycle. A final 
extension followed at 72 °C for 8 min. Samples were then cooled and stored 
at 4 °C.
95
Chapter 2 - Materials and Methods
2.4.3.3 PCR for the urease gene of Ureaplasma Spp. and use in 
confirming positive clinical samples
To detect or confirm the presence of Ureaplasma DNA within samples an 
established PCR method was used which amplified a 430 bp region of the 
urease operon (Table 2.4) (Blanchard et al. 1993). This region is unique to 
Ureaplasma species and universal across both U. parvum and U. urealyticum.
2.4.3.4 PCR for speciation of Ureaplasma isolates and serovar 
determination of U. parvum
Ureaplasma isolates were divided into either U. parvum or U. urealyticum 
using a previously documented PCR protocol (Teng et al. 1994). Primer set 
UM-1 amplified both U. parvum and U. urealyticum but gave a 403 bp and 
448 bp product, respectively (Table 2.4). U. parvum isolates were classified 
to a serovar level by PCR sequencing of the UM-1 primer set (See section
2.4.5 for sequencing protocol). Returned sequence data was then aligned 
with the known MBA sequences of U. parvum serovars 1, 3, 6 and 14 (Kong 
et al. 2000). Two regions between -54 to -56 and -81 to -83 of the MBA gene 
were used to differentiate between the four U. parvum serovars as seen in 
Table 2.5.
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Serovar Nucleotide position within MBA gene
-84 -83 -82 -56 -55 -54
SV1 G C T A C A
SV3 A C C A T A
SV6 A A T T A G
SV14 A A T A T A
Tab le  2.5. Serovar specific nucleotide differences which can be used to 
differentiate between U. parvum serovars.
2.4.3.5 PCR for macrolide resistant Ureaplasm a
To selectively amplify each of the two 23S rRNA operons independently, the 
following primer combinations were used (Pereyre et al. 2007). For operon 1, 
the cross-23S rRNA operon primer MH23s-1 was used in conjunction with the 
operon 1 selective primer UP23S-OP1 (which annealed within the 5’ region of 
the adjacent folA gene). For operon 2, MH23s-1 was used with the operon 2 
selective primer UP23S-OP2R2, which annealed to the 5’ region within the 
adjacent greA gene. Genes were then sequenced as described in section 
2.4.5.
Amplification of the L4 and L22 genes, previously associated with macrolide 
resistance in Ureaplasma, were carried out using PCR and sequencing 
protocols.
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2.4.3.6 PCR for the tetM transferable element associated with 
tetracycline resistance
The presence of the tetM transferable element in Ureaplasma isolates was 
determined by PCR using the primers described by Blanchard et al. (Table 
2.4), which amplified the 398 bp product (Blanchard et al. 1992). The whole 
tetM coding sequence from positive isolates was determined by using the 
primer combinations set out in Table 2.4 and sequences as described 2.4.5.
2.4.3.7 PCR for identification of mutations within the Ureaplasma 
gyrA, gyrB, parC and parE genes associated with ciprofloxacin 
resistance and additional whole gene sequencing
Primers gyrAA and gyrA-2 were used to amplify the quinolone resistance 
determining region (QRDR) of the gyrA gene, gyrB-3 and gyrB-4 were used to 
amplify the QRDR of the gyrB gene, parC-5 and parC-6 were used to amplify 
the QRDR of the parC gene and the parE-7 and parE-8 primer pair were used 
to amplify the QRDR of the parE gene all of which were described by Bebear 
et al. (Bebear et al. 2000). To determine the full sequence for each of the 
respective amplicons from primer combinations in Table 2.4, standard PCR 
protocols were used, with exception of primer combination parE -54 and parE- 
8 which required 40 cycles instead of 35. Products were sequenced as stated 
in section 2.4.5.
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2.4.4 Agarose gel electrophoresis
To determine the presence and size of amplified DNA following a PCR 
reaction, DNA fragments were separated using agarose gels. Gels were 
prepared by dissolving molecular grade agarose (Invitrogen, Paisley) in 1x 
tris/borate/EDTA buffer (MP biomedicals, France) at 0.7 -  1.5% w/v 
(dependent upon size of product expected). The mixture was heated in a 
microwave until all agarose granules were dissolved then cooled to around 55 
°C. When cooled and immediately prior to gel casting, ethidium bromide (MP 
biomedicals, France) was added to a final concentration of 1 pg/ml. Gels 
were poured into a sealed casting tray and allowed to set at room 
temperature. When the gel was set, casting trays were placed in to a running 
tank in the orientation of well to be loaded at the cathode. 5pl of DNA ladder, 
either Hyperladder I or IV (Bioline, London), was added to the first well as a 
size marker. Gels were then run at 130 V for one hour. Ethidium bromide 
stained gels were visualized in a BioDoc-IT™ UV Tansilluminator (Ultra-Violet 
products, Cambridge).
2.4.5 Sequencing of PCR products
If a PCR product was to be sequenced, five replicate PCR reactions (identical 
to the successful PCR) were performed, the reactions pooled and the 
amplicons purified (below) prior to sequencing to yield a sufficient quantity of 
DNA. For each sample 5 pi of the reaction was ran on an agarose gel to 
confirm that reaction was successful.
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2.4.6 Purification of DNA PCR products for sequencing
Novagen SpinPrep™ PCR Clean-up Kits (Novagen, Nottingham) were used 
to purify PCR products in preparation for sequencing. The five PCR 
replicates were pooled in a 1.5 ml tube with the addition of 4 volumes of 
SpinPrep Bind Buffer (A) (400pl per 100^1 PCR reaction). The PCR/Bind 
Buffer mixture was transferred to a SpinPrep PCR Filter which was inserted 
into a 2-ml Receiver Tube. The unit was then spun at >10,000 xg for 1 min. 
400pl of SpinPrep Bind Buffer (A) was added to the filter followed by a second 
spin at >10,000 xg for 1 min. Flow-through from the spin steps were 
discarded. The filter was then placed back into the receiver tube and 500pl of 
reconstituted SpinPrep Wash Buffer (B) was added and passed through the 
filter by centrifugation at >10,000 xg for 1 min. Flow through was discarded 
and the unit was spun for an additional 2 min at >10,000 xg so to remove any 
residual SpinPrep Wash Buffer (B). The filter was then transferred to a 1.5 ml 
Eluate Reciever Tube. 15pl of prewarmed (70 °C) SpinPrep Elute Buffer (C) 
was added directly to the filter membrane and incubated at RT for 3 min. The 
unit was then centrifuged at >10,000 xg for 1 min. To increase the yield of 
DNA, a second elution with 1 5jllI of prewarmed SpinPrep Eluate Buffer (C), 
followed by a 3 min RT incubation and centrifugation at >10,000 xg was 
performed. Assessment of quantity and purity of purified DNA was made by 
measuring DNA and protein concentrations at wavelengths A260/A280, 
respectively, in a BIO-SPEC-1601 dual beam spectrophotometer (Shimadzu, 
Milton Keynes) by diluting 2jliI of purified product into 98pl of de-ionized water 
(1:50).
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2.4.7 BigDye Terminator v3.1 sequencing
Sequencing reactions were set up in 200 pi PCR tubes containing the 
reagents listed in Table 2.6a and performed using the conditions listed in 
Table 2.6b using QB96 Server Gradient Thermal Cyclers (Quanta, Surrey) . 
Following the sequencing reaction, products were transferred to a 1.5 ml tube 
with the addition of 50pl ice cold 100% ethanol, 2 pi 125 mM EDTA and 2 pi 
3M sodium acetate. Tubes were vortexed and incubated at room temperature 
for 15 min. Tubes were then spun at 16, 000 xg in a bench top centrifuge for 
30 seconds. Supernatants were removed and DNA pellets were washed with 
70 pi 70% ice cold ethanol, spun again for 15 min and washed and pelleted 
for a final time. Supernatants were removed and DNA pellet was air dried. 
The sequencing reaction was run in an ABI Prism Genetic Analyzer 3100 
(Applied Biosystems Warrington, UK) by central biotechnology services at 
Cardiff University.
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B. 25 cycles
Denaturation 50 °C 30 sec
Annealing 50 °C 15 sec
Extension 60 °C 4 min
Store 4 °C OO
A. Reagent Volume
Better buffer 5 pi
ABI big-dye 1.5 pi
Primer (5 pmol) 1 pi
DNA template (200 -  500 ng) 7.5 pi
Total 15 pi
Table 2.6. Reaction mix (A) and cycling parameters (B) for BigDye® 
Terminator v3.1 Cycle Sequencing protocol.
2.4.8 Sensitivity o f primers
The sensitivity of the urease, UM-1 and 16S rRNA primers against CCU of 
Ureaplasma was determined as follows. A 1 ml logarithmic culture of SV8 
was titrated out to 10'8 in a microtitre plate and incubated at 37 °C for 48 
hours. The 1ml culture was immediately centrifuged at 16,000 xg for 20 min. 
All supernatant was removed and the pellet was resuspended in 50 pi sterile 
H20. The sample was boiled (lysed) at 95 °C for 10 min with the sample then 
diluted to 10"8 with 1 pi of each dilution used in each PCR reaction as 
described in 2.4.3. Degree of colour change was then compared with that of 
PCR positivity at each dilution.
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2.5. Antibiotic susceptibility testing
2.5.1 Stocks of antibiotics
All antibiotics were purchased from Sigma-Aldrich (Dorset, UK) and 
reconstituted to concentrations indicated in Table 2.7. Erythromycin was 
bought as a 1 mg/ml stock solution in water. Azithromycin was prepared to a 
concentration of 10 mg/ml in ethanol. Clarithromycin was prepared to a 
concentration of 1 mg/ml in methanol. Tetracycline and doxycycline were 
both prepared to a concentration of 1 mg/ml in sterile water. Ciprofloxacin 
was prepared to a concentration of 5 mg/ml in DMSO. Working stocks were 
diluted immediately prior to use, in USM, to the indicated concentrations. The 
sensitivity of isolates to ethanol, methanol and DMSO (used to dilute 
antibiotics) were tested against USM only to ensure no non-specific 
antibacterial activity was mediated by these substances.
103
Chapter 2 - Materials and Methods
Antibiotic Solvent Stock concentration
Erythromycin Water 1 mg/ml
Azithromycin Ethanol 10 mg/ml
Clarithromycin Methanol 1 mg/ml
Tetracylcine hydrochloride Water 1 mg/ml
Doxycycline hyclate Water 1 mg/ml
Ciprofloxacin DMSO 5 mg/ml
Table 2.7. Antibiotics used to examine the sensitivity of Ureaplasma isolates. 
The solvents used to prepare each drug and the stock concentrations are 
indicated.
2.5.2 Break point screening o f isolates
A break-point titration was used to identify resistant Ureaplasma from a cohort 
of 61 isolates from UHW and HPA. As reference ranges were not available 
for levels of resistance in Ureaplasma, values were determined from previous 
studies looking at the MIC as well as data on within the literature (Waites et al. 
2001) as well as personal communication with C. M. Bebear. In a flat-bottom 
96 well plate row A1-H1 contained 180 pi of 4 pg/ml erythromycin (all given as 
final concentrations), row A2-H2 contained 180 pi 4 pg/ml ciprofloxacin, row 
A3-H3 contained 180 pi 2 pg/ml tetracycline, and row A4-H4 contained 180 pi 
antibiotic free USM (Figure 2.3). Twenty microlitres of ureaplasma culture 
was then added to each well of A1-A4, and serial 10-fold dilutions performed
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as above (diluting Ureaplasma but not antibiotic), but restricted to the 4 test 
rows. In this manner, the 96-well plate was organised to investigate 3 
different isolates per plate by repeating the layout for A5-H8 and A9-H12 as 
above, but using different test isolates of ureaplasma. SV9 (Vancouver strain) 
was used as a positive control for tetracycline resistance, however, no known 
characterised resistant strains were available to use as controls for 
erythromycin and ciprofloxacin resistance. Any strains that showed growth in 
wells which corresponded to 103-104 CCU in the antibiotic free positive control 
row was subsequently fully investigated using the full plate method.
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Figure 2.3. Break point analysis used to screen three different isolates (A, B 
and C) per 96-well plate. A culture of unknown CCU was titrated across the 
x-axis of the plate with set break point concentrations of each antibiotic and a 
growth control for each isolate. Erythro = erythromycin 4 pg/ml, Cip = 
ciprofloxacin 4 pg/ml and Tet = Tetracycline at 2 pg/ml.
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2.5.3 96-well plate set up for determination of MIC for a single 
isolate with varying inoculum sizes
In a 96-well plate, wells A1-H1 received 360 pi of 64 pg/ml antibiotic in USM 
and 180 pi sterile USM was added to the remaining wells of the plate. Using 
a multi-channel pipette, rows of doubling dilutions were made by transferring 
180 pi from wells in row 1 through to wells in row 11 with excess 180 pi 
discarded as seen in Figure 2.4. Thus an antibiotic gradient was created from 
64 pl/ml to 0.0625 pl/ml (by rows). Row 12 remained free of antibiotic for 
unrestricted growth comparison. Ureaplasma isolates to be tested were 
prepared as stated in section 2.1.5. Twenty microlitres of Ureaplasma from 
the prepared culture was added to each well in the column A (1:10 dilution). 
A ten-fold dilution of bacteria was then titrated at 90 degrees across the 
antibiotic gradient. The plate was sealed and incubated at 37 °C in a 
humidified cell culture incubator and observed for colour change at 24h 
intervals for 4 days. The MIC was defined as the lowest concentration of 
antibiotic that prevented a colour change after 48h when read at 103 - 104 
colour change unit (CCU) (relative to the growth in the antibiotic free medium). 
USM with and without antibiotics were also incubated in the absence of added 
Ureaplasma to serve as a negative colour change control.
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Figure 2.4. A schematic diagram of the 96-well plate was set up to determine
the MIC of an Ureaplasma isolate to a single antibiotic
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2.5.4 Control isolates
To ensure that the conditions for susceptibility testing were correct the MIC 
values were determined for standardised control isolates, as recommended 
by the British Society for Antimicrobial Chemotherapy (BSAC) (Andrews, 
2001) in Mueller-Hinton broth using the methodology described in section 
2.5.3. Control isolates were kindly donated by Dr Vicki Chalker from the HPA 
and were as follows S. aureus ATCC 29213, E. coli 25922 and E. faecalis 
29212.
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2.6. Bioinformatics
2.6.1 Sequence analysis
Analysis and manipulation of DNA sequence data was carried out using 
DNASTAR SeqMan™ II expert sequence analysis software Version 5.07. 
DNA and protein alignments were prepared using DNASTAR MegAlign™ 
expert sequence analysis software Version 5.07.
2.6.2 Phylogenetic trees
Phylogenetic trees were initially produced in DNASTAR MegAlign™ expert 
sequence analysis software Version 5.07 with final versions produced by Dr 
Vicki Chalker (HPA) using CLUSTALW with distances calculated using 
maximum likelihood. The evolutionary history was inferred using the 
Neighbour-Joining method and the optimal trees after 500 bootstraps. Repeat 
testing using Jukes Cantor and Tamura Nei distance calculations gave 
identical tree topology. Trees were rooted using respective gyrase or 
topoisomerase genes from Mycoplasma pneumoniae.
2.7 Statistics
All statistics in this thesis were calculated using GraphPad Prism Version 
5.01.
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3.1 Introduction
Invasive Ureaplasma infections primarily occur in preterm neonates with an 
immature immune system or in immune compromised patients such as those 
who are hypogammaglobulinaemic or receiving immunosuppressive therapy. 
This suggests an essential role for a healthy immune system to fight off 
Ureaplasma infection.
Little is know about the interactions between Ureaplasma and the complement 
system. The predisposition of hypogammaglobulinaemic patients to 
Ureaplasma infections as well as reports of an antibody response to 
Ureaplasma suggests an essential role for the classical pathway (Watson et 
al. 1990; Furr et al. 1994). A single report has commented on the ability of 
MBL to bind to Ureaplasma, but no function was determined (Benstein et al. 
2004). No reports have been made regarding the impact of the alternative 
pathway upon Ureaplasma, but due to being recognised as “foreign” by the 
immune system would be predicted as having an effect.
In this first results chapter I focus on the ability of the complement system to 
naturally fight off infection in an in vitro system using serum from 12 healthy 
volunteers and determine which complement activation pathways are 
responsible for the killing of representative serovars of U. pan/urn.
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3.2 Results
3.2.1 Titration of serum for optimal killing
To determine the optimal concentration of serum for the complement killing 
assays which gave results similar to that of 100 % serum, but scaled down the 
volume of serum required, a series of doubling dilutions of 100 % serum in 
VBS were set up. As can be seen from Figure 3.1 the killing of Ureaplasma 
was dependent upon the concentration of serum used with levels of killing 
noticeably declining from 25 % serum. Killing of SV3 decreased by a log at 
every dilution from 25 % to 3 %, whereas SV1 killing began to decrease by a 
log at every dilution from 12 % to 3 %. As the use of 50 % serum gave 
comparable results to that of 100 % serum it was therefore determined to be 
suitable for use in the complement killing assays.
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oT 105
2  102
Figure 3.1. The ability of varying concentrations of human serum to kill 
Ureaplasma. Black bars represent killing of SV1 and white bars represent the 
killing of SV3. Numbering of the x-axis represents concentration of human 
serum.
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3.2.2 Analysis of the complement killing assay
The killing assay described in the materials and methods chapter 2.2.2. 
allowed the determination of degree of bactericidal killing of serum from 
twelve human volunteers. As degree of killing was calculated via the 
decrease in CCU from a HI-NHS matched control, there was no need to know 
the CCU of the initial inoculum. Occasionally wells were observed in which 
colour change was absent although subsequent wells further down the 
titration were positive (Figure 3.2). To keep consistency in determining 1 CCU 
(the final well in which colour change occurs), negative wells were counted as 
positive if a single negative well was subsequently followed by two or more 
positive wells. To additionally rule out any bias in spontaneous negative wells 
within the titration all killing assay experiments were repeated in triplicate on 
independent days, and the mean and standard error of the mean determined 
prior to comparison. As degree of killing was dependent upon the reduction in 
NHS wells relative to a matched HI control, the poor growth in the HI control 
would result in an artificially low kill. Using the preparation methodology 
described, all serovars grew to at least 103 CCU in all experiments therefore 
ruling out any possible methodological bias in degree of killing.
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Figure 3.2. Complement killing assay to determine the bactericidal activity of 
human serum. The four representative serovars of U. parvum were DKF-1 
(SV1), HPA5 (SV3), HPA2 (SV6) and HPA32 (SV14). The killing capacity of 
50 % normal human serum (NHS) from the pan-ureaplasmacidal VxF3 serum 
(A) verses that of the low ureaplasmacidal VxF1 (excluding SV3 killing) (B). 
Pink wells represent growth of Ureaplasma whereas yellow wells represent 
absence of growth. Killing was determined by calculating the fold-decrease in 
CCU from the NHS relative to the heat-inactivated normal human serum (Hl- 
NHS) control.
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3.2.3 Variations in SV1, 3, 6 and 14 killing by all complement
pathways compared to alternative pathway only
The ability of 50% human serum to kill representative strains of each U. 
parvum serovar is shown in Figure 3.3a-d. With all three activation pathways 
intact, the sera from 5/12 volunteers reduced the CCU of DFK-1 (SV1) by 
greater than 1000-fold, 2/12 reduced CCU by 100 to 1000-fold, 3/12 
volunteers reduced CCU by 10 - 100-fold and the remaining 2 volunteers 
reduced CCU by less than 10-fold (Figure 3.3a). All volunteers serum 
reduced HPA5 (SV3) CCU by greater than 1000-fold (Figure 3.3b). One third 
(4/12) of sera reduced HPA2 (SV6) CCU by 100 to 1000-fold, one third (4/12) 
of sera reduced CCU between 10 to 100-fold and the final third (4/12) reduced 
CCU by less than 10-fold (Figure 3.3c). A single serum decreased HPA32 
(SV14) CCU by greater than 1000-fold, two sera decreased the CCU by 100 
to 1000-fold and the remaining nine sera decreased numbers by less than 10- 
fold (Figure 3.3d). The alternative pathway from all sera had a negligible 
effect upon killing of all serovars by reducing the CCU by less than 10-fold 
after one hour (Figure 3.3a-d).
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Figure 3.3. The killing capacity of 12 human sera against the four serovars of 
U. parvum. (A) SV1 isolate DKF-1, (B) SV3 isolate HPA5, (C) SV6 isolate 
HPA2 and (D) SV14 isolate HPA32. Dark bars indicated killing in the 
presence of three activation pathways. White bars indicate killing in the 
presence of the alternative pathway only. Numbering on the x-axis refers to 
volunteer serum used.
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3.2.4 Detection of anti-Ureaplasma IgG response with 
volunteer serum by western blot
Figure 3.4 shows immunoblots from the 12 volunteers against the four serovar 
representatives of U. parvum. The blot from VxF1 shows the first of two 
seronegative sera identified in this study. This blot was subsequently probed 
with seropositive serum to rule out the possibility of a false negative result. 
Blots from VxF2 and VxF3 had similar banding patterns for each respective 
serovar. DKF-1 lanes produced a dark band of just over 60 kDa with a 
second, less intense, band of just greater than 70 kDa. This band was 
conserved across all serovars blotted with these sera, but with greater 
intensities. Faint bands were also seen for all serovars of about 85 -  90 
kDa. In addition, the blot using VxF3 serum produced intense, low molecular 
weight bands which ran with the dye front. These were noticed in blots from 
VxF5 and VxF7. Serum from VxF4 revealed a conserved band from all 
serovars of less than 50 kDa with an additional, lower molecular weight band 
present for HPA5. In addition to the low molecular weight band already 
described for VxF5, faint bands at approximately 60 kDa were seen. A 
serovar specific band around 70 kDa was present in for DKF-1 with a 85 -  90 
kDa band present for the remaining isolates. HPA2 had a unique band with a 
slightly higher molecular weight than the 85 -  90 kDa band just described. 
Only faint bands were present for VxF6 in the lane containing DKF-1 (85 kDa), 
HPA5 (less than 50 kDa) and HPA2 (70 -  75 kDa). No bands were present 
for HPA5 or HPA32. VxF7 produced a number of bands to each isolates with 
varying intensities. As described earlier, an intense low molecular weight
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band was seen in all lanes. Further intense bands were present for DKF-1 
one at 65 kDa and a second at 90 kDa. A final intense band of high molecular 
weight (less than 220 kDa) was seen in the lane containing HPA32. Although 
a gel loading control was not present, the comparable intensities of additional 
bands suggested that loading was equal therefore not a reason for variation in 
some band intensities. Weaker conserved bands across all isolates were 
additionally noticed. Blots probed with VxF8 serum resembled those probed 
with VxF2: with three bands present for DKF-1 and a single 70 kDa band for 
the remaining isolates. VxF9 represented the second seronegative blot. Blots 
from using this serum consistently had a high background, but not so bad as 
to obscure any potential bands. As with VxF1, these were then serially 
probed with seropositive serum to rule out false-negatives. VxM10 blots were 
similar to that of VxF2 and VxF8. VxM11 blots bound to a number of unique 
bands (not observed for the other sera) of high molecular weight. A faint 70 
kDa band was present in the lane containing DKF-1, as well as a < 50 kDa 
band in the HPA5 lane. VxM12 serum produced 70 kDa and 50 kDa bands 
for DKF-1 and HPA5, respectively, similar to that of VxM11, but with a greater 
intensity. A high molecular weight band of 220 kDa was noticed along with a 
number of doublet bands of around 90 kDa.
Due to using whole-cell lysates the bands present on the western blot 
represented both internal (non-complement activating) and external 
(complement activating) antigens. As only the external antigens would be 
able to activate complement attempts were made to isolate these antigens 
using a tritonX 114 methodology. Unfortunately the methodology described in
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section 2.2.8 failed to yield a large enough quantity of protein therefore cloud 
point was never reached and these experiments were abandoned.
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Figure 3.4. Immunoblots of SV1 isolate DKF-1, SV3 isolate HPA5, SV6 
isolate HPA2 and SV14 isolate HPA32 probed with volunteer serum (Vx1-12).
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3.2.5 Killing of U. parvum with human serum following 
depletion of IgG using a protein A column
A protein A-sepharose column was used to deplete IgG from the serum of six 
volunteers and assayed as in section 3.2.2 against the respective serovar 
isolates (Figure 3.5-d). These sera were selected on the basis of three having 
a low killing capacity (VxF1, VxF6, VxF9) as well as three having a high killing 
capacity (VxF3, VxF7, VxM12) in addition to these sera having the greatest 
amount of aliquots remaining following previous experiments. In those sera 
which killed SV1, IgG depletion reduced the killing by 53-fold for VxF6, 9057- 
fold for VxF3, 16261-fold for VxF7 and 10787-fold for VxM12 (Figure 3.5a). 
Similar patterns were observed for killing against SV6 and SV14 (Figure 3.5c- 
d). SV6 killing in the absence of IgG was reduced by 663-fold for VxF3, 231- 
fold for VxF7 and 296-fold for VxM12. SV14 killing in the absence of IgG was 
reduced by 108-fold for VxF3, 163-fold for VxF7 and 2827-fold for VxM12. 
Little difference in killing was seen when SV3 was challenged with IgG 
depleted sera with depleted sera still killing by greater than 1000-fold with 
exception to VxF1 and VxF9 which was reduced by 4901 and 3829-fold, 
respectively (Figure 3.5).
123
Chapter 3 -  The effect of human complement upon killing of U. parvum
A.SV1
10n  C.SV6
B.SV3
D.SV14
9 3 7 12
■  Normal human s e ru m  
□  Ig G  d e p le te d  h u m a n  s e ru m
Figure 3.5. Effects of various sera depleted of IgG using a protein A 
sepharose column, on the killing capacity of the four serovars of U. parvum. 
(A) SV1 isolate DKF-1, (B) SV3 isolate HPA5, (C) SV6 isolate HPA2 and (D) 
SV14 isolate HPA32. Dark bars indicated killing in the presence IgG sufficient 
normal human serum. White bars indicate killing from IgG depleted human 
serum. Numbering on the x-axis refers to volunteer serum used.
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3.2.6 MBL ELISA data and killing assay with MBL depleted 
serum
All sera were found to be above the cut-off for normal MBL levels (< 190 pg/L) 
(Crosdale et al. 2000) as defined by the commercial ELISA kit as seen in 
Table 3.1. The highest MBL concentration was seen in VxF1 (2673 ng/ml) 
and the lowest concentration VxF9 (348 ng/ml). MBL was depleted from both 
seronegative sera (VxF1 and VxF9) and used in an attack assay against 
HPA5 following confirmation of depletion via ELISA (Figure 3.6). Due to the 
possibility of complement activation occurring as a result of pre-decoration of 
Ureaplasma by pig lectins present in the growth media, HPA5 (SV3) was 
adapted to grow in USM absent of pig serum, but was supplemented with 1% 
HI-MBL depleted serum from either VxF1 or VxF9. By passaging HPA5 three 
times in the modified USM, the isolate was completely free of all pig lectins 
and human MBL. When the “adapted” HPA5 isolate was attacked with the 
respective MBL depleted serum from either VxF1 or VxF9 no decrease in 
killing was seen in neither the MBL depleted sera or that of HPA5 adapted to 
growth in modified USM without pig serum and supplemented with 1% HI- 
MBL depleted sera.
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Serum pg/L
VxF1 2673
VxF2 441
VxF3 2530
VxF4 1979
VxF5 1386
VxF6 862
VxF7 850
Serum pg/L
VxF8 1260
VxF9 348
VxM10 585
VxM11 826
VxM12 634
VxF1 dep 48
VxF9 dep 49
Table 3.1. Serum MBL levels from the 12 volunteer sera. The data also 
includes MBL depleted seronegative sera from VxF1 & VxF9 as determined 
by ELISA, “dep” refers to MBL depleted serum.
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Figure 3.6. Effects of MBL depleted sera upon killing of U. parvum SV3 
isolate HPA5. Two seronegative sera (VxF1 & VxF9) were depleted of MBL 
and assayed as normal. Black bars represent normal human serum (MBL 
sufficient). White bars represent MBL depleted human serum. Grey bars 
represent HPA5 grown in modified MBL without pig serum, but supplemented 
with 1% HI-MBL depleted sera and subsequently attacked.
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3.2.7 Confirmation of compiement mediated killing of SV3 
using C6 deficient serum
To fully confirm the killing of SV3 was complement mediated, the serum from 
a naturally C6 deficient patient was used. Figure 3.7 shows the killing 
capacity of C6 deficient serum against that of the seronegative VxF9. As 
consistent with previous results VxF9 did not kill DKF-1, but reduced HPA5 by 
10000-fold whereas the C6 deficient serum did not reduce the CCU of neither 
DKF-1 nor HPA5.
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Figure 3.7. Killing capacity of C6 deficient serum against SV1 isolate DKF-1 
(black bars) and SV3 isolate HPA5 (white bars) versus the C6 sufficient 
seronegative VxF9 serum.
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3.2.8 CH50 assay to determine concentration of anti-C1q 
function biocking antibody.
The data from Figure 3.8 shows the CH50 assay for the determination of 
optimal concentration of the function blocking anti-C1q antibody required to 
block the classical pathway (clone 2204, (Roos et al. 2001). Figure 3.8a 
shows that normal human serum could lyse sensitised sheep red blood cells 
at a dilution of 1/126 (the dilution at which the red control line intersects the 50 
% lysis line) where as in the presence of 140 pg/ml of blocking antibody a 
greater amount of serum was required to achieve 50 % lysis (less than 1/67 
serum), suggesting the successful blocking of the classical pathway. As the 
antibody was received in a PBS buffer, which is known to chelate cations and 
therefore inhibit the classical pathway, equal volumes of PBS were run to see 
if any non-specific inhibition occurred. There was a small degree of inhibition 
of the classical pathway by the PBS which inhibited activation to a similar 
extent as the 70 pg/ml concentration of blocking antibody. To reduce volume 
of antibody used, and therefore reduce any potential side affects from the 
PBS the antibody was concentrated to a 5 mg/ml stock. The assay was then 
repeated with the same volumes of sample added (7 pi and 14 pi) along with 
control PBS, but this time the PBS was obtained from the flow through of the 
column (Figure 3.8b). These results showed much greater inhibition with 700 
pg/ml of blocking antibody completely inhibiting activation even at a 1/20 
dilution of serum. Using a volume of 7 pi (giving a final concentration of 350 
pg/ml) gave inhibition at a dilution of (1/56), which was significantly different to 
that from the PBS flow through examined (1/100) as well as the control serum 
(1/152).
130
Chapter 3 -  The effect of human complement upon killing of U. parvum
<§* S f t -  -
s<P ^  **/ * *
Dilution of serum
Serum control 
7ni a-C1q (70 i^g/mO 7^ 1 PBS 
14(il a-C1q (140 pg/ml) -e- 14pl PBS
B.
1001
■® 7C» 75* 
a>
9
§
fc£L
50--------
25*
&  #  * *  f
Dilution of serum
Serum control 
-*■ 7pJ a-C1q (350 pg/ml) 7pl flowthrough 
14pla-C1q (700 pg/ml)14pl  flowthrough
Figure 3.8. CH5o data showing the blocking of the classical pathway using an 
anti-C1q antibody. (A) Data representing the neat 1 mg/ml antibody received 
and (B) representing data from the concentrated 5 mg/ml antibody with results 
read at 15 min after the start of the assay. The dashed line represents 50% 
lysis (CH50). Note the 700 pg/ml data line directly on the x-axis in graph B.
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3.2.9 Complete blocking of the classical pathway using a
function blocking anti-C1q globular head antibody
Data presented in Figure 3.9 shows the effect of the function blocking anti- 
C1q antibody upon the killing of SV3 by the seronegative sera from VxF1 and 
VxF9. Further proof of classical pathway blocking, backing up the CH50 data, 
was demonstrated by blocking the antibody dependent killing of SV1 from 
VxF7 serum. NHS from VxF1 and VxF9 SV3 killed SV3 by 103 -  104-fold, 
whereas in the presence of C1q blocking antibody this killing was completely 
removed. An relevant isotype-matched control antibody of the same 
concentration showed little effect upon the killing of Ureaplasma 
demonstrating this effect was not due to any differences in protein 
concentration.
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Figure 3.9. Effects of anti-C1q antibody upon killing of SV3 by seronegative 
sera (VxF1 and VxF9) and SV1 by seropositive serum (VxF7). Black bars 
represent the killing in normal conditions whereas grey bars, which are absent 
due to no killing at all, represent serum pre-treated with the anti-C1q antibody. 
White bars represent the killing in the presence of an isotype control antibody 
to show any non-specific protein effect.
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3.2.10 Killing of U. parvum with human serum following 
depletion of IgG using a protein G column
Following the protein A depletion experiments it was noted that the protein A 
column previously used to deplete IgG would only deplete subclasses 1, 2 
and 4 whereas a protein G column was able to deplete all four IgG 
subclasses. The results from these data (Figure 3.10) showed that again the 
killing for SV1 was removed from those sera with previously high killing 
capacity following the removal of IgG, but when depleted sera was examined 
against SV3 the results were variable. Killing was removed for 3 out of the 8 
sera with 3 out of the 8 sera retaining full killing and 2 out of the 8 losing 2 
logs worth of killing. Interestingly the killing was retained in one of the 
previous seronegative sera (VxF9), but removed in the second seronegative 
sera (VxF1).
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Figure 3.10. Effects of various sera depleted of IgG, using a protein G 
sepharose column, on the killing capacity of serovars 1 and 3 of U. parvum. 
(A) SV1 isolate DKF-1, (B) SV3 isolate HPA5. Dark bars indicated killing in 
the presence IgG sufficient normal human serum. White bars indicate killing 
from IgG depleted human serum. Numbering on the x-axis refers to volunteer 
serum used.
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3.2.11 Intra-serovar variation
To rule out the possibility of any bias in results due to using a single prototype 
serovar strain, a selection of clinical isolates from each serovar were 
examined (Figure 3.11a-d). Serum from the seronegative VxF1 reduced the 
CCU of all five SV1 isolates by greater than 10-fold (Figure 3.11a). VxF4 
serum also had poor killing activity for isolates DKF1, UWHQ3 and UHWO10 
but greater killing of 300 and 30-fold was seen in isolates HPA11 and HPA18, 
respectively. The highly SV1-cidal VxF3 and VxM12 reduced the CCU of all 
isolates by at least 1000-fold with exception to VxF3 which reduced the CCU 
of UHWQ3 by 333-fold and VxM12 which reduced the CCU of UHWO10 by 
110-fold. With only two exceptions, all sera reduced SV3 growth by 100-fold 
CCU and most reduced the CCU of SV3 isolates by > 1000-fold (Figure 
3.11b). Exceptions to this rule was VxF1 serum which reduced HPA1, HPA6 
and HPA29 by between 100 to 1000-fold also VxF6 serum which reduced 
HPA29 by 550-fold. HPA1 and HPA29 were reduced by VxF7 serum by only 
48 and 80 fold, respectively. Fewer SV6 and SV14 isolates were available for 
intra-serovar variation analysis (Figure 3.11c-d). VxF1 and VxF4 consistently 
failed to reduce the CCU of both SV6 isolates by anymore than 10-fold. 
Reduction in CCU between the SV14 representative HPA2 and HPA23 with 
VxF3 serum was similar with a reduction of over 430-fold. HPA23 was less 
susceptible than HPA2 with a reduction of 45-fold relative to 880-fold, 
respectively. No killing was seen for either SV14 isolates with VxF1 serum. 
Similarly VxF6 killed HPA10 and HPA32 by equal or less than 10-fold. The 
highly SV14-cidal sera reduced the CCU of both isolates by between 100 and 
1000-fold.
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Figure 3.11. Differences in killing capacity of human serum against U. parvum 
isolates of the same serovar. (A) Five SV1 isolates, (B) Five SV3 isolates, (C) 
two SV6 isolates and (D) two SV14 isolate. Numbering on the x-axis refers to 
volunteer serum used.
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3.2.12 Western blots of intra-serovar variation
For those isolates examined for intra-serovar variation killing were 
subsequently examined for intra-serovar variation differences in banding 
pattern. Figure 3.12a,b shows immunoblots of five SV1, five SV3, two SV6 
and two SV14 isolates probed with seronegative VxF1 serum as well as 
seropositive VxF12 serum, respectively. The seronegative serum was 
consistent in producing negative blots as seen in the first series of 
immunoblots (Figure 3.12a), whereas conserved large bands of just less than 
220 kDa as well as one of around 120 kDa were present in all isolates from all 
serovars examined using VxM12 serum. A band of approximately 85 kDa 
was also present in all isolates with exception to the SV1 isolate, UHWO10. 
Band conservation and intensities were less apparent in lower molecular 
weight proteins. A number of bands displayed greater intensities between 
isolates, albeit probed with same serum. A 60 kDa band of the SV1 isolate, 
DKF-1, as well as two SV3 isolates, HPA1 and HPA14, were noticed. A 
number of unique bands were seen both at a serovar, but additionally at the 
intra-serovar level. For example a 90-95 kDa band was seen in the SV3 
isolate HPA1 which was absent in all remaining SV3 isolates. HPA14 
displayed a lower molecular weight band of less than 60 kDa which was 
absent from all remaining SV3 isolates. Figure 3.12c shows the banding 
variation when probed with VxF7 serum. There were a number of bands 
conserved across the isolates examined, but a few bands showed varying 
degrees of intensity. The SV1 isolates HPA1, HPA7, HPA14 and SV14 
isolate HPA10 produced intense bands of just greater than 60 kDa, but were 
not present in remaining wells. Additionally the high molecular weight band
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seen previously in the SV14 isolate (HPA32) (Figure 3.4) was absent in 
comparison SV14 isolate HPA10. Immunoblots probed using VxF6 serum 
again produced a limited number of bands. The low molecular weight band 
for HPA5 was present again, but absent from all other SV3 isolates. Each 
isolate contained a single band of unique size of approximately 80 kDa, 50 
kDa and 70 kDa for isolates HPA1, HPA14 and HPA29, respectively. No 
clear band was seen for HPA7. A weak intensity band of greater than 120 
kDa band was present for HPA10 whereas no band was present for HPA32. 
Blots probed with serum from VxF4 produced faint bands of around 50 kDa as 
previously seen in Figure 3.4. Banding pattern for blots probed with VxF3 
serum was similar to those of VxF7 albeit against SV3 and SV14 isolates.
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Figure 3.12. Immuno blots showing intra-serovar variations of banding 
patterns when probed with varying human serum. Blot A. contains 5 SV1, 5 
SV3, 2 SV6 and 2 SV14 isolates probed with VxF1 serum. Blot B contains 5 
SV1, 5 SV3, 2 SV6 and 2 SV14 isolates probed with VxM12 serum. Blot C 
contains 5 SV1 and 2 SV14 isolates probed with VxF7. Blot D contains 5 SV1 
and 2 SV14 isolates probed with VxF6 serum. Blot E contains 5 SV3 and 2 
SV6 isolates probed with VxF4 serum. Blot F contains 5 SV3 and 2 SV6 
isolates probed with VxF3 serum.
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3.3 Discussion
3.3.1 Analysis of the complement killing assay
The killing assay described in this study was successfully used to firstly, 
identify serum from a group of volunteers with bacteriocidal activity against 
representative serovars of U. parvum and secondly to elucidate which 
complement activation pathways were essential for killing of U. parvum and 
finally to determine the serovar specific variations.
Two previous studies examined antibody-mediated killing of Ureaplasma, 
using similar methods to those described here; however, the focus of these 
studies was to determine serological status of patient sera, rather than 
determining the mechanism or sensitivity to complement (Purcell et al. 1966; 
Lin et al. 1972). The metabolic inhibition assay described by Purcell et al., in 
1966 used guinea pig serum (GPS) as a source of complement to determine 
the titre of antibody from HI-NHS or hyper-immune serum. Ureaplasma 
cultures were incubated with HI-NHS and GPS in a urea-containing media at 
34 °C until colour change was observed in positive control cultures which 
contained no antiserum. This methodology was successful in categorising 
Ureaplasma into to their respective serovars, but did not take into account the 
potential effects of the alternative or lectin pathways of GPS in addition to 
having low levels of sensitivity (Lin et al. 1972). Lin et a/.’s complement- 
dependent mycoplasmacidal test was a similar assay as that developed by 
Purcell et al., but differed by the omission of urea containing media during the 
complement attack stage (Lin et al. 1972). The omission of urea was due to
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the Ureaplasma growth source acting as a dominant nucleophile, abrogating 
the efficient attachment of C3b and C4b to bacteria (Lin and Kass, 1970). A 
difference between Lin’s assay and the one described here involved the 
removal of all serum before resuspending in USM to maximise post-attack 
Ureaplasma growth whereas in contrast to Lin et al., who stopped the 
complement attack by addition of urea containing Ureaplasma media. 
Additionally Lin et al., used low number of Ureaplasma for their assay, 10 
CCU, whereas my complement attack assay used greater than 103 CCU so 
that those sera with high killing capacity could be distinguished from those 
with low killing. ‘The method described here additionally differed from these 
other studies by using modifications to the preparation of the serum (specific 
calcium chelation or MBL-depletion prior to attack) to determine the 
contribution of the alternative and lectin pathways upon killing.
3.3.2 Variations in SV1, 3, 6 and 14 killing by all complement 
pathways and alternative pathway only
Prototype strains for each U. parvum serovar were thoroughly characterised 
for their susceptibility to human serum in the presence of all three complement 
activation pathways (Figure 3.3). All sera killed SV3, but only a proportion of 
sera killed the other SVs, although those that killed SV14 seemed to be 
bacteriocidal for all SV. Serum from VxF2, VxF3, VxF7, VxM11 and VxM12 
consistently killed all SV to a greater degree than the remaining seven sera, 
with exception to VxF3 which had a decreased killing capacity for HPA32 
(SV14). To address the role of the alternative pathway in bacteriocidal
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activity, a well established method of calcium, but not magnesium, chelation 
was utilised leaving only the alternative pathway intact. Surprisingly the 
alternative pathway had little effect upon killing of any U. parvum serovar. 
The alternative pathway is primarily regarded as an important bacteriocidal 
pathway, due to the failure of bacteria to express sialic acid on their 
glycoproteins and therefore fail to recruit soluble serum regulator factor H. 
This is the mechanism that protects the host’s cells from significant damage 
when in proximity to high levels of complement activation. In fact, recruitment 
of factor H by particular bacterial cell wall proteins, is the often attributed as 
the mechanism of increased virulence for particularly pathogenic bacterial 
strains. Examples include Streptococcus pneumoniae recruits fH from its 
surroundings as an evasion mechanism to protect against the bactericidal 
nature of human serum (Lambris et al. 2008; Rooijakkers and van Strijp, 
2007). It can be speculated that fH recruitment may be a mechanism by 
which U. parvum is resistant to alternative pathway killing. ~ \
3.3.3 Serological status of the 12 volunteers
To determine the serological status of the twelve sera, western blots 
containing whole-cell lystaes of Ureaplasma antigen were probed with 
volunteer serum (Figure 3.4). From the twelve sera examined ten showed 
some degree of reactivity, whereas two were fully seronegative for IgG. For 
these seronegative blots they were subsequently probed with an anti-lgG/M/A 
antibody to look for any immunoglobulin binding (as IgM is a potent 
complement activator that is not bound by protein A or protein G), but 
remained negative. To ensure results were not false negative results, the
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blots were subsequently probed with seropositive serum where expected 
banding was confirmed, therefore ruling out poor transfer. These 
seronegative sera failed to kill DKF-1, HPA2 and HPA32, but not HPA5 
initially suggesting antibody dependent killing for serovars 1, 6 and 14, but 
antibody independent killing for SV3. For those which were seropositive, a 
variety of different and conserved banding patterns of varying intensities were 
seen within blots probed with different sera. High levels of killing were 
associated with the presence of multiple bands of higher binding intensity. 
For example, the high level of DKF-1 killing seen with VxF2, VxF3, VxF7 
VxM11 an VxM12 correlated with intense binding of bands approximately 62- 
65 kDa. Further support for the presence of specific bands and killing was 
seen for SV14 isolate HPA32. Killing was associated with high molecular 
weight bands or greater than 120 kDa as seen in blots probed with serum 
form VxF7, VxM11 and VxM12. An outlier to this rule was the serum from 
VxF2 which showed killing of around a 100-fold, but no large molecular weight 
band was present. An interesting observation was the banding profiles of 
blots probed with the sera from VxF2, VxF3, VxF8 and VxM10 as the banding 
patterns produced by these sera against the SV1 isolate DKF-1 was similar to 
that of the monoclonal antibody 8B5.2. described by Watson et al. which 
detected bands of 85, 74 and 58 kDa. This suggested multiple bands may 
represent alternative forms of the same protein or closely related proteins 
(Watson et al. 1990). In a number of cases, such as with VxF4, bands were 
present, but the degree of killing was minimal. This may represent an 
antibody response which was raised against internal antigens which would be 
hidden by intact viable cells. Of course activation of complement can only
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occur following binding of the antibody to antigens present upon the surface of 
bacteria, and as western blot does not distinguish between surface and 
internal antigens this could account for this finding. Attempts were made to 
isolate external antigens by using a Triton X114 methodology but failed to 
produce a large enough quantity of assessable protein. The most likely 
explanation for this would be due to the low volume of culture used (5 ml). 
Previous studies have used TX-114 to isolate Ureaplasma lipoproteins, but 
neither of these publications comment on the size of initial culture used 
(Shimizu et al. 2008; Peltier et al. 2007).
%
It can be hypothesised that the primary external candidate protein recognised 
by the antibody response would be the multiple banded antigen (MBA) based 
on previous existing work (Watson et al. 1990; Zheng et al. 1995; Kong et al. 
2000; Monecke et al. 2003; Zimmerman et al. 2009). Watson et al., 
proposed that the MBA of Ureaplasma was the predominant antigen 
recognised by the immune system using sera from Ureaplasma positive 
patients who were attending an infertility clinic (Watson et al. 1990). In sera 
from these patients, the investigators noticed, as observed in this study, there 
were serovar specific as well as cross-reactive epitopes. In addition, a 
monoclonal antibody (3B1.5) raised against SV3 produced a laddering effect 
upon blotting. This was the basis for the naming of the MBA. The size 
variation seen in the MBA antigen was a result of altering the number of 
repeat units in the 3’ end of the protein and proposed as an antibody evasion 
mechanism (Zheng et al. 1995). The expected size of the MBA are around 
70 kDa and consistent with a number of bands present within this study.
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Recent work has suggested a more radical method of altering the antigenicity 
of the surface by full removal of the MBA protein. Monecke et al. first 
described MBA negative variants following selection of strains which were 
unable to adhere to HeLa cells (Monecke et al. 2003), but Zimmerman et al. 
were first to propose a mechanism for this removal of antigen. These authors 
suggested that the mba gene and the adjacent UU376 gene (encoding a 26.9 
kDa protein named Ureaplasma phase-variable membrane protein 376 
(Upvmp376)) are separated by an inverted promoter, such that only one gene 
can be expressed for each bacterium. They suggested that within a mixed 
population of Ureaplasma a proportion of variants would express MBA 
whereas another proportion would express Upvmp376. By selection 
pressures imposed by antibodies to either of these proteins, selection would 
select for the survival of the bacterial sub-group expressing the less dominant 
immunoepitope. Blots for VxF3 identified a low molecular weight protein, but 
the potential identity in relation to the low molecular weight Upvmp376 protein 
is unknown. Only N-terminal sequencing, or post-decay analysis of mass- 
spectroscopy of purified bands would identify if the immunoreactive proteins 
on my blots were MBA (higher) or Upvmp376 (lower bands). Future studies 
would focus on protein sequencing methods, such as n-terminal sequencing, 
to determine the identity of the dominant immunoreactive epitopes or scaling 
up of Ureaplasma cultures for use in triton X114 lipoprotein isolations.
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3.3.4 The role of the classical pathway as assessed by IgG 
depleted serum (using a protein A column) and western blot
As the alternative pathway had little effect upon killing, three sera with low
killing and three sera with high killing were depleted of IgG using a protein A
sepharose column with depleted sera then used in the standard assay
(Figure 3.5). The depletion of IgG from the sera resulted in a loss of the
majority of killing of DKF-1 (SV1), HPA2 (SV6) and HPA32 (SV14) relative to
non-depleted bacteriocidal serum. HPA5 (SV3), which was killed by all sera
tested, retained most of the bacteriocidal activity following depletion. By using
the same batch of protein A depleted serum for all serovars, the presence of
0
reduced killing of the non-SV3 isolates served as an internal control to rule out 
the result being due to either dilution or activity loss caused by the depletion 
process.
3.3.5 The role of the lectin pathway
As mentioned from the twelve sera studied, two of volunteers were 
seronegative for IgG by western blot (VxF1 and VxF9). Although via IgG 
depletion experiments antibody was shown to be essential for the killing of 
DKF-1, HPA2 and HPA32 these seronegative sera were still able to kill HPA5 
to the same degree as those which were seropositive. One possibility 
included complement activation occurring via the lectin pathway. Depleting 
the MBL from the two seronegative sera and applying this serum to the killing 
assay has shown that killing of HPA5 still occurred (Figure 3.6), but this was 
not to suggest that MBL opsonisation does not occur. Benstein et al.}
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demonstrated the ability of rabbit and human MBL to bind Ureaplasma
(Benstein et al. 2004), although they did not demonstrate functional killing (or
complement activation) as a result, nor provide evidence for non-specific
guinea pig anti-rabbit MBL binding. An additional finding from this group was
the ability of horse MBL from serum components of the growth media to bind
Ureaplasma. This was not a surprising finding as Ureaplasma had previously
been shown to contain mannose within the outer-membranes (Whitescarver et
al. 1975; Smith, 1985). To rule out the possibility of pig MBL from within the
USM binding and eliciting killing in the MBL depleted sera experiments, HPA5
cultures were grown in USM without pig serum and supplemented with 1%
#
heat-inactivated MBL depleted serum from either VxF1 or VxF9 prior to 
complement attack. This ensured no decoration of Ureaplasma with MBL 
during the growth of target bacteria, which would remain bound prior to serum 
exposure. This did not result in any reduction of killing further supporting the 
inability of MBL binding to result in terminal complex formation.
Although classical, alternative and MBL in the lectin pathway were ruled out 
as the mechanisms of HPA5 killing, the inability of C6 deficient serum to 
mediate killing proved that terminal complex formation was essential (Figure 
3.7).
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3.3.6 The role of the classical pathway as assessed by 
blocking o f C1q function and IgG depletion using a protein G 
column
To this point the mechanism of SV3 killing was unknown with all three 
activation pathways being ruled out. To fully rule out the classical pathway a 
function blocking anti-C1q antibody was used to fully block the classical 
pathway with proof of principle demonstrated by inhibition in a CH50 assay 
(Figure 3.8).
The findings from the C1q function blocking experiments proved the essential 
role for the classical pathway in SV3 killing and therefore contradicted the 
results from IgG depletion data, which suggested killing of SV3 seemed to be 
IgG independent, as well as questioning the data from the western blots, 
which suggested that VxF1 and VxF9 were seronegative for both IgG and 
IgM.
The most likely explanation for the contradiction of the IgG depletion data 
would be due to a methodological error. By looking back at the literature 
regarding protein A columns, it is now clear that a protein A only depletes IgG 
subclasses 1, 2 and 4, therefore leaving the potent complement activator lgG3 
within the serum, whereas a protein G column would deplete all subclasses 
(lgG1, 2, 3 and 4). For this reason a selection of sera were depleted of total 
IgG by this methodology. The results from these data were mixed, with half of 
the sera examined retaining killing post depletion, including one of the
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previous seronegatives (VxF9), whereas the killing was removed in the 
remaining half, including the second seronegative sera (VxF1) (Figure 3.10).
These results from the protein G data (Figure 3.10) additionally contradict the
results from the western blot data (Figure 2.4) by suggesting that the
previously designated seronegative serum from VxF9 did contain anti-
Ureaplasma IgG. A possible reason for the absence of reactive bands upon
western blot probed with serum from VxF9 include the possibility that the lgG3
antibodies recognise an conformational dependent epitope, therefore when
the protein is denatured and separated on a western blot, the binding is lost.
0
A second possibility may be due to the low sensitivity of the western blot 
technique. lgG3 makes up only 7% of total IgG and is found at a circulating 
concentration of 0.8 mg/ml whereas the most abundant IgG, lgG1, makes up 
around 65 % of circulating IgG and exists at serum concentrations of ten times 
that of lgG3 (8 mg/ml).
As mentioned the results from the protein G depletion experiment accounted 
for the removal of killing of sera from VxF1, 3, 7 and partial removal of killing 
for VxF2 and 4, but could not explain the retention of killing for sera from 
VxF9, VxM11 and VxM12. This killing in the previously designated 
seronegative sera of VxF9 could be attributed to an undetectable IgM 
response by western blot. Unfortunately a IgM specific anti-p antibody was 
not used to look for this antibody in IgG positive VxM11 and VxM12 sera as 
the polyvalant anti-lgM/G/A antibody used to confirm the absence of IgM 
response in the previously designated seronegative sera detected IgM as well
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IgG and IgA. For this reason future work should use a IgM specific anti-p 
antibody to rule out its role.
Although this methodological error initially suggested an IgG independent 
killing mechanism for SV3, it presented interesting data on what subclass of 
IgG is raised to this serovar. From the combination of the protein A and 
protein G depletion data we can speculate an IgG response raised to SV1, 6 
and 14 would be predominantly skewed towards the lgG1 subclass as lgG4 
does not activate complement and lgG2 has relatively poor activating 
properties. In contrast the removal of all IgG results in the removal of SV3 
killing in a number of sera suggesting a bias towards an lgG3 response.
The data from the anti-C1q function blocking experiment also confirmed 
previous results regarding the lack of killing from the alternative and lectin 
pathways. If these pathways were functional, killing would be present 
following the blocking of C1q and therefore the classical pathway.
This evidence for the essential role of IgG in complement mediated killing of 
Ureaplasma supports the association between Ureaplasma infection and 
hypogammaglobulinemic patients who have an inherent inability to produce 
antibodies and therefore receive intravenous IgG on a regular basis. Furr et 
al., described their observations of the occurrence of Mycoplasma and 
Ureaplasma infections in hypogammaglobulinaemic patients over a period of 
20 years (Furr et al. 1994). They found that from 91 
hypogammaglobulinaemic patients 21 (23%) had septic arthritis in the
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absence of either aerobic or anaerobic bacteria, with 8 of these (38 %) 
positive for Mollicutes, 4 of which were Ureaplasma. In one case Ureaplasma 
were isolated from four independent joints (shoulder, elbow, wrist, knee).
3.3.7 Variations in killing at the intraserovar level
Results from the four U. parvum serovar representatives suggested that SV3 
was the most serum sensitive isolate identified in this study. This finding was 
counter-intuitive to what would be expected, due to the most sensitive serovar 
being the most commonly isolated as shown by my results in chapter 5 as well 
as other investigators (Nelson &  al. 1998; Glass et al. 2000). To rule out 
that this was not a strain specific finding of HPA5, the variation of killing at the 
intra-serovar level was examined for all serovars against a selection of high 
and low bacteriocidal sera (as judged against the prototype strains; Figure
3.11). Data from VxF1 consistently showed an inability to kill five different 
SV1, two SV6 and two SV14 strains, whereas killing was present against all 
five strains of SV3, albeit to varying amounts. Western blot analysis again 
failed to show any banding for any of the 14 different strains examined (Figure
3.12). A similar picture was seen for the low killing VxF4 which had reduced 
killing to three out of five SV1 and all SV6 isolates. VxF6 had low killing 
against both SV14 strains, but killed all SV3 strains. All the high killers, VxF3, 
VxF7 and VxM12 killed all strains in a similar manor to that of the prototype 
strains used. An interesting exception to this rule was the 1624-fold reduced 
ability, relative to other SV1 isolates, of VxM12 serum to kill UHWO10. This 
correlated with the absence of an approx 85 kDa band which was present in 
all remaining SV1 isolates (asterix in Figure 3.12) and of the same size as the
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SV1 specific 85 kDa band described by Watson et al. from Ureaplasma 
infected patients (Watson et al. 1990). As discussed later in Chapter 5 this 
isolate was additionally resistant to macrolide antibiotics, but it is unlikely that 
there is any link between the mechanism of macrolide resistance and this 
finding. Further discrepancies were seen in the reduced killing capacity of 
serum form VxF7 against SV3 strains HPA1 and HPA14.
3.3.8 Previous findings on complement activation and 
Ureaplasma
The results described in this study contradict those found previously by 
Webster et al., who concluded that complement alone had little effect upon 
the killing of Ureaplasma (Webster et al. 1988). Two possible reasons can 
account for these discrepancies. Firstly Webster et al., added human serum 
directly into actively growing cultures in Ureaplasma media. As described in 
section X Urea is a nucleophile and would abrogate the efficient attachment of 
C3b and C4b to bacteria, hence the reason for this assay in which U. parvum 
were transiently exposed to human serum in the absence of urea. Secondly 
evidence present here has shown that the presence of antibody is essential 
for the killing of U. parvum serovars, but the presence of antibodies alone may 
not be enough to elicit killing if the dominant antigenic targets are internal. 
Webster et al., demonstrated low concentration of antibodies to the SV5 U. 
urealyticum isolate used in the experiments, but these, as discussed, may 
have been against internal antigens and be ineffective.
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3.3.9 Relevance to the clinical picture
The work presented in this chapter only takes into consideration a very small 
component of the complement system and its role in modulating the host 
immune system. This work has shown that SV3 is particularly susceptible to 
MAC-mediated killing, but MAC killing only represents a small fraction of the 
role of complement in the clearance of infection and potentially of serovars 1, 
6 and 14. The complement system bridges the gap between the innate and 
cellular immune response so that even in the absence of MAC-mediated 
killing, complement activation can result in the release of anaphlatoxins (C3a 
and C5a) which will recruit phagocytes to the site of infection and aid in 
clearing infection. Clearance of Ureaplasma can also occur as a result of 
opsonisation with either antibodies, C3b or MBL. As previously mentioned 
Benstien et al., demonstrated MBL can bind Ureaplasma, but, as my data 
suggests, does not lead to MAC mediated killing (Benstein et al. 2004). For 
this reason we cannot rule out the possibility that MBL may opsonise 
Ureaplasma therefore allowing clearance by macrophages by recognition 
through collectin receptors such as calrecticulin in complex with CD91.
As Ureaplasma are primarily found on mucosal surfaces, such as the lung, an 
understanding of the complement system at this area is needed. Complement 
components C1r, C1s, C4, C3, C5, C6, C7, C8, C9, fB, fH and fl have all been 
shown to be produced within the lung by either alveolar type II epithelial cells 
or alveolar macrophages (Rothman et al. 1989; Strunk et al. 1988). Later 
work by Rothman et al., showed that expression of complement components 
could be regulated by cytokines in a dose dependent manner with IL-ip
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producing a two-fold increase in C3, but a 50 % decrease in C5 (Rothman et 
al. 1990). Using clinical BALF samples Watford et al., confirmed the earlier in 
vitro cell line data along with functional studies (Watford et al. 2000). These 
data present evidence for a local source of complement within the lung which 
Ureaplasma would have to overcome. The complement system in the context 
of CLD may be important as clearance by MAC mediated lysis could 
potentially reduce the number of neutrophils’ entering the lung and releasing 
tissue damaging proteases.
Although classical complement components are found locally within the lung 
the predominant activators, IgG and IgM, are in significantly lower abundance 
relative to the imunoglobulins of the IgA class. Unlike IgG and IgM, IgA does 
not have the capacity to activate complement, but is thought to inhibit the 
adherence of invading pathogens and therefore prevent further invasion 
(Underdown and Schiff, 1986). IgA must pose a significant hurdle for 
Ureaplasma to overcome as all serovars have been found to contain human- 
specific IgA proteases (Robertson et al. 1984), but has little role in 
complement mediated killing. Therefore an IgG and IgM response may play 
more of a role in the prevention of further systemic infection and confining the 
bacteria to mucosal surfaces. Clinical evidence for this was discussed earlier 
with hypogammaglobulinaemic patients being prone to invasive disease 
caused by Ureaplasma (Watson et al. 1990; Furr et al. 1994).
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3.4 Summary
This chapter has firstly described an assay to quantify the bactericidal effects 
of human serum upon Ureaplasma. This methodology was manipulated in a 
way to pin-point the key complement activation pathways involved in U. 
parvum killing. The key findings identified that the classical pathway as the 
predominant pathway involved in killing all serovars. Killing of SV1, 6 and 14 
was dependent upon the presence of IgG subclasses 1, 2 and 4 whereas 
killing of SV3 was dependent, in half of the cases, on lgG3. It can be 
speculated that the remaining sera which killed SV3 an anti-SV3 IgM was 
present. The alternative and lectin pathways were ruled out due to negligible 
killing in the absence of Ca2+ and MBL, respectively, as well as lack of killing 
in the absence of the classical pathway as demonstrated by the anti-C1q 
function blocking antibody.
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4.1 Introduction
Chronic lung disease of prematurity (CLD) remains a cause of significant 
morbidity and mortality in preterm infants. Although it’s risk factors have been 
defined for many years, its exact aetiology remains unknown. A strong link 
between microbial infections, with particular reference to bacteria within the 
genus Ureaplasma, has been strongly debated
In the first results chapter I examined the body’s innate ability to prevent 
infections caused by Ureaplasma via complement mediated killing. This 
results chapter will therefore focus on the consequences if the balance 
between immunity and infection tips in favour of the infecting organism. I aim 
to address the question of the role of bacterial infection, with particular focus 
on Ureaplasma spp., on the development of CLD in a cohort of 192 babies. 
By sequencing 16S rRNA products, the identity of infecting organism can be 
matched to clinical outcome. Data from co-workers on the inflammatory 
response in these samples using the markers IL-6 and IL-8 will be used to 
compare the presence of bacteria with an immune response.
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4.2 Results
4.2.1 Differences in DNA integrity between clinical sample 
type relative to sampling method and site
DNA was extracted from 392 bronchioalveolar lavage (BAL), 134 gastric fluids 
(GF), 66 endotracheal aspirates (ETA) and 248 nasopharyngeal aspirate 
(NPA) samples from 192 patients. Successful isolation of intact human DNA 
was determined by positive PCR reaction amplifying the human mitochondrial 
cytochrome oxidase gene (HMCO). Although there is no clear relationship 
between host DNA integrity and bacterial DNA integrity, following extraction, 
failure to amplify host DNA would suggest that a failed 16S PCR could be due 
to poor DNA integrity rather than lack of bacteria. The return in HMCO DNA is 
shown in Figure 4.1 and expressed as percentage of the total number of 
samples. NPA samples had the greatest return in DNA (80%) while ETA and 
BAL were similar (77 and 74%, respectively) and GF were lowest (63%). BAL 
samples analysed came from two independent studies, both of which used 
different numbers of eukaryotic cells in initial experiments which therefore 
could potentially influence the amount of residual material available for 
extraction. When analysed separately 82 % of BAL samples from the 
protease study were positive (greater residual for processing) compared with 
66 % of samples from the flow cytometry and apoptosis study (sometimes 
very little residual sample).
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Figure 4.1. DNA recovery from various sample types following extraction with 
the QIAGEN® RNA/DNA Mini kit (25). (A) DNA integrity from all sample types; 
GF - Gastric fluid, NPA - nasopharyngeal aspirate, ETA - endotracheal 
aspirate, BAL - Bronchioalveolar lavage (all BAL samples). (B) Difference in 
DNA integrity between BAL samples from a study examining neutrophil 
proteases and one studying neutrophil apoptosis
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4.2.2 Culture versus PCR on DNA extracts for the detection of 
Ureaplasma
Table 4.1 examines the longitudinal relationship between DNA integrity, as 
measured by presence of HMCO, with ability to detect Ureaplasma by PCR in 
a selection of BAL samples. These results are compared to results from 
direct culture of samples and subsequent PCR confirmation. From the 12 
BAL samples taken from Baby O only four were positive for HMCO. This 
intermittent positivity was additionally seen in Ureaplasma positivity as 
assessed by PCR on the extracted DNA. Two of the HMCO positive samples 
correlated with Ureaplasma positive samples (02 and 06). The third 
Ureaplasma positive sample, 03, correlated with a negative HMCO sample. 
In comparison, the results by culture were consistently positive. All 12 
samples were Ureaplasma culture positive (colour change) as were the 
urease PCR reactions performed on the cultures (6 out of the 12 were cloudy 
indicating additional bacterial presence). Four out of six 16S rRNA positive 
samples for Baby O were positive despite an HMCO negative result. A similar 
trend in relationship between HMCO, Ureaplasma PCR on DNA extract, 16S 
rRNA PCR and Ureaplasma culture were seen for babies Q, W and Y (Table 
4.1).
4.2.3 Sensitivity of primers
To determine the detection limits of the urease (pan-Ureaplasma), UM-1 
(Ureaplasma speciation) and 16S rRNA primers 10-fold dilutions of DNA of a 
known 106 CCU culture were tested. From Figure 4.2 it is clear that the
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urease primers were most sensitive by detecting DNA as low as 1 CCU. 
Primer set UM-1, used for identifying U. parvum from U. urealyticum isolates, 
could weakly detect 102 CCU, but intense bands were only seen at 104 CCU. 
Finally the 16S rRNA primers required 105 CCU for a successful PCR 
reaction.
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Baby O 01 02 03 04 05 06 07 08 09 010 011 012
Ureaplasma culture + + + +/- +/- +/- +/- + + + +/- +/-
PCR confirmation1
Ureaplasma PCR2 - + + - - + - - - - - -
16s rRNA PCR2 + + + - + + - - + - - -
HMCO PCR2 - + - - - + - + - - + -
Baby Q Q1 Q2 Q3 04 Q5 Q6 Q7 Q8 Q9 Q10
Ureaplasma culture - + + + + +/- + + + -
PCR confirmation1 - + + + + + + + + -
Ureaplasma PCR2 - - + + + - - + + -
16s rRNA PCR2
HMCO PCR2 + - + + + - + + + -
Baby W W1 W2 W3 W4 W5 W6 W7 W8 W9 W10
Ureaplasma culture + + + + + +/- - - +/- +/-
PCR confirmation1 + + + + + - - - + +
Ureaplasma PCR2 + + - +
16s rRNA PCR2
HMCO PCR2 + + - + - - - + - -
Baby Y Y1 Y2 Y3 Y4 Y5 Y6 Y7 Y8 Y9 Y10 Y11 Y12
Ureaplasma culture - - - - +/- +/- +/- +/- + +/- +/- +
PCR confirmation1 - - - - + + + + + + + +
Ureaplasma PCR2 + -
16s rRNA PCR2 +
HMCO PCR2 + + + + - + - - + + + -
Table 4.1. A longitudinal examination of Ureaplasma colonisation status in 
four neonates comparing PCR results for HMCO, Ureaplasma, and 16S rRNA 
versus specific Ureaplasma culture. +/- denotes a mixed culture. 
1Ureaplasma positive cultures were confirmed via PCR amplification of the 
urease gene on DNA extracted from cultures. 2Template DNA for these PCR 
reactions was obtained from direct DNA extraction of clinical samples
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Figure 4.2. Agarose gels showing the sensitivity of (A) urease primers, (B) 
UM-1 speciation primers and (C) 16S rRNA primers against Ureaplasma. The 
final dilution to show colour change (i.e. 1 CCU) was to the dilution of 10'6 (106 
CCU).
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4.2.4 Patient demographics
From 192 babies enrolled to the study 61 were born at term (gestation >37 
weeks). 131 preterm infants of <34 weeks gestation were enrolled of which 
88 developed and recovered from RDS, 35 developed CLD (defined as 
oxygen dependence at 36 weeks post-conceptional age) and 8 died. Of the 
840 samples collected 88 were from the term group, 408 from infants with 
RDS, 309 from the CLD group and 35 from babies who died. A full list of 
patient demographics are shown in Table 4.2.
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CLD RDS Term Death
Number of 
patients
35 88 61 8
Number of 
samples
GF:BAL:NPA:ET
309
10:260:9:30
408
69:73:236:30
88
51:37:0:0
35
4:22:3:6
Gestational age 
(weeks)
26+b + 2+1 
(23+4-3 1 +6)
30+b + 2+z 
(26 -  34)
38+b+ 1+b 
(37 -  42+1)
26+6+ 1 +2 
(25+6 -  30+3)
Birth weight Kg 1.03 + 0.65 1.50 + 1.43 2.92 + 0.64 0.87 + 1.59
(Range) (0.53 -  2.73) (0.61 -3.41) (0.91 -  4.35) (0.55-1.49)
Male: Female 18:17 41:47 41:20 6:2
VaginakCaesarean
Delivery
19:16 24:64 33: 28 3:5
Antenatal steroids 
>24 hours
22/35 (63%) 71/88 (81%) 2/61 (3.3%) 7/8 (88%)
Surfactant 35/35 (100%) 43/88 (49%) 1/61 (1.6%) 8/8 (100%)
pPROM 6/35 (17%) 15/88 (17%) 7/61 (11%) 1/8 (13%)
Ventilation
(IPPV:CPAP:SV) 35:0:0 47:28:13 19:13:29 8:0:0
Ureaplasma spp 
positive
13/35 (37%) 9/88 (10%) 9/61 (15%) 3/8 (38%)
16S rRNA positive 27/35 (77%) 35/73* (48%) 14/34** (41%) 2/8 (25%)
Table 4.2. Patient characteristics for those who developed CLD, RDS and 
those who were born at full term gestation. *Only 73 patients within the RDS 
group were examined for presence of 16S rRNA. Values are mean or 
proportion of total patients within each group. ** Only 41 patients within the 
term group were examined for presence of 16S rRNA. IPPV = intermittent 
positive-pressure ventilation. CPAP = continuous positive airway pressure. 
SV = self-ventilation.
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4.2.5 Association between infection and development of CLD
An association was noted between the presence of Ureaplasma and 
development of CLD as shown in Table 4.3a. Of the 35 babies in the CLD 
group, 37% were positive for Ureaplasma relative to 10% of RDS babies and 
15% of terms. When the preterm groups who developed either RDS or CLD 
were compared, the association with development of CLD and presence of 
Ureaplasma was highly statistically significant by the Mann-Whitney unpaired 
t-test (p=0.0004). 16S rRNA PCR was performed on samples from 164
infants. When the association of presence of microbial genes and 
development of CLD samples were examined, 77% of the infants in the CLD 
were positive compared with 48% of the RDS babies and 41% of terms 
(p=0.004) (Table 4.3b).
In order to determine if the infection occurred antenatally or postnatally, I 
divided the samples into those which were positive on or before three days 
(likely ante- or perinatally acquired) of age and those who only became 16S 
PCR positive after the first three days of life (postnatal acquired). The 
association between day of detection of colonisation with Ureaplasma and 
other microbes relative to development of CLD is shown in Table 4.4a and 
4.4b, respectively. There was a significant association between Ureaplasma 
and 16S rRNA genes within the first three days of life (p=0.005 and p=0.003, 
respectively) whereas the association was significant post three days, but to a 
lesser extent. (p=0.01 and 0.04, respectively).
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A.
Ureaplasma
detected
Ureaplasma not 
detected
TOTAL
Term 9(15%) 52 (85%) 61
RDS 9(10%) 79 (90%) 88
CLD 13 (37%) 22 (63%) 35
Died 3 (38%) 5 (62%) 8
Total 34 158 192
B.
16SrRNA 
detected
16S rRNA 
not detected
TOTAL
Term 14(41%) 20 (59%) 34
RDS 35 (48%) 38 (52%) 73
CLD 27 (77%) 8 (23%) 35
Died 2 (25%) 6 (75%) 8
Total 78 86 164
Table 4.3. Contingency tables demonstrating the relationship between (A) the 
presence of Ureaplasma spp. and (B) 16S rRNA with clinical outcome. The 
relationship between Ureaplasma and 16S rRNA was statistically significant 
between RDS and CLD groups (p=0.0004 and p=0.004, respectively)
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A.
Ureaplasma 
< 3 days
Ureaplasma 
+ 4 days Total
+ - + -
RDS 6 (7%) 82 (93%) 3 (3%) 85 (97%) 88
C LD 8 (23%) 27 (77%) 5 (14%) 30 (86%) 35
Total 14 109 8 115 123
B.
16S 16S
< 3 days + 4 days Total
+ - + -
RDS 14(19%) 59 (81%) 21 (29%) 52 (71%) 73
C LD 14 (40%) 21 (60%) 13 (37%) 22 (63%) 35
Total 28 80 34 74 108
Table 4.4. Contingency tables demonstrating the relationship between the 
initial detection of (A) Ureaplasma and (B) 16S rRNA before and post three 
days of birth. There was statistical significance between presence of 
Ureaplasma and development of CLD within three days (p = 0.005) and 
additionally to a lesser extent for post three days (p= 0.01). Similarly there 
was statistical significance between presence of 16S rRNA and the 
development of CLD within three days (p = 0.003), but again to a lesser extent 
post three days (p= 0.04).
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4.2.6 Relationship between /L-6 and IL-8 with infection and 
ciinical outcome
Concentrations of the pro-inflammatory cytokines IL-6 and IL-8 were 
examined by ELISA (Dr Eamon McGreal and Dr Mallinath Chakraborty) in 
BAL samples from 63 and 62 infants, respectively. The peak results for each 
individual infant were correlated with the presence or absence of either 
Ureaplasma or 16S rRNA genes as shown in Figures 4.3a and 4.3b. Samples 
positive for either Ureaplasma or microbial genes had median BAL fluid IL-6 
and IL-8 values of 12,389 pg/ml and 9,690 pg/ml, respectively, which were 6- 
fold and 4-fold greater than the respective median values in the microbial 
negative samples (both p<0.0001). Only when samples within the first three 
days were examined a significant relationship was also noted between IL-6 
(p=<0.05) and IL-8 concentrations (p=<0.05) and presence of microbes 
(Figure 4.3c and 4.3d, respectively).
The peak values for the IL-6 and IL-8 for each diagnostic group is shown in 
Figure 4.4 with presence of microbes shown as filled (present) and unfilled 
(absent) markers. BAL fluid samples from term babies had both the lowest IL- 
6 and IL-8 median values of 980 and 12,107 pg/ml, respectively. RDS babies 
had median IL-6 and IL-8 levels of 5,170 and 17,502 pg/ml, respectively, 
whereas CLD babies had median levels of 15,594 and 122,550 pg/ml, 
respectively. Using a Mann Whitney U-test the differences between RDS and 
CLD IL-6 and IL-8 were statistically significant (p=<0.005 and p=<0.0001, 
respectively).
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Figure 4.3. Correlation between peak IL-6 and IL-8 levels and presence of 
bacteria within BAL samples. (A) Peak IL-6 levels across sampling period, (B) 
peak IL-8 levels across sampling period, (C) peak IL-6 within three days and 
(D) peak IL-8 within three days.
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Figure 4.4. Peak levels of IL-6 (A) and IL-8 (B) from BAL samples for term, 
RDS, CLD and infants which died. Open shapes represent bacteria negative 
patients and closed shapes represent bacteria positive patients.
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4.2.7 Bacteria associated with peaks in IL-6 and IL-8
Amplicons from 16S rRNA positive samples which coincided with peaks in IL- 
6 and IL-8 were sequenced to determine the species of infecting organism 
(Table 4.5). Staphylococcus epidermidis was the most prevalent organism 
which was isolated from infants who went on to develop RDS with one peak 
being associated with Fusobacterium nucleatum. Gram-negative organisms 
were more frequently associated with peaks in CLD babies and included 
Escherichia coli, Haemophilus influenzae, Enterobacter spp. and P. 
aeruginosa, although Gram-positives including S. epidermidis and 
Staphylococcus haemolyticus were additionally identified. Twice as many U. 
parvum were isolated relative to U. urealyticum in both RDS and CLD babies.
4.2.8 Sequence homology between 16S rRNA primers and 
bacteria detected.
To rule out the possibility of any bias in the binding of either the 27f or 1492r 
16S rRNA primers, the binding sequence for each organism detected in this 
study was examined using genome sequence data (Figure 4.5). As can be 
seen the degeneracy in each of the primers allows specific and unbias binding 
to all of the bacteria identified in this study.
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4.2.8 Day of initial 16S rRNA positive sample and clinical 
outcome
The relationship between 16S rRNA positivity and day of first acquiring an 
infection is presented in Figure 4.6. From the 27 CLD babies which were 16S 
rRNA gene positive, 56% (15/27) were positive within the first 3 days, which 
decreased to 26% (7/27) at days 4 to 6 and then 7% (2/27) at days 7-9 and 
10-12. In the RDS group, 37% (13/35) of babies were colonised within the 
first 3 days of with subsequent colonisation occurring in 17% (6/35) of babies 
on days 4-6, 14 % (5/35) on days 7-9.
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RDS
Gram-positive Incidence
Staphylococcus epidermidis 3
Gram-negative
Fusobacterium nucleatum 1
Other
Ureaplasma parvum 2
Ureaplasma urealyticum 1
CLD
Gram-positive Incidence
Staphylococcus epidermidis 4
Staphylococcus haemolyticus 1
Gram-neaative
Escherichia coli 2
Haemophilus influenzae 1
Enterobacter spp. 1
Pseudomonas aeruginosa 1
Other
Ureaplasma parvum 4
Ureaplasma urealyticum 2
Mixed 2
Table 4.5. Bacteria associated with peaks in IL-6 and IL-8 from BAL samples. 
Peak levels of IL-6 and IL-8 from BAL fluids from preterm infants were 
correlated with the presence of infection. 16S rRNA positive samples were 
then sequenced to identify the infecting organism. The number of samples 
containing each organism is indicated.
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16S rRNA primers
(with degeneracy in green)
27f 1492r
AGAGTTTGATCfcGGCTCAG TACGGiTACCTTGTTACGACTT
agagtttgatcJtggctcag tacggJtac cttgttacgactt
Bacteria Primer binding sites
S. epidermidis TCTCAAACTAGGACCGAGTC ATGCCGATGGAACAATGCTGAA
S. haemolyticus TCTCAAACTAGGACCGAGTC ATGCCGATGGAACAATGCTGAA
F. nucleatum TCTCAAACTAGGACCGAGTC ATGCCAATGGAACAATGCTGAA
U. parvum TCTCAAACTAGGACCGAGTC ATGC CAATGGAACAATGCTGAA
U. urealyticum TCTCAAACTAGGACCGAGTC ATGCCAATGGAACAATGCTGAA
H. influenzae TCTCAAACTAGTACCGAGTC ATGCCAATGGAACAATGCTGAA
Enterobacter spp TCTCAAACTAGTACCGAGTC ATGCCAATGGAACAATGCTGAA
E. coli TCTCAAACTAGTACCGAGTC ATGCCAATGGAACAATGCTGAA
P. aeruginosa TCTCAAACTAGTACCGAGTC ATGCCGATGGAACAATGCTGAA
Figure 4.5. 16S rRNA primer homology to sequences from bacteria detected 
in BAL supernatants. Green highlighted areas show the area of degeneracy 
in the primers (A/C at position 19 in primer 27f and T/C at position 1497 in 
primer 1492r). Yellow highlighted areas show region of divergence in primer 
binding sequence which coincide with primer degeneracy. 16S rRNA 
sequences were from the following organisms; S. epidermidis (ATCC 12228), 
S. haemolyticus (JCSC 1435), F. nucleatum (ATCC 25586), U. 
parvum (ATCC 700970), U. urealyticum (ATCC 33699), H. influenzae (Rd 
KW20) Enterobacter spp (638), E. coli (K12 MG1655) and P. aeruginosa 
(PA01).
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Figure 4.6. Rate at which samples first became 16S rRNA by day. Closed 
and open bars represent the number of babies which were initially 16S rRNA 
positive within the designated day and went on to develop CLD or RDS, 
respectively. The number of individual patients per the total of each group are 
represented above the respective bar.
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4.2.9 Relationship between Ureapiasma infection and 
gestational age
Figure 4.7 shows the relationship between gestational age and acquisition of 
Ureaplasma broken down into clinical outcome. Percentage of colonisation 
between 23 and 26 weeks ranged between 41 and 67 %. All infants 
colonised with Ureaplasma between 23 and 25 weeks developed CLD 
whereas of the 7/17 colonised, born at 26 weeks: 3 developed CLD (18 %), 2 
developed RDS (12 %) and 2 died (12 %). The percentage of colonisation 
dropped to 20 % in infants born at 27 weeks and continued to decline as 
gestation increased.
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Figure 4.7. The association between Ureaplasma positivity and gestational 
age. Closed, open, light grey and dark grey bars represent percentage of 
babies born at respective gestational age who were colonised with 
Ureaplasma and developed CLD, RDS, died or were born at term, 
respectively. The number of Ureaplasma positive patients per the total born 
for each week are shown above the respective bar.
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4.3 Discussion
The primary aim of this chapter was to examine the role of infection, with 
particular focus to Ureaplasma, in development of CLD. From 192 neonates a 
total of 840 samples (392 BAL, 134 GF, 66 ETS and 248 NPA) were 
examined for the presence of infection and correlated with both clinical 
outcome as well as presence of inflammatory markers IL-6 and IL-8.
4.3.1 Quality of DNA and from extraction
Detection of the HMCO gene was used as a method of confirming successful 
DNA isolation from a variety of clinical samples. Of the four sample types 
NPA gave the greatest return in HMCO followed by ETA, BAL and finally GF. 
Factors which may potentially influence the presence of HMCO following 
extraction include the amount of start material, DNA degradation during the 
extraction process or false-negatives on PCR due to the presence of PCR 
inhibitors. Nelson et a!.., examined the presence of PCR inhibitors in a 
selection of 115 DNA extracts from ETA samples which were negative for 
Ureaplasma DNA (Nelson et ai. 1998). By adding the equivalent of 10 -  20 
CCU of Ureaplasma DNA to each sample they identified 7% of samples 
contained inhibitors. This may account for a number of the negative samples 
identified in my studies. Additionally they stated that samples which were 
muqoid in consistency were more likely to contain PCR inhibitors as 
demonstrated by the presence of samples which were PCR negative following 
extraction, but positive by culture. This could account for the lowest level in
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DNA return from GF samples as a number of these were mucoid in 
consistency.
The BAL samples that I investigated were obtained following prior use in two 
independent studies. Those BAL samples which came from the protease 
study had greater rate of DNA positivity (82%) than those from the apoptosis 
study (62 %). The different rate of positivity likely reflects the amount of cells 
remaining for DNA extraction following use in the primary projects. A greater 
number of cells were most likely remaining following preparation of cytospins 
for the protease study whereas in some cases almost all of the cells were 
required for the apoptosis study which utilised flow cytometry as well as 
cytospins. If the BAL samples from the apoptosis study were removed, then 
BAL samples from the protease study would be the most reliable sample to 
obtain HMCO DNA (82% vs. 80% from NPA).
4.3.2 Culture versus PCR for the detection of Ureaplasma
Table 4.1 shows a selection of four babies (Baby O, Q, W and Y) comparing 
the ability of PCR upon DNA extracts and culture based methods to detect 
Ureaplasma. Additionally it shows the presence of 16S rRNA and the HMCO 
DNA quality control marker. HMCO results were intermittently positive for all 
babies suggesting, as discussed in section 4.3.1, either no human DNA was 
isolated or the presence of PCR inhibitors. Although inhibitors are a 
possibility, a number of samples, for example 01 , 03, 05  and 09, were 
positive for 16S rRNA, but HMCO negative. One possible explanation for this 
would be the lack of human cells in the sample, yet presence of bacteria. In
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some samples, the amount of human start material may have been low, 
whereas bacteria may have been present in the saline supernatant which was 
extracted along with the pellet. External contamination may be ruled out as 
sequencing of the 16S rRNA product for Baby O revealed the presence of E. 
coli, which correlated with the clinical findings of the NHS diagnostic 
laboratories. Due to the HMCO being an indicator for successful isolation of 
human DNA, and not prokaryote DNA, and the presence of 16S rRNA and 
Ureaplasma PCR positive in HMCO negative samples, little emphasis was 
placed on those samples which were HMCO negative. In addition, multiple 
samples were taken from each baby; therefore intermittent positivity for 
HMCO was not of significant concern.
An unexpected finding was the poor ability of the 16S rRNA primers to amplify 
Ureaplasma DNA. For example extracted DNA for samples Q3, Q4, Q5, Q8 
and Q9 were positive by urease PCR primers, suggesting presence of 
Ureaplasma DNA, but were negative by 16S rRNA. By looking at the data on 
the sensitivity of primers in Figure 4.2, it was seen that the lower level of 
detection for the 16S rRNA primers against Ureaplasma was 105 CCU; 
therefore, any samples containing less than this threshold limit would not be 
detected. One explanation for this is may be the due to the low copy number 
of ribosomal operons present in Ureaplasma (two) relative to other organisms, 
such as the most commonly identified S. epidermidis (five). Poor homology 
between the 16S rRNA primers and the respective binding sequence in each 
of the Ureaplasma spp was ruled out as seen in Figure 4.5. The degenerate 
primers used take into account the small degree of divergence, a single base
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in each region, seen within this highly conserved region from all bacteria. 
Although the ability to amplify Ureaplasma 16S rRNA was poor, 16S rRNA 
sequences for samples 34.4 and 41.8 came back as U. urealyticum and U. 
parvum respectively.
The general consensus, although not as expected, suggested that culture was 
more reliable than PCR on DNA extractions for the detection of Ureaplasma. 
As seen in Table 4.1 no samples were positive by PCR if negative by culture. 
Nelson et al.. reported that PCR was a more sensitive method relative to 
culture (Nelson et al.. 1998). Figure 4.2 shows that the sensitivity of the 
urease primers within my studies were similar to that described by Nelson 
which could detect to 1 CCU. As the sensitivity for detection of both culture 
and PCR were the same, the reason for the poor correlation between PCR on 
DNA extracts and culture, could be due to failure to isolate Ureaplasma DNA 
using the QIAGEN® RNA/DNA Mini kit (25) columns. A further advantage of 
using bacterial culture for detecting Ureaplasma, versus detection via 
molecular methods, means that the antimicrobial susceptibilities of isolates 
can be examined which was crucial for the data presented in the final results 
chapter (Chapter 5).
The intermittent culture positivity seen for Baby W related to antimicrobial 
therapy received during the individual’s participation within the study period. 
The infant was treated with erythromycin for 7 days (IV infusion 10-12.5 mg/kg 
every 6 hours (4 times a day) following the confirmation of the presence of 
Ureaplasma, but when cultures became negative treatment was stopped
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leading to a resurgence of infection. Due to macrolide antibiotics, such as 
erythromycin, being bacteriostatic in action, the clearance of infection is 
dependent on the patient’s immune system being able to clear the growth- 
inhibited bacteria. The relatively naive immune status of preterm infants, such 
as Baby W, may result in a slight impairment in the clearance of infection 
relative to that of a healthy individual. Of further interest related to 
antimicrobial therapy in this patient group was the failure of Baby O to clear 
Ureaplasma following a 10 day course of erythromycin. Retrospective 
examination of the antimicrobial susceptibility of the Ureaplasma isolated from 
this patient, referred to as isolate UHWO10 in chapter 5, was found to be 
highly resistant to erythromycin with resistance to clarithromycin as well as an 
elevated minimum inhibitory concentration to the third macrolide, 
azithromycin. This information is discussed in detail in chapter 5. Baby Q 
treated for 10 days and cleared the infection at the end of therapy whereas 
Baby Y was never treated.
4.3.3 Association between infection and development of CLD
In this chapter I examined various clinical samples from term and preterm 
infants for the presence of infection by detection of 16S rRNA genes as well 
as selective culture and PCR for the detection Ureaplasma spp. Levels of the 
inflammatory mediators IL-6 and IL-8 in a selection of BAL samples were 
assayed and correlated with infection status and clinical outcome. The data 
presented agrees with the consensus of previous studies that perinatal 
infection is a significant risk factor in the development of CLD, especially if
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acquired within the first three days of life (Kotecha et al.. 2004; Miralles et al.. 
2005).
Ureaplasma was detected in 13 out of 35 (37%) babies who developed CLD 
relative to 9 out of 88 (10%) of RDS babies and 9 out of 61 (15%) term 
infants. The day at which samples became positive related to development of 
CLD. Significance between Ureaplasma colonisation and development of 
CLD was lower when comparing those babies who gave positive PCR results 
after the first three days of life relative to those who acquired postnatally within 
three days (Table 4.4a).
The presence of bacterial conserved 16S rRNA genes in DNA extracted 
samples was used to study the relationship between other bacterial infections 
and development of CLD. Of the 35 babies who developed CLD and were 
examined for 16S rRNA, 27 were positive (77%) relative to the 35 out of 73 
(48%) babies who developed RDS and 14 out of 34 (41%) who were born at 
term. As with Ureaplasma positivity, presence of the 16S rRNA gene and 
development of CLD was strongly significant in those babies who acquired the 
infection within the first three days of life (Table 4.4b). Samples within the first 
three days of life were twice as likely to be positive in both CLD and RDS 
infants (50% and 39% of total, respectively) than in samples on days 4 to 6 
(26% and 18% of total, respectively) (Figure 4). By sequencing the 16S rRNA 
products from samples which correlated with peaks in IL-6 and IL-8 from RDS 
and CLD infected patients, the species of organisms was identified. Gram- 
negative organisms such as E. coli, H. influenzae, Enterobacter Spp and P.
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aeruginosa were more frequently isolated from CLD patients compared with 
RDS. The pro-inflammatory nature of the Gram-negative endotoxin LPS has 
been shown in a preterm lamb model to contribute to lung damage (Kramer et 
al.. 2002). Ventilated lambs, born to pregnant ewes which had received intra- 
amniotic LPS, had elevated inflammatory markers and fewer alveoli compared 
with ventilated controls. These data suggest that the species of organism 
acquired may influence the outcome of disease. S. epidermidis was prevalent 
in a number of both RDS and CLD babies.
4.3.4 Relationship between IL-6 and IL-8 with infection and 
clinical outcome
Inflammatory mediators IL-6 and IL-8 were quantified in BAL samples from a 
selection of term, RDS and CLD patients as well as those who died. Peak 
levels of both cytokines positively correlated with the presence of infection in 
both <3 and >3 day groups. When the cytokine data was separated on 
clinical outcome, babies who developed CLD had significantly higher levels 
when compared to RDS. This association between IL-6 and IL-8 with 16S 
rRNA positivity and development of CLD has previously been shown by 
Miralles et al.. who examined tissue samples and BAL fluids from a collection 
of 41 preterm infants (Miralles etal.. 2005). Similarly, Kotecha et al.. showed 
that levels of IL-6 and IL-8 were significantly higher within the first day of life in 
Ureaplasma infected babies relative to those who were negative (Kotecha et 
al.. 2004). The significance of high IL-8 levels in BAL samples could result in 
the recruitment of neutrophils, the predominant inflammatory cell in CLD lungs
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(Kotecha et al.. 1995). Studies within our laboratories have shown that 
lavage fluids contain high levels of neutrophil elastase in CLD samples 
relative to RDS therefore potentially contributing lung damage and 
development of CLD (Davies et al.. 2009).
4.3.5 Relationship between Ureaplasma infection and 
gestational age
The relationship between Ureaplasma colonisation of neonates and 
gestational age is known to be inversely proportional (Sanchez and Regan, 
1990; Kafetzis et al.. 2004). My findings support this data by giving an in- 
depth week by week break down of colonisation rates from 23 weeks 
gestation to term (Figure 4.6). An interesting observation was 41 % (5/12) of 
infants born at 25 weeks were colonised with Ureaplasma, all of which 
developed CLD, whereas 39 % (7/18) of those bom at 26 weeks were 
colonised but only 17 % (3/18) developed CLD. This may represent a specific 
time point in the development of the neonate whereby birth after this week of 
gestation allows the infant to manage infection in a way that it is limited to 
being acute and not progresses to a chronic state.
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4.4 Conclusion
This chapter has added further evidence for the role of bacterial infection as a 
risk factor in development of CLD with specific relevance being attached to 
bacteria from genus Ureaplasma as well as Gram-negative organisms. My 
studies highlight the significance of antenatal acquisition of infection (as 
judged by detection of microbial 16S rRNA gene presence) within the first 
three days of life and are supported by the high levels of inflammatory 
mediators IL-6 and IL-8 for these patients. I have additionally shown that 
culture based methods are the most reliable means for detection of 
Ureaplasma relative to molecular based techniques following the extraction of 
DNA and allows for antimicrobial susceptibility testing therefore allowing 
treatment to be tailored to the isolate in question.
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Chapter 5
Antibiotic resistance in 
Ureaplasma spp.
189
Chapter 5 - Antibiotic resistance in Ureaplasma spp
5.1 Introduction
Antibiotic resistance among human pathogens continues to have a major 
impact on patient morbidity, mortality and economic cost to the health service 
(Lode, 2009). Due to the limited number of antibiotic effective against 
Ureaplasma as well as the further treatment limitations in neonates and 
immune compromised patients, the emergence of resistant strains can further 
complicate treatment.
Due to the technical difficulties in cultivation of Ureaplasma, susceptibility 
testing is predominantly carried out by the microbroth dilution technique using 
a standardised 104-105 CCU. In clinical isolates tetracycline resistance results 
from the expression of the horizontally acquired tetM gene, whereas 
mutations in the quinolone resistance determining regions (QRDRs) of type II 
topoisomerase genes, predominately encoding a D112E substitution in GyrA 
protein and/or Ser83Leu, Ala125Thr Ala136Thr substitutions in ParC protein, 
gives a fluoroquinolone resistant phenotype. To date the molecular 
mechanisms of macrolide resistance in clinical Ureaplasma isolates has not 
been determined; although laboratory derived strains have shown mutations 
in domain V of the 23S rRNA as well as changes in the L4 and L22 proteins to 
(Pereyre et al. 2007).
This final results chapter focuses on the potential difficulties encountered as a 
result of antibiotic resistant strains of Ureaplasma. I aim to develop a method 
of determining antibiotic resistance without prior knowledge of cell number.
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Using this methodology examine the incidence of antibiotic resistance among 
a retrospective cohort of archived samples and subsequently deduce the 
molecular mechanisms of resistance accounting to any resistant phenotypes.
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5.2 Results
5.2.1 Species distribution of screened Ureaplasma isolates 
between UHW and HP A.
Seventy-five percent (15/20) of the archived UHW samples were successfully 
revived from -80°C storage, while only 59.7% (46/77) of archived HPA 
samples were successfully revived. This may reflect the relatively short 
storage time for the former samples (less than 18 months) compared to that of 
the latter samples (up to 4 years), although differences in isolate preparation 
prior to freezing may have equally contributed. For all 61 revived samples, 49 
were found to belong to U. parvum (80%) and 12 to U. urealyticum (20%). A 
minor difference in species distribution was identified between HPA and UHW 
collections, but this was not deemed significant by Fisher’s exact test analysis 
(78% U. parvum versus 87% U. parvum, respectively). A selection of U. 
parvum isolates were further serotyped by genetic methods described by 
Teng et al. (Teng et al. 1994). From 16 isolates serotyped, four were 
classified as SV1, eight were classified as SV3, two as SV6 and two as SV14.
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5.2.2 Interpretation of results from adapted 96-well micro­
broth technique and breakpoint analysis.
An example showing strains resistant to erythromycin, ciprofloxacin, and 
tetracycline is shown in Figure 5.1. Non-turbid, dark red wells (which appear 
dark gray in the Figure) are indicative of positive Ureaplasma growth in the 
selective medium. If the last well showing growth in the 10-fold dilution (in the 
top row, lacking antibiotics) is considered to have 1 CCU, then four columns to 
the left represents 103 CCU, and five columns to the left represents 104 CCU 
(isolated by the dotted box). Following previously published recommendations 
that Ureaplasma resistance needs to be assessed using an input of 104CCU 
(Waites etal. 2001), resistance-to-threshold antibiotic concentrations (4 mg/L 
erythromycin, 4 mg/L ciprofloxacin, or 2 mg/L tetracycline) were identified by 
comparison of wells within the dotted box. Figure 5.1a shows breakpoint 
identification of an erythromycin-resistant clinical SV1 isolate (UHWO10), a 
ciprofloxacin-resistant clinical SV1 isolate (HPA18, Figure 5.1b), and a 
tetracycline-resistant clinical SV6 isolate (HPA23, Figure 5.1c). While 104CCU 
has been used to assess antibiotic resistance, using 103to 101 CCU would be 
equally valid, and no difference in our MICs was found when reading either 
the 103or 104CCU.
For those isolates identified by breakpoint analysis to have MICs greater than 
the breakpoint, the exact MIC for a single antibiotic was determined using a 
range of concentrations with a full-plate single antibiotic assay (Figure 5.2). 
Using the same method used for determining which column contained 104 
CCU (isolated by dotted box), examples of an erythromycin-susceptible
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clinical isolate (MIC 1 mg/ L) (Figure 5.2a) and the highly resistant clinical 
isolate (MIC >64 mg/L) (Figure 5.2b) are shown.
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Figure 5.1. Photographs of antibiotic breakpoint investigation showing an 
erythromycin (Erythro)-resistant strain (UHWO10) (A), a ciprofloxacin (Cipro)- 
resistant strain (HPA18) (B), and a tetracycline (Tet)- resistant strain (HPA23) 
(C). Dark red wells indicate growth of Ureaplasma while orange-yellow wells 
represent no Ureaplasma growth. Columns containing 104 CCU are identified 
by a dotted box, and comparison of growth in the absence of antibiotics 
(control) was used to determine resistance to 4 mg/L erythromycin, 4 mg/L 
ciprofloxacin, or 2 mg/L tetracycline.
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Figure 5.2. Full-plate determination of MIC for erythromycin for a susceptible 
SV1 isolate (A) and a resistant (UHWO10) isolate (B). Plates contain a 
gradient of antibiotic from 64 mg/liter to 0.06 mg/liter. Dark red wells indicate 
growth of Ureaplasma while orange-yellow wells represent no Ureaplasma 
growth. Columns representing 104 CCU growth in the absence of antibiotic 
are shown by the dotted box, and for the susceptible strain, a circle shows the 
first concentration of erythromycin to inhibit growth (MIC = 1 mg/L). Since the 
resistant isolate (UHWO10) grew even in the presence of 64 mg/L 
erythromycin, the MIC is determined to be >64 mg/L.
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5.2.3 Control isolates
To ensure that conditions for MIC determination, such as temperature and 
atmospheric conditions, were standardised control isolates recommended by 
the British Society for Antimicrobial Chemotherapy (BSAC) were examined 
using the methodology described. As seen in Table 5.1 all isolates were 
within a 2-fold dilution of that set out by BSAC recommendations (Andrews, 
2001).
Erythromycin Tetracycline Ciprofloxacin
BSAC Beeton BSAC Beeton BSAC Beeton
S. aureus (ATCC 29213) 0.25 0.5 0.5 0.5 0.5 0.25
E. coli (25922) >32 >32 2 2 0.015 <0.03
E  faecalis (29212) 4 4 16 16 1 0.5
Table 5.1 Comparison of BSAC MIC results for control strains versus that of 
results obtained in this study
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5.2.4 Incidence of antibiotic resistance in Ureaplasma isolates 
from UHW and HP A.
A total of 61 Ureaplasma isolates consisting of 46 from the HPA, Colindale, 
and 15 from UHW were examined for the presence of antibiotic resistance to 
erythromycin, tetracycline and ciprofloxacin with the isolates of interest 
summarized in Table 5.2. Six isolates were identified to have an MIC greater 
than the MIC range previously published in Cumitech 34 (0.02 to 4 mg/L) 
(Waites et al. 2001), giving the isolates a prevalence of 9.8%, although only 
one of these isolates (UHWO10) was likely to represent true antibiotic 
resistance with an MIC of >64 mg/L. Among the erythromycin-resistant 
isolates, azithromycin and clarithromycin MICs were comparable to those of 
susceptible controls, with the exception of the highly resistant UHWO10, 
which was additionally resistant to clarithromycin (MIC 4 mg/L), but 
susceptible to azithromycin albeit slightly raised (normal MIC ranges, 0.5 to 4 
mg/L for azithromycin and 0.004 to 2 mg/L for clarithromycin). A single 
tetracycline-resistant clinical isolate, HPA23, was identified with tetracycline 
and doxycycline MICs of 64 and 16 mg/L, respectively (1.6% prevalence). A 
single ciprofloxacin-resistant clinical isolate, HPA18, was also identified with 
an MIC of 8 mg/L (1.6% prevalence).
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Isolate Species MIC
Ery Azi Cla Tet Dox Cip
HP A3 U. urealyticum 4 0.5 <0.125 2 0.5 4
HPA6 U. urealyticum 4 <0.25 <0.125 2 0.5 4
HPA12 U. urealyticum 8 <0.25 <0.125 2 0.5 4
HPA17 U. urealyticum 8 0.5 <0.125 1 0.25 4
HPA18 U. parvum 8 <0.25 <0.125 2 0.25 8
HPA20 U. urealyticum 8 <0.25 <0.125 2 0.5 4
HPA23 U. parvum 4 <0.25 <0.125 64 16 <2
HPA32 U. parvum 8 <0.25 <0.125 1 0.25 <2
UHWJM U. parvum 4 <0.25 <0.125 2 0.5 4
UHWO10 U. parvum >64 2 4 1 0.25 4
UHWP2 U. parvum 4 <0.25 <0.125 2 0.5 4
UHWQ3 U. parvum 4 <0.25 <0.125 1 0.25 4
Table 5.2. MIC results for resistant and control U. parvum and U. urealyticum 
strains. MIC results from a selection of resistant (in bold) and susceptible 
isolates as determined by growth comparison at 104 CCU. Ery - erythromycin, 
Azi - azithromycin, Cla - clarithromycin, Tet - tetracycline, Dox - doxycycline, 
Cip - Ciprofloxacin.
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5.2.5 Macrolide resistance
Mutations in domain V of the 23S rRNA genes (two separate operons) and 
associated L4 or L22 protein from the prokaryotic ribosomal complex have 
previously been reported to be associated with macrolide resistance (Pereyre 
et al. 2007). These genes were sequenced from the highly resistant clinical 
isolate UHWO10 as well as HPA17 and HPA32, MIC of 8 mg/L, as well as the 
fully susceptible Q3 and compared with the published sequences (Glass et al. 
2000). No mutations were found in either the 23S rRNA operon (Figure 5.3a 
and 5.3b) or the L22-encoding gene of any of the isolates (Figure 5.4a) within 
the area previously reported contain mutations; however, a 6-bp deletion 
(AAGACA) was identified in the L4 protein gene from the highly resistant 
UHWO10 resulting in a two amino acid deletion of an arginine and glutamine 
(AR66Q67) (Figure 5.4b).
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A.
Isolate Spp. Nucleotide alignment
U. parvun? U.p 2 04 6gtgattggacggaaagaccccatgaag2 072
UHWQ3 s U.p 2 04 6GTGATTGGACGGAAAGACCCCATGAAG2 072
HPA171 U.u 2046gtgattggacggaaagaccccatgaag2072
HPA321 U.p 2 0 4 6 GTGATTGGACGGAAAGACC ccatgaag2 0 7 2
uhwoior U.p 2046gtgattggacggaaagaccccatgaag2072
B.
Isolate Spp. Nucleotide alignment
U. parvurrF U.p 2  ° 4 6 GTGATTGGACGGAAAGACCCCATGAAG2 072
UHWQ38 U.p 2046gtgattggacggaaagaccccatgaag2072
HPA171 U.u 2 0 4  6 G T G A T T G G A C G G A A A G A C C C C A T G A A G 2 0 7  2
HPA321 U.p 2 04 6GTGATTGGACGGAAAGACCCCATGAAG2 072
uhwoior U.p 2046gtgattggacggaaagaccccatgaag2072
Figure 5.3. DNA sequence alignments from the area of interest within the 
genes encoding domain V of the 23S rRNA operon 1 (A) and operon 2 (B) 
from isolates which were macrolide susceptible (s), intermediately resistant (') 
and resistant (R). U. parvum sequence from isolate ATCC 700970 (Glass et 
al. 2000). The region which has previously been associated with macrolide 
resistance corresponding to A2058 (E. coli numbering) is highlighted in yellow. 
U.p corresponds to U. parvum while U.u corresponds to U. urealyticum. 
Superscript numbering corresponds to nucleotide numbering.
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A.
Isolate Spp. L22 Amino acid alignment
U. p a rv u n f U.p 76VANQGPTMKRTLPRAKGSADQLFKRTTHL104
Q3S U.p 76v anqgptmkrtlprakgsadqlfkrtthl104
HPA171 U.u 76VANQGPTMKRTLPRAKGSADQLFKRTTHL104
HPA3 21 U.u 76VANQGPTMKRTLPRAKGSADQLFKRTTHL104
UHWO10r U.p 76v an qg p tm krtlprakgsadqlfkrtthl104
B.
Isolate Spp. L4 Amino acid alignment
U. p a rv u n f U.p 58GEVRGGGKKPWRQKHTGKARTGSTRNPHW83
Q3S U.p 58gevrgggk k pw rq k ht gk a rt g st rn p hw83
HPA171 U.u 58GEVRGGGKKPWRQKHTGKARTGSTRNPHW83
HPA3 21 U.u 58GEVRGGGKKPWRQKHTGKARTGSTRNPHW83
UHW010R U.p 58GEVRGGGKKPW- - KHTGKARTGSTRNPHW83
Figure 5.4. Partial alignments of amino acid sequence from (A) L22 and (B) 
L4 ribosomal protein from isolates which were macrolide susceptible (s), 
intermediately resistant (') and resistant (R). U. parvum sequence from isolate 
ATCC 700970 (Glass et al. 2000). U.p corresponds to U. parvum while U.u 
corresponds to U. urealyticum. Superscript numbering corresponds to 
nucleotide numbering.
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5.2.6 Tetracycline resistance
From the 61 isolates screened for tetracycline resistance, all isolates, but 1, 
had an MIC <2 pg/ml and were deemed as sensitive. Only one U. parvum 
clinical isolate (HPA23) was found to be tetracycline and doxycycline resistant 
(Table 5.2), coincident with the identification of the tetM gene by PCR (Figure 
5.5). PCR screening of all 61 isolates identified a tefM-positive U. urealyticum 
clinical isolate (HPA6) that was susceptible to both tetracycline and 
doxycycline (Table 5.2). The entire tetM gene was sequenced and compared 
to resistant reference strain SV9 (Vancouver) and HPA23 and susceptible 
strain HPA6 (Figure 5.6). No mutations in the coding region of the tetM gene 
were found for HPA6 that could account for the inability of a resultant protein 
to mediate tetracycline resistance, nor was any alteration to the endogenous 
tetM gene promoter found that may have stopped TetM protein expression. 
Therefore, there was no explanation for the susceptibility of this tef/W-positive 
isolate. Interestingly, three amino acid polymorphisms (H209Q, V216L, 
N223S) were found in HPA23 that did not affect function and were identical to 
those originally reported for a Tetr strain isolated in Seattle, Washington, in 
1988 (Sanchez-Pescador et al. 1988).
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1
Figure 5.5. Agarose gel showing the results of a PCR looking for the 
presence of the 397 bp fragment of the tetM gene in isolates HPA 23 (tetR) 
(lane 2) HPA 6 (tets) (lane 4). The tetM is gene is present in the positive 
control (SV9) (lane 4) and absent in the negative controls HPA1 (tets) (lane 3) 
and no DNA (lane 5).
Isolate Spp. Amino acid alignment
Seattle1- N.D 202QEESIRFHNCSLFPVYHGSAKNNIGIDN229
HPA23r U.p 202QEESIRFHNCSLFPVYHGSAKNNIGIDN229
HPA6S U.u 202QEESIRFQNCSLFPLYHGSAKSNIGIDN229
SV9 Vancouver1- U.u 202QEESIRFQNCSLFPLYHGSAKSNIGIDN229
Figure 5.6. Amino acid alignments demonstrating the amino acid sequence 
diversity between four different TetM proteins isolated from various 
tetracycline resistant (r) and susceptible (s) Ureaplasma. U.p corresponds to 
U. parvum while U.u corresponds to U. urealyticum. Not determined (N.D). 
Superscript numbering corresponds to nucleotide numbering.
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5.2.7 Ciprofloxacin resistance
A single ciprofloxacin-resistant (Cipr) clinical isolate, HPA18, was identified 
with an MIC of 8 mg/L. The QRDRs of the bacterial gyrase (gyrA and gyrB) 
and topoisomerase IV {parC and parE) genes, of this isolate as well as 
sensitive U. parvum (UHWQ3) and U. urealyticum (UHWW11) controls were 
sequenced and amino acid sequences were aligned (Figure 5.7). A single 
base pair change at position 244 (G244A) in the parC gene was identified 
resulting in a codon change and subsequent substitution of aspartic acid for 
asparagine (D82N) relative to those of other U. parvum sequences from 
susceptible controls from both species. Additional differences were seen 
between the U. urealyticum susceptible control, UHVWV11, and both the 
resistant and susceptible U. parvum isolates. Differences between the U. 
parvum and U. urealyticum isolates were a D112E substitution in the GyrA 
protein and a A125T as well as A136T substitutions in the ParC proteins, 
respectively.
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A.
Isolate
HPA18r
UHWQ3S
UHWW11*
U.p
U.p
U.u
Spp.
96
Amino acid sequence - GyrA
PHGDQAVYQTIVRMAQDFSMRYLLVDGHGNFGSIDGDS 133
96phgdqavyqtivrmaqdfsmryllvdghgnfgsidgds133
96 PHGDQAVYQTIVRMAQE FSMRYLLVDGHGNFGSIDGDS133
B.
Isolate Spp. Amino acid sequence -  ParC
•  •
HPA18r U.p-- 81gnssiyeamvrmsqd95---- 123tearlskiasvmlan137
UHWQ3S U.p-- 81GDSSIYEAMVRMSQD95---- 123TEARLSKIASVMLAN137
UHWW11S U.u-- 81gdssiyeamvrmsqd95---- 123t etrlskiasvmltn137
Figure 5.7.. Amino acid alignments of GyrA (A.) and ParC (B.) proteins from
a ciprofloxacin resistant SV1 (HPA18) and susceptible SV1 (UHWQ3) and U.
urealyticum (UHWW11) controls. Alignments demonstrate the resistance
determining substitution Asp82Asn in HPA18 (highlighted in yellow) which
was not present in the sensitive controls, but also the newly identified species-
specific differences at positions 112 in GyrA and 125/136 in ParC (filled circle)
which had previously been reported as resistance determinants. U.p = U.
parvum, U.u = U. urealyticum. A hyphen indicates a break in amino acid
sequence. Superscript numbering refers to Ureaplasma protein sequence
numbering.
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5.2.8 Misreporting of ciprofloxacin resistance in Ureaplasma
5.2.8.1 Phylogenetic analysis of gyrA, gyrB, parC and parE gene 
sequences
From the phylogenetic trees in Figure 5.8, it is clear that a number of species- 
specific nucleotide polymorphisms occur among the gyrA, gyrB and parC genes 
causing defined clustering of U. parvum and U. urealyticum. Within each cluster 
there is little in the way of intra-species differences with exception to parC which 
contains unique serovar-specific substitutions. The species-specific clustering 
trend is less clear when examining the tree constructed from parE sequences 
(Figure 5.8d). There is greater sequence homology between U. urealyticum SV2, 
5, 7, 8, 9 and 11 with U. parvum than with the remaining U. urealyticum isolates.
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Figure 5.8. Evolutionary relationship of gyrA (a), gyrB (b), parC (c) and parE 
(d) genes of 14 human associated Ureaplasma serovars. Sequences were 
aligned with CLUSTALW and distances calculated using maximum likelihood. 
The evolutionary history was inferred using the Neighbour-Joining method and 
the optimal trees after 500 bootstraps. Repeat testing using Jukes Cantor and 
Tamura Nei distance calculations gave identical tree topology. Trees were 
rooted using respective gyrase or topoisomerase genes from Mycoplasma 
pneumoniae.
208
Chapter 5 - Antibiotic resistance in Ureaplasma spp
5.2.S.2 List of all serovar and species specific differences
Species-specific differences at both the nucleotide and amino acid levels were 
found in all gyrase and topoisomerase IV genes and proteins, respectively. 
Tables in the appendix list the amino acid differences with a total of 39 in 
GyrA, 26 in GyrB, 107 in ParC and 34 in ParE. GyrA contained a total of 39 
amino acid differences of which 37 were species-specific polymorphisms. At 
position 468 all U. parvum and SV4, 5, 7, 8, 9, 11 and 12 of U. urealyticum 
encoded a Lys whereas SV2, 10 and 13 encoded a Glu. This pattern was 
also true at position 834 in which SV2, 10 and 13 encoded a Lys whereas the 
remaining U. urealyticum encoded a Glu. GyrB contained 26 differences 
which was the lowest of all the proteins examined.
All GyrB polymorphisms were species restricted with no serovar or 
intraspecies-specific differences.
A total of 107 differences were noted in the ParC protein, which was the 
largest number seen within all the proteins, with 102 polymorphisms being 
species-specific. Deviations from species-specific polymorphism were seen 
at position 3 for SV3 (Val rather than Asp, which was observed for all U. 
urealyticum), position 735 for SV1 (Thr rather than Ala for U. parvum or Met 
for U. urealyticum), Serovar-specific polymorphism were also seen for SV11 
(Ala171Val and Ser347Leu) and SV1 (Glu455Lys). All U. parvum were also 
found to be missing Gln835 and Asp836.
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ParE encoded a total of 34 differences of which only 9 were species restricted 
polymorphisms. For 21 of the substitutions there was clustering of U. parvum 
with U. urealyticum serovars 2, 5, 7, 8, 9 and 11 whereas serovars 4, 10, 12 
and 13 were divergent. A SV14 specific polymorphism was present at 
Gly106Ser. SV3 contained Asn151, while the remaining U. parvum and SV4, 
10, 12 and 13 encoded an Asp and the U. urealyticum encoded a His. SV1 
had two serovar-specific polymorphisms in ParE (Asp249Glu and Ser274Asn) 
as well as a Val417Thr polymorphism relative to other U. parvum SVs, but 
identical to the 10 U. urealyticum sequences.
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Table 5.3. GyrA amino acid difference between Ureaplasma serovars________
_______Uj)____________________________________ UjJ___________________________
Position 1 3 6 14 2 4 5 7 8 9 10 11 12 13
112 D E
219 N D
220 V I
221 T S
223 S P
228 Y H
248 K N
287 A V
341 P A
377 I V
383 N K
387 K R
425 S A
428 Q A
431 D G
464 I L
466 V l
468 K E
473 V I
475 N E
478 N D
624 D E
660 D E
710 N D
761 K R
774 E D
792 K Q
827 N D
829 - N
830 - D
831 - D
834 - K
835 L T
836 L S
837 Q H
838 E G
840 D E
841 Y H
844 K E
K K K K E K K
Q Q Q Q Q K Q Q K
Amino acids are written by the single letter coding system. Numbering refers 
to Ureaplasma protein number. The amino acid in the first column is 
conserved to the right until otherwise indicated.
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Table 5.4. GyrB amino acid difference between Ureaplasma serovars______
______ Uj)__________________________________Ujj__________________________
Position 1 3 6 14 2 4____ 5 7 8 9 10 11 12 13
8 K N
62 I V
64 R K
67 L I
72 S V
73 V I
74 I V
75 E G
142 H Y
145 Y H
161 P I
164 N D
167 V I
215 L M
233 T A
245 L A
256 R K
262 E D
315 V I
342 V I
556 A G
570 R K
575 I L
576 S L
578 I T
632 A T
Amino acids are written by the single letter coding system. Numbering refers 
to Ureaplasma protein number. The amino acid in the first column is 
conserved to the right until otherwise indicated.
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Table 5.5. ParC amino acid difference between Ureaplasma serovars
U.p_______________________________  U.u_________________
'osition 1 3 6 14 2
3 D V D D V
5 H Q
59 Y H
125 A T
136 A T
171 A A
181 N S
205 V I
210 E K
241 I V
245 C S
247 D E
250 I T
251 N S
252 D E
261 S N
300 I V
310 I V
324 N S
345 N S
347 S S
372 I V
400 E D
408 T A
412 V T
414 N A
440 K R
444 Q E
445 T S
448 D Q
449 E Q
454 Q K
455 K E E E E
458 N K
477 T E
480 F Y
481 E Q
490 L F
491 V I
493 V A
495 I V
505 N S
539 I L
545 I V
551 K R
565 V I
570 T S
571 S C
585 V A
595 I V
599 w C
605 I V
608 Y H
613 A G
615 R K
625 S N
629 I L
10 11 12 13
V
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643 D E
646 N G
656 G D
661 I V
662 I V
670 A V
672 L M
699 V I
701 A S
704 T V
711 N S
712 V I
717 E D
718 R Q
720 S N
724 N S
735 T A A A M
738 T S
739 N P
742 P L
743 I P
747 V A
749 N S
757 A G
758 H N
767 Q E
777 S P
779 P L
782 T I
786 T S
789 S N
790 I K
795 Q L
796 M I
804 C S
809 E S
810 A V
818 N S
826 N S
828 M L
831 I T
833 K E
835 - Q
836 - E
837 H Q
840 S L
846 D N
848 E K
851 K N
852 K D
Table 5.5. continued. Amino acids are written by the single letter coding 
system. Numbering refers to Ureaplasma protein number. The amino acid in 
the first column is conserved to the right until otherwise indicated.
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Table 5.6. ParE amino acid difference between Ureaplasma serovars________
_______Uj)____________________________________UjJ____________________________
Position 1 3 6 14 2 5 7 8 9 11 4 10 12 13
8 N N S
33 T A
39 I V
59 N N S
61 I I V
70 V V I
83 S S P
106 S S S G S
128 S S A
145 I I S
151 D N D D H D
153 S S P
180 V V F
185 I I T
203 I I S
210 K K N
218 N N D
231 A T
240 Y Y F
242 R K
243 S S N
244 N N T
249 E D D D D
252 I I V
274 N S S S S
299 N N D
377 L L V
417 T V V V T
542 N N T
588 N S
589 N K
594 K R
595 I V
619 K R
Amino acids are written by the single letter coding system. Numbering refers 
to Ureaplasma protein number. The amino acid in the first column is 
conserved to the right until otherwise indicated.
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5.2.8.3 Table of past quinolone resistant isolates
A summary of all previous studies reporting fluoroquinolone-resistant 
Ureaplasma strains is presented in Table 5.7. Prior to December 2008, the 
molecular characterisation of 33 isolates, including HPA18 described here, 
had been described. Of these isolates, 15 were identified by species: three U. 
parvum isolates and 12 U. urealyticum isolates. (Ligon and Kenny, 1991; 
Blanchard, 1990; Andrews et al. 2000; De Silva and Quinn, 1986; De Silva 
and Quinn, 1991; Smith et al. 1993) All U. urealyticum isolates described 
contained the Asp112Glu/Ala125Thr/Ala126Thr polymorphism, while the U. 
parvum isolates did not. For the remaining 18 non-speciated strains, we can 
predict which species they were likely to be by using the amino acid 
consensus for GyrA, ParC and ParE proteins. Using this method, we can 
predict that one quarter were U. parvum and the remainder were U. 
urealyticum. If substitutions that have found to be species-specific 
polymorphisms in the fluoroquinolone-susceptible strains are discounted then, 
only 22 of the 33 isolates have unique substitutions that could contribute to a 
fluoroquinolone-resistant phenotype. Therefore, that would mean that no 
mutation in the topoisomerase and gyrase genes and no potential mechanism 
of resistance had been identified for the remaining 11 isolates. The unique 
mutations that would remain candidates for resistance mechanism include 
Gln100Arg (1) and Gln104Lys (1) in GyrA, Asp82Asn (1), Ser83Leu (19), 
Glu87Lys (1), Ala88Gly (1), Ser734Gly (1), Ala735Thr (1) in ParC and 
Asp249Gln (1), Ser274Asp (1), and Ala457Thr (1) in ParE. However, some of 
these substitutions occur in the same isolate (i.e. all the ParE mutations were
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found in the same isolate), which may indicate that multiple substitutions are 
required to mediate a resistant phenotype.
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Table 5.7. Summary of mutations described for fluoroquinolone resistant Urenplosmas in gyrase and topopisomerase genes between 2000-2009 .
Author Isolate Spp. MIC (mg/L)
Amino acid substitution
GyrA ParC ParE
CIP OFX MXF 100 104 112 3 59 82 83 87 88 125 136 301 734 735 151 249 274 417 457
Bebear et al., 2000 UUa U.u* 64 64 4 Arg Glu Thr Thr
Zhang et al., 2002
19 - 32 16 N/A Leu
52 - >64 8 N/A Glu Leu
70 - 64 8 N/A Glu Leu
87 - 64 8 N/A Glu
92 - 128 16 N/A Glu Leu
104 - 64 8 N/A Glu Leu
105 - 128 16 N/A Glu
107 - 64 8 N/A Glu Leu
108 - 64 8 N/A Leu
131 - 32 8 N/A Glu
176 - 64 8 N/A Glu Leu
215 - 16 8 N/A Glu
224 - 64 8 N/A Glu Leu
Bebear et al., 2003
UUe2 U.p 8 8 1 Leu
UUb U.u 4-16 4-8 0.5-1 Glu Thr Thr
UUd U.u 4-16 4-8 0.5-1 Glu Thr Thr
UUfl U.u 4-16 4-8 0.5-1 Glu Thr Thr
UUgl U.u 4-16 4-8 0.5-1 Glu Thr Thr
UUf2 U.u 16 4-8 1 Glu Leu Thr Thr
UUg2 U.u 16 4-8 1 Glu Leu Thr Thr
_ UUg3 U.u 16 4-8 1 Glu Leu Thr Thr
UUg4 U.u 16 4-8 1 Glu Leu Thr Thr
UUg5 U.u 16 4-8 1 Glu Leu Thr Thr
UUc U.u 8 8 1 Glu Lys Thr Thr
Duffy et a l., 2006 48105 U.p N/A 128 8 Lys Asp Leu Gly Gly Thr Thr Asp Glu Asp Thr Thr
Xie et al., 2006
163 - 1 1 N/A
168 - >2 <1 N/A Thr
46 - >2 >4 N/A Glu Leu Thr Thr
161 - >2 >4 N/A Leu
7 - >2 >4 N/A Glu Leu Thr
Geissdorfer et al., 2008 CM239 U.u >2 1 N/A Glu His Thr Thr
Beeton et al., 2009 HPA 18 U.p 8 N/A N/A Asn
U. parvum** Gin Gin Asp Asp1 Tyr Asp Ser Glu Ala Ala Ala Ser Ala Ala2 Asp* Asp^ Ser* Va* Ala
U. urealyticum*** Gin Gin Glu Val His Asp Ser Glu Ala Thr Thr Ser Ala Met His* Asp Ser Thr Ala
* Species determined in the later paper from Bebear et al., 2003. -  denotes that the species was not determined. U.u = U. urealyticum. U. p = U. parvum. N/A represents the antibiotic was not examined. Amino acids in bold and in italics are non-species or serovar specific 
differences and are potentially the reason for the resistant phenotypes seen. ** The consensus amino acid sequences for all sequenced U. parvum. *** The consensus amino acid sequences for all sequenced U. urealyticum. 1SV3 has a Val at this position. 2 SV1 has a Thr 
at this position.3 SV3 has Asn at this position; SV1,6,14,10,12,13,4 have Asp at this position; SV 2, 5,7,8,9,11 have a His at this position. 4 SV1 has a Glu at this position. 5 SV1 has a Asp at this position. 4 SV1 has a Thr at this position.
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5.3 Discussion
5.3.1 Species distribution
The species distribution of 80 % U. parvum to 20 % U. urealyticum seen 
among the collection of 61 samples was consistent with previous reports 
(Schelonka and Waites, 2007). From the 16 U. parvum isolates serotyped, 
SV3 was found to be the most common (eight) followed by SV1 (four) with 
equal numbers of SV2 and SV14 (two each). Previous reports have also 
found SV3 to be the most commonly isolated serovar (Nelson et al. 1998; 
Cassell et al. 1993) and was the basis of choice when undertaking 
sequencing the first U. parvum genome (Glass et al. 2000).
5.3.2 Analysis of the method used
The primary advantage to using the modified breakpoint methodology 
described here, as well as full plate method, is the simultaneous determination 
of input inoculum for determination of susceptibility at the 104 CCU inoculum. 
The absence of prior inoculum size determination, unlike with previously 
described methods (Waites et al. 1992), meant that the turn around time from 
isolation of bacteria to sensitivity profile was greatly reduced with a preliminary 
idea of sensitivity available at 24 hours with full confirmation at 48 hours. This 
could be of significant clinical importance in cases of Ureaplasma meningitis 
in neonates where rapid administration of effective therapy would be crucial. 
Although 104 CCU were used as the standardised inoculum size to read the 
MIC, Figures 5.1a-c and 5.2a-b show clearly the difference between resistant
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and sensitive isolates. In the breakpoint method seen in Figure 5.1 the 
resistant isolates were able to grow in antibiotic containing media even at a 
low inoculum of 10 CCU whereas sensitive isolates caused colour change at 
105 -  106. Although the full 96 well plate can be seen as seven times more 
expensive than standard microbroth dilution technique, due to assessing the 
MIC at multiple bacterial loads, it did produce an accurate and rapid method of 
determining the antibiotic sensitivity profile of an Ureaplasma isolate without 
prior knowledge of inoculum size. The method was validated by the use of 
BSAC defined control isolates (Table 5.1) which gave comparable MIC values 
to that expected. With regards to the breakpoint values set, these were 
several-fold greater than those recommended for the closet Ureaplasma 
match, Moraxella catarrhalis. For example M. catarrhalis with an erythromycin 
MIC of greater than 0.5 pg/ml would be regarded as resistant whereas the 
breakpoint for erythromycin resistance in Ureaplasma was set higher at 4 
pg/ml. This was due to the slightly acidic pH of the USM media used (pH 6.6) 
raising the MIC. A second example was the higher breakpoint for 
ciprofloxacin resistance in Ureaplasma (4 pg/ml) relative to that of M. 
catarrhalis (0.5 pg/ml). Although the breakpoints were higher than suggested 
by BSAC for organisms such as M. catarrhalis, they were in accordance with 
recommendations by C. M. Bebear (personal communication).
5.3.3 Macrolide resistance
Erythromycin resistance in bacteria can be mediated by a number of different 
routes including active drug efflux, post-transcriptional modification of the drug 
target via methylation or by point mutations at or adjacent to residue A2067
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(A2058 E. coli numbering) in the 23S rRNA. Mutations in the L4 and L22 
ribosomai proteins have also been linked to erythromycin resistance. Bacteria 
with a low number of 23S rRNA operons, such as mycoplasmas, mutations in 
the 23S rRNA and/or the L4 and L22 ribosomai proteins appear to be the 
most commonly found (Vester and Douthwaite, 2001).
This investigation identified one highly resistant erythromycin resistant isolate 
(MIC, >64 mg/L); however, five additional isolates each consistently showed 
an MIC of 8 mg/L, which is higher than the range of 0.02 to 4 mg/L listed in 
the Cumitech 34 reference manual (Waites et al. 2001). Interestingly, 4 out 
of 5 of the less susceptible isolates were U. urealyticum, which represented 
33% of the total U. urealyticum isolates screened, suggesting a possible 
inherently increased tolerance of U. urealyticum isolates to erythromycin 
relative to that of U. parvum isolates. Little information is available about the 
mechanism of erythromycin resistance in Ureaplasma spp. In fact, this is the 
first full molecular characterization of a clinical Ureaplasma isolate with 
erythromycin resistance. The physiological mechanism of erythromycin 
resistance was first indicated by Palu et al. (Palu et al. 1989) almost 20 years 
ago, who demonstrated reduced radiolabeled erythromycin binding to 
ribosomes of resistant Ureaplasma compared to that of a susceptible strain. 
However, technical advances since that report have greatly enhanced the 
ability to investigate molecular mechanisms. Investigation of other macrolide- 
resistant bacteria has identified mutations that inhibit erythromycin binding to 
the bacterial 50S ribosomai complex, where it exhibits bacteriostatic activity 
through inhibition of protein synthesis. Pereyre et al. serially passaged a U.
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parvum reference strain 45 to 50 times in increasing amounts of erythromycin 
and sequenced associated genes: two 23S rRNA operons and L4 and L22 
ribosome-associated proteins (Pereyre et al. 2007). They consistently found 
mutation of the erythromycin-binding site around nucleotide position 2067 
(2058 numbering based on homology to E. coli) near the peptidyl transferase 
loop in domain V of one of the 23S rRNA operons and occasionally found 
additional mutation of the associated L4 or L22 protein. Dongya et al. 
identified a number of point mutations within the 23S rRNA of 18 clinical 
isolates with various degrees of resistance to the macrolides josamycin, 
clarithromycin, roxithromycin, and azithromycin; however, they did not 
investigate resistance to erythromycin (Dongya et al. 2008). Interestingly, 
none of the mutations described were in the region of nucleotide 2067. The 
investigation carried out here did not find mutations in either the 23S rRNA 
operon or the L22 protein but did detect a deletion of two adjacent amino 
acids in the L4 protein for the highly resistant strain (MIC, >64 mg/L). No 
mutations were found in the isolates with an erythromycin MIC of 8 mg/L, yet 
compensating mutations outside of the investigated regions, DNA methylation, 
expression of bacterial proteins that modify macrolides, or increased drug 
efflux via ion channels may have been responsible for the relative increase in 
tolerance to erythromycin for these strains. Kenny and Cartwright previously 
showed that susceptibility to erythromycin was reduced in acidic growth 
medium; however, medium pH had to fall below 6.5 before an effect was 
observed (Kenny and Cartwright, 1993). As our USM had a pH of 6.65, the 
MICs were determined relative to each other in the same batch of USM, and 
the findings were consistent upon repeated testing. As a result, the reduced
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susceptibility of the five isolates was not due to a pH artefact for the USM 
used. Mutations within the highly conserved region of L4 ribosomal protein 
have previously been noted in both laboratory-derived and clinically isolated 
macrolide-resistant pneumococci and E. coli strains (Chittum and Champney, 
1994; Tait-Kamradt et al. 2000b; Tait-Kamradt et al. 2000a). Both a 
substitution mutation (G69C) and an insertion mutation (6-bp insertion 
between the codons encoding Q67 and K68) were found in two resistant 
pneumococcus strains (Tait-Kamradt et al. 2000b; Tait-Kamradt et al. 
2000a). Clinical isolates found by the same group made up a distinct clonal 
cluster which contained a substitution from 69GTG71 to 69TPS71 as well as 
one isolate which contained a 6-amino-acid insertion, REKGTG, after a 
glycine at position 71 within the same region (Tait-Kamradt et al. 2000b). A 
similar mutation (K63E) within L4 of E. coli has also been found to be 
associated with resistance to erythromycin (Chittum and Champney, 1994) 
and was located adjacent to the deletion described here. The resultant three- 
dimensional alteration to the entire ribosomal complex as a result of the 
structural L4 mutation must prevent the interaction of the C5 sugar of the 
macrolide with the residues around A2067 (A2058 E. coli numbering) and 
abrogate the ability of erythromycin to inhibit protein synthesis in the resistant 
strain (Poehlsgaard and Douthwaite, 2002).
5.3.4 Tetracycline resistance
Currently, the only known mechanism of tetracycline resistance for Mollicutes 
is the presence of the tetM-transferable genetic element. It was first described 
in Ureaplasma by Roberts and Kenny in 1986 (Roberts and Kenny, 1986) and
223
Chapter 5 - Antibiotic resistance in Ureaplasma spp
has been the focus of investigations by several groups since then. Unlike the 
studies by Robertson et al. (Robertson et al. 1988), who found that all 26 of 
their Tetr isolates were also resistant to erythromycin at or above 2 mg/L, our 
control SV9 Tetr and clinical Tetr isolates were susceptible to erythromycin 
(MIC, 4 mg/L). Blanchard et al. (Blanchard et al. 1992) have previously 
shown that screening Ureaplasma isolates by PCR readily identified Tetr 
strains. However, we found a tetracycline-susceptible strain (HPA6) that 
screened tetM positive. Recently, Degrange et al. identified two tef/W-positive 
Mycoplasma hominis isolates that were tetracycline susceptible (Degrange et 
al. 2008). One of these M. hominis isolates had a 1,260 bp insertion in the 
leader peptide sequence (likely preventing successful transcription), while no 
mutations were found within the tetM gene or promoter region of the second 
isolate. Like the latter case for our Tets tetM_ HPA6 strain, we could find no 
explanation for the susceptibility when comparing the sequence to that of the 
control Tetr SV9 (Vancouver) strain. Interestingly though Degrange et al., 
found that if the Tets tetM positive isolate was serially sub-cultured in 
increasing levels of doxycycline the MIC rapidly increased suggesting that 
doxycycline is a greater inducer of resistance than tetracycline. A further 
explanation for the lack of expression may be due to gene silencing. A study 
by Enne et al., demonstrated that in a selection of E. coli isolates, all of which 
containing the pVE46 resistance plasmid, a sub-population were 
phenotypically sensitive (Enne et al. 2006). The plasmid DNA sequence of 
the sensitive isolates were found to be identical to that of the resistant strains, 
but interestingly when the plasmid from the sensitive strain were introduced to 
a different E. coli strain, the resistant phenotype was restored. This
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suggested that chromosomal difference were to explain these differences in 
gene silencing and could potentially be the mechanism for tetM silencing in 
HPA6. We also found that our Tetr strains were resistant to both tetracycline 
and doxycycline, which is in contrast with the findings of Blanchard et al. 
(Blanchard et al. 1992) who identified that from 21 clinical Tetr Ureaplasma 
isolates 8 were resistant to doxycycline, 2 were intermediate, and 11 were 
susceptible. It has been proposed that doxycycline is less of an inducer of 
tetM transcription in some organisms than tetracycline. In this study, we 
demonstrated that our clinical tetracycline-resistant isolate HPA23, which 
harboured a functional TetM protein, was additionally resistant to doxycycline.
5.3.5 Quinolone resistance
Ciprofloxacin was used as a representative of the bactericidal fluoroquinolone 
antibiotic family that targets two bacterial topoisomerases, namely 
topoisomerase IV and DNA gyrase. Numerous mechanisms have been 
described by which bacteria can mediate resistance to fluoroquinolones, 
including mutation of the topoisomerase genes, decreased membrane 
permeability, active drug efflux, modification by a fluoroquinolone-inactivating 
enzyme, or the presence of a Qnr protein (Robicsek et al. 2006). In this 
study a point mutation was identified which lead to an D82N amino acid 
substitution, two amino acids downstream from the proposed active site of the 
ParC protein (Morais Cabral et al. 1997). Six separate groups have 
investigated a total of 32 resistant isolates and reported mutations in 
Ureaplasma genes associated with fluoroquinolone resistance (Bebear et al. 
2003; Bebear et al. 2000; Moser et al. 2006; Geissdorfer et al. 2008; Xie
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and Zhang, 2006; Zhang et al. 2002). Nineteen of 32 fluoroquinolone- 
resistant strains investigated by these groups had the same S83L mutation in 
the ParC protein (or S80L, if using homology to the E. coli position to identify 
the location); furthermore, similar mutations in ParC have been found in 
fluoroquinolone-resistant S. aureus and Streptococcus pneumoniae, which 
are reported to have MICs similar to those of resistant Ureaplasma strains 
(Ince and Hooper, 2000). The mutation in the Cipr isolate D82N is adjacent to 
this region, and this isolate has a ciprofloxacin MIC similar to that of isolate 
UUc identified by Bebear et al. (Bebear et al. 2003), who also found an E87K 
mutation in the near vicinity, indicating this is a dominant target for 
fluoroquinolone resistance.
5.3.6 Misreporting of polymorphisms associated with 
resistance
5.3.6.1 Alignment of amino acid sequences
Previously, the combined substitutions of Asp112Glu in the GyrA protein 
along with Ala125Thr and Ala136Thr in the ParC protein have been 
highlighted in fluoroquinolone-resistance in Ureaplasma (Bebear et al. 2000; 
Bebear et al. 2003; Geissdorfer et al. 2008; Xie and Zhang, 2006; Zhang et 
al. 2002). The alignment data in Figure 5.7 compared the QRDR of a 
ciprofloxacin-resistant U. parvum (HPA18) with susceptible U. parvum 
(UHWQ3) and U. urealyticum (UHWW11) controls. Interestingly both the U. 
parvum isolates, including the ciprofloxacin resistant HPA18, had the profile of 
previously described sensitive isolates whereas the susceptible U.
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urealyticum, UHWW11, had the profile which had been previously linked to 
resistance. This evidence formed the basis for the further investigation of 
amino acid polymorphisms for all serovars of both U. parvum and U. 
urealyticum species.
5.3.6.2 Species- and serovar-specific amino acid differences
Phylogenetic analysis demonstrated distinct clustering of species in three out 
of the four genes analysed (Figures 5.8 A-D). These data support the 
decision to separate the human associated Ureaplasmas into two distinct 
species based on previous genotypic traits (Robertson et al. 2002). 
However, an unexpected and unexplainable divergence was noticed between 
SV4, 12, 10 and 13 from the remaining U. urealyticum in the parE tree. 
Additionally serovar-specific substitutions were noted for SV1 and 11 in the 
ParC and SV1, 3 and 14 in ParE. These species and serovar-specific 
substitutions will be important for comparison of resistant and susceptible 
strains in the future to avoid incorrect identification of potential resistance 
mechanisms.
5.3.6.3 Review of previously described mechanisms of 
fluoroquinolone resistance in Ureaplasma.
Between 2000 and 2009 thirty-two fluoroquinolone resistant Ureaplasma 
strains including the one described here, from 7 different investigations were 
identified, of which amino acid substitution in the type II topoisomerase
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proteins were proposed as the molecular mechanism of resistance (Bebear et 
al. 2000; Bebear et al. 2003; Geissdorfer et al. 2008; Xie and Zhang, 2006; 
Zhang et al. 2002; Moser et al. 2006). The substitutions which were 
proposed to result in the resistant phenotype are summarised in Table 5.7 and 
fully described as follows.
In 2000 Bebear et al.,. (Bebear et al. 2000) described the molecular 
characterisation of a ciprofloxacin resistance in Ureaplasma. The sequence 
from isolate UUa, which was later to be determined to be U. urealyticum, was 
compared with the published SV3 genome (ATCC 700970) (Glass et al.
2000) and identified to contain four amino acid transitions which were 
proposed to be related to resistance: Gln100Arg and Asp112Glu in GyrA and 
Thr125Ala and Thr136Ala in ParC. The evidence presented in here suggests 
that only Gln100Arg could potentially be responsible for the ciprofloxacin MIC 
of >128 mg/L with the remaining three differences all being species-specific 
polymorphisms.
A report by Zhang et al., (Zhang et al. 2002) found a total of 13 resistant 
isolates with varying degrees of resistance to fluoroquinolones. Nine of the 
thirteen isolates had a Ser83Leu substitution within the ParC protein. 
Unfortunately, they did not determine the species of the isolates, but based on 
the GyrA sequence data it can be speculated that 11 out of 13 isolates were 
U. urealyticum with 2 out 13 being U. parvum. The Ala125Thr and Ala136Thr 
mutations were not reported in the suspected U. urealyticum isolates, but it is 
unsure if this is because the investigators did not sequence this portion of the
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gene. As the primers used were not included in the manuscript, it has not 
been possible to speculate further on this point. Interestingly the authors not 
only compared the resistant isolate sequences with the SV3 genome, but also 
with U. urealyticum controls from SV4 (ATCC27815) and SV8 (ATCC27618) 
with the intention of ruling out species-specific polymorphism. Twelve base 
differences within gyrA and 10 within parC were identified, but the deduced 
amino acid sequences were quoted as being identical between serovars.
Subsequent investigations by Bebear et al. in 2003 examined a further 11 
resistant isolates and compared sequence data with the SV3 genome and a 
sensitive control UUe1 .(Bebear et al. 2003) As would be predicted, resistant 
U. urealyticum isolates were consistently found to have the species-specific 
polymorphism at amino acid 112 in GyrA and 125 and 136 in ParC. The two 
U. parvum isolates examined, one resistant (UUe2) and the sensitive control 
(Uue1), did not contain these substitutions. Six of the eleven isolates 
contained the Ser83Leu mutation with a single isolate containing a unique 
mutation in the ParC protein only 5 amino acids downstream for isolate UUc 
(Glu87Lys).
The first molecular characterisation of fluoroquinolone resistance in the United 
States was provided by Duffy et al., who reported a U. parvum isolate 
designated 48105 with an ofloxacin MIC of 128 mg/L.(Moser et al. 2006) 
This isolate was documented as having 12 mutations resulting in the resistant 
phenotype including Ser83Leu, but from the data in Table 5.5, six of these 
substitutions can be ruled out as species or serovar-specific polymorphisms.
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The Val3Asp mutation in ParC was proposed as a resistant determinant but 
this substitution turns out to be a serovar-specific substitution for SV3 (which 
was used as the comparator for their sequence); consensus sequence for 
SV1, 6 and 14 shows Asp at this position (Table 5.5). Although the serovar of 
this isolate was not determined it can be hypothesised that it was likely to be 
SV1 as they also identified the SV1-specific polymorphisms found at position 
735 in ParC and positions 249, 274, 417 in ParE (Tables 5.5 and 5.6, 
respectively).
Investigations of resistance in Ureaplasma isolates from China between 1999 
and 2004 was reported by Xie et al. (Xie and Zhang, 2006) They sequenced 
the QRDR region from the resistant isolates and three of the five isolates 
contained the common Ser83Leu resistance-associated mutation. However, 
comparison of their reported sequences do not align fully with the determined 
consensus sequences stated in this project. For example isolates 161, 163 
and 168 all show the polymorphisms that identify them as U. parvum (Asp112 
in GyrA and Ala125 and Ala136 in ParE) and isolate 168 also had Thr417 in 
ParE suggesting that it was an SV1. However, isolates 7 and 46 had Glu112 
in GyrA suggesting they were U. urealyticum, but isolate 46 was had Ala125 
and Ala136 in ParE consistent with U. parvum consensus sequences and 
isolate 7 had Thr125 but Ala136 giving a mixture of the consensus sequences 
in ParE. We are unable to explain this mixing of consensus sequences. 
However, isolates 163 and 168 do not have any mutations that are not also 
found in susceptible U. urealyticum or U. parvum isolates.
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Geissdorfer et al. characterised isolate CM239 from a 38 year old male who 
developed meningitis following kidney transplantation.(Geissdorfer et al. 
2008) Comparison of the reported sequence against the consensus Tables 
5.5 -  5.8 identifies the isolate as belonging to U. urealyticum, but no unique 
resistance candidate mutations remain after species-specific polymorphisms 
are taken into account.
By critically examining the ciprofloxacin resistant isolate in this study only a 
single and unique Asp82Asn mutation within the ParC protein was identified. 
This was immediately adjacent to the commonly found Ser83Leu mutation 
and is therefore a strong candidate as a resistance-mediating mutation.
This review of the literature highlights that 75% of the fluoroquinolone 
resistant strains identified to date were U. urealyticum, even though this 
species is isolated much less frequently from patients (20% of patient isolates 
in this study, which is consistent with other group’s findings). (Schelonka and 
Waites, 2007) Furthermore, the ParC Ser83Leu mutation was found in 58% 
of the fluoroquinolone resistant Ureaplasma strains, which is homologous to 
the resistance-mediating mutation identified in many other fluoroquinolone 
resistant bacteria including S. aureus and S. pneumoniae. (Piddock, 1999) 
Fluoroquinolones are known to have preferential sites of action: the gyrase 
proteins for Gram-negative bacteria and the topoisomerase IV proteins for 
Gram-positive bacteria. (Hooper, 1999) The proposed evolution of 
Ureaplasmas from Gram-positive progenitors may be responsible for the 
higher incidence of mutations within the topoisomerase IV proteins relative to
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gyrase proteins. As a result of this analysis the molecular mechanism of 
fluoroquinolone resistance in 11 out of the 33 isolates is still undetermined. 
Resistance in these isolates may have been due to mutation outside of the 
sequenced regions or through alternative mechanisms such as altered 
membrane permeability. (Hooper, 1999)
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5.4 Summary
In conclusion, a reliable method to determine antimicrobial susceptibility of 
Ureaplasma isolates without prior knowledge of inoculum size is now 
available. Although this is the second molecular investigation of macrolide 
resistance in clinical Ureaplasma isolates, more erythromycin resistant strains 
are required to determine the prevalence of mutations in the relevant genes 
associated with resistance. Screening for the tetM gene can identify 
tetracycline-resistant strains; however, the finding of a false-positive strain, 
raises a note of caution for the use of PCR screening for antibiotic resistance. 
It appears that mutations within an eight amino-acid region of the 
topoisomerase IV protein is commonly found in fluoroquinolone-resistant 
Ureaplasma, with S83L being the dominant mutation. Additionally this chapter 
highlights the importance of determining the species of Ureaplasma and the 
caution which should be taken when comparing future sequence data for both 
fluoroquinolone resistance and other genes potentially associated with 
antibiotic resistance. To avoid similar misinterpretation, sequences should be 
compared with the appropriate species and in some circumstances the 
appropriate serovar.
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6.1 Discussion
6.1.1 General discussion
This thesis has addressed and answered a diverse range of novel research 
questions with the central theme revolving around bacteria from the genus 
Ureaplasma. The first results chapter identified the essential role for the 
classical complement activation pathway for the killing of U. parvum in an in 
vitro system. The second chapter examined the consequences behind a 
failure to clear Ureaplasma in a neonatal population and development of the 
disease chronic lung disease of prematurity (CLD). In addition the role of 
general bacterial infection was also examined. Finally, this thesis addressed 
the potential complications in treatment of Ureaplasma infection, such as 
CLD, with relation to antibiotic resistance.
Ureaplasma have been linked to disease such as non-gonococcal ureithritis 
as well as septic arthritis in hypogammaglobulinemic patients, but the patient 
group which has been the focus of this thesis have been preterm neonates. 
Ureaplasma have been strongly linked to an infectious cause of premature 
birth where the organism can additionally be transmitted from mother to child 
either in utero, as a result of an ascending infection from the mother’s 
urogenital tract, or acquisition during birth. Premature birth is the largest risk 
factor for the development of CLD, a disease whereby the immature status of 
the neonates lung results in a dependence upon artificial ventilation which 
extends past the time at which the neonate should have been born (36 
weeks).
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The rates of lung colonisation by Ureaplasma as well as development of CLD 
has, on numerous occasions, been shown to be inversely proportional to 
gestational age (Chua et al. 1998; Izraeli et al. 1991). My data from a cohort 
of 192 neonates agreed with theses finding as seen in Figure 4.7 of chapter 4. 
Those infants born at 23 -  26 weeks gestational age were more likely to have 
lung colonisation by Ureaplasma relative to those born nearer to term 
gestation of 37 weeks as well as more likely to develop CLD. All neonates 
born between 23 and 25 weeks who were colonised by Ureaplasma 
developed CLD, but although the rate of colonisation at 26 weeks was 
comparable with those at 25 weeks, the number of those who went on to 
develop CLD was lower at less than 20 % compared with 100 %. Admittedly 
some infants born at 26 weeks died before a diagnosis of CLD could be 
made, but this data may represent some form of gestational-dependent 
developmental factor which allows the infant to cope with the inflammatory 
stimuli of the bacteria, or ventilation-induced damage, at 26 weeks relative to 
that of 25. The role of other bacterial species was not overlooked. The data 
presented in this thesis demonstrated a role of Gram negative bacteria in the 
development of CLD. As progression of CLD is driven by an uncontrolled and 
self-harming immune response, my data suggested a role in CLD for pro- 
inflammatory LPS containing Gram negative bacteria (chapter 4, Table 4.5). 
These data were supported by my finding of a statistically significant 
association between inflammatory cytokines IL-6 and IL-8 with the presence 
of infection and development of CLD (chapter 4, Figure 4.3).
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Although data, such as that which has been presented in this thesis, 
implicates a role for Ureaplasma in the causation of CLD, the associated is 
still highly debated. One means to define Ureaplasma as a causative agent of 
CLD is to run a randomised clinical trial examining the effects of antibiotics on 
eradicating the presence of Ureaplasma in the lungs of preterm neonates and 
examining the impact on disease development. Two factors exist which could 
potentially confound the results of such a trial. Firstly the antibiotics of choice, 
the macrolides, have known anti-inflammatory properties (Jaffe and Bush,
2001). If Ureaplasma are not contributing a role to the development of CLD, 
this would be missed as the dampening down of the inflammatory response, 
the driver of disease progression, would be a result of the drug and not the 
bacteria. The second confounding factor would be the presence of antibiotic 
resistant clones. If Ureaplasma are a major factor in the development of CLD, 
the presence of resistant strains, which would not be cleared by therapy, 
would affect the results obtained. To help over come this second confounding 
factor I have, as presented in chapter 5, developed a method to rapidly 
identify the presence of resistant strains to a selection of antibiotics as well as 
determining the molecular mechanisms of resistance to resistant strains 
found. From this study of 61 strains a single highly resistant erythromycin 
strain (UHWO10) was isolated from a premature baby (010). The resistant 
phenotype was a result of a two amino acid deletion within the L4 ribosomal 
protein, which was surprising as resistance was hypothesised to result from a 
point mutation within a region close to the nucleotide at position 2058 in the 
23S rRNA as seen in other bacteria with low numbers of ribosomal operons. 
The L4 deletion resulted in resistance to erythromycin and clarithomycin, but
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retained sensitivity to azithromycin. So from these data the issue of 
azithromycin resistant Ureaplasma impacting on a clinical trail is unlikely, but 
this is not to say that azithromycin resistant strains do not exist. Several 
laboratory generated resistant strains have been produced with levels of 
resistance ranging from 8 to >2048 pg/ml (Pereyre etal. 2007). Although the 
antibiotics from the tetracycline and fluoroquinolone families are unlikely to be 
used in neonatal therapy, the incidence and mechanisms of resistance were 
still examined. As with the macrolides only a single ciprofloxacin resistant 
isolate (HPA18) and a single tetracycline resistant isolate (HPA23) were 
found. Although the mutation leading to the ciprofloxacin resistant phenotype 
was at a unique position not described previously (D82N), the region which it 
was found in was not surprising as mutations within the parC genes is a 
common means for resistance in both Ureaplasma as well as numerous Gram 
positive bacteria (Gellert et al. 1977; Fournier and Hooper, 1998). What was 
interesting was the finding that previously described mutations which had 
been associated with fluoroquinolone resistance were a species specific 
difference and not related to resistance as demonstrated by my sequencing of 
sensitive control isolates from each species (chapter 5, Table 5.7). This 
finding was overlooked by previous investigators due to comparing U. 
urealyticum sequences with that of the published genome of U. parvum (Glass 
et al. 2000). To avoid any further misreporting of resistant genotypes a 
complete series of amino acid tables for each serovar of each species has 
been constructed so that not only the correct species can be compared, but in 
some circumstance the correct serovar (chapter 5, Tables 5.3 - 5.6). The only 
mechanism of tetracycline resistance described in Ureaplasma results from
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the presence of a functional tetM gene with the tetracycline resistant isolate 
HPA23 being no exception. An interesting finding relating to tetracycline 
resistance was the presence of a tetM positive, but tetracycline susceptible 
isolate (HPA6). Examination of the tetM sequence did not provide any clues 
to the lack of function, but did argue the need to phenotypically determine the 
susceptibility of an organism as genotypic resistance does not necessarily 
mean phenotypic resistance. Fortunately the work presented in chapter 4 
found that culture was the most reliable method for detecting Ureaplasma 
which would allow the phenotypic demonstration of resistance (chapter 4, 
Table 4.1).
The issue of antibiotic resistance in Ureaplasma, in the context of a neonatal 
population, is not likely to be significant due to the mechanisms of resistance 
in Ureaplasma to antibiotics used. The drugs of choice, the macrolides, have 
good selective toxicity in these patients and as shown in this study with the 
isolate UHWO10, the mechanism of resistance was due to a deletion within 
the L4 ribosomal protein. For this reason the spread of macrolide resistance 
in Ureaplasma, such as UHWO10, would be by clonal expansion which is 
much less of a threat than resistance conferred by a transferable element, 
such as tetM, which has the ability to disseminate throughout a population of 
bacteria. Additionally no plasmids have been described in Ureaplasma 
therefore transmission of resistance would be further impeded. Ultimately the 
greatest risk factor to antibiotic resistance in Ureaplasma isolated from 
neonates is the presence of resistant clones in the mother. Therefore the 
incidence of antibiotic resistance in GUM populations could be a predictor for
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incidence of resistance in neonatal populations as the mother, or the farther if 
the mother has acquired the organism, is the source of infection.
Although a clinical trail examining the ability of antibiotics to reduce the rate of 
CLD by clearance or Ureaplasma may prove a causative role, ultimately 
prevention of acquisition of the organism would be better than attempted cure. 
Additionally the non-prudent use of antibiotics is frowned upon as it can lead 
to the emergence of resistant strains, not only of Ureaplasma but potentially 
more virulent organisms. Therefore by understanding the mechanisms of 
immune clearance of Ureaplasma and potentially developing a humanised 
Ureaplasma specific antibody it would be possible to implement a more 
“natural” way to control an infection.
To try and further understand how the body prevents infection by Ureaplasma 
an in vitro system was developed to asses the role of membrane attack 
complex mediated (MAC) killing of the complement system using the serum 
from 12 healthy adult volunteers of unknown colonisation status. A significant 
finding was the critical role for the classical pathway in MAC mediated killing 
of all Ureaplasma examined. The pivotal experiment demonstrating this 
finding was achieved by the blocking of the first complement component C1q 
by a function blocking antibody (chapter 3, figure 3.9). In the absence of 
functional C1q, no killing was present suggesting an essential role for the 
classical pathway, but a negligible role for the alternative and lectin pathways. 
These finding were unexpected due to the alternative pathway being activated 
by foreign surfaces, such as bacteria, as well as the previous data by other
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investigators demonstrating the ability of MBL to bind Ureaplasma (Benstein 
et al. 2004). These data were subsequently backed up by additional 
experiments (chapter 3, figure 3.3 and 3.6, respectively).
A further interesting finding was the antibody sensitivity of the four serovars 
examined. SV1, 6 and 14 killing was solely dependent upon the presence of 
IgG. Using serum which had been depleted of IgG subclasses 1, 2 and 4 or 
of all IgG subclasses by either a protein A or protein G sepharose columns, 
respectively; it was possible to conclude that the killing of SV1, 6 and 14 was 
reliant on lgG1 subclass of antibodies (chapter 3, Graphs 3.5 and 3.10). 
Further supporting this data were western blots with multiple intense bands 
which correlated with high levels of killing (chapter 3, Figures 3.4 and 3.3, 
respectively). Data on SV3 on the other hand was less clear cut. Depletion of 
lgG1, 2 and 4 did not remove killing whereas the removal of all subclasses 
removed killing in half of the cases examined. This data suggested that SV3 
was unique in that it generated an lgG3 specific response in a number of 
individuals, but questioned the western blot data regarding the serological 
status of the designated sero-negative volunteers VxF1 and VxF9. VxF1 for 
example produce no bands by western blot for either anti-Ureaplasma IgG or 
IgM, but killing was removed in the absence of all IgG suggesting an lgG3 
response. In addition VxF9 was also negative by western blot for IgG and 
IgM, but in the absence of total IgG killing was retained. In both cases the 
data suggested that western blot was either not sensitive enough to detect low 
levels of either IgG or IgM, or that the epitope recognised by these antibodies
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were confirmationally dependent and as a result of linearization by sample 
preparation for western blot, binding was prevented.
This finding on the critical dependence upon antibodies for the clearance of 
Ureaplasma is further supported in the clinical field by the association of 
Ureaplasma infection in CVID patients who are deficient in IgG. Although this 
work was carried using adult serum, it can now be directly transferred to using 
neonatal serum and potentially exploring the ability of preterm cord blood to 
kill Ureaplasma. These sets of experiments would aid in testing the previous 
hypothesis of a gestational-dependent developmental ability to clear 
Ureaplasma at 27 weeks relative to that at 26 weeks.
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6.1.2 Scope for future lines of investigation
The data presented in this thesis has answered multiple questions, but at the 
same time has produced many more. With regards to the data on the role of 
complement in the killing of Ureaplasma it would be of interest to examine the 
prevalence of different invasive serotypes of Ureaplasma infecting 
hypogammaglobuneamic patients. Due to the antibody deficient status of 
these individuals, and the potentially low titre of ant\-Ureaplasma antibodies in 
the pooled serum used to produce the IVIG administered potentially bias the 
serovars which are able to lead to invasive disease due to the antibody- 
dependent nature of killing required whereas susceptible serovars, such as 
SV3, would not disseminate systemically due to the high serum susceptibility?
The alternative pathway had little effect upon killing of any serovar studied. In 
chapter 3 it was suggested that recruitment of complement regulators such as 
fH could be the reason for this lack of killing (Figure 6.1). As this is not an 
uncommon method utilized by bacterial pathogens to evade the immune 
system it is a plausible hypothesis. Methods by which this could be 
investigated would either use western blot analysis to look for binding of whole 
fH molecules or synthetically produced short consensus repeats which could 
be used to determine which regions of the molecule were required for binding. 
Alternatively neuraminidase treatment of Ureaplasma may cleave off sialic 
acid and prevent recruitment of fH as been demonstrated in N. gonorrhoeae 
(Ram et al. 1998), but this would be dependent on sialic acid being the ligand 
for fH as well as being present upon Ureaplasma.
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A Activation B Inactivation
Factor H
Amplification
C3 convertase
>  C3b cell surface
_ . . .. . .. . Evasion of complementComplement mediated lysis
mediated lysis and proliferation
Figure 6.1. A diagrammatic explanation of how the binding of factor H to 
Ureaplasma can protect from complement mediated lysis. Panel A shows 
binding of C3b to a non-factor H protected cell and subsequent production of 
the C3 convertase (C3bBb). This leads to the continued cascade of the 
complement system resulting in Ureaplasma lysis (green spheres). Panel B 
shows that factor H bound to Ureaplasma acts as a co-factor for factor I 
mediated degradation of the C3 convertase leading the subsequent survival of 
Ureaplasma and further proliferation. Adapted from Atkinson and Goodship 
2007.
i
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MBL has been previously shown to bind Ureaplasma, but ability to result in 
MAC formation was not provided (Benstein et al. 2004). The results 
presented here suggest that MBL has little role in the MAC-mediated killing of 
Ureaplasma. As mentioned in Chapter 3 this is not to suggest that MBL does 
not bind and contribute to clearance of Ureaplasma by the cell-mediated 
immune system. It is most likely that MBL would bind due to the carbohydrate 
composition of external surface (Whitescarver et al. 1975; Smith, 1985). A 
possible reason to why bound MBL does not result in MAC formation maybe 
due to the recruitment of complement regulators which allow binding, but 
prevent cascade from continuing such as C4 binding protein of the classical 
pathway (Gadjeva et al. 2001). An argument against this theory would be if 
this was so then how come the classical pathway would still be effective as 
the regulator controls both lectin and classical pathways? Alternatively, there 
may be lectin pathway specific regulators as yet not described. To address 
the question of the role of MBL opsonisation of Ureaplasma a simple 
experiment could be carried out whereby Ureaplasma are incubated with and 
without MBL and then fed to phagocytes to see if there is difference in uptake 
due to opsinisation.
An unfortunate draw back of this study was the unknown colonisation status of 
the individuals examined. It would have been of interest to correlate 
colonisation status, as well as species if not serovar of isolates with the ability 
to individual sera to kill the representative serovars. In addition, if individuals 
were colonised a further interesting question would have been how serum 
from the colonised volunteer dealt with the organism isolated. Would those
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who were colonised be able to kill the matched isolate, or would the reason for 
the persistent colonisation be a result of the infecting organism to continually 
evade killing? Previous studies have shown that the presence of antibody can 
promote the switching off of the MBA gene so to evade killing (Monecke et al. 
2003; Zimmerman et al. 2009). These experiments have solely relied on the 
animal raised antibodies for the selection process. Using the sero-positive 
serum identified in this study it would be interesting to see if this switching off 
of gene expression occurred as a result of selection by human antibody in the 
presence of human serum as this would represent a more accurate picture of 
human infection (Figure 6.2). From the work by Zimmerman et al., two genes 
were proposed which alternately express depending on antibody selective 
pressure. These may not be the only genes which are alternately expressed 
under antibody selection. By using techniques to look at global gene 
expression, such as micro-array, a variety of antibody/complement challenges 
could be used to fish out other possible candidate genes and increase our 
knowledge of surface expressed Ureaplasma antigens. For strategy of 
antigen variation to be an evolutionary adaptive one, sub-populations within a 
community of Ureaplasma must exist expressing different surface antigens. 
This would allow for those variants to which an antibody response is not 
raised against to proliferate due to the non-selective pressure. Zheng et al., 
showed that from a pure culture of a single clinical SV3 isolate multiple bands 
could be detected by western blot using a monoclonal antibody. They found 
that this was a result of subpopulations within the culture expressing different 
sized antigens. This finding could have accounted for the different sized 
bands present in the lanes of the western blots shown in Chapter 3. To
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determine if this was so, plating of cultures upon solid media and subsequent 
propagation of individual colonies would allow identification of proposed sub­
populations.
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Figure 6.2. An explanation of how sero-positive serum could be used to 
demonstrate antigenic shift in Ureaplasma. By incubating Ureaplasma with 
matched sero-positive serum identified in this thesis it would be interesting to 
see if it would be possible to shift the predominant antigenic variants within a 
population. In panel A. the predominant Ureaplasma variants are expressing 
blue antigens to which an antibody response is present. By selection with this 
serum would the predominant variation then shift to that seen in panel B. with 
variants expressing red antigens? This would be identified by the lack of 
killing in the complement assay described in this thesis.
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This project has only examined the susceptibilities of four representatives of 
the species U. parvum. Follow on work would repeat this work to see if there 
are firstly any differences within the 10 serovars of U. urealyticum. These 
results may account for the difference in prevalence between the two species. 
As this thesis has been examining the role of Ureaplasma in neonatal 
disease, a logical progression would also examine the ability of serum from 
neonates to kill U. parvum using this assay. These results may help to 
elucidate why preterm neonates are more susceptible to Ureaplasma infection 
relative to those born at term.
With reference to the data on tetracycline resistance in Ureaplasma it would 
be exciting to demonstrate that the tetM gene of HPA23 was not permanently 
fixed within the genome and could be transferred to another isolate such as 
HPA18 where the combination of ciprofloxacin and tetracycline could be used 
to select for double resistant strains. If this was possible then the transposon 
which the element is located upon could be engineered to incorporate a 
marker such as fluorescence. A luciferase expressing Ureaplasma would be 
an invaluable tool in quantifying the ability of neutrophils to phagacytose 
complement coated Ureaplasma relative to non-coated controls. This tool 
would also address the hypothesis that Ureaplasma can survive within 
neutrophils and use this to aid in dissemination around the body to locations 
such as joints in hypogammaglobumic patients (Webster et al. 1988).
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If more time was available then further work could be carried out upon 
understanding the failure of the tetM gene in HPA6 to produce a resistant 
phenotype. By isolating mRNA from actively growing HPA6, cDNA could be 
produced by reverse transcription to identify if tetM was transcribed. 
Additionally the effects of doxycycline on inducing resistance in HPA6 could 
be examined as previously shown by Degrange et al on M. hominis 
(Degrenge et al. 2008). Also if it was possible to transfer the tetM gene from 
HPA6 to another Ureaplasma strain it would be interesting to examine the 
possibility of gene silencing as described in E. coli (Enne et al. 2006). Finally 
the identification of the presence of tetM upon a plasmid within Ureaplasma 
would be a novel finding. By making a single cut within the Ureaplasma 
chromosome with an endonuclease and running the DNA on a pulse-field gel 
the small plasmid DNA would run ahead of that chromosome. Using souther- 
blot a tetM probe could then be used to identify if the tetM gene is upon the 
chromosome or upon a plasmid (Figure 6.3).
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1 2 3 4 5 6 7 8
Figure 6.3. A hypothetical southern blot of a range of tetM positive 
Ureaplasma following pulse-field gel electrophoresis. Numbers from 1 - 8  
represent various tetM positive Ureaplasma with strains 1, 4 and 5 encoding a 
chromosomal tetM (larger fragments) whereas strains 2, 3, 6, 7 and 8 harbour 
tetM upon a plasmid (smaller fragments).
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Further interesting and novel lines of research which could be followed up 
from the work on antibiotic resistance include determining how the two amino 
acid deletion in the L4 ribosomal protein produces a macrolide-resistant 
phenotype and what are the mechanism(s) of fluoroquinolone resistance in 
the 11 out of 33 isolates now known to have no mechanisms of resistance. 
The mutation in the L4 protein was unique and has not been described 
before. By cloning and expressing the mutant protein in E. coli it would be 
possible to determine the crystal structure of the protein. Using this data it 
would be possible to model how the mutation affects the three-dimesional 
structure of the protein. Technical difficulties of such a project would include 
the usage of the UGA codon to encode tryptophan within Ureaplasma which 
acts as a stop codon in other organisms (three present within the L4 gene). 
To determine the mechanisms of resistance in the 11 resistant isolates with 
unknown mechanisms, whole genome sequencing can be used. By 
comparative genomics, resistant and susceptible isolates can be compared 
for common single nucleotide polymorphisms (SNPs) which may relate to 
resistance. These could be in any of the topoisomerase genes, within the 
MATE pumps described (Glass et al. 2000), or in other membrane proteins 
responsible for entry of drug.
Finally, from the data examining the incorrectly identified fluoroquinolone 
resistant mutations it was noticed that a great deal of variation occurs at the 
DNA level among the various serovars of Ureaplasma. Variations in 
housekeeping genes, such as the topoisomerases, are used to characterise 
isolates into groups by the technique known as multilocus sequence typing
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(MLST). By using the topoisomerase genes, as well as other housekeeping 
genes it would be possible to group Ureaplasma isolates in to specific clusters 
and track the epidemiology of strains both at a national and international level 
as well as potentially correlate strains with disease outcome.
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6.2 Concluding statement
The innate immune system may play a substantial role in preventing 
colonisation of Ureaplasma from progressing to full infection. In cases where 
the balance is tipped in favour of the pathogen, such as immune immature 
preterm neonates, infection can result in significant morbidity (CLD) and 
potentially mortality. The ability to treat such morbidities and reduce 
mortalities is dependent upon rapid and effective antimicrobial therapy, but 
may be compromised due to resistant strains.
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Antibiotic resistance determination of Ureaplasma spp. (Ureaplasma parvum and Ureaplasma urealyticum) 
usually requires predetermination of bacterial titer, followed by antibiotic interrogation using a set bacterial 
input. This 96-well method allows simultaneous quantification of bacteria in the presence and absence of 
antibiotics. A method for determining precise MICs and a method for screening against multiple antibiotics 
using breakpoint thresholds are detailed. Of the 61 Ureaplasma-positive clinical isolates screened, one (1.6%) 
was resistant to erythromycin (MIC, >64 mg/liter) and clarithromycin (MIC, 4 mg/liter), one to ciprofloxacin 
(1.6%), and one to tetracycline/doxycycline (1.6%). Five isolates were also consistently found to have an elevated 
MIC of 8 mg/liter for erythromycin, but this may not represent true antibiotic resistance, as no mutations were 
found in the 23S rRNA operons or ribosome-associated L4 and L22 proteins for these strains. However, two 
amino acids (R66Q67) were deleted from the L4 protein of the erythromycin-/clarithromycin-resistant strain.
The tetM genetic element was detected in the tetracycline-resistant clinical isolate as well as in the positive 
control Vancouver strain serotype 9. The tetM gene was also found in a fully tetracycline-susceptible Urea­
plasma clinical isolate, and no mutations were found in the coding region that would explain its failure to 
mediate tetracycline resistance. An amino acid substitution (D82N) was found in the ParC subunit of the 
ciprofloxacin-resistant isolate, adjacent to the S83L mutation reported by other investigators in many cipro­
floxacin-resistant Ureaplasma isolates. It is now possible to detect antibiotic resistance in Ureaplasma within 
48 h of positive culture without prior knowledge of bacterial load, identifying them for further molecular 
analysis.
Ureaplasmas and mycoplasmas are eubacteria belonging to 
the class Mollicutes. These unique organisms are the smallest 
self-replicating cells that lack a cell wall. Lack of a rigid cell 
wall prevents reactivity with Gram staining and makes them 
insusceptible to antibiotics that target bacterial cell walls (i.e., 
(3-lactams and glycopeptides), while imparting a frailty that 
mostly limits them to a parasitic existence in association with 
the eukaryotic cells of their host (39). Shepard first described 
ureaplasmas, or T-mycoplasmas, in the 1950s, following isola­
tion from a male patient with nongonococcal urethritis (31). 
This remains the most widely recognized patient group; how­
ever, they are also commonly found as commensals in the 
genital tract in as many as 80% of women of child-bearing age 
(30). Although the factors leading to intrauterine infection are 
unclear, detection of Ureaplasma in the amniotic fluid is fre­
quently associated with chorioamnionitis, spontaneous abor­
tion, and premature birth (13, 14, 40). It has been suggested 
that the rate of vertical transmission is inversely proportional 
to gestational age at time of delivery (1). Furthermore, the
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presence of Ureaplasma in the lungs of very premature neo­
nates has been associated with the development of chronic 
lung disease (or bronchopulmonary dysplasia) and long-term 
hospitalization (7, 19, 29, 30).
Ureaplasma spp. are susceptible to bacteriostatic agents such 
as protein synthesis-inhibiting tetracyclines and macrolides as 
well as bactericidal agents, including fluoroquinolones. For 
premature neonatal patients, however, the removal of a mi­
crobe must be balanced against the potential (and often un­
known) toxicity of the antibiotics in these patients (38). For 
this reason, physicians routinely favor macrolide antibiotics 
such as erythromycin when deciding to treat Ureaplasma infec­
tions in premature neonates.
Only a limited number of reports have been made regarding 
the trends in resistance among Ureaplasma isolates from neo­
nates (18, 34, 37), and all of these comment on the lack of a 
standardized methodology, which hinders comparison of re­
sults. Factors such as inoculum size, pH of media, and time of 
incubation are known to dramatically alter the MIC, and stan­
dardized means of detecting resistance are needed.
Here, we describe a modified breakpoint analysis in a 96- 
well broth microdilution format that enables a concurrent de­
termination of bacterial load in a sample simultaneously with 
the determination of resistance without prior knowledge of 
bacterial load. For isolates showing resistance within the 
breakpoint concentration, full MICs can be determined using a 
similar full-plate methodology. The breakpoint method was
2020
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used to screen 15 strains isolated during 2006 and 2007 from 
bronchoalveolar lavage samples from neonates of various ges­
tational ages at the University Hospital of Wales (UHW), 
Cardiff, United Kingdom, in addition to 46 frozen isolates from 
a reference repository of samples submitted to the Health 
Protection Agency at Colindale (London, United Kingdom) 
from 2003 to present. Within these 61 isolates, we identified 
one erythromycin-/clarithromycin-resistant, one ciprofloxacin- 
resistant, and one tetracycline-resistant Ureaplasma strain. 
Further PCR and sequence analyses were performed to deter­
mine the mechanism of resistance.
MATERIALS AND M ETHODS
USM and culture conditions. Ureaplasmas were grown in commercially avail­
able ureaplasma selective medium (USM ) purchased from Mycoplasma Experi­
ence Ltd. (Surrey, United Kingdom). While the exact formula o f the com m er­
cially obtained medium is proprietary, the simple broth base medium was 
supplemented with yeast extract, 1 g/liter urea, and 10% porcine serum, with 
phenol red as the pH indicator (starting pH, 6.65) and with 2.5 pg/ml am pho­
tericin B and 0.25 mg/ml ampicillin (neither of which inhibit the  growth of 
ureaplasmas). The adapted microbroth technique was carried out in flat-bottom 
96-well plates covered with adhesive sealing tape (Elkay, Basingstoke, United 
Kingdom) in a humidified tissue culture incubator set at an am bient C 0 2 con­
centration at 37°C. The sealing tape does not allow gas exchange, and the 
humidified incubator ensures that the integrity of the outerm ost wells is the same 
as those that are more central to the plate.
Sample collection. Bronchoalveolar lavage (BAL) samples were collected 
from 20 preterm and term neonates requiring mechanical ventilation on the 
neonatal ward at the UHW  (Cardiff, United Kingdom). Samples were initially 
screened for Ureaplasma infection by addition o f 25 pi BAL fluid to  2 ml USM  
and incubation at 37°C for 1 week. Samples that turned a clear red  color 
(indicating Ureaplasma growth in the absence of contaminating bacteria) follow­
ing incubation were confirmed by PCR using the Ureaplasma-specific prim ers U4 
and U5, which selectively amplify the urease gene (see below). Positive samples 
were diluted 1:100 and 1:1,000 in USM, incubated overnight, divided into ali­
quots, and frozen at — 80°C for later batch analysis. Fifteen clinical Ureaplasma 
isolates were successfully archived at —80°C in USM and used for later suscep­
tibility testing. An additional 46 archived Ureaplasma isolates were revived from 
a potential 77 samples submitted for testing to the Health Protection Agency 
(HPA) at Colindale. The HPA clinical laboratory confirmed that no samples 
used were contaminated with mycoplasma using specific culture methods. Known 
serovar (SV) isolates used as reference strains were also obtained from H P A  
although SV1 (DKF-1) and SV9 (Vancouver isolate) were originally obtained 
from the Institute of Medical Microbiology, University of Aarhus, Denmark.
Screening of HPA isolates using a modified breakpoint method. Erythromycin 
was purchased from Sigma-Aldrich (Dorset, United Kingdom) as a 1-mg/ml 
stock solution, while azithromycin, clarithromycin, ciprofloxacin, doxycycline, 
and tetracycline (also purchased from Sigma-Aldrich) were prepared as 1-mg/ml 
stocks dissolved in dimethyl sulfoxide or ethanol as directed by the manufacturer. 
Working stocks of antibiotics consisted of freshly diluted antibiotics at concen­
trations of 64 mg/liter in USM. An adapted breakpoint analysis was used to 
screen for the presence of resistant m utants within the 61 isolates. Although no 
official breakpoint values are available for Ureaplasma, we determ ined the fol­
lowing values based on the normal ranges of MICs reported for Ureaplasma, as 
stated in Cumitech 34 (36). As seen in Fig. 1, the bottom row of wells contained 
2 mg/liter tetracycline, the next row up contained 4 mg/liter ciprofloxacin, the 
second row contained 4 mg/liter erythromycin, and the top row did not contain 
an antibiotic for a growth control. Two milliliters of USM was inoculated with 
either growing or frozen Ureaplasma spp. the night before titration was to  be 
performed. Twenty microliters o f this culture of unknown color-changing units 
(CCU) was then added to each well from A l to A4, and serial 10-fold dilutions 
were performed from columns A to H. In this manner, the 96-well plate was 
organized to investigate the susceptibility of three different strains to three 
antibiotics per plate by repeating the layout for wells A5 to H8 and A9 to H12 
as described above, but using different test strains of Ureaplasma. Plates were 
sealed and incubated at 37°C in a humidified cell culture incubator with ambient 
C 0 2 for 48 h, at which time color change within the growth control rows had 
ceased. From the titration of the antibiotic-free row, it was possible to calculate 
back through the titration from 1 CCU, the final well in which color change 
occurred, to the recommended 104 CCUs. Any strain which showed growth in
antibiotic-containing media at this level was subsequently fully investigated using 
the full-plate method (see below), with additional MIC determ inations for the 
macrolides clarithromycin and azithromycin for suspected erythromycin-resistant 
isolates and doxycycline for suspected tetracycline-resistant isolates. SV9 (Van­
couver strain) was used as a positive control for tetracycline resistance; however, 
no known characterized resistant strains were available to  use as controls for 
erythromycin and ciprofloxacin resistance. USM (with and w ithout antibiotics) 
was also incubated in the absence of added Ureaplasma spp. to  serve as a 
negative color-changing control. Validation of this technique was perform ed by 
determining the antibiotic M ICs for ATCC (American Type Culture Collection, 
Bethesda, M D) isolates of Staphylococcus aureus (ATCC 29213), Enterococcus 
faecalis (ATCC 29212), and Escherichia coli (ATCC 25922). MICs determ ined in 
M ueller-Hinton medium for erythromycin, ciprofloxacin, and tetracycline were 
within the accepted M IC ranges for these bacteria.
Modified broth  microdilution technique for determination of antibiotic MICs. 
In a 96-well plate, wells A l to  H I received 360 pi of 64 mg/liter antibiotic in 
USM, and 180 p i sterile USM  was added to the remaining wells (A2 to  H12) of 
the plate. Using a multichannel pipette, rows of doubling dilutions were made by 
transferring 180 p.1 from row A l to H l l  (and an excess of 180 pi was discarded 
from row A l l  to  H l l ;  see the instructional diagram in Fig. SI in the  supple­
m ental m aterial). Rows A12 to  H12 rem ained free of antibiotic for unrestricted 
growth comparison. Thus, an antibiotic gradient was created from 64 mg/liter to
0.0625 mg/liter for the antibiotic in question. Twenty microliters of Ureaplasma 
from the overnight culture o f unknown CCU was added to  each well in the 
columns A l to A12 (1:10 dilution). A  10-fold dilution curve of bacteria was then 
titrated at 90 degrees across the antibiotic gradient (i.e., A l to -12 to H I to -12). 
Plates were sealed and incubated at 37°C in a humidified cell culture incubator 
with ambient C 0 2 for 48 h, a t which tim e color change within the growth control 
had ceased (see Fig. 2). The M IC was defined as the lowest concentration of 
antibiotic that prevented a color change after 48 h when read at 104 CCU 
(relative to growth in the antibiotic-free medium). USM (with and without 
antibiotics) was also incubated in the absence of added Ureaplasma isolates to 
serve as a negative color-changing control.
Speciation of Ureaplasma isolates. Confirmation of Ureaplasma was deter­
mined by amplification of the Ureaplasma-specific urease gene (a 430-bp DNA 
product) using Blanchard and coworkers’ (5) U4 and U5 prim ers (Table 1). 
Clinical isolates were further separated into species based on PC R prim ers which 
amplify a region of the m ultiple-banded antigen (MBA), as published by Teng et 
al. (35), also listed in Table 1. Prim er set UM-1 for Ureaplasma parvum  yielded 
a 403-bp product, with a 448-bp product for Ureaplasma urealyticum. For anti­
biotic-resistant U. parvum  strains, SVs were determined by sequencing the  UM-1 
prim er set amplicon and com paring SV-specific base compositions at nucleotides 
—54 to —56 and —82 to —84 (17, 35). Bacterial DNA from a 1.5-ml overnight 
culture was released by boiling lysis (95°C for 10 min) following centrifugation at 
13,000 X  g  for 10 min, removal of all USM, and resuspension in 50 p.1 sterile 
water. A 20-pl PCR (containing IX  GoTaq Flexi buffer [Promega], 1.5 mM 
MgCl2, 0.2 mM  deoxynucleoside triphosphates, 0.25 pM  each prim er, and 1.25 
units of GoTaq DNA polymerase) was perform ed on 1 p i (as well as 1 pi of a 
1:100 dilution to  lessen possible polymerase inhibitor concentrations) for 35 
cycles using the annealing tem peratures listed in Table 1. To determ ine the DNA 
sequence, five 20-pl PCRs were pooled and purified from other reaction com­
ponents using a Novagen SpinPrep PC R clean-up kit (M erck Chemicals Ltd., 
Nottingham, U nited Kingdom) per the m anufacturer’s instructions and then 
sequenced using the BigDye Term inator v3.1 cycle sequencing kit and analyzed 
with an ABI Prism 3130x1 genetic analyzer (Applied Biosystems, W arrington, 
United Kingdom).
Amplification and sequence determ ination of putative resistance targets. For
erythromycin- and ciprofloxacin-resistant isolates, mutations in bacterial genes 
previously associated with resistance (3, 22) were investigated.
D N A  encoding bacterial 23S rR N A  gene, L22, and L4 proteins was amplified 
and sequenced for macrolide-resistant strains; gyrase subunits and topoisomer­
ase subunits were sequenced for ciprofloxacin-resistant strains, and tetM  genes 
from both tetracycline-susceptible and -resistant isolates were sequenced. PCR 
primers and annealing tem peratures are outlined in Table 1. Amplicons were 
purified and sequenced as detailed above.
RESULTS
Species distribution among Ureaplasma isolates tested. Sev­
enty-five percent (15/20) of the archived UHW samples were 
successfully revived from — 80°C storage, while only 59.7% 
(46/77) of archived HPA samples were successfully revived.
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T A B L E  1. P rim ers and conditions"
Primers used for PCR amplification Primer sequence Annealing temp (°C) Size (bp) Reference
Ureaplasma-specific urease gene prim ers
U4
U5
UM-1
5 ' A C G A C G T C C A T A A G C A A C T  3'
5 ' C A A T C T G C T C G T G A A G T A T T A C  3 '
54 430 5
UMS-125
UM A226
Erythromycin resistance prim ers 
23S OP1 dom ain V
5 ' G T A T T T G C A A T C T T T A T A T G T n T C G  3'
5 ' C A G C T G A T G T A A G T G C A G C A T T A A A T T C  3
52 403 (U .p) 
448 ( U.u)
35
MH23S-11 
UP23S-OP1 
23S OP2 dom ain V
5 ' T A A C T A T A A C G G T C C T A A G G  3 ' 
5 ' A C C A C C A T T C A A T G T T T G A C  3 '
56 1,339 22
M H23S-11 
UP23S-OP2R2 
L4
5 ' T A A C T A T A A C G G T C C T A A G G  3 '
5 ' C G T A T A C T T T G C C A T A G T G T T G C C  3 '
56 1,427 22
UPL4-U
U PL4-R
L22
5 ' T C T A T T G A T G G T A A C T T C G C  3'
5 ' G T T G A A G G T G T T T C T A A A T C G C  3 '
60 392 22
UPL22-U
UPL22-R
Tetracycline resistance prim ers 
TetM  primers for screening
5 ' T T C G C A C C G T A A A G C T T C T C  3 ' 
5 ' G T T C T G G A T C A A C G T T T T C G  3 '
60 458 22
TetM F
TetM R
TetM  prim ers for sequencing
5 ' T T A T C A A C G G T T T A T C A G G  3' 
5 ' C G T A T A T A T G C A A G A C G  3 '
48 397 4
TetM F-78
T etM R
5 ' G T A T A C C T A T G G T T A T G C  3'
5 ' C G T  A T A  T A T  G C A  A G A  C G  3 '*
48 901
TetM F 
T etM R  2123
Ciprofloxacin resistance prim ers 
GyrA
5 ' T T A T C A A C G G T T T A T C A G G  3 '
5' G C A T T T C G G A C A A T A G A G G G G G  3'*
54 1,715
gyrA-1
gyrA-2
GyrB
5' T T G C T G C T T T C G A A A A C G G  3' 
5 ' C T G A T G G T A A A A C A C T T G G  3'
50 336 3
gyrB-3 
gyrB-4 
ParC
5 ' C C T G G T A A A T T A G C T G A C T G  3 ' 
5 ' T T C G A A T A T G A C T G C C A T C  3 '
55 310 3
parC-5
parC-6
ParE
5 ' A C G C A A T G A G T G A A T T A G G  3 '
5 ' C A C T A T C A T C A A A G T T T G G A C  3 '
55 309 3
parE-1
parE-S
5 ' A T G G G C G G A A A A T T A A C G C  3' 
5 ' C T T G G A T G T G A C T A C C A T C G  3'
55 313 3
° PCR primers used for the amplification and sequencing of genes associated with resistance to respective antibiotics. Annealing tem peratures and predicated product 
sizes are indicated. U. p , U. parvum; U. u, U. urealyticum; *, primers which were designed for this study.
This may reflect the relatively short storage time for the former 
samples (less than 18 months) compared to that of the latter 
samples (up to 4 years), although differences in isolate prepa­
ration prior to freezing them may have equally contributed. 
For all 61 revived samples, 49 were found to belong to U. 
parvum (80%) and 12 to U. urealyticum (20%). A minor dif­
ference in species distribution was identified between HPA 
and UHW collections, but this was not deemed significant by 
Fisher’s exact test analysis (78% U. parvum versus 87% U. 
parvum, respectively).
Examples Of breakpoint and detailed MIC determination. 
Ninety-six-well plates were set out as detailed in Materials and 
Methods for breakpoint screening of antibiotic resistance. An 
example showing strains resistant to erythromycin, ciprofloxa­
cin, and tetracycline is shown in Fig. 1. Nonturbid, dark red
wells (which appear dark gray in the figure) are indicative of 
positive Ureaplasma growth in the selective medium. If the last 
well showing growth in the 10-fold dilution (in the top row, 
lacking antibiotics) is considered to have 1 CCU, then four 
columns to the left represents 103 CCU, and five columns to 
the left represents 104 CCU (isolated by the dotted box). Fol­
lowing previously published recommendations that Urea­
plasma resistance needs to be assessed using an input of 104 
CCU (36), resistance-to-threshold antibiotic concentrations (4 
mg/liter erythromycin, 4 mg/liter ciprofloxacin, or 2 mg/liter 
tetracycline) were identified by comparison of wells within the 
dotted box. Figure 1 shows breakpoint identification of an 
erythromycin-resistant clinical SV1 isolate (UHWO10; i.e., 
10th sample from UHW patient O) (Fig. 1, top), a ciprofloxa­
cin-resistant clinical SV1 isolate (HPA18; i.e., 18th HPA sam-
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A. isolate UHWO10
CCU: 104 1 03 102 1 0 1 10°
Contra
B. isolate HPA18
CCU: 104 103 102 101 10°
Control
Erythro
C. isolate HPA23
CCU: 104 1 03 1 02 1 0 1 10°
Control
Erythro
FIG . 1. Photographs o f antib io tic b reakpo in t investigation show ing 
an erythromycin (E ry thro)-resistan t strain  (U H W O 10) (A ), a cip ro­
floxacin (C ipro)-resistant strain  (H PA 18) (B), and a te tracycline (T et)- 
resistant strain (H PA 23) (C). D ark  red  wells indicating  grow th of 
ureaplasm a appear dark  gray, while orange-yellow  wells represen ting  
no ureaplasm a growth appear light gray in th e  grayscale pho tograph . 
Columns containing 10 C C U  are identified  by a d o tted  box, and 
com parison of growth in the absence o f  antibiotics (con tro l) was used 
to determ ine resistance to  4 m g/liter erythrom ycin, 4 m g/lite r cipro­
floxacin, o r 2 mg/liter tetracycline.
pie) (middle), and a tetracycline-resistant clinical SV6 isolate 
(HPA23) (bottom). While we have used the 104 CCU column 
to assess antibiotic resistance, using 103 CCU would be equally 
valid, and no difference in our MICs was found when reading 
either the 103 or 104 CCU column.
For those isolates identified by breakpoint analysis, MICs 
for a single antibiotic were determined using a range of con­
centrations with a full-plate single antibiotic assay (Fig. 2). 
Using the same method used for determining which column 
contained 104 CCU (isolated by dotted box), examples of an 
erythromycin-susceptible clinical isolate (HPA18; MIC, 1 mg/ 
liter) (Fig. 2A) and the highly resistant clinical isolate 
(UHWO10; MIC, >64 mg/liter) (Fig. 2B) are shown.
Summary of MICs among resistant isolates. All isolates 
were examined for resistance to erythromycin, ciprofloxacin, 
and tetracycline with the resistant isolates summarized in Ta­
ble 2. Six isolates were identified to have an MIC greater than 
the normal MIC range previously published in Cumitech 34 
(0.02 to 4 mg/liter) (36), giving the isolates a prevalence of 
9.8%, although only one of these isolates (UHWO10) is likely 
to represent true antibiotic resistance with an MIC of >64 
mg/liter. Among the erythromycin-resistant isolates, azithro­
mycin and clarithromycin MICs were comparable to those of 
susceptible controls, with the exception of the highly resistant 
UHWO10, which was additionally resistant to clarithromycin
A.
mg/L: 0 
c 0.06 
1  0.125 
E 0.25 
§ 0.5
8 1.0 
§ 2.0 
£ 4.0|  8.0 
#  16 
32 
64
LU
S o  B© o  © u *
CCU' °  °  °  °^  r- r- r* r*
vs
•  • « • • • > >  0.5
•4tidt>»«gr 10
•  # ! > >  >  >  >  J  2.0mm A 4 . 0•  8.0 
16 
32
#  *, 64
CCU: °  ®  o  o
M * *&
•  v  V
• v *  --
FIG . 2. F u ll-p la te  determ ination  o f M IC  for erythrom ycin for a 
susceptible SV1 iso late  (A ) and a resistant (U H W O 10) isolate (B) in 
p lates contain ing  a  grad ien t o f antibiotic from  64 m g/liter to 0.06 
mg/liter. D ark  re d  wells indicating grow th o f ureaplasm a appear dark 
gray, w hile orange-yellow  wells represen ting  no  ureaplasm a growth 
ap p ear light gray in th e  grayscale photograph. Colum ns representing 
10 C C U  grow th in  th e  absence o f antibiotic are  shown by the dotted  
box, and  fo r the  susceptib le  strain , a circle shows the first concentration 
o f erythrom ycin to  inhib it growth (M IC  =  1 m g/liter). Since the  resis­
tan t isolate (U H W O 10) grew even in the  presence o f 64 m g/liter 
erythrom ycin, th e  M IC  is de term ined  to be > 6 4  m g/liter.
(MIC = 4 mg/liter) but susceptible to azithromycin (normal 
MIC ranges, 0.5 to 4 mg/liter for azithromycin and <0.004 to 
2 mg/liter for clarithromycin) (36). A single tetracycline-resis­
tant clinical isolate, HPA23, was identified with tetracycline 
and doxycycline MICs of 64 and 16 mg/liter, respectively (1.6% 
prevalence). A single ciprofloxacin-resistant clinical isolate, 
HPA18, was also identified with an MIC of 8 mg/liter (1.6% 
prevalence).
Molecular characterization of macrolide resistance. Muta­
tions in the 23S rRNA genes (two separate operons) and as­
sociated L4 or L22 protein from the prokaryotic ribosomal 
complex have previously been reported to be associated with 
macrolide resistance (22). These genes were sequenced from 
the highly resistant clinical isolate UHWO10 as well as the five 
isolates with an erythromycin MIC of 8 mg/liter and a selection 
of the susceptible isolates. No mutations were found in either 
the 23 S rRNA operon or the L22-encoding gene of any of the 
isolates; however, a 6-bp deletion was identified in the L4 
protein gene from the highly resistant UHWO10. This in­
frame deletion resulted in the loss of arginine and glutamine 
residues at residue numbers 66 and 67, respectively 
(AR66Q67) (Table 3). This region was sequenced in clinical 
isolates representing susceptible SV1 strains (representing an 
SV control) and other U. parvum strains. All were identical to 
the published SV3 genome sequence (accession number 
AF222894) (12). Furthermore, this region was also conserved 
in the SV8 reference strain and a U. urealyticum clinical strain 
(Table 3). Comparison of all sequences found three species- 
specific conserved nucleotide polymorphisms (all silent) in the 
L4 protein gene (U. parvum T309, G357, and C373 compared 
to U. urealyticum C309, A357, and T373). While 80% of all 
isolates were found to belong to U. parvum, four out of five of 
the isolates with MICs of 8 mg/liter belonged to U. urealyticum.
Downloaded 
from 
aac.asm
.org 
at Cardiff Univ 
on 
May 
6, 2009
2024 BEETON ET AL. A n t im ic r o b . A g e n t s  C h e m o t h e r .
T A B L E  2. M IC s fo r resistan t and control U. parvum  and  U. urealyticum  strains
Isolate Species (SV)
MICs with indicated antibiotics"
Ery Azi Cla Tet Dox Cip
H P A3 U. urealyticum 4 0.5 <0.125 2 0.5 4
HPA6 U. urealyticum 8 <0.25 <0.125 2 0.5 4
HPA12 U. urealyticum 8 <0.25 <0.125 2 0.5 4
HPA17 U. urealyticum 8 0.5 <0.125 1 0.25 4
HPA18 U. parvum  (SV 1) 4 <0.25 <0.125 2 0.25 8
HPA20 U. urealyticum 8 <0.25 <0.125 2 0.5 4
HPA23 U. parvum  (SV 6) 4 <0.25 <0.125 64 16 < 2
HPA32 U. parvum  (SV 14) 8 <0.25 <0.125 1 0.25 < 2
U HW JM U. parvum 4 <0.25 <0.125 2 0.5 4
U HW O10 U. parvum  (SV 1) >64 2 4 1 0.25 4
U HW P2 U. parvum 4 <0.25 <0.125 2 0.5 4
U HW Q3 U. parvum  (SV 1) 4 <0.25 <0.125 1 0.25 4
" MIC results from a selection of resistant isolates (in boldface) and susceptible isolates, as determ ined by growth comparison at 104 CCU. Ery, erythromycin; Azi, 
azithromycin; Cla, clarithromycin; Tet, tetracycline; Dox, doxycycline; Cip, ciprofloxacin.
Therefore, 33% of the all U. urealyticum isolates identified 
were found to be less susceptible to erythromycin (but suscep­
tible to clarithromycin and azithromycin) (Table 2).
Molecular characterization of tetracycline resistance. Tet­
racycline-resistant bacterial strains are often found to have the 
transferable tetM genetic element encoded in their genome. 
The SV9 (Vancouver) reference strain, known to contain the 
tetM gene (25), demonstrated a tetracycline-resistant (Tetr) 
phenotype, with tetracycline and doxycycline MICs of >64 
mg/liter and 64 mg/liter, respectively. Only one U. parvum 
clinical isolate (HPA23) was found to be Tetr and doxycycline 
resistant (Table 2), coincident with the identification of the 
tetM gene by PCR (data not shown). PCR screening of all 61 
isolates identified a te/M-positive U. urealyticum clinical isolate
TA BLE 3. Partia l pro tein  sequence alignm ents o f  antibiotic- 
resistant and -susceptible isolates
Isolate tested with „ *
indicated antibiotic" equen e
Erythromycin 
L4 isolates
SV3S..........................................63K PW R Q K H T 70
U H W O 10r.............................. 63K P W — K H T 70
Tetracycline 
T i s o l a t e s
SV9 S eattle"...........................209H N C SL FPV Y H G SA K N N IG ID 228
HPA23"....................................209H N C SL FPV Y H G SA K N N IG ID 228
H PA 6S...................................... 209Q N C SL FPL Y H G SA K SN IG ID 228
SV9 V ancouver"...................^Q N C S L F P L Y H G S A K S N IG ID 228
Fluoroquinolone 
ParC  isolates
Consensus5.............................78H P H G D S S IY E 87
HPA18"....................................^ H P H G N S S IY E 87
Bebear U U g2-5"...................78H P H G D L S IY E 87
Bebear U U c " .........................78H PH G D SSIY K 87
" Superscript letters (r and s) indicate resistance and susceptibility, respec­
tively, to the indicated antibiotics.
b Boldfaced amino acids identify areas of sequence divergence within a vari­
able region of the protein. The sequence of TetM  of the Vancouver strain was 
determined at the UHW. Underlined amino acids identify areas of sequence 
divergence relative to the sequences of susceptible strains. Previous S83L amino 
acid substitutions arising from mutation and E87K substitutions associated with 
resistance as described by Bebear et al. (2) are also shown. - ,  deletion of amino 
acids R and Q.
(HPA6) that was susceptible to both tetracycline and doxycy­
cline (Table 2). The entire tetM gene was sequenced and com­
pared to resistant strains SV9 (Vancouver) and HPA23 and 
susceptible strain HPA6 (Table 3). No mutations in the coding 
region of the tetM gene were found for HPA6 that could 
account for the inability of a resultant protein to mediate 
tetracycline resistance, nor was any alteration to the endoge­
nous tetM gene promoter found that may have stopped TetM 
protein expression. Therefore, we have no explanation for the 
susceptibility of this tetM-positive isolate. Interestingly, three 
amino acid polymorphisms (H209Q, V216L, N223S) were 
found in HPA23 that did not affect function and were identical 
to those originally reported for a Tetr strain isolated in Seattle, 
Washington, in 1984 (Table 3) (28).
Molecular characterization of ciprofloxacin resistance. A 
single ciprofloxacin-resistant (Cipr) clinical isolate, HPA18, 
was identified with an MIC of 8 mg/liter. Mutations in the 
subunits of the bacterial gyrase (gyrA and gyrB) and topoisom­
erase IV (parC and parE) genes, known as the quinolone re­
sistance-determining regions, have previously been associated 
with resistance to other fluoroquinolone antibiotics (2, 3, 10, 
11, 41, 42). The sequences of these genes were determined 
from the Cip" HPA18 isolate and several susceptible clinical 
isolates and compared to both known SV reference strains and 
the published SV3 sequence (12). A single base pair change at 
position 244 (G244A) in the parC gene was identified (Table 
3), resulting in a codon change and subsequent substitution of 
aspartic acid for asparagine (D82N) relative to those of other 
U. parvum sequences from susceptible controls from both 
species.
DISCUSSION
Summary of mutations found. This study describes a mod­
ified breakpoint analysis used to screen for antibiotic resistance 
among a large number of clinical Ureaplasma samples of un­
known initial CCU titration. U. parvum strains resistant to 
ciprofloxacin and tetracycline as well as one highly erythromy­
cin-resistant strain were identified. The species of all clinical 
isolates were determined by PCR analysis of the gene encoding 
the MBA protein, and in many cases, the SV was determined 
through analysis of the amplicon sequence in this region. Po­
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tential underlying molecular mechanisms of antibiotic resis­
tance were investigated, based on target genes identified by 
previous investigators. A unique deletion of AR66Q67 was 
identified in the L4 protein of the bacterial 50S ribosomal 
complex in an isolate with high erythromycin resistance, a 
unique point mutation of D82N in the ParC subunit of bacte­
rial topoisomerase in the ciprofloxacin-resistant isolate, and 
the presence of the tetM element in the tetracycline-resistant 
isolate.
Advantages of the breakpoint method. The primary advan­
tage to using the modified breakpoint methodology described 
here is the simultaneous determination of input inoculum for 
determination of susceptibility at the 104 CCU inoculum. Us­
ing this methodology, the investigator also has the option of 
determining the amount of CCU reduction at a defined anti­
biotic concentration. By defining the final well in which color 
change occurred in the growth control as 1 CCU, comparison 
of growth in the column representing an initial inoculum of 104 
CCU (as indicated in Fig. 1) identifies resistant organisms to 
be further interrogated by the full-plate, single-antibiotic 
method. As seen in Fig. 1, the presence of a resistant isolate is 
readily noticeable: 10-fold reduction (or less) in growth was 
observed at a 2 or 4 mg/liter concentration of antibiotic. Fur­
ther investigation with the full-plate method found that less 
than 10-fold reduction in growth was seen for UHWO10 when 
grown in up to 64 mg/liter erythromycin (Fig. 2).
Ciprofloxacin resistance. Ciprofloxacin was used as a repre­
sentative of the bactericidal fluoroquinolone antibiotic family 
that targets two bacterial topoisomerases, namely topoisomer­
ase IV and DNA gyrase. Numerous mechanisms have been 
described by which bacteria can mediate resistance to fluoro­
quinolones, including mutation of the topoisomerase genes, 
decreased membrane permeability, active drug efflux, modifi­
cation by a fluoroquinolone-inactivating enzyme, or the pres­
ence of a Qnr protein (27). We have identified a point muta­
tion leading to an amino acid substitution which was two amino 
acids downstream from the proposed active site of the ParC 
protein (20). Sue separate groups have investigated a total of 32 
resistant isolates and reported mutations in Ureaplasma genes 
associated with fluoroquinolone resistance (2, 3,10,11,41, 42). 
Nineteen of 32 fluoroquinolone-resistant strains investigated 
by these groups have the same mutation in the parC gene, S83L 
(or S80L, if using homology to the E. coli position to identify 
the location) (Table 3); furthermore, similar mutations in ParC 
have been found in fluoroquinolone-resistant S. aureus and 
Streptococcus pneumoniae, which are reported to have MICs 
similar to those of resistant Ureaplasma strains (15). The mu­
tation in the Cipr isolate D82N is adjacent to this region, and 
this isolate has a ciprofloxacin MIC similar to that of isolate 
UUc identified by Bebear et al. (2), who also found an E87K 
mutation in the near vicinity, indicating this is a dominant 
target for fluoroquinolone resistance. (Table 3).
Erythromycin resistance. This investigation also identified 
one highly resistant erythromycin resistant isolate (MIC, >64 
mg/liter); however, five additional isolates each consistently 
showed an MIC of 8 mg/liter, which is higher than the range of 
0.02 to 4 mg/liter listed in the Cumitech 34 reference manual 
(36). Interestingly, 4/5 of the less susceptible isolates were U. 
urealyticum, which represented 33% of the total U. ureafyticum 
isolates screened, suggesting a possible inherently increased
tolerance of U. urealyticum isolates to erythromycin relative to 
that of U. parvum isolates. There is much less information 
available about the mechanism of erythromycin resistance in 
Ureaplasma spp. In fact, this is the first full molecular charac­
terization of a clinical Ureaplasma isolate with erythromycin 
resistance. The physiological mechanism of erythromycin re­
sistance was first indicated by Palu et al. (21) almost 20 years 
ago, who demonstrated reduced radiolabeled erythromycin 
binding to ribosomes of resistant Ureaplasma compared to that 
of a susceptible strain. However, technical advances since that 
report have greatly enhanced the ability to investigate molec­
ular mechanisms. Investigation of other macrolide-resistant 
bacteria has identified mutations that inhibit erythromycin 
binding to the bacterial 50S ribosomal complex, where it ex­
hibits bacteriostatic activity through inhibition of protein syn­
thesis. Pereyre et al. serially passaged a U. parvum reference 
strain 45 to 50 times in increasing amounts of erythromycin 
and sequenced associated genes: two 23S rRNA operons and 
L4 and L22 ribosome-associated proteins (22). They consis­
tently found mutation of the erythromycin-binding site around 
nucleotide position 2067 (2058 numbering based on homology 
to E. coli) near the peptidyl transferase loop in domain V of 
one of the 23S rRNA operons and occasionally found addi­
tional mutation of the associated LA or L22 protein. Dongya et 
al. identified a number of point mutations within the 23S 
rRNA of 18 clinical isolates with various degrees of resistance 
to the macrolides josamycin, clarithromycin, roxithromycin, 
and azithromycin; however, they did not investigate resistance 
to erythromycin (9). Interestingly, none of the mutations de­
scribed were in the region of nucleotide 2067. Our investiga­
tion did not find mutations in either the 23S rRNA operon or 
the L22 protein but did detect a deletion of two adjacent amino 
acids in the L4 protein for the highly resistant strain (MIC, 
>64 mg/liter). No mutations were found in the isolates with an 
erythromycin MIC of 8 mg/liter, yet compensating mutations 
outside of the investigated regions, DNA methylation, expres­
sion of bacterial proteins that modify macrolides, or increased 
drug efflux via ion channels may have been responsible for the 
relative increase in tolerance to erythromycin for these strains. 
Kenny and Cartwright previously showed that susceptibility to 
erythromycin was reduced in acidic growth medium; however, 
medium pH had to fall below 6.5 before an effect was observed 
(16). As our USM had a pH of 6.65, the MICs were determined 
relative to each other in the same batch of USM, and the 
findings were consistent upon repeated testing. As a result, we 
do not feel that the reduced susceptibility of these five isolates 
was due to a pH artifact for the USM used.
Mutations within the highly conserved region of L4 have 
previously been noted in both laboratory-derived and clinically 
isolated macrolide-resistant pneumococci and E. coli strains (6, 
32, 33). Both a substitution mutation (G69C) and an insertion 
mutation (6-bp insertion between the codons encoding Q67 
and K68) were found in two resistant pneumococcus strains 
(32, 33). Clinical isolates found by the same group made up a 
distinct clonal cluster which contained a substitution from 
69GTG71 to 69TPS71 as well as one isolate which contained a 
6-amino-acid insertion within the same region (33). A similar 
mutation (K63E) within L4 of E. coli has also been found to be 
associated with resistance to erythromycin (6) and was located 
adjacent to the deletion described here. The resultant three­
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dimensional alteration to the entire ribosomal complex as a 
result of the structural L4 mutation must prevent the interaction 
of the C5 sugar of the macrolide with the residues around A2067 
(A2058 E. coli numbering) and abrogate the ability of erythromy­
cin to inhibit protein synthesis in the resistant strain (23).
Tetracycline resistance. Currently, the only known mecha­
nism of tetracycline resistance for mollicutes is the presence of 
the tetM--transferable genetic element. It was first described in 
Ureaplasma by Roberts and Kenny in 1986 (24) and has been 
the focus of investigations by several groups since then. Unlike 
the studies by Robertson et al. (26), who found that all 26 of 
their Tetr isolates were also resistant to erythromycin at or 
above 2 mg/liter, our control SV9 Tetr and clinical Tetr isolates 
were susceptible to erythromycin (MIC, 4 mg/liter). Blanchard 
et al. (4) have previously shown that screening Ureaplasma 
isolates by PCR readily identified Tetr strains. However, we 
found a tetracycline-susceptible strain (HPA6) that screened 
tetM positive with these strains. Recently, Degrange et al. iden­
tified two te/M-positive Mycoplasma hominis isolates that were 
tetracycline susceptible (8). One of these M. hominis isolates 
had a 1,260-bp insertion in the leader peptide sequence (likely 
preventing successful transcription), while no mutations were 
found within the tetM gene or promoter region of the second 
isolate. Like the latter case for our Tets tetM+ HPA6 strain, we 
could find no explanation for the susceptibility when compar­
ing the sequence to that of the control Tetr SV9 (Vancouver) 
strain. We also found that our Tetr strains were resistant to 
both tetracycline and doxycycline, which is in contrast with the 
findings of Blanchard et al. (4). They identified 21 clinical Tetr 
Ureaplasma isolates and found that 8 were resistant to doxy­
cycline, 2 were intermediate, and 11 were susceptible. It has 
been proposed that doxycycline is less of an inducer of tetM 
transcription in some organisms than tetracycline. In this study, 
we demonstrated that our clinical tetracycline-resistant isolate 
HPA23, which harbored a functional TetM protein, was addi­
tionally resistant to doxycycline.
Conclusion. In conclusion, we have developed a reliable 
method to determine antimicrobial susceptibility of Urea­
plasma isolates without prior knowledge of inoculum size. Al­
though this is the second molecular investigation of macrolide 
resistance in clinical Ureaplasma isolates, more erythromycin- 
resistant strains are required to determine the prevalence of 
mutations in the relevant genes associated with resistance. 
Screening for the tetM gene could identify tetracycline-resis­
tant strains; however, we found one false-positive strain, which 
raises a note of caution for the use of PCR screening for 
antibiotic resistance. It appears that mutation within an 8- 
amino-acid region of topoisomerase IV parC is commonly 
found in fluoroquinolone-resistant Ureaplasma, with S83L be­
ing the dominant mutation, but molecular screening methods 
would have to employ more-complex methods, such as capil­
lary electrophoresis-based single-strand conformation poly­
morphism, to screen for all potential mutations.
A CKNOW LEDGM ENTS
W e thank Phil D avies and Sister D ianne N uttall for th e ir help  in 
acquiring neonatal B A L sam ples from  neonates at the  U H W . W e also 
thank the parents, babies, and staff o f the neonatal un it a t th e  U H W  
for their participation in this study.
NCM  is funded by a project gran t from  the W ellcom e Trust.
REFERENCES
1. Abele-Hom, M., J . Peters, O. Genzel-Boroviczeny, C. Wolff, A. Zimmer- 
m ann, and W. Gottschling. 1997. Vaginal Ureaplasma urealyticum coloniza­
tion: influence on pregnancy outcome and neonatal morbidity. Infection 
25:286-291.
2. Bebear, C. M., H. Renaudin, A. Charron, M. Clerc, S. Pereyre, and C. 
Bebear. 2003. DNA gyrase and topoisomerase IV mutations in clinical iso­
lates of Ureaplasma spp. and Mycoplasma hominis resistant to fluoroquino­
lones. Antimicrob. Agents Chemother. 47:3323-3325.
3. Bebear, C. M., H. Renaudin, A. Charron, D. Gruson, M. Lefrancois, and C. 
Bebear. 2000. In vitro activity of trovafloxacin com pared to those of five 
antimicrobials against mycoplasmas including Mycoplasma hominis and 
Ureaplasma urealyticum fluoroquinolone-resistant isolates that have been 
genetically characterized. Antimicrob. Agents Chem other. 44:2557-2560.
4. B lanchard, A , D. M. Crabb, K. Dybvig, L. B. Duffy* and G. H. Cassell. 1992. 
Rapid detection of tetM  in Mycoplasma hominis and Ureaplasma urealyticum 
by PCR: tetM  confers resistance to  tetracycline but not necessarily to doxy­
cycline. FEMS Microbiol. Lett. 74:277-281.
5. B lanchard, A , J. Hentschel, L. Duffy, K. Baldus, and G. H. Cassell. 1993. 
D etection o f Ureaplasma urealyticum by polymerase chain reaction in the 
urogenital tract of adults, in amniotic fluid, and in the respiratory tract of 
newborns. Clin. Infect. Dis. 17(Suppl. 1):S148-S153.
6. Chittum , H. S., and W. S. Champney. 1994. Ribosomal protein gene se­
quence changes in erythromycin-resistant mutants o f Escherichia coli. J. 
Bacteriol. 176:6192-6198.
7. Davies, P. L., N. C. Maxwell, and S. Kotecha. 2006. The role o f inflammation 
and infection in the development of chronic lung disease o f prematurity. 
Adv. Exp. Med. Biol. 582:101-110.
8. Degrange, S., H. Renaudin, A  C harron, C. Bebear, and  C. M. Bebear. 2008. 
Tetracycline resistance in Ureaplasma spp. and Mycoplasma hominis: preva­
lence in Bordeaux, France, from 1999 to 2002 and description o f two tet{M)- 
positive isolates of M. hominis susceptible to tetracyclines. Antimicrob. 
Agents Chem other. 52:742-744.
9. Dongya, M., X. Wencheng, M. Xiaobo, and W. Lu. 2008. Transition m uta­
tions in 23S rRN A  account for acquired resistance to  macrolides in Urea­
plasma urealyticum. Microb. Drug Resist. 14:183-186.
10. Duffy, L., J . Glass, G. Hall, R. Avery, R. Rackley, S. Peterson, and K. Waites. 
2006. Fluoroquinolone resistance in Ureaplasma parvum  in the United 
States. J. Clin. Microbiol. 44:1590-1591.
11. G eipdorfer, W., G. Sandner, S. John, A  Gessner, C. Schoerner, and K. 
Schroppel. 2008. Ureaplasma urealyticum meningitis in an adult patient. 
J. Clin. Microbiol. 46:1141-1143.
12. Glass, J . I., E. J . Lefkowitz, J . S. Glass, C. R. Heiner, E. Y. Chen, and G. H. 
Cassell. 2000. The complete sequence of the mucosal pathogen Ureaplasma 
urealyticum. N ature 407:757-762.
13. Gray, D. J., H. B. Robinson, J . M alone, and R. B. Thomson, J r . 1992. 
Adverse outcome in pregnancy following amniotic fluid isolation of Urea­
plasma urealyticum. Prenat. Diagn. 12:111-117.
14. Horowitz, S., M . M azor, R. Romero, J . Horowitz, and  M . Glezerman. 1995. 
Infection of the amniotic cavity with Ureaplasma urealyticum in the midtri­
m ester of pregnancy. J. Reprod. M ed. 40:375-379.
15. Ince, D., and D. C. Hooper. 2000. Mechanisms and frequency o f resistance to 
premafloxacin in Staphylococcus aureus: novel m utations suggest novel drug- 
target interactions. Antimicrob. Agents Chem other. 44:3344-3350.
16. Kenny, G. E., and F. D. C artw righ t 1993. Effect o f pH , inoculum size, and 
incubation time on the susceptibility of Ureaplasma urealyticum to erythro­
mycin in vitro. Clin. Infect. Dis. 17(Suppl. 1):S215-S218.
17. Kong, F., X. Zhu, W. Wang, X. Zhou, S. Gordon, and  G. L. Gilbert. 1999. 
Comparative analysis and serovar-specific identification of multiple-banded 
antigen genes of Ureaplasma urealyticum biovar 1. J. Clin. Microbiol. 37:538- 
543.
18. Matlow, A , C. Th’ng, D. Kovach, P. Quinn, M. D unn, and E. Wang. 1998. 
Susceptibilities of neonatal respiratory isolates of Ureaplasma urealyticum to 
antimicrobial agents. Antimicrob. Agents Chem other. 42:1290-1292.
19. Maxwell, N. C., P. L. Davies, and S. Kotecha. 2006. A ntenatal infection and 
inflammation: what’s new? Curr. Opin. Infect. Dis. 19:253-258.
20. M orais Cabral, J . H., A  P. Jackson, C. V. Smith, N. Shikotra, A  Maxwell, 
and R. C. Liddington. 1997. Crystal structure o f the breakage-reunion do­
main o f DNA gyrase. Nature 388:903-906.
21. Palu, G., S. Valisena, M. F. Barile, and G. A  Meloni. 1989. Mechanisms of 
macrolide resistance in Ureaplasma urealyticum: a study on collection and 
clinical strains. Eur. J. Epidemiol. 5:146-153.
22. Pereyre, S., M. Metifiot, C. Cazanave, H. Renaudin, A  C harron, C. Bebear, 
and C. M. Bebear. 2007. Characterisation o f in vitro-selected mutants of 
Ureaplasma parvum  resistant to macrolides and re la ted  antibiotics. Int. J. 
Antimicrob. Agents 29:207-211.
23. Poehlsgaard, J., and S. Douthwaite. 2002. The m acrolide binding site on the 
bacterial ribosome. Curr. Drug Targets Infect. D isord. 2:67-78.
24. Roberts, M. C., and G. E. Kenny. 1986. Dissemination o f the tetM  tetracy­
cline resistance determ inant to Ureaplasma urealyticum. Antimicrob. Agents 
Chem other. 29:350-352.
Downloaded 
from 
aac.asm
.org 
at Cardiff Univ 
on 
May 
6, 2009
V o l .  53, 2009 CHARACTERIZING ANTIBIOTIC-RESISTANT UREAPLASMA SPP. 2027
25. Roberts, M. C., and G. E. Kenny. 1986. TetM  tetracycline-resistant deter­
minants in Ureaplasma urealyticum. Pediatr. Infect. Dis. 5:S338-S340.
26. Robertson, J . A., G. W. Stemke, S. G. M aclellan, and D. E. Taylor. 1988. 
Characterization of tetracycline-resistant strains o f Ureaplasma urealyticum. 
J. Antimicrob. Chem other. 21:319-332.
27. Robicsek, A., J . Strahilevitz, G. A. Jacoby, M. Macielag, D. Abbanat, C. H. 
Park, K. Bush, and D. C. Hooper. 2006. Fluoroquinolone-modifying enzyme: 
a new adaptation of a common aminoglycoside acetyltransferase. Nat. Med. 
12:83-88.
28. Sanchez-Pescador, R., J . T. Brown, M. Roberts, and M . S. Urdea. 1988. The 
nucleotide sequence o f the tetracycline resistance determ inant tetM  from 
Ureaplasma urealyticum. Nucleic Acids Res. 16:1216-1217.
29. Schelonka, R. L., B. Katz, K. B. W aites, and D. K. Bepjamin, J r . 2005. 
Critical appraisal of the role of U reaplasm a in the developm ent o f broncho­
pulmonary dysplasia with metaanalytic techniques. Pediatr. Infect. Dis. J. 
24:1033-1039.
30. Schelonka, R. L., and K. B. Waites. 2007. Ureaplasm a infection and neonatal 
lung disease. Semin. Perinatol. 31:2-9.
31. Shepard, M. C. 1954. The recovery of pleuropneum onia-like organisms from 
Negro men with and w ithout nongonococcal urethritis. Am. J. Syph. G on­
orrhea Vener. Dis. 38:113-124.
32. Tait-Kam radt, A., T. Davies, P. C. Appelbaum, F. Depardieu, P. Courvalin, 
J. Petitpas, L. W ondrack, A. W alker, M. R. Jacobs, and J . Sutcliffe. 2000. 
Two new mechanisms of macrolide resistance in clinical strains of Strepto­
coccus pneumoniae from Eastern Europe and N orth America. Antimicrob. 
Agents Chemother. 44:3395-3401.
33. Tait-Kam radt, A., T. Davies, M. Cronan, M. R. Jacobs, P. C. Appelbaum, 
and J . Sutcliffe. 2000. M utations in 23S rRN A  and ribosomal protein L4 
account for resistance in pneumococcal strains selected in vitro by macrolide 
passage. Antimicrob. Agents Chem other. 44:2118-2125.
34. Tay, S. T., N. Y. Boo, T. B. Khoo, A. S. Koay, and M. Y. Rohani. 1997. 
Prevalence and antibiotic susceptibility of Ureaplasma urealyticum in Malay­
sian neonates with respiratory distress. Med. J. Malaysia 52:409-411.
35. Teng, L. J., X. Zheng, J . I. Glass, H. L. W atson, J . Tsai, and G. H. Cassell. 
1994. Ureaplasma urealyticum biovar specificity and diversity are encoded in 
multiple-banded antigen gene. J. Clin. Microbiol. 32:1464-1469.
36. Waites, K., C. Bebear, J. Robertson, D. Talkington, and G. Kenny. 2000. 
Cumitech 34: laboratory diagnosis of mycoplasmal infections. ASM Press, 
W ashington, DC.
37. Waites, K. B., D. T. Crouse, and G. H. Cassell. 1992. Antibiotic susceptibil­
ities and therapeutic options for Ureaplasma urealyticum infections in neo­
nates. Pediatr. Infect. Dis. J. 11:23-29.
38. W aites, K. B., D. T. Crouse, and G. H. Cassell. 1993. Therapeutic consider­
ations for Ureaplasma urealyticum infections in neonates. Clin. Infect. Dis. 
17(Suppl. 1):S208-S214.
39. Waites, K. B., B. Katz, and R. L. Schelonka. 2005. Mycoplasmas and urea- 
plasmas as neonatal pathogens. Clin. Microbiol. Rev. 18:757-789.
40. W itt, A., A. Berger, C. J . Gruber, L. Petricevic, P. Apfalter, C. Worda, and P. 
Husslein. 2005. Increased intrauterine frequency of Ureaplasma urealyticum 
in women with preterm  labor and preterm  premature rupture of the mem­
branes and subsequent cesarean delivery. Am, J. Obstet. Gynecol. 193:1663- 
1669.
41. Xie, X., and J . Zhang. 2006. Trends in the rates of resistance of Ureaplasma 
urealyticum to antibiotics and identification of the mutation site in the quin- 
olone resistance-determining region in Chinese patients. FEMS Microbiol. 
Lett. 259:181-186.
42. Zhang, W., Y. Wu, W. Yin, and M. Yu. 2002. Study of isolation of fluoro­
quinolone-resistant Ureaplasma urealyticum and identification of mutant 
sites. Chin. Med. J. (Engl. Ed.) 115:1573-1575.
Downloaded 
from 
aac.asm
.org 
at Cardiff Univ 
on 
May 
6, 2009
Journal o f Antimicrobial Chemotherapy (2009) 64, 529-538 
doi: 10.1093/jac/dkp218 
Advance Access publication 30 June 2009
Comparison of full gyrA, gyrB, parC and parE gene sequences between 
all Ureaplasma parvum and Ureaplasma urealyticum serovars 
to separate true fluoroquinolone antibiotic resistance mutations 
from non-resistance polymorphism
Michael L. Beeton1, Victoria J. Chalker2, Sailesh Kotecha1 and O. Brad Spiller1*
depa rtm en t o f  Child Health, School o f  M edicine, C ardiff University, University Hospital o f  Wales, Heath Park, 
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Objectives: To determine the role of amino acid substitutions in Ureaplasma GyrA, GyrB, ParC and 
ParE proteins in mediating fluoroquinolone resistance.
Methods: Nucleic acid sequences from gyrA, gyrB, parC and parE  genes from all 14 Ureaplasma sero­
vars were aligned. Full genome sequences for serovars 1, 3 -7 , 9 and 11-14  were available from the 
National Center for Biotechnology Information database and we sequenced the full topoisomerase 
genes from ciprofloxacin-susceptible reference strains of serovars 2, 8 and 10. Phylogenetic trees were 
constructed to analyse nucleotide sequence similarity. Deduced amino acid sequences were compared 
with all 33 previously reported fluoroquinolone-resistant strains to clarify true fluoroquinolone- 
resistance-associated substitutions.
Results: Non-resistance-associated polymorphisms were identified in GyrA (39), GyrB (26), ParC (107) 
and ParE (34) proteins. Phylogenetic analysis demonstrated species clustering for all genes, except parE 
in which serovars 4 ,12 ,10  and 13 formed a separate cluster more similar to Ureaplasma parvum than the 
remaining Ureaplasma urealyticum serovars. Examination of all previously reported fluoroquinolone- 
resistant strains found that one-third of identified residue substitutions could be attributed to normal 
species polymorphism; therefore, the mechanism of resistance for these strains is still undetermined.
In particular, Glu or Asp at position 112 in GyrA and Ala or Thr at 125/136 in ParC were substitutions 
identified when U. urealyticum strain sequences were previously aligned with the published serovar 3 
genome sequence.
Conclusion: Combining analysis of the recently available Ureaplasma genomes with sequences from 
the additional serovars has enabled us to clarify which substitutions found by previous investigators 
could potentially be responsible for fluoroquinolone resistance.
Keywords: genetic polymorphisms, ciprofloxacin, DNA gyrase, topoisomerase IV
Introduction
Ureaplasmas are among the smallest and simplest self-replicating 
organisms known. They belong to the order Mycoplasmatales, 
family Mycoplasmataceae, but are distinguished from the genus 
Mycoplasma by their ability to hydrolyse urea as their main 
energy source. They have been associated with a range of pathol­
ogy, including non-gonococcal urethritis, reactive arthritis, neo­
natal pneumonia and chronic lung disease in pre-term neonates.1
Prior to 2002, a single human-associated species, Ureaplasma 
urealyticum, was recognized, consisting of two biovars that were 
subsequently further differentiated into 14 serovars (SVs). 
However, the combination of sequence analysis of 16S rRNA 
genes, the 16S-23S rRNA intergenic region and the urease 
gene together with DNA-DNA hybridization experiments led to 
the reclassification of the two biovars as two independent 
species, designated Ureaplasma parvum (SVs 1, 3, 6 and 14) and 
U. urealyticum (SVs 2, 4, 5 and 7-13).2
*Corresponding author. Tel: + 44-(0)2920-742394 ; Fax: + 44-(0 )2920-744283 ; E -m ail: SpillerB @ cardiff.ac.uk
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Beeton et al.
T reatm en t o f  Ureaplasma in fe c tio n s  is  l im ite d  to  te tra ­
cyclines, m ac ro lid es a n d  f lu o ro q u in o lo n e s .3 R e sis tan c e  to  all 
th ree an tib io tic  c la s se s  h a s  b e e n  d o c u m e n te d  in  c lin ica l 
Ureaplasma iso la tes , w ith  u n iq u e  n u c le ic  ac id  su b s titu tio n s 
iden tified  as p o te n tia l m o le c u la r  m e c h a n is m s  fo r  ea c h .4 -6  T o  
date, a  to tal o f  33  c l in ic a l  iso la te s  o f  f lu o ro q u in o lo n e -re s is ta n t 
Ureaplasma have b e e n  d e s c rib e d . S u b s titu tio n s  o f  S e r8 3 L e u  in  
the ParC  p ro te in , o r  a  tr ip le  s u b s titu tio n  o f  A s p l l2 G lu  in  G y rA  
p ro te in  along  w ith  A la l2 5 T h r  an d  A la l3 6 T h r  in  P a rC  p ro te in , 
all w ith in  th e  q u in o lo n e  re s is ta n c e  d e te rm in in g  reg io n s  
(Q R D R s), b e in g  m o s t c o m m o n ly  n o te d .5-11 H ere  w e  d esc rib e  
that the la tte r trip le  m u ta tio n  is n o t re la te d  to  a  re s is ta n c e  p h e n o ­
type, b u t is the  re su lt o f  sp e c ie s -sp e c if ic  p o ly m o rp h ism , w h ic h  is 
found  in  all Ureaplasma S V s. W e  a lso  re v ie w  th e  p re v io u s  li t ­
erature on  m u ta tio n s  re p o r te d  in  f lu o ro q u in o lo n e -re s is ta n t 
Ureaplasma iso la tes  a n d  d isc u ss  th e  e v id e n c e  th a t su p p o rts  th is 
hypothesis .
Sequencing o f gyrB/A and parE/C genes
PC R  for the Q R D R s o f  H PA 18, U H W Q 3 and U H W W 11 were 
carried ou t as described by  B ebear et a l.6 PC R  prim ers fo r am plifi­
cation  o f  the w hole gyrA /B  and p a rC /E  genes fo r SVs 2, 8 and 9 
w ere designed from  consensus sequences o f  know n U. urealyticum  
and are listed in Table 1. PC R  reaction conditions consisted o f 
lx G o T aq ®  Flexi B uffer (Prom ega), 1.5 m M  M gC l2, 0.2 m M  
dN T Ps, 0 .25 p.M each prim er and 1.25 units o f  G oTaq D N A  poly­
m erase. PC R  w as perform ed on 1 p L  o f  D N A  for 35 cycles at 
5 0 -5 5 ° C . F ive 20  p L  PC R  reactions were pooled  and am plicons 
purified using a N ovagen spin-prep PCR clean-up k it™  (M erck 
C hem icals Ltd, N ottingham , UK), as per the m anufacturer’s instruc­
tions, sequenced using the B igD ye T erm inator v3.1 cycle sequen­
cing  k it and analysed by  an A BI Prism  3130x1 G enetic A nalyzer 
(A pplied B iosystem s, W arrington, UK).
Materials and methods
Ureaplasma strains and ciprofloxacin susceptibilities
Isolates UHW Q3 (c ip rofloxacin-suscep tib le  U. parvum) and 
UHW W 11 (ciprofloxacin-susceptib le U. urealyticum) w ere collected  
from lung lavage fluids from  p re-term  neonates at the U niversity  
H ospital o f W ales (U H W ). T he cip rofloxacin -resis tan t isolate 
HPA18 (SV1) and c ip rofloxacin -suscep tib le  con tro l strains o f  SVs 
2, 8 and 9 were k indly p rov ided  by the  H ealth  P ro tection  A gency 
(Colindale, UK). Suscep tib ility  to  ciprofloxacin  w as determ ined  as 
described previously.5
Collection o f gyrA, gyrB, parC and parE sequences 
from Entrez genome database
D N A  and protein  sequences w ere retrieved from  the Entrez genom e 
database (http://w w w .ncbi.n lm .nih .gov/sites/entrez?db=genom e) for 
SV1 (ATCC 27813), SV 3 (ATCC 700970), SV 4 (ATCC 27816), 
SVS  (A TCC 27817), SV 6 (A TCC 27818), SV7 (A TCC 27819), SV 9 
(ATCC 33175), SV 10 (A TC C 33699), SV11 (ATCC 33695), SV12 
(ATCC 33696), SV 13 (A TC C 33698) and SV 14 (ATCC 33697). A t 
the tim e o f  co llation , gyrA , gyrB , p a rC  and p a rE  sequences for 
SV 2, SV8 and SV 10 as w ell as p a rC  and p a rE  fo r SV9 were not 
available, and w ere sequenced  at the U H W  as described above.
T ab le  1. Prim ers used to  sequence gyrB /A  and  p a rE /C  operons from  Ureaplasm a  SVs
PCR prim er nam e P rim er sequence U. pa rvum
Size (bp)
U. urealyticum
gyrB -98F 
gy rB A *
5 ' -G  A  A  A  A TA G  A C G T  G G T C G -3' 
5 '-TT C G A A TA T G A C T G C C A TC -3 '
1668 1668
gyrB-3a
gyrA-2a
5 '-C C TG G T A A A T TA G C TG A C TG -3 '
5 '-C T G A TG G TA A A A C A C T T G G -3 '
1249 1249
g y rA - la 
gyrA  1655R
5'-T T G C T G C T T T C G A A A A C G G -3 '
5 '-C C TTG TA C A C C TA C A C C A C -3'
1456 1456
gyrA  1504F 
gyrA  2743R
5 '-G G T G A T G A G C G T C G T A C A G -3 '
5 '-C C TG C A A C T TC A C C A A TT G -3 '
1258 1270
parE -  54 
pa rE -  8a
5 '-C A G C A A C C A TT TT A T G C C G A TC C -3 '
5 '-C T TG G A TG T G A C T A C C A TC G -3 '
1576 1576
p a rE - la
parC -6a
5 '-A TG G G C G G A A A A TT A A C G C -3 '
5 ' -C ACTATC ATC A A A G T TT G G A C -3 '
1182 1182
pa rC -5a 
p a r  1545R
5 '-A C G C A A T G A G TG A A TT A G G -3 '
5 '-G TA TC C A TC A C G A CTTA TTA C -3'
1397 1397
pa rC  1367F 
p a rC  2553R
5 '-G C T A A A A C G C T A C A A G A A C G -3 '
5 '-C A A C G TT G G C A TA A A T T G G -3 '
1318 1324
Bold font denotes product size variation between species. 
“Taken from Bebear et a l.6
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Alignment o f sequences and construction o f phylogenetic 
trees
Sequences were aligned w ith  C L U STA L W  and  d istances calculated  
using m axim um  likelihood. T he evo lu tionary  h istory  w as inferred
using the neighbour-jo in ing  m ethod and the optim al trees after 500 
bootstraps are show n (Figure 2). R epeat testing using Ju k e s-C an to r  
and T a m u ra -N e i d istance calculations gave identical tree top­
o logy .12 T rees w ere rooted  using  respective gyrase or topoisom erase 
genes from  M ycoplasm a pneumoniae.
(a)
Iso la te
H PA 18r 
UHWQ3 S 
UHWW1Is
sp.
U. p
U. p
U .u
A m ino acid  sequence - G yrA
6 PHGDQAVYQTIVRMAQDF SMRYLLVDGHGNFGSIDGDS133 
6 PHGDQAVYQTIVRMAQDFSMRYLLVDGHGNFGSIDGDS13 3 
6PHGDQAVYQTIVRMAQEFSMRYLLVDGHGNFGSIDGDS133
(b)
Iso la te
HPA 18r
UHWQ3S
UHWWll5
sp.
U. p
U. p
U. u
A m ino acid  sequence -  P a rC
•  •
1GIISSIYEAMVRMSQD95---------123TEARLSKIASVMLAN137
1GDSSIYEAMVRMSQD95---------123TEARLSKIASVMLAN137
1GDSSIYEAMVEMSQD95---------123TETRLSKIASVMLTN137
Figure  1. Amino acid alignments o f GyrA  (a) and ParC (b) proteins from  a ciprofloxacin-resistant SV1 (HPA18) isolate, and susceptible SV1 (UHWQ3) and 
U. urealyticum  (UHW W 11) controls. A lignm ents dem onstrate the resistance-determ ining substitution Asp82Asn in HPA18 (highlighted and in bold), which 
was not present in the susceptible controls, and also the newly identified species-specific differences at positions 112 in GyrA and 125/136 in ParC (filled 
circles), which had previously been reported as resistance determ inants. U.p, U. parvum; U.u, U. urealyticum. A hyphen indicates a break in the amino acid 
sequence. Superscript numbering refers to  Ureaplasma  protein sequence numbering.
(a) gyrA gene
67
100
90
100
91
SV2
SV10
SV8
SV9
SV7
SV12
SV4
SV5
SV11
SV13
SV1
SV6
SV3
SV14
-  M. pneum oniae
(b) gyrB  gene
66
100
90
100
91
SV4
SV9
SV10
SV11
SV2
SV5
SV7
SV8
SV12
SV13
SV1
SV6
SV3
SV14
. M. pneumoniae
0.05 0.05
(c) parC  gene
70 SV4
69 SV12
SV10
47 SV13
SV2
40 SV9
SV11
100 SV5
57 SV8
SV7
r SV1
ioo r
84 SV3
55
(d) p arE  gene
66
100
100
i SV6
■ M. pneum oniae
SV5 
SV11 
SV9 
SV7 
SV8 
SV2
r sv i 
SV3 8 1 > S V 6  
79 L SV14 
SV10 
SV13 
SV4 
SV12
— M. pneumoniae
100
0.01 0.05
F igure  2. Evolutionary relationship o f gyrA (a), gyrB  (b), p arC  (c) and p a rE  (d) genes o f 14 human-associated Ureaplasma SVs. Sequences were aligned 
with CLUSTALW and distances calculated using m aximum likelihood. The evolutionary history was inferred using the neighbour-joining method and the 
optimal trees after 500 bootstraps are shown. Repeat testing using Ju k es-C an to r and T am ura-N e i distance calculations gave identical tree topology. Trees 
were rooted using respective gyrase or topoisomerase genes from M. pneum oniae.
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Results
Alignment o f amino acid sequences from UHW isolates
Figure 1 show s th e  a m in o  ac id  a lig n m e n ts  o f  th e  Q R D R s o f  G yrA  
and  ParC  p ro te in s fro m  th e  c ip ro flo x ac in -re s is ta n t (M IC = 8  m g /L ) 
U. parvum H P A 1 8  (SV 1) iso la te  a s  w ell a s  su sc e p tib le  U. parvum 
U H W Q 3 (S V 1) a n d  U. urealyticum U H W W 1 1  co n tro ls . T h e  su s­
cep tib le  U. urealyticum co n tro l h a d  a  G lu  re s id u e  a t p o sitio n  112 
o f  the G y rA  p ro te in , w h ereas  th e  res is tan t an d  suscep tib le  
U. parvum iso la tes  (H P A 1 8  an d  U H W Q 3 , re sp ec tiv e ly )  co n ta in ed  
an  A sp residue. W h e n  lo o k in g  a t p o sitio n s  125 a n d  136 o f  ParC , 
U H W W 11 w as ag a in  u n iq u e  in  th a t it  e n c o d e d  T h r  at b o th  p o s­
itions, w hereas b o th  H P A 1 8  an d  U H W Q 3  e n c o d e d  an  A la. W e 
found the  A sp 8 2 A sn  su b s titu tio n  to  b e  u n iq u e  to  th e  resis tan t 
strain , w hich  su p p o rts  o u r  p re v io u s  h y p o th es is  th a t th is  m u ta tio n  
m ediates f lu o roqu ino lone  re s is ta n c e .5
Phylogenetic analysis o f gyrA, gyrB, parC and parE 
sequences
From  the phy lo g en e tic  trees in  F ig u re  2, it w as c le a r  th a t a  n u m b er 
o f  species-specific  n u c leo tid e  p o ly m o rp h ism s o c c u r  am o n g  the 
gyrA, gyrB and  parC g en es , c a u s in g  defin ed  c lu s te rin g  o f  
U. parvum and  U. urealyticum. W ith in  each  c lu s te r  th e re  is little  in  
the way o f  in trasp ec ies  d iffe ren ces , w ith  th e  e x cep tio n  o f  parC, 
w hich  con ta in s un iq u e  S V -specific  substitu tio n s . T h e  species- 
specific c lu ste ring  trend  w as less  c le a r  w h en  ex am in in g  the tree 
constructed  from  parE seq u en ces  (F ig u re  2d). T h e re  w as g rea te r 
sequence h o m ology  betw een  U. urealyticum S V s 2, 5, 7 - 9  an d  11 
w ith  U. parvum th an  w ith  th e  rem a in in g  U. urealyticum iso la tes .
List o f all SV- and species-specific differences
S pecies-specific  d iffe ren ces  a t b o th  th e  n u c le o tid e  a n d  am in o  
acid  levels w ere fo u n d  in  a ll g y rase  an d  to p o iso m e ra se  IV  g en es  
and  pro teins, resp ec tiv e ly . T a b le s  2 - 5  lis t th e  a m in o  ac id  d if fe r­
ences, w ith  a  to ta l o f  39  in  G y rA , 2 6  in  G y rB , 107 in  P arC  and  
34 in ParE . O f  th e  39  a m in o  ac id  d if fe re n c e s  in  G y rA , 37  w ere 
species-specific  p o ly m o rp h ism s. A t p o sitio n  4 6 8  a ll U. parvum 
and  SV s 4, 5, 7 - 9 ,  11 an d  12 o f  U. urealyticum e n c o d e d  L ys, 
w hereas S V s 2 , 10 and  13 e n c o d e d  G lu . T h is  p a tte rn  w as a lso  
true  at p o sitio n  8 34 , in  w h ich  S V s 2, 10 an d  13 e n c o d e d  L ys, 
w hereas the  rem a in in g  U. urealyticum e n c o d e d  G lu . G y rB  co n ­
ta in ed  26  d iffe ren ces  w h ic h  w as th e  lo w es t o f  a ll th e  p ro te in s 
exam ined . A ll G y rB  p o ly m o rp h ism s  w ere  sp e c ie s-re s tr ic ted , 
w ith  no  SV - o r  in tra sp ec ie s -sp ec if ic  d iffe ren ces .
A m ong the  107 d ifferences n o ted  in  th e  P arC  p ro te in , 102 w ere 
species-specific. U n iq u e  se rovar-specific  p o ly m o rp h ism s w ere seen  
at position  3 fo r  SV 3 (V al ra th er th an  A sp , w h ich  w as o b se rved  
fo r all U. urealyticum) and  p o sitio n  735 fo r  SV 1 (T h r  ra th er  th an  
A la fo r U. parvum o r  M et fo r  U. urealyticum). A d d itio n a l serovar- 
specific po lym orph ism s w ere a lso  seen  fo r  SV 11 ( A la i71 V al and  
S er347L eu) and  SV1 (G lu455L ys). A ll U. parvum w ere a lso  fo u n d  
to  b e  m issing  G ln835  and  A sp836 .
ParE  exh ib ited  a  to tal o f  3 4  d ifferences, o f  w h ich  o n ly  9  w ere 
species-restric ted  p o lym orph ism s. F o r  21 o f  the  su b stitu tio n s there  
w as clustering  o f  U. parvum w ith  U. urealyticum S V s 2, 5 , 7 - 9  
and 11, w hereas SV s 4 , 10, 12 and  13 w ere d iverg en t. A  
SV 14-specific p o ly m o rp h ism  w as p resen t a t G ly l0 6 S e r . S V 3 co n ­
tained  A s n l5 1 , w h ile  th e  rem ain in g  U. parvum an d  S V s 4 , 10, 12
Table 2. G yrA  am ino acid difference betw een Ureaplasma serovars
U. parvum U. urealyticum
Position  1 3 6 14 2 4  5 7 8 9 10 11 12 13
112 D E
219 N D
220 V I
221 T S
223 S P
228 Y H
248 K N
287 A V
341 P A
377 I V
383 N K
387 K R
425 S A
428 Q A
431 D G
464 I L
466 V I
468 K E  ]
473 V I
475 N E
478 N D
624 D E
660 D E
710 N D
761 K R
774 E D
792 K Q
827 N D
829 — N
830 — D
831 — D
834 — K  <
835 L T
836 L S
837 Q H
838 E G
840 D E
841 Y H
844 K E
K K K K K E K K
Q Q Q Q Q K Q Q K
A m ino acids are w ritten by the single letter coding system. Numbering refers 
to Ureaplasma  protein number. The amino acid in the first column is 
conserved to the right until otherwise indicated. A dash denotes no 
respective sequence in  U. parvum.
an d  13 en c o d e d  A sp  and  U. urealyticum e n co d ed  H is. SV1 had 
tw o  S V -sp ec ific  p o ly m o rp h ism s in  P arE  (A sp249G lu  and 
S e r2 7 4 A sn ) as w ell as a  V a l4 1 7 T h r p o ly m o rp h ism  relative to  o ther 
U. parvum S V s, b u t iden tica l to  the  10 U. urealyticum sequences.
Comparison o f all previously characterized 
fluoroquinolone-resistant isolates
A  su m m a ry  o f  a ll p rev io u s  stu d ies rep o rtin g  flu o roqu ino lone- 
re s is ta n t Ureaplasma stra in s is p re sen ted  in  T ab le  6. O f  33
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Table 3. GyrB am ino acid d ifference betw een  Ureaplasma serovars Table 4. ParC  am ino  acid difference betw een Ureaplasma serovars
U. parvum U. urealyticum U. parvum U. urealyticum
Position 1 3 6 14 2 4  5 7 8 9 10 11 12 13 Position 1 3 6 14 2 4  5 7 8 9 10 11 12 13
8 K N
62 I V
64 R K
67 L I
72 S V
73 V I
74 I V
75 E G
142 H Y
145 Y H
161 P I
164 N D
167 V I
215 L M
233 T A
245 L A
256 R K
262 E D
315 V I
342 V I
556 A G
570 R K
575 I L
576 S L
578 I T
632 A T
Amino acids are written by the single letter coding system. Num bering refers 
to Ureaplasma protein number. The am ino acid in the first colum n is 
conserved to the right until otherwise indicated.
iso lates describ ed  p rio r  to  Ju n e  2 0 0 9 , 15 w ere  id e n tifie d  to  
species and  co m p rised  3 U. parvum a n d  12 U. urealyticum.5 ~u 
A ll U. urealyticum iso la tes  d e sc rib e d  c o n ta in e d  th e  A s p l l2 G lu /  
A la l2 5 T h r/A la l2 6 T h r  p o ly m o rp h ism , w h ile  th e  U. parvum iso ­
lates d id not. U sing  the  a m in o  ac id  co n se n su s  fo r  G y rA , P arC  
and  ParE  pro teins, it w as p re d ic te d  th a t o f  th e  re m a in in g  18 non- 
speciated  iso lates, o n e -q u a r te r  w ere lik e ly  to  b e  U. parvum and  
the rem ainder U. urealyticum. D isc o u n tin g  th e  su b s titu tio n s  
found  to  be species-specific  p o ly m o rp h ism s  in  th e  p re se n t s tudy , 
on ly  22  o f  the  33 iso la tes  hav e  u n iq u e  su b s titu tio n s  th a t c o u ld  
con tribu te  to  a flu o ro q u in o lo n e -re s is tan t p h en o ty p e . T h u s , n o  
m utation  in  the to p o iso m erase  an d  g y rase  g en es , an d  n o  p o te n ­
tial m echan ism  o f  re sis tan ce  w ere  id en tified  fo r  th e  re m a in in g  
11 iso lates. T he u n iq u e  m u ta tio n s  th a t re m a in  as c a n d id a te s  fo r  
the resis tance m ech an ism  in c lu d e  G lnlO O A rg (1) an d  G ln K M L y s 
(1) in  G yrA , A sp 8 2 A sn  (1), S e r8 3 L eu  (19), G lu 8 7 L y s (1 ), 
A la88G ly  (1), S er7 3 4 G ly  (1) and  A la 7 3 5 T h r  (1) in  P arC , an d  
A sp249G ln  (1), S e r2 7 4 A sp  (1 ) an d  A la 4 5 7 T h r  (1) in  P arE . 
H ow ever, som e o f  th ese  su b s titu tio n s  o c c u r  in  th e  sa m e  iso la te  
(i.e. all the P arE  m u ta tio n s w ere  fo u n d  in  th e  sam e iso la te ), 
w hich  m ay  in d ica te  th a t m u ltip le  su b s titu tio n s  are  re q u ire d  to  
m ediate  a resis tan t p h en o ty p e .
3 D  V  D  D  V
5 H  Q
59 Y  H
125 A  T
136 A  T
171 A  A A A A A A A  V  A A
181 N  S
205 V  I
210 E  K
241 I V
245 C S
247 D  E
250 I T
251 N  S
252 D  E
261 S N
300 I V
310 I V
324 N  S
345 N  S
347 S S S S S S S S L S S
372 I V
400  E  D
408 T  A
412 V  T
414 N  A
440 K  R
444 Q  E
445 T  S
448 D  Q
449 E  Q
454  Q  K
455 K  E  E  E  E
458 N  K
477 T  E
480 F  Y
481 E  Q
490 L  F
491 V  I
493 V  A
495 I V
505 N  S
539 I L
545 I V
551 K  R
565 V  I
570 T  S
571 S C
585 V  A
595 I V
599 W  C
605 I V
608 Y H
Continued
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Table 4. Continued
U. parvum U. urealyticum U. parvum U. urealyticum
Position 1 3 6 14 2 4 5 7 8 9 10 11 12 13 Position 1 3 6 14 2 4 5 7 8 9 10 11 12 13
613 A G 851 K N
615 R K 852 K D
625 S N
629 I L Amino acids are written by the single letter coding system. Numbering refers
643 D E to Ureaplasma protein number. The amino acid in the first column is
646 N G conserved to 1the rightt until otherwise indicated. .\  dash denotes no
656 G D respective sequence in U. parvum.
661 I V
662 I V
670 A V
672 L M Table 5. ParE amino acid difference between Ureaplasma serovars
699 V I
701 A S U. parvum U. urealyticum
704 T V
711 N s Position 1 3 6 14 2 5 7 8 9 11 4 10 12 13
712 V I
717 E D 8 N N S
718 R Q 33 T A
720 S N 39 I V
724 N s 59 N N S
735 T A A A M 61 I I V
738 T S 70 V V I
739 N P 83 s S P
742 P L 106 s S S G s
743 I P 128 s s A
747 V A 145 I I S
749 N S 151 D N D D H D
757 A G 153 s s P
.758 H N 180 V V F
767 Q E 185 I I T
777 s P 203 I I S
779 p L 210 K K N
782 T I 218 N N D
786 T S 231 A T
789 S N 240 Y Y F
790 I K 242 R K
795 Q L 243 S S N
796 M I 244 N N T
804 C S 249 E D D D D
809 E S 252 I I V
810 A V 274 N S S S S
818 N s 299 N N D
826 N s 377 L L V
828 M L 417 T V V V T
831 I T 542 N N T
833 K E 588 N S
835 — Q 589 N K
836 — E 594 K R
837 H Q 595 I V
840 S L 619 K R
846 D N
848 E K Amino acids are written by the single letter coding system. Numbering refers
-----------  to Ureaplasma protein number. The amino acid in the first column is
Continued conserved to the right until otherwise indicated.
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Discussion
Previously, the combined substitutions of Aspll2Glu in the 
GyrA protein along with Alal25Thr and Alal36Thr in the ParC 
protein were highlighted in fluoroquinolone-resistance in 
Ureaplasma.619-11 In this study, a comparison of the QRDRs 
of a ciprofloxacin-resistant U. parvum (HPA18) with susceptible 
U. parvum (UHWQ3) and U. urealyticum (UHWW11) isolates 
showed that both U. parvum isolates had the same profile as pre­
viously described susceptible isolates, whereas the susceptible 
U. urealyticum had the profile previously linked to resistance. 
This finding stimulated further investigation of amino acid poly­
morphisms for all SVs of both U. parvum and U. urealyticum.
Phylogenetic analysis demonstrated distinct clustering of 
species in three out of the four genes analysed, supporting the 
decision to separate the human-associated ureaplasmas into two 
distinct species based on previous genotypic traits.2 However, 
this study revealed an unexpected divergence of SVs 4, 12, 10 
and 13 from the remaining U. urealyticum in the parE tree. 
SV-specific substitutions were noted for SVs 1 and 11 in ParC, 
and SVs 1, 3 and 14 in ParE. These species and SV-specific sub­
stitutions will be important for comparison of resistant and sus­
ceptible strains in the future, to avoid incorrect identification of 
potential resistance mechanisms.
Thirty-three fluoroquinolone-resistant Ureaplasma isolates 
from seven different investigations were identified, for which 
amino acid substitution in the type II topoisomerase proteins 
was proposed as the molecular mechanism of resistance.5-11 
The substitutions that were proposed to result in the resistant 
phenotype are summarized in Table 6. In 2000, Bebear et al.6 
described the molecular characterization of a ciprofloxacin 
resistance in Ureaplasma. The sequence of an isolate of 
U. urealyticum was compared with the published SV3 genome 
(ATCC 700970)13 and identified to contain four amino acid tran­
sitions (GlnlOOArg and Aspll2Glu in GyrA, and Thr 125Ala 
and Thrl36Ala in ParC), which were proposed to be related to 
resistance. The evidence presented in the present study suggests 
that only GlnlOOArg could potentially be responsible for the 
ciprofloxacin MIC of >128mg/L, with the remaining three 
differences all being species-specific polymorphisms. A report 
by Zhang et al.u  found that 9 of 13 isolates with varying 
degrees of resistance to fluoroquinolones had a Ser83Leu substi­
tution within the ParC protein. Unfortunately, the authors did 
not determine the species of the isolates, but based on the GyrA 
sequence data we can speculate that 11 of the 13 isolates were 
U. urealyticum and 2 were U. parvum. The Alal25Thr and 
Alal36Thr mutations were not reported in the suspected 
U. urealyticum isolates, but it is not known if the investigators 
sequenced this portion of the gene as the primers used were not 
reported. Interestingly, the authors not only compared the resist­
ant isolate sequences with the SV3 genome, but also with 
U. urealyticum controls from SV4 (ATCC 27815) and SV8 
(ATCC 27618) with the intention of ruling out species-specific 
polymorphism. Twelve base differences within gyrA and 10 
within parC were identified, but the deduced amino acid 
sequences were quoted as being identical between SVs.
Subsequent investigations by Bebear et al.1 in 2003 examined 
a further 11 resistant isolates and compared sequence data with 
the SV3 genome and a susceptible control, UUel. As would be 
predicted, resistant U. urealyticum isolates were consistently 
found to have the species-specific polymorphism at amino acid
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112 in GyrA and 125 and 136 in ParC, although two U. parvum 
isolates examined (one resistant and one susceptible) did not 
contain these substitutions. Six of the eleven isolates contained 
the Ser83Leu mutation, with a single isolate containing a unique 
mutation in the ParC protein only five amino acids downstream 
for isolate UUc (Glu87Lys).
The first molecular characterization of fluoroquinolone resist­
ance in the USA was provided by Duffy et al.,s who reported a 
U. parvum isolate with an ofloxacin MIC of 128 mg/L. This 
isolate was documented as having 12 mutations, including 
Ser83Leu, but from the data in Table 6, six of these substitutions 
can be ruled out as contributing to resistance as they are species- 
or SV-specific polymorphisms. The VaBAsp mutation in ParC 
was proposed as a resistance determinant, but this substitution 
turns out to be a SV-specific substitution for SV3 (which was 
used as the comparator for their sequence); consensus sequences 
for SVs 1, 6 and 14 show Asp at this position (Table 4). 
Although the SV of this isolate was not determined it can be 
hypothesized that it was likely to be SV1, as they also identified 
the SVl-specific polymorphisms we have found at position 735 in 
ParC, and positions 249, 274 and 417 in ParE (Tables 4 and 5, 
respectively).
Resistance in Ureaplasma isolates from China between 1999 
and 2004 was reported by Xie et al.,10 who found the Ser83Leu 
resistance-associated mutation in the QRDR of three of five 
resistant isolates. However, their reported sequences do not align 
fully with our determined consensus sequences. For example, 
isolates 161, 163 and 168 all show polymorphisms that identify 
them as U. parvum (Aspll2 in GyrA, and Alai25 and Alai36 
in ParE), and isolate 168 also had Thr417 in ParE suggesting 
that it was an SV1. However, isolates 7 and 46 had Glul l2 in 
GyrA suggesting they were U. urealyticum, but isolate 46 had 
Alal25 and Alal36 in ParE consistent with U. parvum consen­
sus sequences, and isolate 7 had Thrl25 but Alal36 giving a 
mixture of the consensus sequences in ParE. We are unable to 
explain this mixing of consensus sequences; however, isolates 
163 and 168 do not have any mutations that are not also found 
in susceptible U. urealyticum or U. parvum isolates.
Geissdorfer et al.9 characterized an isolate from a patient 
who developed meningitis following kidney transplantation. 
Comparison of the reported sequence with our consensus 
Tables identifies the isolate as U. urealyticum, but no unique 
resistance candidate mutations remain after species-specific 
polymorphisms are taken into account. Finally, we previously 
described a single ciprofloxacin-resistant isolate from a cohort of 
61 Ureaplasma isolates from neonates.5 We identified the isolate 
as an SV1 strain with a unique Asp82Asn mutation within the 
ParC protein. This is immediately adjacent to the commonly 
found Ser83Leu mutation and is therefore a strong candidate as 
a resistance-mediating mutation.
This review of the literature highlights that 75% of 
the fluoroquinolone-resistant strains identified to date were 
U. urealyticum (Table 6), even though this species is isolated 
much less frequently from patients (20% of patient isolates in 
our previous study,5 which is consistent with other groups’ find­
ings).1 Furthermore, the ParC Ser83Leu mutation was found in 
58% of the fluoroquinolone-resistant Ureaplasma strains, which 
is homologous to the resistance-mediating mutation identified in 
many other fluoroquinolone-resistant bacteria, including 
Staphylococcus aureus and Streptococcus pneumoniae.14 
Fluoroquinolones are known to have preferential sites of action:
the gyrase proteins for Gram-negative bacteria and the topoi­
somerase IV proteins for Gram-positive bacteria.15 The proposed 
evolution of ureaplasmas from Gram-positive progenitors may 
be responsible for the higher incidence of mutations within the 
topoisomerase IV proteins relative to gyrase proteins. Based on 
our analysis, the molecular mechanism of fluoroquinolone resist­
ance in 11 out of the 33 isolates is still undetermined. 
Resistance in these isolates may have been due to mutations 
outside of the sequenced regions or through alternative mechan­
isms, such as altered membrane permeability.15
This report highlights the importance of determining the 
species of Ureaplasma and the caution that should be taken 
when comparing future sequence data for both fluoroquinolone 
resistance and other genes potentially associated with antibiotic 
resistance. To avoid similar misinterpretation, sequences should 
be compared with the appropriate species and, in some circum­
stances, the appropriate SV.
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ABSTRACT
Background A proteolytic imbalance has been 
implicated in the development of "classical" chronic lung 
disease of prematurity (CLD). However, in "new" CLD this 
pattern has changed. This study examines the 
longitudinal relationship between neutrophil proteinases 
and their inhibitors in ventilated preterm infants and their 
relationship to microbial colonisation.
Methods Serial bronchoalveolar lavage fluid was 
obtained from ventilated newborn preterm infants. 
Neutrophil elastase (NE) activity, cell counts, 
metalloproteinase (MMPJ-9, MMP-9/TIMP-1 complex, 
SerpinBI concentration and percentage of SerpinBI and 
a!-antitrypsin (AAT) in complex with elastase were 
measured. The presence of microbial genes was 
examined using PCR for 16S rRNA genes.
Results Statistically more infants who developed CLD 
had NE activity in at least one sample (10/20) compared 
with infants with resolved respiratory distress syndrome 
(RDS) (2/17). However, NE activity was present in 
a minority of samples, occurring as episodic peaks. Peak 
levels of MM P-9, MMP-9/TIMP-1 complex, percentage 
of AAT and SerpinBI in complex and cell counts were all 
statistically greater in infants developing CLD than in 
infants with resolved RDS. Peak values frequently 
occurred as episodic spikes and strong temporal 
relationships were noted between all markers. The peak 
values for all variables were significantly correlated to 
each other. The presence of bacterial 16S rRNA genes 
was associated with the development of CLD and with 
elevated elastase and MM P-9.
Conclusion NE activity and M M P-9 appear to be 
important in the development of "new" CLD with both 
proteinase and inhibitor concentrations increasing 
episodically, possibly in response to postnatal infection.
This paper is freely available 
online under the BMJ Journals 
unlocked scheme, see http:// 
thorax, bmj .com/site/about/ 
unlocked.xhtml.
INTRODUCTION
Chronic lung disease of prematurity (CLD, also 
called bronchopulmonary dysplasia, BPD) causes 
ongoing respiratory morbidity and mortality in 
preterm infants1 and is associated with large 
oversimplified alveoli suggesting aberrant lung 
development (sometimes called “new” CLD/BPD). 
Inflammation is a hallmark in the development of 
CLD, with neutrophils and macrophages releasing 
reactive oxygen species and proteolytic enzymes 
including the serine proteinase neutrophil elastase 
(HE)4 and matrix metalloproteinases including 
MMP-9.5 6 Normally, any free proteinase is effec­
tively neutralised by proteinase inhibitors. Tissue 
inhibitors of matrix metalloproteinases (TIMPs) are
regulators of MMPs, which for MMP-9 in the lung is 
primarily TIMP-1.5-7 For NE, the best characterised 
is ai-antitrypsin (AAT) with which it forms an 
irreversible covalent 1:1 complex; other proteinase 
inhibitors include secretory leukoproteinase inhibitor 
(SLPI), elafin, a2-macroglobulin and SerpinBI (origi­
nally called monocyte neutrophil elastase inhibitor) 
which rapidly binds covalently with NE. SerpinBI 
has been studied in rat and mouse models and in 
newborn baboons but not in human preterm infants.
Early studies reported proteolytic imbalance in 
preterm infants developing classical CLD.8-10 
“New” CLD shows a different pattern with elastase 
activity being less frequently reported.11-15 An 
imbalance between MMP-9 and TIMP-1 has also 
been described, but the importance of MMP-9 in the 
development of CLD remains unclear 5-7 16-18
The aims of this study were (1) to serially measure 
NE, AAT, SerpinBI, MMP-9 and MMP-9/T1MP-1 
complex in bronchoalveolar lavage (BAL) fluid of 
preterm infants at risk of developing CLD; (2) to 
examine the relationships between these variables 
and their relationship with CLD development; and 
(3) to correlate enzyme dysregulation with bacterial 
colonisation as identified by the presence of bacterial 
16S ribosomal RNA (rRNA) genes.
METHODS 
Patient groups
Three groups of mechanically ventilated infants 
were studied: (1) preterm infants (<32 weeks 
gestation) who developed mild, moderate or severe 
CLD using National Institute of Child Health 
criteria1; (2) preterm infants who developed and 
recovered from neonatal respiratory distress 
syndrome (RDS); and (3) a control group comprising 
term infants who required ventilation for non-respi- 
ratory reasons needing <28% oxygen throughout the 
study period. Participants were recruited from the 
neonatal unit at the University Hospital of Wales, 
Cardiff between May 2005 and December 2006.
Bronchoalveolar lavage
BAL was performed as previously described.19 20 
BAL fluid was collected daily for the first week of life 
then twice a week until 28 days of age or until 
extubation. Two aliquots of 1 ml/kg normal saline 
were instilled and suctioned immediately. Samples 
were centrifuged at lOOOg for 10 min at 4°C within 
30 min of collection. The supernatant was aliquoted 
and stored at — 80°C. Pelleted cells were resuspended 
in phosphate buffered saline, counted with 
a haemocytometer and cytospins were stained with
246 Thorax 2010;65:246-251. doi:10.1136/thx.2009.116061
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Diff-Quik for cell differential counts. The unused cell suspension 
was recentrifuged and the pellet stored at -80°C.
NE activity
NE activity in BAL fluid was measured by the kinetic conversion 
of Suc-Ala-Ala-Pro-Val-pNA (Bachem, St Helens, UK), as 
described previously.11 14 The specificity of free NE activity was 
verified by neutralisation with recombinant AAT (Arriva Phar­
maceuticals, Alameda, California, USA).
AAT analysis
The protein concentration in BAL fluid was determined using 
a BCA Protein Assay Kit (Pierce, Rockford, Illinois, USA). BAL 
fluid AAT was analysed by western blot analysis with equal 
protein load as described elsewhere13 using horseradish per­
oxidase (HRP)-conjugated goat polyclonal anti-human AAT 
(AB7635; Abeam PLC, Cambridge, UK). Excess purified NE 
(0.5 jig) was added to BAL fluid for 30 min at room temperature 
prior to western blot analysis when immunoreactive native AAT 
was observed coincident with NE activity to test specificity.
SerpinBI analysis
SerpinBI was assessed in equal volumes of BAL fluid by western 
blot analysis using a rabbit polyclonal anti-SerpinBl primary 
and an HRP-conjugated goat anti-rabbit secondary antibody.21 A 
standard curve (3—30 ng) of recombinant SerpinBI was included 
on each gel. SerpinBI was quantified by densitometry using 
ImageJ software (http://rsb.info.nih.gov/ij/).
Total MMP-9 and MMP-9/TIMP-1 complex
These were measured by ELISA (R&D Systems, Minneapolis, 
USA) according to the manufacturer's instructions.
Bacterial 16S rRNA analysis
Cell pellet DNA was isolated using the Qiagen RNA/DNA Mini 
kit (Qiagen, Crawley, UK). PCR was used to amplify the 16s 
rRNA gene using the primers 27f (5-AGAG111 GATC(AC) 
TGGCTCAG-3 ) and 1492r (5' -TACGG(CT)TACCTTGTTAC- 
GACTT-3 ).22 23 The integrity of extracted DNA was assessed by 
amplifying human mitochondrial cytochrome oxidase (HMCO) 
using specific primers. PCR products were separated on 0.7% 
agarose gels stained with ethidium bromide and visualised in 
a BioDoc-IT UV Transilluminator (Ultra-Violet Products, 
Cambridge, UK).
Sequencing of 16s rRNA genes
Amplicons from samples positive for 16s rRNA genes were purified 
using a Novagen spin-prep PCR clean-up kit (Merck Chemicals, 
Nottingham, UK) and sequenced using the BigDye Terminator 
V3.1 cycle sequencing kit (Applied Biosystems, Warrington, UK) 
and an ABI Prism 3130x1 Genetic Analyzer (Applied Biosystems). 
Sources of bacterial 16S rRNA genes were determined by amplicon 
sequence comparison using the BlastN website.
Statistical methods
Statistical analysis was performed using SPSS V.15.0. The 
Mann—Whitney U test was used for non-parametric data and 
correlations between groups were performed using Spearman 
correlation coefficients. The presence of NE or 16s rRNA genes 
between groups was compared using / 2 tests, p Values of <0.05 
were considered statistically significant.
RESULTS 
Patients
Eorty-two infants of <32 weeks' gestational age were recruited: 
20 developed CLD (5 mild, 12 moderate, 3 severe CLD); 17 
recovered from RDS; 5 infants died before they could be classified
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and were excluded from the analysis; there were also 6 term 
controls (table 1). Two hundred and twenty BAL fluid samples 
were collected: 130 from the CLD group, 45 from the RDS group, 
22 from infants who died and 23 from term controls. The median 
BAL fluid yield was 50% (IQR 38—63%).
Cell counts
Median (IQR) peak cell counts in BAL fluid were statistically 
greater in infants developing CLD (6.75xl06cells/ml; 
3.54—17.9X106) than in the RDS group (2.22X106 cells/ml; 
1.05—5.50X106, p=0.002) and controls (0.63xlO6 cells/ml; 
0.156—1.26x106, p<0.001). The moderate/severe CLD group 
(6.30X106 cells/ml; 3.97—11.3X106) had a statistically greater 
peak cell count than the RDS group (p=0.005). Neutrophils 
dominated the cell counts but macrophages and some epithelial 
cells were observed. Peak neutrophil counts were statistically 
greater in infants developing CLD (3.36X106 cells/ml; 
1.79—9.93 XlO6) than in infants with resolved RDS 
(1.14X106 cells/ml; 0.65—2.88X106, p=0.005) and term controls 
(0.38XlO6cells/ml; 0.048—0.63x10, p=0.001). Infants with 
moderate/severe CLD (2.56X106 cells/ml; 1.91—7.13X106) had 
statistically more neutrophils than the RDS group.
Elastase activity
Free NE activity was detected in 26/198 BAL fluid samples 
(13%). Statistically more infants who developed CLD (10/20) 
had free NE activity in at least one BAL fluid sample compared 
with the RDS group (2/17, p=0.013) or controls (0/6, p=0.027). 
Three of 5 infants with mild CLD had detectable NE in at least 
one BAL fluid sample. More infants with moderate/severe CLD 
had free NE detected in BAL fluid than infants in the RDS group 
(p=0.035). No statistical difference was noted between the RDS 
and control groups. No sample from the term controls had free 
NE activity. NE activity was present in 23/129 (18%) lavages 
from the infants developing CLD and in 3/46 (7%) samples from 
infants with resolved RDS.
Detection of NE activity was episodic, with the day of first 
occurrence varying from days 2 to 26 (median 7 days), and NE 
activity coincided with increased BAL fluid cell counts (figure 1 
and online data supplement). In all cases, NE activity was 
blocked by the addition of exogenous recombinant AAT (data not 
shown), suggesting an imbalance between proteinases and 
proteinase inhibitors.
Table 1 Patient characteristics
Chronic lung 
disease
Resolved
respiratory
distress
syndrome Term control
Number of patients 20 17 6
Number of samples 130 45 23
Gestational age (weeks) 27
(25+4—29+3)*
28 +6
(27—29+2)*
Term
Birth weight (g) 835 1120 2550
(695-1025 ) (935-1315 ) (2090-2825 )
M:F 11:9 10:7 3:3
Vaginalxaesarean delivery 10:10 6:11 5:1
Antenatal steroids 
> 2 4  h
16/20 (80%) 12/17 (71%) 0/6 (0%)
Surfactant therapy 20/20 (100%) 17/17 (100%) 0/6 (0%)
Prolonged rupture of membranes 
(> 2 4  h)
4/20 (20%) 1/17 (6%) 0/6
Length of ventilation (days) 7 (5 .5 -1 1 ) 1 (1 -4 .5 ) 3
*  Values are shown as median (IQR).
Superscript numbers indicate the number of days in addition to gestation in weeks.
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ai-Antitrypsin
Western blotting detected free AAT as a 53 kDa band, AAT- 
proteinase complex at 80 kDa and apparent degraded AAT at 
48 kDa (figure 2A). AAT-NE complex was detected in 18/20 
(90%) infants who developed CLD, which is statistically more 
than 8/17 (47%) infants whose RDS resolved (p=0.004). The 
maximum percentage of complexed AAT as estimated by densi­
tometry was statistically greater for infants in the CLD group 
(median 22%; IQR 13—32%) than for infants whose RDS 
resolved (median 0; 0—19%, p=0.012) and term controls (median 
0; 0-9%, p=0.003), and between the RDS group and infants 
with moderate/severe CLD (median 22%; 13.5—33.5%, p=0.013).
Interestingly, BAL fluid collected from some infants with CLD 
contained both free NE and unbound AAT (53 kDa) (figure 2B). 
In all cases when a molar excess of NE was incubated with the 
BAL fluid prior to western blot analysis, the unbound AAT 
(53 kDa) formed a complex with NE or was degraded.
SERPINBI
The median (IQR) SerpinBI concentration on the first day of life 
was 155 ng/ml (64—414), which did not increase significantly 
over the first 5 days of life; no statistical difference was noted 
between the CLD and RDS groups over this period. Median 
(IQR) peak SerpinBI concentrations were not statistically 
different between groups (CLD group: 400 ng/ml; 185—2130; 
RDS group: 205 ng/ml; 113—480, p=0.161) and term controls 
(163 ng/ml; 78—164, p=0.107). No statistical difference was seen 
between peak SerpinBI concentrations in the RDS group and 
infants with moderate/severe CLD (455 ng/ml; 191.5—2130, 
p=0.157). Episodic increases in SerpinBI were observed more 
frequently in infants developing CLD than in a minority of RDS 
infants (figure 3), and these increased SerpinBI episodes corre­
sponded to episodic increases of cell counts, free NE and NE-AAT 
complexes (figure 1 and online supplement). Statistically more 
infants with CLD had covalently complexed SerpinBI in at least 
one BAL fluid sample (11/20) compared with infants with
resolved RDS (3/17), p=0.020. SerpinBI complex was not 
observed in control infants.
MMP-9
Median (IQR) peak MMP-9 protein concentrations were statisti­
cally greater in infants who developed CLD (763 ng/ml; 200—1790) 
than in infants in the RDS group (47 ng/ml; 20—352, p=0.004) 
and term controls (74 ng/ml; 36—250, p=0.007). Infants with 
moderate/severe CLD (948 ng/ml; 252—2322) also had statisti­
cally greater MMP-9 than those with RDS (p=0.005). Peak MMP- 
9/TIMP-l complex concentrations were greater in infants who 
developed CLD (29.9 ng/ml; 13.1—51.3) than in the RDS group 
(1.5 ng/ml; 0.9—24.1, p=0.004) and than infants with moderate/ 
severe CLD (29.9 ng/ml; 16.5—51.3) than in infants in the RDS 
group (p=0.017). Differences between CLD and term infants 
(7.0 ng/ml; 1.4—24.2) were not statistically significant (p=0.068).
Relationship between variables
Strong correlations were observed between most peak values, 
particularly MMP-9 and MMP-9/TIMP-1 complexes and NE 
activity relative to the percentage of complexed SerpinBI (table 
2). In addition, there were strong temporal correlations between 
cell counts, proteinases and anti-proteinases (figure 1 and online 
supplement).
Bacterial 16S rRNA genes
DNA was extracted from 198 BAL fluid samples and satisfactory 
DNA integrity was confirmed in 162 by HMCO amplification 
by PCR (only three infants failed to have a satisfactory sample 
DNA). Bacterial 16S rRNA genes were detected in 75/162 (46%) 
of these samples; statistically more infants who developed CLD 
had 16S rRNA genes in their BAL fluid at some point (14/19, 
74%) than infants in the RDS group (5/16 (31%), p=0.012) or 
term controls (2/5 (40%), p=0.155). Statistically more infants 
with moderate/severe CLD (11/14, 79%) had 16s rRNA genes 
detected than infants in the RDS group (p=0.001). Elastase 
activity was found in greater numbers of 16S rRNA gene-positive
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Figure 1 Longitudinal analysis of bronchoalveolar lavage fluid from three infants showing temporal relationships between variables. Graphs A—C show 
SerpinBI concentrations (left axis, solid line) and the proportion of ai-antitrypsin (AAT) in complex with serine protease (right axis, broken line) relative 
to day of life (x-axis). Graphs D—F show the same infants with matrix metalloproteinase (MMP)-9 concentrations (left axis, solid line) and total cell 
counts (right axis, broken line) against days of life. The arrows indicate the days when free neutrophil elastase (NE) was detected. No free NE was 
detected in infant 3.
248 Thorax 2010;65:246-251. doi: 10.1136/thx.2009.116061
Downloaded from thorax.bmj.com on April 30, 2010 - Published by group.bmj.com
Paedia t r ic  lung disease
Standard
I
Age (days): 1 
NE (nM): 0
A A T in com plex  
Free AAT
B
Standard
^  ^  M  mm A A T in com plex
Free AAT
—  —  —  D egraded  AAT
Age (days): 1 2 3 4 5 6
NE (nM): 0 0 0 7 15 98
Figure 2 Western blot of a,-antitrypsin (AAT) species in sequential 
bronchoalveolar lavage (BAL) fluid specimens for (A) a representative 
infant from the resolved respiratory distress syndrome group in whom 
active neutrophil elastase (NE) was not detected and (B) an infant from 
the chronic lung disease of prematurity group in whom active NE was 
detected. Patient age and NE concentrations are shown below each lane 
of the western blot. Equal amounts of protein were loaded for analysis 
and the left lanes show purified plasma AAT migrating at 53 kDa 
(standard). Additional bands in BAL fluid specimens are the complex with 
serine proteases at 80 kDa and degraded AAT at 48 kDa. Note that the 
day 1 samples for both infants contain free AAT only, while day 5 BAL 
fluid for patient A and days 2 - 6  for patient B also contain an additional 
higher AAT-proteinase complex. BAL fluid from days 2—6 of patient B 
also contains degraded AAT.
lavages (19/75, 25%) than 16S rRNA gene-negative lavages (5/87 
(6%), p=0.009). Furthermore, elastase activity was higher in the 
16S rRNA gene-positive lavages than in the negative lavages 
(although the median value for both was zero, p=0.0018). The 
median (IQR) total BAL fluid MMP-9 concentration was greater 
in 16S rRNA gene-positive lavages (211 ng/ml; 64—1047) than in 
16S rRNA gene-negative samples (44 ng/ml; 21—115, pcO.OOl).
PCR amplicon sequencing showed that the samples with the 
greatest NE activity and total MMP-9 concentrations contained 
virulent organisms such as Stegastes aureus and £ coli (figure 4A), 
while the RDS infants with free elastase and the highest MMP-9 
concentrations had organisms regarded as being less virulent such 
as S epidermidis (figure 4B).
DISCUSSION
This study provides a detailed profile of NE and its inhibitors, 
AAT (SerpinAl) and SerpinBI as well as MMP-9 and MMP-9/
Standard
Free ^
SerpinBI ~
Age (days): 1 
NE (nM): 0
complex
Mdegraded  
3 4 5 6 SerpinBI
0 7 15 98
Figure 3 Western blot of SerpinBI species in sequential broncho­
alveolar lavage (BAL) fluid specimens of an infant with chronic lung 
disease of prematurity in whom active neutrophil elastase (NE) was 
detected. Equal volumes of BAL fluid were loaded for analysis and the left 
lane shows purified SerpinBI (10 ng) migrating at 42 kDa (standard). 
Other species present in BAL fluid are the 66 kDa complex with serine 
proteinase, a partially degraded intermediate product and degraded 
SerpinBI at 38 kDa. A statistically significant increase in both the total 
concentration and percentage in the complex is seen, occurring with 
increased NE activity.
Table 2 Correlation coefficients between maximum values of cell 
counts, neutrophil elastase (NE) activity, matrix metalloproteinase 
(MMP)-9 concentrations, SerpinBI concentrations, percentage 
a,-antitrypsin (AAT) and SerpinBI in complex and MMP-9/TIMP-1 
concentrations in BAL fluid from ventilated newborn infants
Maximum value Maximum value
Spearman's 
correlation 
coefficient 
(p value)
Log10 MMP-9 Log10 MMP-9/TIMP-1 0.94
Log10 elastase % SerpinBI in complex 0.88
Log10 SerpinBI % SerpinBI in complex 0.76
Log,0 MMP-9 Logio cell count 0.75
Log10 elastase Logio neutrophil count 0.71
Log10 neutrophil count % SerpinBI in complex 0.70
Log10 elastase Log10 SerpinBI 0.68
Log10 elastase Log10 cell count 0.65
Log10 elastase Log10 MMP-9 0.65
% AAT in complex % SerpinBI in complex 0.64
% AAT in complex Log10 elastase 0.62
Log l0 neutrophil count Log10 SerpinBI 0.62
Log 10 cell count Logio SerpinBI 0.59
Statistical analysis for all correlations shown were statistically significant at p<0 .001 .
TIMP-1 complex in ventilated preterm infants. It identified 
relationships between proteolytic enzymes and their inhibitors 
and highlights the importance of postnatal infection in 
proteinase release and in the development of CLD.
Our study is the most detailed longitudinal analysis to date of NE 
activity in CLD and includes the previously unstudied SerpinBI.
11 13 14 orPrevious studies examined NE at single time points 
examined a limited number of samples.12 15 We found that NE 
activity was episodic and frequently occurred relatively late in the 
development of CLD, which may cause NE activity to be missed 
when summary data are presented rather than longitudinally for 
individual infants. BAL fluid studies of intubated infants prevent 
comparisons with patients with RDS at equivalent time points. 
However, our data suggesting that infection may lead to dysre- 
gulated inflammation are in agreement with published evidence 
that prolonged mechanical ventilation commonly results in the 
development of pneumonia 24
Some infants developed CLD without NE activity being 
detected. It is possible that NE activity occurred between lavages 
or following extubation. Also, NE activity may be increased in 
the pericellular environment as suggested by the presence of 
complexed AAT and SerpinBI. These complexes, which may be 
regarded as surrogate markers for regulated NE release, were 
present in far more samples than was free NE, particularly in 
infants developing CLD, suggesting successful regulation of 
proteinases. The simultaneous presence of free NE and unbound 
AAT (53 kDa) was interesting. This may reflect oxidation of the 
AAT reactive site methionine residue resulting in a decreased rate 
of NE-AAT complex formation.25 Thus complex formation 
occurred after in vitro incubation for a further 30 min with excess 
NE. Alternatively, increased proteinases including MMP-9 may 
degrade and inactivate AAT leading to more NE activity. Infec­
tion may trigger this dysregulation as it was closely correlated 
with the increased NE.
SerpinBI has not been studied in human newborn infants but 
has been examined in a baboon CLD model.26 Higher NE activity 
was reported in baboons with “classical” compared with “new” 
CLD. Baboons developing “new” CLD had 2.5 times the level of 
SerpinBI mRNA in BAL fluid compared with term controls, 
while “classical” CLD was associated with lower SerpinBI
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Figure 4 Scatterplots of (A) peak 
elastase activity and (B) matrix 
metalloproteinase (MMP)-9 
concentrations for each diagnostic class 
of infant. Filled symbols indicate 16S 
rRNA gene-positive specimens and 
empty boxes indicate negative 
specimens. Sequencing data for 16S 
rRNA gene-positive organisms are also 
shown. Some samples were identified 
as 16S rRNA gene-positive but no 
specific microorganism was identified 
by sequencing. Abbreviations for micro­
organisms include S epi (S epidermidis),
S haem (S haemolyticus) and P aeru 
(P aeruginosa). CLD, chronic lung disease 
of prematurity; RDS, respiratory distress 
syndrome.
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concentrations. We thus hypothesised that a higher SerpinBI 
content in “new” CLD may reduce NE activity in human patients 
and we did find a trend towards higher SerpinBI levels in infants 
with CLD than in those with RDS and controls. Temporal rela­
tionships were noted between SerpinBI concentration, active NE 
and the percentage of SerpinBI complexed with proteinase, 
which suggests that the SerpinBI increase was part of a protec­
tive mechanism to regulate NE activity.
AAT is an acute phase reactant.27 Merritt et al8 showed that 
the AAT concentration almost doubled in lung lavages from 
infants developing classical CLD. However, we have shown that 
the SerpinBI concentration increased locally and rapidly in 
association with increased NE activity. Moreover, the increase in 
SerpinBI was far greater (>10-fold increase for some neonates, 
figure 3) than has previously been described for AAT8 and may be 
more important in neutralising NE activity. The mechanisms of 
SerpinBI release are unknown as the protein lacks an N-terminal 
classical secretion sequence.28 The BAL fluid concentration of 
SerpinBI correlated well with infiltrating inflammatory cells, 
particularly neutrophils (which contain the highest concentra­
tion of SerpinBI); therefore, SerpinBI may have been released 
following cell death or by a non-classical mechanism. However, 
the possibility of SerpinBI upregulation and release cannot be 
discounted.29 Our finding of SerpinBI increasing in parallel with 
inflammation is in keeping with those reported in patients with 
cystic fibrosis where a similar correlation between SerpinBI levels 
and neutrophil numbers was also noted.30
The simultaneous episodic increases of neutrophils, proteinases 
(NE and MMP-9) and anti-proteinases (AATand SerpinBI) indicate 
a triggered inflammatory process leading to an increased likelihood 
of developing CLD; postnatal infection was the most likely 
candidate to trigger the inflammation. The role of postnatal 
infection in the development of CLD is recognised31 32 but is 
frequently underrated. Conventional culture techniques of BAL 
fluid are confounded by frequent administration of broad-spec- 
trum antibiotics in these patients. Microbial infection or coloni­
sation has previously been confirmed by identification of 16S 
rRNA genes.33-35 Our finding of 16S rRNA genes detection in 
patients developing CLD lends further support to postnatal 
infection being integral in the pathogenesis of CLD. NE was 
detected more frequently and in higher levels for BAL fluid samples 
when 16S rRNA genes were detected. This suggests that infection 
rather than microbial colonisation of the airways is responsible for 
episodic spikes of protective proteinases and inhibitors.
Previous studies of MMP-9 have reported conflicting results. 
Dik et al17 showed an increased MMP-9 concentration on days 2
and 4 of life in infants with RDS compared with those with 
CLD, but Sweet et al5 and Ekekezie et al6 found no statistical 
difference in MMP-9 levels between groups although both 
reported a higher ratio of MMP-9 to TIMP-1 in the BAL fluid of 
infants with CLD. Danan et al7 showed that MMP-9 concen­
trations, primarily of inactive pro-MMP-9, were increased early in 
life, but no difference was noted between infants with CLD and 
those with RDS. Studies of baboons found higher MMP-9 
concentrations in extremely premature animals with CLD.16 Our 
longitudinal study of human infants suggests that MMP-9 may 
be important in the development of CLD and, as with NE, the 
increased concentrations were episodic. MMP-9/TIMP-1 
concentrations in neonatal BAL fluid have not been reported 
previously. We found a strong correlation between total MMP-9 
and MMP-9/TIMP-1 complex concentrations; however, only 
a small proportion of total MMP-9 appeared to be in complex 
with TIMP-1. Furthermore, western blot analysis of our BAL 
fluid (data not shown) showed that more than half of the MMP-9 
was present as dimer rather than monomer, which may interfere 
with TIMP-1 binding, and the mass of the monomer MMP-9 
appeared to be mostly present as the pro-enzyme form. Our 
finding of an increased MMP-9 concentration in 16S rRNA 
gene-positive samples suggests that the episodic spikes observed 
in proteinase concentrations is probably due to infective 
episodes.
The sequencing data suggest that, while a number of organ­
isms may be associated with high peaks of elastase and MMP-9, 
those infants who develop CLD had more virulent organisms 
within their BAL fluid. S aureus and E coli were particularly 
prominent in infants with CLD with BAL fluid elastase present, 
while the higher proteinase activity in the BAL fluid of infants 
whose RDS resolved was associated with S epidermidis, which is 
frequently dismissed as a commensal.
In conclusion, our study gives a detailed longitudinal profile 
of NE and MMP-9 and their inhibitors AAT and SerpinBI as 
well as MMP-9/TIMP-1 concentrations in the lungs of 
preterm infants. It showed that episodic peaks of both 
proteinases and their inhibitors occurred, which may be impor­
tant in the development of CLD, and we suggest that postnatal 
infection is a crucial trigger for inflammatory infiltration and 
proteinase release leading to lung injury resulting in CLD 
development.
Acknowledgements We are grateful for the assistance of Jessica Cooley (Immune 
Disease Institute, Boston, Massachusetts, USA) and colleagues from the neonatal 
unit in Cardiff, UK. In particular, we would like to thank the parents and infants who 
participated in this study.
250 Thorax 2010;65:246-251. doi: 10.1136/thx.2009.116061
Downloaded from thorax.bmj.com on April 30, 2010 - Published by group.bmj.com
Paedia t r ic  lung disease
Contributors PLD and OBS contributed equally to the research and preparation of the 16.
manuscript and share first co-authorship. All authors listed contributed significantly to 
the research that resulted in the submitted manuscript.
Funding Arriva Pharmaceuticals Inc, 1010 Atlantic Avenue, Alameda, CA 94501. USA.
Other funders: NIH (HL066548) to ERO and Wellcome Trust.
IQ
Competing interests None.
Ethics approval This study was conducted with the approval of the South Wales local 
research ethics committee and written informed consent was obtained from the 19-
parents of study subjects.
Provenance and peer review Not commissioned; externally peer reviewed. 20.
REFERENCES 21
1. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J  Respir Crit Care Med 
2001;163:1723-9.
2. Northway WH Jr, Rosan RC, Porter DY. Pulmonary disease following respirator 22.
therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J  Med 
1967;276:357-68.
3. Coalson JJ. Pathology of new bronchopulmonary dysplasia. Semin Neonatol 23.
2003;8:73-81.
4. Lee WL, Downey GP. Leukocyte elastase: physiological functions and role in acute 24.
lung injury. Am J Respir Crit Care Med 2001;164:896-904.
5. Sweet OG, Curley AE, Chesshyre E, et al. The role of matrix metalloproteinases -9 and
-2 in development of neonatal chronic lung disease. Acta Paediatr 2004;93:791-6. 25.
6. Ekekeae II, Thibeault DW, Simon SD, et al. Low levels of tissue inhibitors of 
metalloproteinases with a high matrix metalloproteinase-9/tissue inhibitor of 
metalloproteinase-1 ratio are present in tracheal aspirate fluids of infants who develop 26. 
chronic lung disease. Pediatrics 2004;113:1709-14.
7. Danan C, Jarreau PH, Franco ML, et al. Gelatinase activities in the airways of
premature infants and development of bronchopulmonary dysplasia. Am J  Physiol 27.
Lung Cell Mol Physiol 2002;283:L1086—93.
8. Merritt TA, Cochrane CG, Holcomb K, et al. Elastase and alpha 1 -proteinase inhibitor 28.
activity in tracheal aspirates during respiratory distress syndrome. Role of
inflammation in the pathogenesis of bronchopulmonary dysplasia. J Clin Invest 
1983;72:656-66. 29.
9. Ogden BE, Murphy SA, Saunders GC, et al. Neonatal lung neutrophils and elastase/
proteinase inhibitor imbalance. Am Rev Respir Dis 1984;130:817-21. 30.
10. Watterberg KL, Carmichael DF, Gerdes JS, et al. Secretory leukocyte protease
inhibitor and lung inflammation in developing bronchopulmonary dysplasia. J  Pediatr 
1994;125:264-9. 31.
11. Speer CP, Ruess D, Harms K, et al. Neutrophil elastase and acute pulmonary damage 
in neonates with severe respiratory distress syndrome. Pediatrics 1993;91:794-9.
12. Groneck P, Gotze-Speer B, Oppermann M, et al. Association of pulmonary 32.
inflammation and increased microvascular permeability during the development of 
bronchopulmonary dysplasia: a sequential analysis of inflammatory mediators in 
respiratory fluids of high-risk preterm neonates. Pediatrics 1994;93:712-8. 33.
13. Griese M, Pudenz P, Gebhard W. Inhibitors of elastase in airway lavage samples from 
ventilated preterm human neonates. Am J  Respir Crit Care Med 1998;158:256-62.
14. Sluis KB, Darlow BA, Vissers MC, et al. Proteinase-antiproteinase balance in tracheal 34.
aspirates from neonates. Eur Respir J  1994;7:251-9.
15. Sveger T, Ohlsson K, Polberger S, et al. Tracheobronchial aspirate fluid neutrophil
lipocalin, elastase- and neutrophil protease-4-alpha 1 -antitrypsin complexes, protease 35.
inhibitors and free proteolytic activity in respiratory distress syndrome. Acta Paediatr 
2002;91:934-7.
Tambunting F, Beharry KD, Hartleroad J, et al. Increased lung matrix 
metalloproteinase-9 levels in extremely premature baboons with bronchopulmonary 
dysplasia. Pediatr Pulmonol 2005;39:5-14.
Dik WA, van Kaam AH, Dekker T, et al. Early increased levels of matrix 
metalloproteinase-9 in neonates recovering from respiratory distress syndrome. Biol 
Neonate 2006;89:6-14.
Cederqvist K, Sorsa T, Tervahartiala T, etal. Matrix metalloproteinases-2, -8, and -9 
and TIMP-2 in tracheal aspirates from preterm infants with respiratory distress. 
Pediatrics 2001;108:686-92.
Kotecha S, Wilson L, Wangoo A, et al. Increase in interleukin (IL)-1 beta and IL-6 in 
bronchoalveolar lavage fluid obtained from infants with chronic lung disease of 
prematurity. Pediatr Res 1996;40:250-6.
de Blic J, Midulla F, Barbato A, et al. Bronchoalveolar lavage in children. ERS Task 
Force on bronchoalveolar lavage in children. European Respiratory Society. Eur Respir 
J  2000;15:217-31.
Rees DD, Rogers RA, Cooley J, et al. Recombinant human monocyte/neutrophil 
elastase inhibitor protects rat lungs against injury from cystic fibrosis airway 
secretions. Am J Respir Cell Mol Biol 1999;20:69-78.
Davies CE, Hill KE, Wilson MJ, et al. Use of 16S ribosomal DNA PCR and denaturing 
gradient gel electrophoresis for analysis of the microfloras of healing and nonhealing 
chronic venous leg ulcers. J Clin Microbiol 2004;42:3549-57.
Lane DJ. 16S/23S rRNA sequencing. In: Stackebrandt E, Goodfellow M, eds. Nucleic 
acid techniques. Bacterial systematics. London: Wiley, 1991:115—75. 
Apisamthanarak A, Holzmann-Pazgal G, Hamvas A, et al. Ventilator-associated 
pneumonia in extremely preterm neonates in a neonatal intensive care unit: 
characteristics, risk factors, and outcomes. Pediatrics 2003;112:1283-9.
Padrines M, Scneider-Pozzer M, Bieth JG. Inhibition of neutrophil elastase by alpha- 
1-proteinase inhibitor oxidized by activated neutrophils. Am Rev Respir Dis 
1989;139:783-90.
Yasumatsu R, Altiok 0, Benarafa C, etal. SERPINBI upregulation is associated with in 
vivo complex formation with neutrophil elastase and cathepsin G in a baboon model of 
bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol 2006;2911619-27. 
Ito H, Kishikawa T, Yamakawa Y, et al. Serum acute phase reactants in pediatric 
patients; especially in neonates. Jpn J  Surg 1983;13:506-11.
Remold-O'Donnell E, Chin J, Alberts M. Sequence and molecular characterization of 
human monocyte/neutrophil elastase inhibitor. Proc Natl Acad Sci U S A  
1992;89:5635-9.
Zeng W, Remold-O'Donnell E. Human monocyte/neutrophil elastase inhibitor (MNEI) is 
regulated by PU.1/Spi-1, Sp1, and NF-kappaB. J  Cell Biochem 2000;78:519-32.
Cooley JRF, Sontag MK, Osberg I, et al. MNEI (monocyte/neutrophil elastase 
inhibitor) is found at increased levels in cystic fibrosis lavage fluid. Pediatr Pulmonol 
2001 ;32(Suppl 22):271.
Groneck P, Goetze-Speer B, Speer CP. Inflammatory bronchopulmonary response of 
preterm infants with microbial colonisation of the airways at birth. Arch Dis Child Fetal 
Neonatal Ed 1996;74:F51—5.
Walti H, Tordet C, Gerbaut L, etal. Persistent elastase/proteinase inhibitor imbalance 
during prolonged ventilation of infants with bronchopulmonary dysplasia: evidence for 
the role of nosocomial infections. Pediatr Res 1989;26:351-5.
Kotecha S, Hodge R, Miralles R, et al. Presence of pulmonary Ureaplasma 
urealyticum is associated with acute pulmonary inflammation in preterm infants. 
Pediatr Res 2004;55:61-8.
Oyarzun E, Yamamoto M, Kato S, et al. Specific detection of 16 micro-organisms in 
amniotic fluid by polymerase chain reaction and its correlation with preterm delivery 
occurrence. Am J  Obstet Gynecol 1998;179:1115-9.
Miralles R, Hodge R, McParland PC, et al. Relationship between antenatal 
inflammation and antenatal infection identified by detection of microbial genes by 
polymerase chain reaction. Pediatr Res 2005;57:570-7.
Thorax 2010;65:246-251. doi:10.1136/thx.2009.116061 251
Appendix II
12th European Meeting on Complement in Human Disease. September 2009 
Visegrad, Hungary
Serovar variations in mechanism and susceptibility for complement 
killing of Ureaplasma parvum
Michael L. Beeton. Saliesh Kotecha, O. Brad Spiller.
Dept. Child Health, Cardiff University School of Medicine, Cardiff, U.K.
Oral presentation
Ureaplasma parvum  is the most common organism associated with premature 
birth, causes non-gonococcal urethritis and neonatal meningitis. U. parvum 
consists of serovars (SV) 1, 3, 6 and 14 with SV3 being the most common. 
We screened for complement killing of clinical isolates of each SV by normal 
serum, as assessed by measuring survival titres following 1 hour incubation at 
37 °C with 50% serum (relative to matched heat-inactivated controls).
No bacterial killing was observed for any SV when serum was diluted in 
alternative pathway buffer (containing EGTA and magnesium), indicating 
Ureaplasma does not overtly activate the alternative pathway. When serum 
diluted in veronal-buffered saline, 5/12 sera killed SV1 by >1000 fold, all sera 
killed SV3 by >1000 fold, 8/12 sera killed SV6 by 10 -  1000 fold and 4/12 sera 
killed SV14 by 10 -  1000 fold (only 1 by >1000 fold). IgG-depletion by protein 
A-sepharose removed the bacteriocidal activity of all serum for SV1, SV6 and 
SV14, but had no effect on killing of SV3. The antibody dependence of 
complement-mediated bacteriocidal activity was supported by Western blot 
analysis, although the molecular mass of bacterial proteins bound by human 
immunoglobulins varied widely between sera and between strains of the same 
SV. Two sera with no immunoreactivity to any SV by Western blot were 
completely MBL-depleted by mannan-agarose, but retained 100% SV3 
bacteriocidal activity, while C6- and C7-deficient sera had no bacteriocidal 
activity.
We found that killing of SV1, SV6 and SV14 was IgG-dependent and 
the alternative and lectin pathways were not bacteriocidal for U. parvum. SV3 
killing is calcium-dependent, but antibody- and MBL-independent. Variability 
of Western blot bands amongst strains of SV suggests hypervariability of 
dominant immunogens, with potential for escape. Preliminary studies suggest 
SV3 directly binds C1q leading to complement activation, although the role of 
ficolin-mediated activation is currently being ruled out.
I3 IRG annual meeting. July 2009. Gregynog, UK
Serovar variations in mechanism and susceptibility for complement 
killing of Ureaplasma parvum
Michael L. Beeton. Sailesh Kotecha and O. Brad Spiller
Dept. Child Health, Cardiff University School of Medicine, Cardiff, U.K.
Oral presentation
Ureaplasma parvum  is the most common organism associated with premature 
birth, causes non-gonococcal urethritis and neonatal meningitis. U. parvum 
consists of serovars (SV) 1, 3, 6 and 14 with SV3 being the most common. 
We screened for complement killing of clinical isolates of each SV by normal 
serum, as assessed by measuring survival titres following 1 hour incubation at 
37 oC with 50% serum (relative to matched heat-inactivated controls). No 
bacterial killing was observed for any SV when serum was diluted in 
alternative pathway buffer (containing EGTA and magnesium), indicating 
Ureaplasma does not overtly activate the alternative pathway. When serum 
diluted in veronal-buffered saline, 5/12 sera killed SV1 by >1000 fold, all sera 
killed SV3 by >1000 fold, 8/12 sera killed SV6 by 10 -  1000 fold and 4/12 sera 
killed SV14 by 10 -  1000 fold (only 1 by >1000 fold). IgG-depletion by protein 
A-sepharose removed the bacteriocidal activity of all serum for SV1, SV6 and 
SV14, but had no effect on killing of SV3. The antibody dependence of 
complement-mediated bacteriocidal activity was supported by Western blot 
analysis, although the molecular mass of bacterial proteins bound by human 
immunoglobulins varied widely between sera and between strains of the same 
SV. Two sera with no immunoreactivity to any SV by Western blot were 
completely MBL-depleted by mannan-agarose, but retained 100% SV3 
bacteriocidal activity, while C6-deficient sera had no bacteriocidal activity. We 
found that killing of SV1, SV6 and SV14 was IgG-dependent and the 
alternative and lectin pathways were not bacteriocidal for U. parvum. SV3 
killing is calcium-dependent, but antibody- and MBL-independent. Variability 
of Western blot bands amongst strains of SV suggests hypervariability of 
dominant immunogens, with potential for escape
I3 IRG annual meeting. July 2008. Gregynog, UK
Identification of antibiotic resistance in Ureaplasma species and 
determination of novel mutations in genes associated with resistance.
Michael L. Beeton,1 Victoria J. Chalker,2 Sailesh Kotecha1 & O. Brad Spiller1
1 Cardiff University, School of Medicine, Dept. Child Health, University 
Hospital of Wales, Heath Park, Cardiff, CF14 4XN, U.K. 2 Respiratory and 
Systemic Infections Laboratory, Sexually Transmitted Bacteria Reference 
Laboratory, Health Protection Agency Centre for Infections, 61 Colindale 
Avenue, London, NW9 5EQ, U.K
Oral presentation -  3rd prize
Ureaplasmas represent the smallest free living bacteria which also lack a cell 
wall conferring an inherent resistance to all beta-lactam antibiotics. The 
genus Ureaplasma is divided into two species encompassing 14 serovars. U. 
parvum (U.p) contains serovars 1, 3, 6 , & 14 whereas U. urealyticum (U.u) 
contains serovars 2, 4, 5, 7, 8 , 9, 10, 11, 12 and 13. Here we have developed 
a rapid microbroth dilution assay that quantifies the initial input of bacteria co­
incident with determination of the antibiotic minimum inhibitory concentration 
(MIC). A total of 61 isolates (10/61 U.u, 50/61 U.p) from newborn neonates 
were screened. 1/61 (1.7%) was found to be resistant to tetracycline (MIC 
>2mg/L), 1/61 (1.7%) was found to be resistant to ciprofloxacin (MIC >4mg/L), 
5/61 (8.2%) were found to be erythromycin resistant (MIC 8 mg/L) with one 
additional isolate (total of 9.8%) was found to have very high erythromycin 
resistance (>64 mg/L). Tetracycline resistance was mediated by presence of 
the transferable tetM resistance gene. Resistance in the highly erythromycin 
resistant isolate was mediated by a novel 2 amino acid deletion (R66Q67) in 
the L4 ribosomal protein, which is likely to mediate resistance by altering the 
ribosome's three-dimensional structure to block erythromycin interacting with 
its binding site within the 23S rRNA. No mutations were found for the 
intermediate erythromycin resistant strains, although 4/5 belonged to the U. 
urealyticum species, suggesting a bias in susceptibility between U.u. and U.p. 
Ciprofloxacin resistance was found to be mediated by an amino acid 
substitution (D82N) in the parC topoisomerase gene. However we found 
species specific mutations in other topoisomerase genes previously 
incorrectly identified as resistance mutations by other investigators
Society for General Microbiology March 2009. Harrogate, UK
Identification and characterisation of antibiotic resistance in Ureaplasma 
spp.
Michael L. Beeton.1 Victoria J. Chalker,2 Sailesh Kotecha1 & O. Brad Spiller1
1 Cardiff University, School of Medicine, Dept. Child Health, University 
Hospital of Wales, Heath Park, Cardiff, CF14 4XN, U.K. 2 Respiratory and 
Systemic Infections Laboratory, Sexually Transmitted Bacteria Reference 
Laboratory, Health Protection Agency Centre for Infections, 61 Colindale 
Avenue, London, NW9 5EQ, U.K
Poster presentation
Background: Ureaplasmas represent some of the smallest free living
bacteria and have been associated with causing a number of diseases from 
nongonococcal urethritis to neonatal pneumonia.
Objective: To identify and characterise the molecular mechanism of
resistance in Ureaplasma to macrolides, tetracyclines and fluroquinolones.
Methods: An adapted breakpoint methodology was used to identify
resistantce. Genes previously associated with resistance to the respective 
antibiotics were sequenced to identify any amino acid differences which 
potentially could account for the resistant phenotypes.
Results: From 61 isolates 1 was highly resistant to erythromycin (MIC > 
64|ig/ml) due to a R66Q67 deletion in the L4 ribosomal protein, 1 resistant to 
ciprofloxacin (MIC 8pg/ml) with a D82N substitution in the ParC protein and 1 
was tetracycline resistant (MIC 64pg/ml) which harboured the tetM gene. 
Additionally we identified 1 isolate which was tetM  positive but tetracycline 
susceptible as well as identifying a number of species specific differences in 
the topoisomerase II proteins which have previously been incorrectly 
associated with quinolone resistance.
Conclusion: Amino acid differences within specific genes as well as
acquisition of the tetM  gene mediated resistance in Ureaplasma. Some 
previous mutations in the topoisomerase II genes are species specific 
differences but are not related to resistance.
23rd Annual Postgraduate Research Day. November 2008. Cardiff University, 
UK
Identification of antibiotic resistance in Ureaplasma species and 
determination of novel mutations in genes associated with resistance.
Michael Beeton1. Dr Victoria Chalker2, Dr Nicola Maxwell1, Prof Saliesh 
Kotecha1 and Dr Brad Spiller1
1 Cardiff University, School of Medicine, Dept. Child Health, University 
Hospital of Wales, Heath Park, Cardiff, CF14 4XN, U.K. 2 Respiratory and 
Systemic Infections Laboratory, Sexually Transmitted Bacteria Reference 
Laboratory, Health Protection Agency Centre for Infections, 61 Colindale 
Avenue, London, NW9 5EQ, U.K
Oral presentation
Ureaplasmas represent some of the smallest free living bacteria with the 
genus Ureaplasma consisting of two species encompassing 14 serovars. U. 
parvum (U.p) contains serovars 1, 3, 6 , & 14 whereas U. urealyticum (U.u) 
contains serovars 2, 4, 5 - 13. Ureaplasma have been associated with 
causing a number of diseases from nongonococcal urethritis to neonatal 
pneumonia. The lack of a cell wall confers an intrinsic resistance to all beta- 
lactam antibiotics rendering treatment to mostly protein synthesis inhibitors. 
Here we have developed a rapid microbroth dilution assay that quantifies the 
initial input of bacteria co-incident with determination of the antibiotic minimum 
inhibitory concentration (MIC). A total of 61 isolates from newborn neonates 
were screened and the molecular mechanism of erythromycin and 
ciprofloxacin resistance determined. Resistance in a highly erythromycin 
resistant isolate (010 ) was mediated by a novel 2 amino acid deletion 
(R66Q67) in the L4 ribosomal protein. Ciprofloxacin resistance was found to 
be mediated by an amino acid substitution (D82N) in the ParC topoisomerase 
protein. However we also found species specific mutations in other 
topoisomerase genes previously incorrectly identified as resistance mutations 
by other investigators
22rd Annual Postgraduate Research Day. November 2007. Cardiff University, 
UK
A new method for determining antibiotic resistance in Ureaplasma 
species; A case report on the characterisation of a clinical erythromycin 
resistance Ureaplasma
Michael Beeton1. Dr Victoria Chalker2, Dr Nicola Maxwell1, Prof Saliesh 
Kotecha1 and Dr Brad Spiller1
1 Cardiff University, School of Medicine, Dept. Child Health, University 
Hospital of Wales, Heath Park, Cardiff, CF14 4XN, U.K. 2 Respiratory and 
Systemic Infections Laboratory, Sexually Transmitted Bacteria Reference 
Laboratory, Health Protection Agency Centre for Infections, 61 Colindale 
Avenue, London, NW9 5EQ, U.K
Poster presentation -  1st prize
The role of the bacterium Ureaplasma spp. in the development of chronic lung 
disease of prematurity (CLD) is highly controversial. To determine its role a 
large multi-centre randomised control trial focusing on the ability of the 
macrolide antibiotic to eradicate the Ureaplasma and subsequent effect on 
reducing CLD is required. Before this can take place a standardised 
methodology to determine the presence of macrolide resistance strains is 
required. Until now the ability to standardise the inoculum size of the 
organism had not been possible without prior knowledge of cell numbers. We 
have developed a 96-well plate assay which allows for reproducible inoculum 
size without prior knowledge of cells numbers. Using this new methodology 
we examined the antibiotic sensitivities profiles of Ureaplasma isolates from 
patients on the neonatal ward at UHW. A clinically erythromycin resistant 
strain was isolated from a preterm neonate who, following a course of 
erythromycin, did not clear Ureaplasma colonisation from the lung. 
Characterisation of the resistant strain was carried out via sequencing of 
regions known to harbour mutations linked to macrolide resistance in other 
clinically significant bacteria. A deletion of 6 base pairs resulting in a 2 amino 
acid deletion was found within a highly conserved region the structural L4 
ribosomal protein of the 50S ribosomal subunit. Alignments of this region 
against phenotypically sensitive strains demonstrated the absence of mutation 
within sensitive strains. This is the first detailed report of the mechanism of 
macrolide resistance in clinically isolated Ureaplasma strain.
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